ID	pubmed	tissue	tumor	treatment	mirna	mirbase_r20	direct_target	id_target	mirna_regulator	mirna_function	mirna_expression	cell	animal_model	clinical_sample	sum_effect
1	23471579	liver	hepatocellular cancer	NPA	miR-216a	miR-216a-5p	PTEN|SMAD7	5728|4092	NPA	induce epithelial-mesenchymal transition|increase stem-like cell population|increase cell migration|increase metastatic ability	"consistently and significantly upregulated in HCC tissue samples associated with early tumor recurrence, poor disease-free survival and an epithelial-mesenchymal transition phenotype"	NPA	NPA	recurrent and non-recurrent human HCC tissue samples	oncogenic
2	23471579	liver	hepatocellular cancer	NPA	miR-217	miR-217	PTEN|SMAD7	5728|4092	NPA	induce epithelial-mesenchymal transition|increase stem-like cell population|increase cell migration|increase metastatic ability	"consistently and significantly upregulated in HCC tissue samples associated with early tumor recurrence, poor disease-free survival and an epithelial-mesenchymal transition phenotype"	NPA	NPA	recurrent and non-recurrent human HCC tissue samples	oncogenic
3	23468134	liver	hepatocellular cancer	NPA	miR-485-3p	miR-485-3p	MAT1A	4143	NPA	promote cell growth|increase apoptosis|increase cell invasion	increased in HCCs	Hep3B|HepG2	mice	NPA	oncogenic
4	23468134	liver	hepatocellular cancer	NPA	miR-495	miR-495-3p	MAT1A	4143	NPA	promote cell growth|increase apoptosis|increase cell invasion	increased in HCCs	Hep3B|HepG2	mice	NPA	oncogenic
5	23468134	liver	hepatocellular cancer	NPA	miR-664	miR-664a-3p	MAT1A	4143	NPA	promote cell growth|increase apoptosis|increase cell invasion	increased in HCCs	Hep3B|HepG2	mice	NPA	oncogenic
6	23466500	stomach	gastric cancer	cisplatin	miR-21	miR-21-5p	PTEN	5728	NPA	increase cell proliferation|decrease apoptosis	upregulated in the cisplatin resistant cells	SGC7901|SGC7901/DDP	NPA	NPA	oncogenic
7	23466356	breast	breast cancer	NPA	miR-206	miR-206	CCND2	894	NPA	inhibit cell growth|block cell cycle G1/S transition|inhibit cell proliferation|inhibit colony formation	lower expression in breast cancer tissues associated with larger tumour size and a more advanced clinical stage	MCF-7	NPA	breast cancer and normal breast tissues	tumor-suppressive
8	23462723	breast	breast cancer	NPA	miR-203	miR-203a	CDK6|ABL1|SRC	1021|25|6714	ING1	inhibit cell growth|inducec cell cycle G1 arrest	NPA	U2OS|MDA-MB-231	NPA	NPA	tumor-suppressive
9	23460133	prostate	prostate cancer	NPA	miR-152	miR-152-3p	TGFA	7039	NPA	inhibit cell migration|inhibit cell invasion	significantly decreased in primary PCa samples compared with that in non-malignant samples	NPA	NPA	48 primary PCa and 15 non-malignant tissue samples	tumor-suppressive
10	23458685	lung	lung cancer bone metastasis	NPA	miR-33a	miR-33a-5p	PTHLH	5744	NPA	decrease osteolytic bone metastasis	downregulated in lung cancer cells	A549	NPA	NPA	tumor-suppressive
11	23456549	prostate	prostate cancer	NPA	miR-335	miR-335-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell invasion|inhibit cell migration	significantly down-regulated in human PCa tissues comparing with paired adjacent benign prostate tissues	LNCaP|DU145|PC3	NPA	human PCa tissues comparing and paired adjacent benign prostate tissues	tumor-suppressive
12	23453369	cervix	cervical cancer	NPA	miR-497	miR-497-5p	IGF1R	3480	NPA	inhibit cell growth|inhibit colony formation|inhibit cell invasion|inhibit cell migration	downregulated in cervical cancer tissues compared to paired nontumor tissues	HeLa|Caski|SiHa|HeLa-S3	NPA	cervical cancer tissues and paired nontumor tissues	tumor-suppressive
13	23449143	lung	lung cancer metastasis	NPA	miR-126	miR-126-3p	CXCL2	2920	NPA	inhibit metastasis|reduce the recruitment of mesenchymal stem cells and inflammatory monocytes to primary tumours	NPA	NPA	NPA	NPA	tumor-suppressive
14	23449143	lung	lung cancer metastasis	NPA	miR-126*	miR-126-5p	CXCL2	2920	NPA	inhibit metastasis|reduce the recruitment of mesenchymal stem cells and inflammatory monocytes to primary tumours	NPA	NPA	NPA	NPA	tumor-suppressive
15	23447578	breast	breast cancer	NPA	miR-290-3p	miR-290-3p	ARID4B	51742	NPA	increase apoptosis|inhibit metastatic progression	NPA	NPA	highly metastatic MMTV-PyMT mice and AKXD (AKR/J x DBA/2J) recombinant inbred strains	NPA	tumor-suppressive
16	23447531	breast	breast cancer	NPA	miR-203	miR-203a	SNAI2	6591	SNAI2|TGFB1	inhibit cell invasion|inhibit metastasis	significantly downregulated in highly-metastatic breast cancer cells	NPA	NPA	NPA	tumor-suppressive
17	23446999	blood	multiple myeloma	NPA	miR-21	miR-21-5p	NPA	NPA	NPA	increase cell proliferation	NPA	NPA	SCID mice	NPA	oncogenic
18	23446431	liver	cholangiocarcinoma	NPA	miR-138	miR-138-5p	RHOC	389	NPA	inhibit cell proliferation|inhibit cell cycle G1/S transition|inhibit cell migration|inhibit cell invasion	downregulated in CC tissues	RBE|QBC939	NPA	NPA	tumor-suppressive
19	23443110	cervix	cervical cancer	cisplatin	miR-218	miR-218-5p	NPA	NPA	NPA	reduce cell proliferation|increase cisplatin chemosensitivity	NPA	HeLa	orthotopic mouse model	NPA	tumor-suppressive
20	23441135	kidney	renal cell carcinoma	NPA	miR-145	miR-145-5p	ADAM17	6868	ADAM17|TNFA	inhibit cell proliferation|inhibit cell migration	downregulated in renal cancer patients	NPA	NPA	renal cancer patients	tumor-suppressive
21	23438844	NPA	NPA	5-FU|FAK inhibitor|Y15|doxorubicin	miR-135	miR-135a-5p|miR-135b-5p	PTK2	5747	NPA	inhibit cell invasion|increase 5-FU sensitivity	NPA	HEK293|HeLa	NPA	NPA	tumor-suppressive
22	23438844	NPA	NPA	5-FU|FAK inhibitor|Y15|doxorubicin	miR-138	miR-138-5p	PTK2	5747	NPA	inhibit cell invasion|increase 5-FU sensitivity	NPA	HEK293|HeLa	NPA	NPA	tumor-suppressive
23	23438830	ovary	ovarian cancer	genistein	miR-27a	miR-27a-3p	NPA	NPA	NPA	promote cell growth|promote cell migration	higher in human ovarian cancer relative to benign ovarian tissues	SKOV3	NPA	human ovarian cancer and benign ovarian tissues	oncogenic
24	23437304	colorectum	colorectal cancer	etoposide	miR-18a	miR-18a-5p	ATM	472	NPA	inhibit the DNA damage repair|increase cell apoptosis	upregulated in primary CRC tumors compared with adjacent normal tissues	NPA	NPA	45 primary CRC tumors and the adjacent normal tissues	tumor-suppressive
25	23437196	ovary	ovarian cancer	NPA	miR-125b	miR-125b-5p	ERBB3	2065	NPA	inhibit angiogenesis	downregulated in ovarian cancer tissues	NPA	NPA	NPA	tumor-suppressive
26	23437196	ovary	ovarian cancer	NPA	miR-199a	miR-199a-5p	ERBB2|ERBB3	2064|2065	NPA	inhibit angiogenesis	downregulated in ovarian cancer tissues	NPA	NPA	NPA	tumor-suppressive
27	23436804	colorectum	colon cancer	NPA	miR-17	miR-17-5p	NCOA3|CLU	8202|1191	ESR2|MYC	promote cell proliferation	NPA	SW480	NPA	NPA	oncogenic
28	23436804	colorectum	colon cancer	NPA	miR-200	miR-200a-3p|miR-200b-3p|miR-200c-3p	ZEB1	6935	ESR2	inhibit cell migration	NPA	SW480	NPA	NPA	tumor-suppressive
29	23436656	breast	breast cancer	multidrug resistance	miR-663	miR-663a	HSPG2	3339	DNA methylation	increase chemoresistance	its overexpression in breast tumour tissues was associated with chemoresistance	MDA-MB-231|MDA-MB-231/ADM	NPA	breast cancer tissues	NPA
30	23435376	stomach	gastric cancer	NPA	miR-146a	miR-146a-5p	WASF2	10163	NPA	inhibit cell migration|inhibit cell invasion	NPA	NPA	NPA	NPA	tumor-suppressive
31	23435373	colorectum	colon cancer	NPA	miR-25	miR-25-3p	SMAD7	4092	NPA	inhibit cell proliferation|inhibit cell migration	down-regulated in human colon cancer tissues compared to the matched non-neoplastic mucosa tissues	NPA	xenograft	human colon cancer tissues and the matched non-neoplastic mucosa tissues	tumor-suppressive
32	23430586	breast	triple-negative breast cancer	NPA	miR-182	miR-182-5p	PFN1	5216	NPA	increase cell viability|inhibit apoptosis|increase cell proliferation	significantly increased in the triple-negative breast cancer tissues	MDA-MB-231	NPA	triple-negative breast cancer tissues and normal adjacent tissues	oncogenic
33	23426183	lung	lung cancer	deoxy-azacytidine|cigarette smoke condensate	miR-487b	miR-487b-3p	SUZ12|BMI1|WNT5A|MYC|KRAS	23512|648|7474|4609|3845	NPA	inhibit cell proliferation|inhibit cell invasion|decrease tumor growth|decrease metastatisis	NPA	NPA	NPA	NPA	tumor-suppressive
34	23425975	bladder	bladder cancer	NPA	miR-125b	miR-125b-5p	MMP13	4322	NPA	inhibit cell migration|inhibit cell invasion	NPA	T24|EJ	NPA	NPA	tumor-suppressive
35	23418360	breast	breast cancer	NPA	miR-24	miR-24-3p	PTPN9|PTPRF	5780|5792	NPA	promote cell migration|promote cell invasion|promote tumor growth|promote metastasis	higher in breast carcinoma samples than in breast benign tissues	NPA	mouse model	breast carcinoma samples and breast benign tissues	oncogenic
36	23417242	prostate	prostate cancer	NPA	miR-185	miR-185-5p	AR	367	NPA	inhibit cell proliferation|induce cell cycle G0/G1 arrest|inhibit cell migration|inhibit cell invasion	down-regulated in clinical prostate cancer samples	LNCaP	CaP xenografts model	clinical prostate cancer tissues	tumor-suppressive
37	23416980	head and neck	head and neck squamous cell carcinomas	NPA	miR-125b	miR-125b-5p	TACSTD2	4070	DNA methylation	NPA	decreased in cancer tissues	NPA	NPA	normal head and neck tissues and normal keratinocytes	NPA
38	23410973	ovary	ovarian cancer	NPA	miR-506	miR-506-3p	SNAI2|VIM	6591|7431	NPA	inhibit cell migration|inhibit cell invasion|inhibit epithelial-mesenchymal transition|reduce tumor growth	NPA	NPA	orthotopic OvCa mouse models	459 cases of serous ovarian cancer and 560 cases from independent cohorts	tumor-suppressive
39	23408138	breast	breast cancer	tamoxifen	miR-342	miR-342-3p	NPA	NPA	NPA	sensitize tamoxifen-induced apoptosis|inhibit cell proliferation	NPA	MCF-7	NPA	human breast cancer samples	tumor-suppressive
40	23404256	skin	melanoma	NPA	miR-145	miR-145-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion	NPA	BLM|FM3P|WM793	NPA	NPA	tumor-suppressive
41	23401231	liver	hepatocellular cancer	NPA	miR-140-5p	miR-140-5p	TGFBR1|FGF9	7046|2254	NPA	inhibit cell proliferation|inhibit metastasis	significantly decreased in HCC tissues	NPA	NPA	clinical HCC samples	tumor-suppressive
42	23400877	skin	melanoma	NPA	miR-221	miR-221-3p	FOS	2353	HOXB7/PBX2	NPA	NPA	NPA	NPA	NPA	NPA
43	23400877	skin	melanoma	NPA	miR-222	miR-222-3p	FOS	2353	HOXB7/PBX2	NPA	NPA	NPA	NPA	NPA	NPA
44	23400681	nerve	neuroblastoma	NPA	miR-137	miR-137	KDM1A	23028	NPA	increase apoptosis|inhibit cell migration|inhibit cell proliferation	low expression levels in primary neuroblastomas correlated with poor patient prognosis	SHEP|HEK293	NPA	primary neuroblastomas	tumor-suppressive
45	23399735	colorectum	colorectal carcinoma	NPA	miR-224	miR-224-5p	CDKN1A	1026	NPA	promote cell cycle G1/S transition	increased successively at each stage of IBD progression and accurately discriminated cancers from normal or chronically inflamed IBD tissues	NPA	NPA	chronically inflamed mucosae and cancers arising from IBD tissues	oncogenic
46	23399321	breast	non-invasive breast cancer	NPA	miR-312	NO_RECORD	NPA	NPA	NPA	inhibit cell proliferation|inhibit colony formation	significantly downregulated in cancer tissues	NPA	NPA	21 ductal carcinoma in situ (DCIS) and the corresponding normal tissues	tumor-suppressive
47	23396050	breast	breast cancer	NPA	miR-126	miR-126-3p	CXCL12	6387	DNA hypermethylation	inhibit metastasis	downregulated in cancer cells	NPA	NPA	NPA	tumor-suppressive
48	23396050	breast	breast cancer	NPA	miR-126*	miR-126-5p	CXCL12	6387	DNA hypermethylation	inhibit metastasis	downregulated in cancer cells	NPA	mouse xenograft model	NPA	tumor-suppressive
49	23394580	ovary	ovarian adenocarcinoma	NPA	miR-200c	miR-200c-3p	TUBB3	10381	NPA	NPA	NPA	A2780|Hey	NPA	220 ovarian cancer patients	NPA
50	23393589	colorectum	colon cancer	NPA	miR-130a	miR-130a-3p	SMAD4	4089	NPA	increase cell proliferation|increase cell migration	up-regulated in colon cancer tissues compared to paired adjacent normal mucosa	HCT116|SW480	NPA	colon cancer tissues and paired adjacent normal mucosa	oncogenic
51	23393589	colorectum	colon cancer	NPA	miR-301a	miR-301a-3p	SMAD4	4089	NPA	increase cell proliferation|increase cell migration	up-regulated in colon cancer tissues compared to paired adjacent normal mucosa	HCT116|SW480	NPA	colon cancer tissues and paired adjacent normal mucosa	oncogenic
52	23393589	colorectum	colon cancer	NPA	miR-454	miR-454-3p	SMAD4	4089	NPA	increase cell proliferation|increase cell migration	up-regulated in colon cancer tissues compared to paired adjacent normal mucosa	HCT116|SW480	NPA	colon cancer tissues and paired adjacent normal mucosa	oncogenic
53	23393335	blood	acute leukemia	NPA	miR-181a	miR-181a-5p	NPA	NPA	NPA	inhibit cell proferation|inhibit metabolic activity	NPA	NPA	NPA	NPA	tumor-suppressive
54	23392577	uterus	endometrial cancer	NPA	miR-130b	miR-130b-3p	DICER1	23405	NPA	promote tumor aggression	NPA	NPA	NPA	NPA	oncogenic
55	23392170	bladder	bladder cancer	NPA	miR-145	miR-145-5p	SOCS7	30837	NPA	induce caspase-dependent apoptosis	NPA	T24|NKB1	NPA	NPA	tumor-suppressive
56	23391410	liver	hepatocellular cancer	NPA	miR-198	miR-198	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell migration	downregulated in the cancer tissues with low differentiation grade	Pop10	NPA	NPA	tumor-suppressive
57	23389960	prostate	androgen-independent prostate cancer	NPA	miR-200b-3p	miR-200b-3p	NPA	NPA	TP73	inhibit cell proliferation	NPA	PC3	NPA	NPa	tumor-suppressive
58	23389848	liver	hepatocellular cancer	NPA	miR-26a	miR-26a-5p	IL6	3569	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion|induce cell cycle G1 arrest|induce apoptosis|inhibit tumor growth|inhibit metastasis	frequently down-regulated in HCC issues	NPA	nude mice models bearing human HCC	HCC patients	tumor-suppressive
59	23389731	ovary	ovarian cancer	NPA	miR-138	miR-138-5p	SOX4|HIF1A	6659|3091	NPA	inhibit cell invasion|inhibit metastasis	downregulated in late stage cancers	NPA	orthotopic xenograft mouse model	human ovarian tumors	tumor-suppressive
60	23384942	breast	breast cancer stem-like cells	NPA	miR-7	miR-7-5p	KLF4	9314	NPA	inhibit cell invasion|inhibit brain metastasis	significantly down-expressed in cancer stem-like cells	NPA	NPA	NPA	tumor-suppressive
61	23383988	prostate	prostate cancer stem cells	NPA	miR-143	miR-143-3p	FNDC3B	64778	NPA	promote migration and invasion|promote metastasis	NPA	PC3	NPA	NPA	oncogenic
62	23383271	stomach	gastric cancer	NPA	miR-9	miR-9-5p	CCND1|ETS1	595|2113	NPA	inhibit cell proliferation|inhibit cell invasion|inhibit metastasis	down-regulated in gastric cancer tissues	SGC-7901|AGS	NPA	gastric cancer tissues	tumor-suppressive
63	23383207	prostate	prostate cancer	NPA	miR-182-5p	miR-182-5p	FOXF2|RECK|MTSS1	2295|8434|9788	NPA	promote cell proliferation|promote cell migration|promote cell invasion	significantly higher in prostate cancer tissues compared to normal prostate tissues	NPA	NPA	prostate cancer tissues and normal prostate tissues	oncogenic
64	23380758	colorectum	colorectal cancer	NPA	miR-16	miR-16-5p	BIRC5	332	TP53	inhibit cell proliferation|induce apoptosis	downregulated in 67% of CRC tissues	NPA	NPA	CRC tissues	tumor-suppressive
65	23374284	breast	breast cancer	NPA	miR-26b	miR-26b-5p	PTGS2	5743	NPA	inhibit cell proliferation	decreased in breast cancer specimens compared with adjacent normal tissues	MDA-MB-231	NPA	38 breast cancer specimens and adjacent normal breast tissues	tumor-suppressive
66	23373996	brain	malignant glioma	NPA	miR-7	miR-7-5p	EGFR	1956	NPA	induce apoptosis|inhibit cell proliferation|inhibit cell migration|inhibit cell invasion	NPA	NPA	glioma xenografts	NPA	tumor-suppressive
67	23364795	breast	breast cancer	ionizing radiation	miR-31	miR-31-5p	PRKCE	5581	NPA	promote apoptosis|increase radio-chemotherapy sensitivity	NPA	MCF10A|MDA-MB-231	NPA	NPA	tumor-suppressive
68	23355454	liver	liver cancer	NPA	miR-21	miR-21-5p	NPA	NPA	ZBTB7A	promote cell growth|promote cell proliferation	NPA	HL-7702|QGY-7703	NPA	NPA	oncogenic
69	23355420	prostate	prostate cancer	NPA	miR-145	miR-145-5p	NEDD9	4739	NPA	inhibit cell invasion|inhibit epithelial-mesenchymal transition	NPA	PC-3	NPA	NPA	tumor-suppressive
70	23354685	prostate	prostate cancer	NPA	miR-182	miR-182-5p	SNAI2	6591	NPA	induce mesenchymal to epithelial transition	completely repressed during epithelial to mesenchymal transition	EP156T|EPT1|PC3	NPA	NPA	NPA
71	23354685	prostate	prostate cancer	NPA	miR-203	miR-203a	SNAI2	6591	NPA	induce mesenchymal to epithelial transition	completely repressed during epithelial to mesenchymal transition	EP156T|EPT1|PC3	NPA	NPA	NPA
72	23354167	breast	breast cancer	NPA	miR-29b	miR-29b-3p	VEGFA|ANGPTL4|PDGF|LOX|MMP9|ITGA6|ITGB1|TGFB	7422|51129|100135774|4015|4318|3655|3688|7040	GATA3	inhibit metastasis|promote mesenchymal phenotype	NPA	NPA	NPA	NPA	tumor-suppressive
73	23353818	stomach	gastric cancer	NPA	miR-296-5p	miR-296-5p	CDX1	1044	NPA	promote cell growth|inhibit apoptosis|change cell cycle distribution	NPA	NPA	NPA	primary gastric cancer tissues and adjacent gastric intestinal metaplasia tissues	oncogenic
74	23343715	lung	non-small cell lung cancer	NPA	miR-138	miR-138-5p	EZH2	2146	NPA	inhibit cell proliferation|inhibit tumor growth	frequently downregulated in NSCLC cells and tissues	NPA	NPA	NSCLC tissues	tumor-suppressive
75	23340433	breast	breast cancer	NPA	miR-30c	miR-30c-5p	TWF1	5756	GATA3	reduce chemotherapy resistance	NPA	NPA	NPA	breast cancer patients	NPA
76	23340296	breast	breast cancer	anoikis	miR-200a	miR-200a-3p	YAP1	10413	NPA	promote anoikis resistance|promote metastasis	positively associated with distant metastasis in patients with breast cancer	NPA	NPA	breast cancer clinical specimens	oncogenic
77	23339187	breast	breast cancer with lymph node metastasis	NPA	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	PAK1|DIAPH2|RDX|ITGB8	5585|1730|5962|3696	NPA	inhibit cell migration	significantly decreased in the breast cancer patients with lymph node metastasis compared to those without lymph node metastasis	NPA	NPA	breast cancer patients with lymph node metastasis and those without lymph node metastasis	tumor-suppressive
78	23338972	blood	lymphoma	NPA	miR-26a	miR-26a-5p	NOS2	4843	STAT3	decrease NO production|decrease cell viability|decrease cell adhesion|decrease cell migration	significantly decreased in NPM-ALK(+) T-cell lymphoma cell lines and tumours compared with T lymphocytes and reactive lymph nodes	NPA	NPA	primary tumours and human T lymphocytes	tumor-suppressive
79	23338610	breast	breast cancer	NPA	miR-23b	miR-23b-3p	NPA	NPA	ERBB2|EGF|TNFA|NISCH	promote tumor growth	highly upregulated in human breast cancer	NPA	mouse xenograft model of human mammary tumor	human breast cancers	oncogenic
80	23338610	breast	breast cancer	NPA	miR-27b	miR-27b-3p	NPA	NPA	ERBB2|EGF|TNFA|NISCH	promote tumor growth	highly upregulated in human breast cancer	NPA	mouse xenograft model of human mammary tumor	human breast cancers	oncogenic
81	23338485	stomach	gastric cancer	NPA	miR-301a	miR-301a-3p	RUNX3	864	NPA	promote cell growth|promote soft agar clonogenicity|promote cell migration|promote cell invasion|decrease apoptosis induced by cisplatin|promote the percentage of G2/M phase cells	significantly upregulated both in cells and tissues of gastric cancer	SGC-7901	nude mice with SGC-7901	gastric cancer tissues	oncogenic
82	23337504	colorectum	colorectal cancer	NPA	miR-330	miR-330-5p	CDC42	998	NPA	inhibit cell proliferation|induce cell cycle G1 arrest|induce apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
83	23335975	head and neck	head and neck squamous cell carcinoma	NPA	miR-193b	miR-193b-3p	NF1	4763	NPA	promote cell proliferation|promote cell migration|promote cell invasion|inhibit tumor formation	highly expressed in lower disease-free survival HNSCC patients	FaDu	NPA	HNSCC patients	oncogenic
84	23334332	pancreas	pancreatic duct adenocarcinoma	NPA	miR-124	miR-124-3p	RAC1	5879	DNA hypermethylation in cancer	inhibit cell proliferation|inhibit cell invasion|inhibit metastasis	downregulation was significantly associated with worse survival of PDAC patients	NPA	NPA	pancreatic cancer tissues and non-cancerous tissues	tumor-suppressive
85	23333058	stomach	gastric cancer	NPA	miR-17-5p	miR-17-5p	CDKN1A|TP53INP1	1026|94241	NPA	promote cell cycle progression|inhibit apoptosis	upregulated in human gastric cancer tissues	NPA	mouse xenograft model	110 gastric cancer tissues	oncogenic
86	23333058	stomach	gastric cancer	NPA	miR-20a	miR-20a-5p	CDKN1A|TP53INP1	1026|94241	NPA	promote cell cycle progression|inhibit apoptosis	upregulated in human gastric cancer tissues	NPA	mouse xenograft model	110 gastric cancer tissues	oncogenic
87	23329838	prostate	prostate cancer	NPA	miR-182	miR-182-5p	GNA13	10672	NPA	inhibit cell invasion	NPA	LnCAP|PC3	NPA	NPA	tumor-suppressive
88	23329838	prostate	prostate cancer	NPA	miR-200a	miR-200a-3p	GNA13	10672	NPA	inhibit cell invasion	NPA	LnCAP|PC3	NPA	NPA	tumor-suppressive
89	23322774	colorectum	colorectal cancer	NPA	miR-31	miR-31-5p	RASA1	5921	NPA	promote cell proliferation	the most significantly dysregulated in colorectal cancer compared with normal adjacent tissue samples	NPA	mouse xenograft tumor model	colorectal cancer and normal adjacent tissue samples	oncogenic
90	23321675	liver	heptacellular carcinoma	NPA	miR-148a	miR-148a-3p	PBXIP1	57326	HBx|TP53	inhibit cell growth|inhibit epithelial-mesenchymal transition|inhibit cell invasion|inhibit metastasis	NPA	NPA	mouse xenograft model	patients with HBV-related liver cancer	tumor-suppressive
91	23321667	breast	breast cancer	NPA	miR-374a	miR-374a-5p	WIF1|PTEN|WNT5A	11197|5728|7474	NPA	promote epithelial-mesenchymal transition|promote metastasis	markedly upregulated in primary tumor samples from patients with distant metastases and was associated with poor metastasis-free survival	NPA	NPA	primary tumor samples	oncogenic
92	23318422	ovary	epithelial ovarian cancer	cisplatin resistance	miR-152	miR-152-3p	DNMT1	1786	NPA	inhibit cell proliferation|promote apoptosis|increase cisplatin sensitivity	significantly downregulated in the cisplatin-resistant ovarian cell lines	SKOV3|A2780|SKOV3/DDP|A2780/DDP	CD-1/CD-1 nude mice	NPA	tumor-suppressive
93	23318422	ovary	epithelial ovarian cancer	cisplatin resistance	miR-185	miR-185-5p	DNMT1	1786	NPA	inhibit cell proliferation|promote apoptosis|increase cisplatin sensitivity	significantly downregulated in the cisplatin-resistant ovarian cell lines	SKOV3|A2780|SKOV3/DDP|A2780/DDP	CD-1/CD-1 nude mice	NPA	tumor-suppressive
94	23318420	breast	invasive breast carcinoma	NPA	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	HMGA2	8091	OSM|STAT3|LIN28	inhibit epithelial-mesenchymal transition	NPA	MCF-7	MCF-7 xenografts in nude mice	NPA	tumor-suppressive
95	23313739	cervix	cervical cancer	NPA	miR-182	miR-182-5p	NPA	NPA	NPA	promote tumor growth|apoptosis|cell cycle	significantly elevated in primary cervical carcinoma	HeLa	HeLa xenograft mice model	primary cervical carcinoma	oncogenic
96	23307328	brain	glioblastoma	NPA	miR-10b	miR-10b-5p	NPA	NPA	NPA	promote cell migration|promote cell invasion	upregulated in human glioblastoma tissues compared to normal human tissues	NPA	stem cell-derived orthotopic GBM xenografts	human glioblastoma tissues and normal human tissues	oncogenic
97	23306701	liver	hepatocellular carcinoma	NPA	miR-636	miR-636	NPA	NPA	SLC25A5	inhibit cell proliferation|inhibit colony formation	markedly downregulated in HCC tissues compared with matched non-neoplastic liver in clinical samples	Hep3B	tumor xenograft model of HCC	HCC tissues and matched non-neoplastic liver	tumor-suppressive
98	23305226	pancreas	pancreatic cancer	NPA	miR-34b	miR-34b-5p	SMAD3	4088	NPA	inhibit cancer progression	"down-regulated in pancreatic cancer tissues and negatively correlated with tumor-node-metastasis (TNM) stage, lymph-node metastasis and overall survival"	NPA	NPA	64 pancreatic cancer tissues	tumor-suppressive
99	23300839	NPA	NPA	NPA	miR-138	miR-138-5p	NPA	NPA	NPA	inhibit cell migration|reduce tumor formation	NPA	MCF-7|RL95-2|AsPC-1	nude mice	NPA	tumor-suppressive
100	23300597	prostate	prostate cancer	NPA	miR-23b	miR-23b-3p	NPA	NPA	NPA	inhibit cell migration|inhibit cell invasion	NPA	LNCaP	NPA	NPA	tumor-suppressive
101	23300597	prostate	prostate cancer	NPA	miR-27b	miR-27b-3p	NPA	NPA	NPA	inhibit cell migration|inhibit cell invasion	NPA	LNCaP	NPA	NPA	tumor-suppressive
102	23298478	brain	glioma	NPA	miR-149	miR-149-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell invasion|induce cell cycle G0/G1 arrest	NPA	U251	nude mice subcutaneous xenograft tumors	NPA	tumor-suppressive
103	23296900	ovary	ovarian carcinoma	CDDP|Taxol	miR-182	miR-182-5p	PDCD4	27250	NPA	increase cell viability|increase colony formation|promote cell cycle|promote cell migration|promote cell invasion|reduce chemosensitivity	upregulated in ovarian cancer tissues	NPA	NPA	ovarian cancer tissues	oncogenic
104	23296799	breast	breast cancer	trastuzumab	miR-199b-5p	miR-199b-5p	ERBB2	2064	NPA	inhibit cel migration|inhibit clonogenicity	NPA	NPA	NPA	NPA	tumor-suppressive
105	23296701	stomach	gastric cancer	NPA	miR-133b	miR-133b	FGFR1	2260	NPA	inhibit cell proliferation|inhibti colony formation	downregulated in human gastric cancer tissues compared with nontumor counterparts	MKN-45|SGC-7901	NPA	human gastric cancer tissues and nontumor counterparts	tumor-suppressive
106	23295946	bladder	bladder cancer	NPA	miR-582-3p	miR-582-3p	NPA	NPA	NPA	reduce cell proliferation|reduce cell invasion|reduce tumor growth|reduce metastasis	strongly decreased in high-grade bladder cancer clinical samples	UM-UC-3	NPA	bladder cancer clinical samples	tumor-suppressive
107	23295946	bladder	bladder cancer	NPA	miR-582-5p	miR-582-5p	NPA	NPA	NPA	reduce cell proliferation|reduce cell invasion|reduce tumor growth|reduce metastasis	strongly decreased in high-grade bladder cancer clinical samples	UM-UC-3	NPA	bladder cancer clinical samples	tumor-suppressive
108	23292834	esophagus	esophageal squamous cell carcinoma	NPA	miR-100	miR-100-5p	MTOR	2475	NPA	induce apoptosis	universally downregulated in esophageal squamous cell carcinoma and decreased expression was associated with worse overall survival in ESCC patients	NPA	NPA	101 ESCC surgical tissue samples	tumor-suppressive
109	23292834	esophagus	esophageal squamous cell carcinoma	NPA	miR-99a	miR-99a-5p	MTOR	2475	NPA	induce apoptosis	universally downregulated in esophageal squamous cell carcinoma and decreased expression was associated with worse overall survival in ESCC patients	NPA	NPA	101 ESCC surgical tissue samples	tumor-suppressive
110	23292172	liver	hepatocellular cancer	NPA	miR-34a	miR-34a-5p	NPA	NPA	NPA	inhibit tumor growth	reduced in hepatocellular carcinoma (HCC) and the reduced expression was associated with worse outcome of HCC patients	NPA	xenograft HCC tumors in a mouse model	hepatocellular carcinoma	tumor-suppressive
111	23285092	colorectum	colon cancer	NPA	miR-203	miR-203a	CBLL1	79872	NPA	inhibit cell growth	reduced in colon tumour tissues compared to normal colon tissues	NPA	NPA	colon tumour tissues and normal colon tissues	tumor-suppressive
112	23285024	NPA	NPA	NPA	miR-204	miR-204-5p	BDNF	627	DNA deletion	inhibit metastasis	drastically reduced in several types of cancers	NPA	NPA	NPA	tumor-suppressive
113	23280316	colorectum	colorectal cancer	NPA	miR-362-3p	miR-362-3p	E2F1|USF2|PTPN1	1869|7392|5770	NPA	reduce cell viability|inhibit cell proliferation|cell cycle	expressed at a higher level in tumors from patients with no recurrence compared with tumors from patients with recurrence|significant association with increased disease free survival	HCT116	NPA	14 normal colon mucosas and 46 microsatellite stable CRC tumors|a second independent cohort of 43 CRC patients	tumor-suppressive
114	23276710	esophagus	esophageal squamous cell carcinoma	NPA	miR-143	miR-143-3p	MAPK7	5598	NPA	inhibit cell growth|induce apoptosis|inhibit cell migration|inhibit cell invasion	significantly decreased in ESCC tissues in comparison with adjacent normal tissues|inversely correlated with tumor invasion depth and lymph node metastasis	NPA	NPA	significantly decreased in ESCC tissues and adjacent normal tissues	tumor-suppressive
115	23274497	NPA	NPA	NPA	miR-30d	miR-30d-5p	BECN1|BNIP3L|ATG12|ATG5|ATG2	8678|665|9140|9474|855479	NPA	inhibit autophagosome formation|inhibit LC3B-I conversion to LC3B-II	NPA	NPA	NPA	NPA	oncogenic
116	23264400	thyroid	papillary thyroid carcinoma	NPA	miR-146b	miR-146b-5p	NPA	NPA	NPA	increase cell migration|increase cell invasion|inhibit chemotherapy induced apoptosis	upregulated in patients with poorer overall survival	BCPAP	NPA	71 cases of papillary thyroid carcinoma with distinct clinico-pathogenetic characteristics	oncogenic
117	23264087	stomach	gastric cancer	NPA	miR-34a	miR-34a-5p	NPA	NPA	NPA	reduce cell viability|inhibit cell proliferation|induce apoptosis|inhibit cell migration	significantly reduced compared to the normal gastric epithelial cell line GES-1	MGC80-3|HGC-27|NCI-N87|SGC-7901|GES-1	NPA	NPA	tumor-suppressive
118	23262295	ovary	ovarian cancer	NPA	miR-182	miR-182-5p	FOXO3	2309	LEP	promote cell proliferation	NPA	SKOV3|A2780	NPA	NPA	oncogenic
119	23262295	ovary	ovarian cancer	NPA	miR-96	miR-96-5p	FOXO3	2309	LEP	promote cell proliferation	NPA	SKOV3|A2780	NPA	NPA	oncogenic
120	23255074	colorectum	colon cancer	NPA	miR-218	miR-218-5p	BMI1	648	NPA	induce apoptosis|inhibit cell proliferation|induce cell cycle G2 arrest	significantly lower in CRC tumor tissues compared with their adjacent normal tissues	Caco2|HT29|SW620|HCT116|LoVo	NPA	46 CRC tumor tissues and their adjacent normal tissues	tumor-suppressive
121	23252827	brain	glioma	Temozolomide	miR-182	miR-182-5p	NPA	NPA	NPA	inhibit ROS-induced apoptosis|promote anticancer Temozolomide effect	NPA	NPA	NPA	NPA	NPA
122	23252827	brain	glioma	Temozolomide	miR-183	miR-183-5p	NPA	NPA	NPA	inhibit ROS-induced apoptosis|promote anticancer Temozolomide effect	NPA	NPA	NPA	NPA	NPA
123	23252827	brain	glioma	Temozolomide	miR-96	miR-96-5p	NPA	NPA	NPA	inhibit ROS-induced apoptosis|promote anticancer Temozolomide effect	NPA	NPA	NPA	NPA	NPA
124	23250910	breast	breast cancer	NPA	miR-124	miR-124-3p	SNAI2	6591	NPA	inhibit cell mobility|inhibit cell invasion|inhibit epithelial-mesenchymal transition|inhibit colony formation|inhibit pulmonary metastasis	significantly suppressed in human breast cancer specimens and reversely correlated to histological grade of the cancer	MDA-MB-231|BT-549	NPA	human breast cancer specimens	tumor-suppressive
125	23250421	colorectum	colorectal cancer	NPA	miR-17-5p	miR-17-5p	RBL2	5934	NPA	NPA	negatively correlated with the overall survival rates	NPA	NPA	two large cohorts of colorectal cancer patients	oncogenic
126	23246488	head and neck	head and neck squamous cell carcinoma	NPA	miR-363	miR-363-3p	PDPN	10630	promoter DNA hypermethylation	inhibit cell invasion|inhibit metastasis	down-regulated in HNSCC tissues with lymph node metastasis	NPA	NPA	HNSCC tissues	tumor-suppressive
127	23245396	skin	melanoma	NPA	miR-29	miR-29a-3p|miR-29b-3p|miR-29c-3p	CDK6	1021	IFNG|STAT1	inhibit cell proliferation	"strikingly elevated in certain patient samples derived from primary melanoma compared to nevi and normal skin, and metastatic melanoma samples"	NPA	NPA	"primary melanoma, nevi and normal skin and metastatic melanoma samples"	tumor-suppressive
128	23243056	brain	glioma	NPA	miR-218	miR-218-5p	VOPP1	81552	NPA	induce apoptosis|inhibit cell viability|inhibit cell proliferation|inhibit tumorigenicity	NPA	NPA	in vivo xenograft	NPA	tumor-suppressive
129	23242208	stomach	gastric cancer	NPA	miR-372	miR-372-3p	TNFAIP1	7126	NPA	apoptosis|cell growth	NPA	AGS	NPA	NPA	oncogenic
130	23241961	liver	hepatocellular carcinoma	NPA	miR-495	miR-495-3p	MAT1A	4143	NPA	promote tumor growth|promote cell invasion|promote metastasis	increased in HCC	Hep3B|HepG2	subcutaneous and intraparenchymal injection of Hep3B cells in mice	NPA	oncogenic
131	23241961	liver	hepatocellular carcinoma	NPA	miR-485-3p	miR-485-3p	MAT1A	4143	NPA	promote tumor growth|promote cell invasion|promote metastasis	increased in HCC	Hep3B|HepG2	subcutaneous and intraparenchymal injection of Hep3B cells in mice	NPA	oncogenic
132	23241961	liver	hepatocellular carcinoma	NPA	miR-664	miR-664a-3p	MAT1A	4143	NPA	promote tumor growth|promote cell invasion|promote metastasis	increased in HCC	Hep3B|HepG2	subcutaneous and intraparenchymal injection of Hep3B cells in mice	NPA	oncogenic
133	23241956	breast	breast cancer	NPA	miR-181a	miR-181a-5p	NPA	NPA	TGFB1	promote epithelial-mesenchymal transition|promote cell migration|promote cell invasion	"dramatically and selectively upregulated in metastatic breast tumors, particularly triple-negative breast cancers|highly predictive for decreased overall survival in human breast cancer patients"	NPA	mouse model	human breast cancer patients	oncogenic
134	23233740	head and neck	oral squamous cell carcinoma	NPA	miR-596	miR-596	LGALS3BP	3959	CpGi DNA hypermethylation	reduce cell growth|induce apoptosis	NPA	NPA	NPA	26 Japanese and 38 Thais primary cases	tumor-suppressive
135	23233531	breast	breast cancer	NPA	miR-148b	miR-148b-3p	ITGA5|ROCK1|PIK3CA|NRAS|CSF1	3678|6093|5290|4893|1435	NPA	inhibit cell invasion|induce anoikis|inhibit lung metastasis formation|increase chemotherapy response	down-regulated in aggressive breast tumors	NPA	NPA	77 primary breast carcinoma	tumor-suppressive
136	23232714	head and neck	mucoepidermoid carcinoma	NPA	miR-127-3p	miR-127-3p	NPA	NPA	NPA	inhibit cell viability|induce cell cycle G1/S arrest	NPA	MC-3	TPA?induced JB6 mouse	NPA	NPA
137	23231923	prostate	prostate cancer	NPA	miR-30d	miR-30d-5p	SOCS1	8651	NPA	promote cell proliferation|promote cell invasion	significantly higher in cancer tissue samples than in the paired normal controls	PC3|DU145|LNCaP|RWPE-1|PrSc	NPA	NPA	oncogenic
138	23226804	uterus	endometrioid endometrial cancer	NPA	miR-21	miR-21-5p	PTEN	5728	NPA	promote cell proliferation	overexpressed in EEC	KLE	NPA	16 paired EEC tumor tissues and adjacent non-tumor endometrium	oncogenic
139	23224145	breast	breast cancer	NPA	miR-30c	miR-30c-5p	TWF1|VIM	5756|7431	NPA	cell invasion	NPA	NPA	NPA	NPA	NPA
140	23221562	liver	hepatocellular carcinoma	NPA	miR-122	miR-122-5p	PTTG1IP	754	HBV	NPA	decreased in chronic hepatitis B and hepatocellular carcinoma	NPA	NPA	NPA	tumor-suppressive
141	23220650	brain	glioma	NPA	miR-107	miR-107	NPA	NPA	TP53	inhibit cell proliferation|induce cell cycle arrest at the G0-G1 phase	down-regulated in glioma tissues	NPA	NPA	glioma tissues	tumor-suppressive
142	23212916	brain	medulloblastoma	NPA	miR-218	miR-218-5p	REST|CDK6|RICTOR|CTSB	5978|1021|253260|1508	NPA	inhibit cell growth|inhibit colony formation|inhibit cell migration|inhibit cell invasion|inhibit tumor sphere size	significantly down-expressed in medulloblastoma	C17.2	NPA	NPA	tumor-suppressive
143	23212913	liver	hepatocellular carcinoma	NPA	miR-490-3p	miR-490-3p	ERGIC3	51614	NPA	increase cell proliferation|increase cell migration|increase cell invasion|promote epithelial to mesenchymal transition	up-regulated in HCC tissues and cells compared with the adjacent non-tumor tissues	NPA	NPA	HCC tissues and the adjacent non-tumor tissues	oncogenic
144	23212344	head and neck	KB oral cancer	NPA	miR-205	miR-205-5p	NPA	NPA	NPA	increase cell cytotoxicity|induce apoptosis	significantly lower in KB oral cancer cells than in human normal oral keratinocytes	NPA	NPA	NPA	tumor-suppressive
145	23211491	breast	breast cancer	NPA	miR-98	miR-98-5p	ACVR1B|MMP11	91|4320	NPA	inhibit cell proliferation|inhibit cell survival|inhibit tumor growth|inhibit cell invasion|inhibit angiogenesis	NPA	NPA	NPA	NPA	tumor-suppressive
146	23209748	breast	breast cancer	doxorubicin	miR-200c	miR-200c-3p	NTRK2|BMI1	4915|648	NPA	increase doxorubicin sensitivity	NPA	BT474	NPA	NPA	NPA
147	23208495	colorectum	colorectal cancer	NPA	miR-7	miR-7-5p	YY1	7528	NPA	inhibit cell proliferation|induce apoptosis|induce cell cycle G1 arrest	down-regulated in colorectal cancer	HCT116|LOVO|DLD1	xenograft-nude mouse model	NPA	tumor-suppressive
148	23208072	bone and muscle	osteosarcoma	NPA	miR-223	miR-223-3p	HSP90B1	7184	NPA	inhibit cell growth|induce apoptosis|inhibit cell cycle G0/G1 arrest	NPA	MG63	mouse xenograft model	NPA	tumor-suppressive
149	23206776	kidney	renal cell carcinoma	NPA	miR-21	miR-21-5p	TCF21	6943	NPA	NPA	upregulated in human renal cell carcinoma specimens compared with its expression in normal renal cell specimens	Caki-1	NPA	human renal cell carcinoma specimens and normal renal cell specimens	NPA
150	23206698	skin	melanoma	NPA	miR-7-5p	miR-7-5p	IRS2	8660	NPA	inhibit cell migration|inhibit cell invasion	reduced in metastatic melanoma-derived cell lines compared with primary melanoma cells	NPA	NPA	NPA	tumor-suppressive
151	23206218	bladder	bladder cancer	NPA	miR-133a	miR-133a-3p	EGFR	1956	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion	NPA	T24|EJ	NPA	NPA	tumor-suppressive
152	23206218	bladder	bladder cancer	NPA	miR-133b	miR-133b	EGFR	1956	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion	NPA	T24|EJ	NPA	NPA	tumor-suppressive
153	23205572	uterus	endometrial adenocarcinoma	NPA	miR-200b-3p	miR-200b-3p	TIMP2	7077	NPA	NPA	highly expressed in cancer tissues than in normal adjacent tissues	HEC-1A	NPA	endometrial adenocarcinomas and normal adjacent tissues	NPA
154	23201162	colorectum	colorectal cancer	NPA	miR-137	miR-137	FMNL2	114793	HMGA1	inhibit cell proliferation|inhibit cell invasion|inhibit metastasis	reduced in CRC samples compared with adjacent normal mucosa	NPA	tumor xenografts in mice	CRC cells and tissue samples from patients (n = 50)	tumor-suppressive
155	23201159	colorectum	colorectal cancer	NPA	miR-145	miR-145-5p	NRAS|IRS1	4893|3667	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion	significantly downregulated in the plasma and cancer tumor tissues of colorectal cancer (CRC) patients	NPA	mouse xenograft tumors	60 pairs of colorectal cancer tissues and adjacent normal tissues	tumor-suppressive
156	23190898	skin	melanoma	NPA	miR-26a	miR-26a-5p	BAG4	9530	NPA	induce apoptosis	strongly downregulated in melanoma cell lines as compared with primary melanocytes	NPA	NPA	NPA	tumor-suppressive
157	23190608	blood	multiple myeloma	bortezomib	miR-29b	miR-29b-3p	NPA	NPA	SP1	inhibit cell growth|induce apoptosis|sensitize bortezomib treatment	NPA	NPA	MM xenografts	NPA	tumor-suppressive
158	23188821	prostate	prostate cancer	NPA	miR-98	miR-98-5p	CCNJ	54619	vitamin D	inhibit cell growth|induce cell cycle G2/M arrest	NPA	LNCaP	NPA	NPA	tumor-suppressive
159	23188675	prostate	prostate cancer	NPA	miR-320	miR-320a|miR-320b|miR-320c|miR-320d|miR-320e	CTNNB1	1499	NPA	decrease tumorigenesis|inhibit cancer stem-like properties|reduce tumorsphere formation|reduce chemoresistance	significantly downregulated in prostate cancer	NPA	NPA	NPA	tumor-suppressive
160	23185040	cervix	cervical carcinoma	NPA	miR-302~367	CLUSTER:miR-302~367	AKT1|CCND1	207|595	NPA	inhibit cell proliferation|inhibit tumor formation|block cell cycle G1/S transition	NPA	HeLa|SiHa	NPA	NPA	tumor-suppressive
161	23184229	breast	breast cancer	radiotherapy	miR-302	miR-302a-3p	NPA	NPA	NPA	sensitize radiotherapy	downregulated in irradiated breast cancer cells	NPA	NPA	NPA	NPA
162	23183822	brain	glioma	NPA	miR-211	miR-211-5p	NPA	NPA	MMP9	inhibit cell invasion|inhibit cell migration|induce apoptosis	suppressed in grade IV GBM specimens	NPA	NPA	NPA	tumor-suppressive
163	23178713	liver	hepatocellular carcinoma	NPA	miR-101	miR-101-3p	SOX9	6662	NPA	inhibit cell proliferation|inhibit tumorigenicity	down-regulation in clinical HCC tissues correlated with tumor aggressiveness and poor prognosis	NPA	NPA	clinical HCC tissues	tumor-suppressive
164	23178712	lung	lung cancer	NPA	miR-137	miR-137	CDC42|CDK6	998|1021	NPA	induce cell cycle G1 arrest|inhibit cell growth	downregulated in lung cancer cells	NPA	NPA	NPA	tumor-suppressive
165	23176581	kidney	renal cell carcinoma	NPA	miR-135a	miR-135a-5p	MYC	4609	NPA	inhibit cell proliferation|induce cell cycle arrest	NPA	caki2|A498	NPA	RCC clinical specimens	tumor-suppressive
166	23175432	liver	hepatocellular carcinoma	NPA	miR-657	miR-657	TLE1	7088	NPA	increase cell proliferation|increase colony formation|promote tumor development	significantly increased in hepatocellular carcinoma tissues	NPA	immunodeficient mice	hepatocellular carcinoma tissues	oncogenic
167	23175429	brain	glioma	NPA	miR-16	miR-16-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion	lower in cancer cells than normal brains	U251|U87	NPA	NPA	tumor-suppressive
168	23175237	stomach	gastric cancer	NPA	miR-27a	miR-27a-3p	NPA	NPA	NPA	promote cell growth	"significantly upregulated in gastric cancer tissues, compared with their non-tumor adjacent tissues"	AGS|MGC-803	NPA	NPA	oncogenic
169	23175151	nerve	peripheral nerve sheath tumours	NPA	miR-29c	miR-29c-3p	NPA	NPA	NPA	reduce cell invasion	downregulated in malignant peripheral nerve sheath tumours	sNF96.2	NPA	neurofibromas and malignant peripheral nerve sheath tumours	tumor-suppressive
170	23174819	colorectum	colorectal cancer	NPA	miR-21	miR-21-5p	PTEN	5728	NPA	increase cell proliferation|incrase cell migration|increase cell invasion|induce apoptosis|inhibit cell cycle progression	overexpressed in CRC compared with adenomas and normal tissues	HCT116	NPA	30 CRC samples	oncogenic
171	23173671	kidney	renal cell carcinoma	NPA	miR-99a	miR-99a-5p	MTOR	2475	NPA	inhibit cell growth|inhibit clonability|inhibit cell migration|inhibit cell invasion|induce cell cycle G1 arrest|inhibit tumor growth	remarkably downregulated in RCC and negatively correlated with poor survival of RCC patients	786-O|OS-RC-2	murine xenograft models of human RCC	40 pairs of RCC and matched adjacent non-tumor tissues	tumor-suppressive
172	23169640	blood	leukemia	NPA	miR-155	miR-155-5p	HDAC4	9759	NPA	increase cell proliferation|increase clonogenity|inhibit apoptosis	NPA	NPA	E¦Ì-miR-155 transgenic mice	the diffuse large B-cell lymphoma patients	oncogenic
173	23166713	skin	cutaneous squamous cell carcinoma	NPA	miR-361-5p	miR-361-5p	VEGFA	7422	NPA	NPA	NPA	NPA	NPA	NPA	NPA
174	23166327	head and neck	oral squamous cell carcinoma	NPA	miR-155	miR-155-5p	CDC73	79577	NPA	promote cell viability|decrease apoptosis|increase cell proliferation	NPA	KB|HEK293	xenografts in nude mice	OSCC patient samples	oncogenic
175	23162665	bone and muscle	osteosarcoma	NPA	miR-195	miR-195-5p	FASN	2194	NPA	decrease cell migration|decrease cell invasion	NPA	U2OS	NPA	NPA	tumor-suppressive
176	23162627	skin	melanoma	NPA	let-7b	let-7b-5p	NPA	NPA	NPA	inhibit cell proliferation|induce apoptosis	NPA	B16F10	NPA	NPA	tumor-suppressive
177	23162627	skin	melanoma	NPA	miR-199a	miR-199a-5p	NPA	NPA	NPA	inhibit cell proliferation|induce apoptosis	NPA	B16F10	NPA	NPA	tumor-suppressive
178	23160634	cervix	cervical cancer	NPA	miR-125b	miR-125b-5p	PIK3CD	5293	NPA	decrease cell proliferation|indcue apoptosis	NPA	HeLa	NPA	NPA	tumor-suppressive
179	23159910	head and neck	head and neck squamous cell carcinoma	NPA	miR-218	miR-218-5p	LAMB3	3914	NPA	inhibit cell migration|inhibit cell invasion	NPA	FaDu|SAS	NPA	NPA	tumor-suppressive
180	23151846	skin	melanoma	NPA	miR-137	miR-137	MET|YBX1|EZH2|MITF	4233|4904|2146|4286	NPA	inhibit cell invasion|induce apoptosis	negatively correlated with poor survival in stage IV melanoma patients	NPA	NPA	NPA	tumor-suppressive
181	23151657	liver	hepatocellular carcinoma	NPA	miR-96	miR-96-5p	NPA	NPA	NPA	increase cell proliferation|increase colony formation	upregulated in HCC	HepG2	NPA	NPA	oncogenic
182	23151088	lung	non-small cell lung cancer	NPA	miR-100	miR-100-5p	PLK1	5347	NPA	inhibit cell growth|induce cell cycle G2/M arrest|induce apoptosis	"significantly downregulated in NSCLC tissues|negatively correlated with higher clinical stage, advanced tumor classification and lymph node metastasis of patients|negatively correlated with survival of NSCLC patients"	A549	NPA	10 NSCLC tissues and corresponding nontumor tissues|110 NSCLC tissues	tumor-suppressive
183	23150176	kidney	renal cell carcinoma	NPA	miR-210	miR-210-3p	NPA	NPA	NPA	increase cell viability|promote cell migration|promote cell invasion	increased in RCC tumor tissue	ACHN|CAKI-2	NPA	35 RCC versus 10 non-tumorous parenchyma samples	oncogenic
184	23145211	prostate	prostate cancer	NPA	miR-34a	miR-34a-5p	AR|NOTCH1	367|4851	NPA	inhibit cell growth|decrease self-renewal capacity	NPA	NPA	NPA	NPA	tumor-suppressive
185	23145039	liver	hepatocellular carcinoma	NPA	miR-550a	miR-550a-3p	CPEB4	80315	NPA	increase cell migration|increase cell invasion	NPA	NPA	NPA	NPA	oncogenic
186	23144691	stomach	gastric cancer	NPA	miR-149	miR-149-5p	ZBTB2	57621	NPA	inhibit cell proliferation|inhibit cell cycle progression	decreased in GC cell lines and clinical specimens in comparison to normal gastric epithelial cell and tissues|correlate with the differentiation degree of GC cells and tissues	NPA	NPA	GC clinical specimens and normal gastric tissues	tumor-suppressive
187	23142292	colorectum	colon cancer	NPA	miR-1290	miR-1290	KIF13B	23303	NPA	postpone cytokinesis|cell reprogramming	significantly up-regulated in clinical colon cancer tissues	NPA	NPA	clinical colon cancer tissues	NPA
188	23142283	head and neck	nasopharyngeal carcinoma	cisplatin-based chemotherapy and radiotherapy	miR-29c	miR-29c-3p	MCL1|BCL2	4170|596	NPA	increase cisplation senstivity|promote apoptosis	negatively associated with therapeutic resistance in 159 NPC cases	NPA	NPA	159 NPC cases	tumor-suppressive
189	23142051	skin	melanoma	NPA	miR-1908	miR-1908-5p	APOE|DNAJA4	348|55466	NPA	promote metastatic invasion|promote angiogenesis|promote colonization	correlated with human metastatic progression outcomes	NPA	NPA	NPA	oncogenic
190	23142051	skin	melanoma	NPA	miR-199a-3p	miR-199a-3p	APOE|DNAJA4	348|55466	NPA	promote metastatic invasion|promote angiogenesis|promote colonization	correlated with human metastatic progression outcomes	NPA	NPA	NPA	oncogenic
191	23142051	skin	melanoma	NPA	miR-199a-5p	miR-199a-5p	APOE|DNAJA4	348|55466	NPA	promote metastatic invasion|promote angiogenesis|promote colonization	correlated with human metastatic progression outcomes	NPA	NPA	NPA	oncogenic
192	23142026	lung	lung cancer	NPA	miR-1	miR-1	SNAI2	6591	NPA	change from a mesenchymal to an epithelial phenotype|inhibit cell migration|inhibit cell invasion|increase doxorubicin sensitivity	NPA	A549	NPA	NPA	tumor-suppressive
193	23140286	pancreas	pancreatic cancer	genistein	miR-34a	miR-34a-5p	NPA	NPA	NPA	inhibit cell growth|induce apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
194	23137536	colorectum	colorectal cancer	NPA	miR-186	miR-186-5p	CSNK2A1	1459	NPA	increase reactive oxygen species (ROS) production|increase cell senescence	NPA	HCT116	NPA	NPA	NPA
195	23137536	colorectum	colorectal cancer	NPA	miR-216b	miR-216b-5p	CSNK2A1	1459	NPA	increase reactive oxygen species (ROS) production|increase cell senescence	NPA	HCT116	NPA	NPA	NPA
196	23137536	colorectum	colorectal cancer	NPA	miR-337-3p	miR-337-3p	CSNK2A1	1459	NPA	increase reactive oxygen species (ROS) production|increase cell senescence	NPA	HCT116	NPA	NPA	NPA
197	23137536	colorectum	colorectal cancer	NPA	miR-760	miR-760	CSNK2A1	1459	NPA	increase reactive oxygen species (ROS) production|increase cell senescence	NPA	HCT116	NPA	NPA	NPA
198	23135998	lung	lung cancer	NPA	miR-7	miR-7-5p	PIK3R3	8503	TLR9	inhibit cell growth|inhibit metastatic potenial	NPA	NPA	NPA	NPA	tumor-suppressive
199	23135265	NPA	NPA	NPA	miR-378	miR-378-3p	VIM	7431	NPA	promote tumor stem cell properties|increase cell survival|increase colony formation	up-regulated in human cancers	NPA	NPA	human breast carcinoma specimens	NPA
200	23134218	lung	non-small cell lung cancer cell	NPA	let-7a	let-7a-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell invasion	NPA	95D	NPA	NPA	tumor-suppressive
201	23133627	lung	lung cancer	NPA	miR-574-5p	miR-574-5p	FOXN3	1112	TLR9	increase tumor progression	NPA	NPA	NPA	NPA	oncogenic
202	23132946	blood	acute myeloid leukemia with mixed lineage leukemia (MLL) arrangements	NPA	miR-495	miR-495-3p	PBX3|MEIS1	5090|4211	NPA	inhibit MLL-fusion-mediated cell transformation|inhibit leukemogenesis|inhibit cell viability|increase apoptosis	expressed at a lower level in MLL-rearranged AML than in non-MLL-rearranged AML|significantly down-regulated in MLL-rearranged AML samples compared with normal control samples	NPA	NPA	85 human AML and 15 normal control samples	tumor-suppressive
203	23128435	stomach	gastric adenocarcinoma	NPA	miR-125b	miR-125b-5p	NPA	NPA	NPA	increase cell proliferation|inhibit apoptosis	significantly higher in the gastric cancer tissues compared to the adjacent normal tissues	HGC-27	NPA	50 samples of gastric cancer tissues and corresponding para-cancerous tissues	oncogenic
204	23128394	colorectum	colorectal cancer	NPA	miR-143	miR-143-3p	CD44|KLF5|KRAS|BRAF	960|688|3845|673	NPA	decrease cell proliferation|decrease cell migration|decrease chemoresistance	NPA	NPA	NPA	NPA	tumor-suppressive
205	23128394	colorectum	colorectal cancer	NPA	miR-145	miR-145-5p	CD44|KLF5|KRAS|BRAF	960|688|3845|673	NPA	decrease cell proliferation|decrease cell migration|decrease chemoresistance	NPA	NPA	NPA	NPA	tumor-suppressive
206	23125220	head and neck	nasopharyngeal carcinoma	NPA	miR-144	miR-144-3p	PTEN	5728	NPA	increase cell proliferation|increase clonogenicity|increase cell migration|increase cell invasion|increase tumor formation	frequently upregulated in NPC specimens	NPA	NPA	NPC specimens	oncogenic
207	23125021	breast	breast cancer	NPA	miR-10*	miR-10a-3p|miR-10b-3p	BUB1|PLK1|CCNA2	699|5347|890	NPA	inhibit cell proliferation|inhibit tumor growth	downregulated in tumoural samples versus matched peritumoural counterparts	NPA	xenograft mouse	NPA	tumor-suppressive
208	23117485	lung	small cell lung cancer stem-like cells	NPA	miR-27a	miR-27a-3p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell self-renewal|inhibit stem-like cell phenotypes	consistently downregulated in sphere-forming cells	NPA	NPA	NPA	tumor-suppressive
209	23115635	head and neck	head and neck cancer	erlotinib	miR-7	miR-7-5p	EGFR	1956	NPA	inhibit cell growth|increase erlotinib sensitivity	NPA	HN5|FaDu	NPA	NPA	tumor-suppressive
210	23113544	blood	chronic myelogenous leukemia	NPA	miR-29	miR-29a-3p|miR-29b-3p|miR-29c-3p	RNASEL	6041	NPA	inhibit cell proliferation	NPA	K562	xenograft model	NPA	tumor-suppressive
211	23113351	bone and muscle	osteosarcoma	NPA	miR-29a	miR-29a-3p	NPA	NPA	NPA	induce apoptosis	downregulated in most of the osteosarcoma tissues	U2OS|SAOS-2	NPA	30 osteosarcoma tissues	tumor-suppressive
212	23111103	colorectum	colorectal cancer	NPA	miR-429	miR-429	SOX2	6657	NPA	inhibit apoptosis	"up-regulated in human colorectal cancer (CRC) tissues|significantly associated with tumor size, lymph node metastasis and poor prognosis"	HT-29	NPA	NPA	oncogenic
213	23104321	bladder	bladder cancer	NPA	miR-143	miR-143-3p	AKT1	207	NPA	inhibit cell growth	NPA	T24|NKB1|SNK57	NPA	NPA	tumor-suppressive
214	23104321	bladder	bladder cancer	NPA	miR-145	miR-145-5p	ILK	3611	NPA	inhibit cell growth	NPA	T24|NKB1|SNK57	NPA	NPA	tumor-suppressive
215	23104180	blood	multiple myeloma	NPA	miR-15a	miR-15a-5p	VEGFA	7422	NPA	inhibit tumor growth|inhibit angiogenesis	significantly underexpressed in primary MM cells as well as in MM cell lines	NPA	nude mice	bone marrow samples from newly diagnosed MM patients	tumor-suppressive
216	23104180	blood	multiple myeloma	NPA	miR-16	miR-16-5p	VEGFA	7422	NPA	inhibit tumor growth|inhibit angiogenesis	significantly underexpressed in primary MM cells as well as in MM cell lines	NPA	nude mice	bone marrow samples from newly diagnosed MM patients	tumor-suppressive
217	23100393	blood	multiple myeloma	5-azacitidine	miR-29b	miR-29b-3p	DNMT3A|DNMT3B	1788|1789	NPA	inhibit cell cycle progression|inhibit cell growth	NPA	NPA	two clinically relevant murine models of human MM	NPA	tumor-suppressive
218	23100311	blood	acute myeloid leukemia	lenalidomide	miR-181a	miR-181a-5p	NPA	NPA	CEBPA	inhibit tumor growth 	NPA	NPA	xenograft mouse models	NPA	tumor-suppressive
219	23097559	head and neck	nasopharyngeal carcinoma	NPA	miR-18a	miR-18a-5p	DICER1	23405	NPA	promote cell growth|promote cell migration|promote cell invasion	"upregulated in the NPC samples|correlated with NPC advanced stage, lymph node metastasis, Epstein-Barr virus infection and a higher death rate from NPC"	NPA	NPA	nasopharyngeal carcinoma (NPC) samples	oncogenic
220	23093778	brain	glioblastoma	NPA	miR-376*	miR-376a-5p	RAP2A	5911	A-to-I editing	promote cell migration|promote cell invasion	NPA	NPA	xenograft mouse models	NPA	oncogenic
221	23087254	lung	lung cancer	NPA	miR-7515	miR-7515	MET	4233	NPA	decrease cell proliferation|decrease cell migration|decrease cell invasion	down-regulated in lung cancer	NPA	NPA	NPA	tumor-suppressive
222	23087084	liver	hepatocellular carcinoma	NPA	miR-106b	miR-106b-5p	APC	324	NPA	induce cell proliferation|induce anchorage-independent cell growth|promote cell cycle G1/S transition	markedly upregulated in hepatoma cells and hepatoma tissues compared with immortalized normal liver epithelial cells and normal hepatic tissues	NPA	NPA	hepatoma tissues and normal hepatic tissues	oncogenic
223	23085757	NPA	NPA	trichostatin A	miR-181a	miR-181a-5p	HSPA5	3309	NPA	induce apoptosis|increase trichostatin A sensitivity	"down-regulated in prostate, colon and bladder tumors, and human cancer cell lines"	C42B|HCT116|HL-60	NPA	NPA	tumor-suppressive
224	23085757	NPA	NPA	trichostatin A	miR-199a-5p	miR-199a-5p	HSPA5	3309	NPA	induce apoptosis|increase trichostatin A sensitivity	"down-regulated in prostate, colon and bladder tumors, and human cancer cell lines"	C42B|HCT116|HL-60	NPA	NPA	tumor-suppressive
225	23085757	NPA	NPA	trichostatin A	miR-30d	miR-30d-5p	HSPA5	3309	NPA	induce apoptosis|increase trichostatin A sensitivity	"down-regulated in prostate, colon and bladder tumors, and human cancer cell lines"	C42B|HCT116|HL-60	NPA	NPA	tumor-suppressive
226	23085450	breast	breast cancer	adriamycin	miR-34a	miR-34a-5p	NOTCH1	4851	NPA	increase adriamycin sensitivity	NPA	MCF-7	NPA	38 selective breast cancer tissue samples	NPA
227	23079745	liver	hepatocellular carcinoma	5-aza-2'-deoxycytidine	miR-125a-5p	miR-125a-5p	SIRT7	51547	TP53|DNA methlyation	induce cell cycle G phase arrest	NPA	Hep3B|SNU-449	mouse xenograft model	NPA	NPA
228	23079745	liver	hepatocellular carcinoma	5-aza-2'-deoxycytidine	miR-125b	miR-125b-5p	SIRT7	51547	TP53|DNA methlyation	induce cell cycle G phase arrest	NPA	Hep3B|SNU-449	mouse xenograft model	NPA	NPA
229	23079661	blood	MLL-associated leukemia	NPA	miR-150	miR-150-5p	FLT3|MYB	2322|4602	MLL	inhibit cell growth|delay MLL-fusion-mediated leukemogenesis	widely repressed in acute leukemia	NPA	NPA	NPA	tumor-suppressive
230	23079660	blood	aggressive B-Cell lymphoma	NPA	miR-29	miR-29a-3p|miR-29b-3p|miR-29c-3p	NPA	NPA	MYC|HDAC3|EZH2	inhibit tumor growth	NPA	NPA	NPA	NPA	tumor-suppressive
231	23077663	blood	acute myeloid leukemia	NPA	miR-370	miR-370-3p	NF1	4763	NPA	increase cell proliferation|increase colony formation	NPA	NPA	NPA	NPA	oncogenic
232	23077620	brain	malignant glioma	irradiation	miR-21	miR-21-5p	NPA	NPA	NPA	increase radio-resistance|inhibit autophagy	NPA	U373|U87|LN18|LN428	NPA	NPA	NPA
233	23074286	prostate	prostate cancer	NPA	miR-23b	miR-23b-3p	SRC|AKT1	6714|207	promoter DNA hypermethylation	inhibit cell proliferation|inhibit colony formation|inhibit cell migration|inhibit cell invasion|induce cell cycle G0/G1 arrest|induce apoptosis|inhibit epithelial-mesenchymal transition	positively correlated with higher overall and recurrence-free survival in patients with prostate cancer	NPA	nude mice	NPA	tumor-suppressive
234	23073851	lung	lung cancer	NPA	miR-203	miR-203a	BIRC5	332	NPA	inhibit cell proliferation|promote apoptosis|inhibit cell invasion	lower in lung cancer cell lines	A549|HCC827|NCI-H1299|95-D	NPA	NPA	tumor-suppressive
235	23071542	breast	breast cancer	NPA	miR-101	miR-101-3p	STMN1	3925	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion|induce apoptosis	significantly decreased in different subtypes of human breast cancer tissues compared with that in adjacent normal breast tissues	NPA	NPA	different subtypes of human breast cancer tissues	tumor-suppressive
236	23071539	lung	lung cancer	NPA	miR-1297	miR-1297	TRIB2	28951	NPA	inhibit cell proliferation	NPA	A549	NPA	NPA	tumor-suppressive
237	23071539	lung	lung cancer	NPA	miR-511	miR-511-5p	TRIB2	28951	NPA	inhibit cell proliferation	NPA	A549	NPA	NPA	tumor-suppressive
238	23070684	pancreas	pancreatic cancer	NPA	miR-143	miR-143-3p	ARHGEF1|ARHGEF2|KRAS	9138|9181|3845	NPA	inhibit cell migration|inhibit cell invasion|inhibit liver metastasis|inhibit tumor growth	NPA	Panc-1	xenograft Panc-1 tumor model	NPA	tumor-suppressive
239	23069658	prostate	prostate cancer	NPA	miR-124	miR-124-3p	AR	367	DNA hypermethylation	inhibit cell growth	significantly downregulated in malignant prostatic cells compared to benign cells	NPA	NPA	NPA	tumor-suppressive
240	23060440	breast	breast cancer	NPA	miR-140	miR-140-3p	SOX2	6657	ESR1	regulate breast tumor-initiating cell survival	NPA	NPA	NPA	NPA	NPA
241	23060044	prostate	prostate cancer	NPA	miR-153	miR-153-3p	PTEN	5728	NPA	promote cell cycle transition|promote cell proliferation	upregulated in prostate cancers|upregulated expression in four paired prostate tumor/adjacent non-cancerous tissues from the same patients	NPA	NPA	NPA	oncogenic
242	23059786	blood	acute myeloid leukemia	NPA	miR-17	miR-17-5p	CDKN1A|STAT3	1026|6774	HIF1A|MYC	promote HIF-1¦Á-induced differentiation	NPA	NPA	NPA	NPA	NPA
243	23059786	blood	acute myeloid leukemia	NPA	miR-20a	miR-20a-5p	CDKN1A|STAT3	1026|6774	HIF1A|MYC	promote HIF-1¦Á-induced differentiation	NPA	NPA	NPA	NPA	NPA
244	23056576	breast	breast cancer	NPA	miR-122	miR-122-5p	IGF1R	3480	NPA	inhibit cell proliferation|inhibit colony formation|induce cell cycle G1 arrest|reduce tumorigenicity	commonly downregulated in BC specimens and BC cell lines	NPA	NPA	breast cancer specimens	tumor-suppressive
245	23056551	cervix	cervical cancer	NPA	miR-205	miR-205-5p	CYR61|CTGF	3491|1490	NPA	promote cell proliferation|promote cell migration	frequently higher in human cervical cancer than their matched normal tissues	NPA	NPA	human cervical cancer and their matched normal tissues	oncogenic
246	23056431	bladder	bladder cancer	NPA	miR-1280	DEAD_ENTRY	ROCK1	6093	NPA	inhibit cell proliferation|inhibit colony formation|induce cell cycle G2/M transition arrest|induce apoptosis|inhibit cell migration|inhibit cell invasion	significantly down-regulated in bladder cancer cell lines and tumors compared to a non-malignant cell line or normal tissue samples|correlated with the overall survival of patients	NPA	NPA	bladder cancer tumors and normal tissue samples	tumor-suppressive
247	23055531	ovary	ovarian cancer	NPA	miR-498	miR-498	TERT	7015	VDR	inhibit tumor growth	decreased in malignant human ovarian tumors as well as human ovarian cancer cell lines	NPA	mouse tumor models	malignant human ovarian tumors	tumor-suppressive
248	23053883	esophagus	esophageal carcinoma	NPA	miR-451	miR-451a	NPA	NPA	NPA	induce apoptosis|inhibit colony formation|inhibit cell proliferation|inhibit cell invasion|inhibit metastasis	NPA	EC9706	a xenograft model of esophageal cancer	NPA	tumor-suppressive
249	23045278	ovary	ovarian cancer	cisplatin	miR-141	miR-141-3p	KEAP1	9817	NPA	increase cisplatin resistance	higher in non-serous ovarian tumors that did not respond well to therapy	A2780	NPA	132 primary ovarian tumors (108 serous and 24 non-serous)	NPA
250	23042116	nerve	neuroblastoma	NPA	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	MYCN	4613	LIN28B	promote cell differentiation	NPA	NPA	mouse model	NPA	NPA
251	23041061	prostate	prostate cancer	docetaxel	miR-200c	miR-200c-3p	NPA	NPA	NPA	increase adhesion|reduce cell invasion|reduce cell migration	NPA	NPA	NPA	NPA	tumor-suppressive
252	23041061	prostate	prostate cancer	docetaxel	miR-205	miR-205-5p	NPA	NPA	NPA	increase adhesion|reduce cell invasion|reduce cell migration	NPA	NPA	NPA	NPA	tumor-suppressive
253	23036084	lung	lung cancer	ADR|DDP	miR-34a	miR-34a-5p	NPA	NPA	NPA	inhibit cell proliferation|induce cell cycle G1 arrest	NPA	A549|SBC-5	NPA	NPA	tumor-suppressive
254	23034333	brain	mesenchymal subtype of glioblastoma multiforme	NPA	miR-10b	miR-10b-5p	NPA	NPA	NPA	increase cell invasion|increase angiogenesis|inhibit apoptosis	NPA	NPA	glioma-bearing mice	NPA	oncogenic
255	23032974	breast	breast cancer	NPA	miR-34a	miR-34a-5p	NPA	NPA	NPA	inhibit cell growth|inhibit cell migration|inhibit cell invasion	"downregulated in breast cancer cell lines and tissues, compared with normal cell lines and the adjacent nontumor tissues"	NPA	an orthotopic mouse model of breast cancer	NPA	tumor-suppressive
256	23029364	brain	glioblastoma	NPA	miR-330	miR-330-5p	SH3GL2	6456	NPA	promote cell proliferation|promote cell migration|promote cell invasion|activate cell cycle|inhibit apoptosis	NPA	U87|U251	NPA	NPA	oncogenic
257	23029264	prostate	prostate cancer	NPA	miR-370	miR-370-3p	FOXO1	2308	NPA	increase cell proliferation|increase anchorage-independent cell growth|increase colony formation|promote cell cycle G1/S transition	"significantly upregulated in five prostate cancer cell lines, compared to normal prostatic epithelial (PrEC) cells"	DU145|LNCaP	NPA	NPA	oncogenic
258	23023426	esophagus	esophageal squamous cell carcinoma	NPA	miR-210	miR-210-3p	FGFRL1	53834	NPA	inhibit cell survival|inhibit cell proliferation	downregulated in ESCC and derived cell lines|decreased in poorly differentiated carcinomas	NPA	NPA	NPA	tumor-suppressive
259	23019365	brain	glioma	NPA	miR-23a	miR-23a-3p	PTEN	5728	CREB1	promote cell growth|promote cell survival	NPA	NPA	NPA	NPA	oncogenic
260	23019226	breast	breast cancer	NPA	miR-128	miR-128-3p	BMI1|CSF1|KLF4|LIN28A|NANOG|SNAI1	648|1435|9314|79727|79923|6615	SNAI1|TGFB1	inhibit incogenic transformation|inhibit stem-like phenotypes	frequently downregulated along with ARPP21 in breast cancer|negatively associated with clinicopathologic characteristics and survival outcome	NPA	NPA	NPA	tumor-suppressive
261	23017832	colorectum	colorectal cancer	NPA	miR-135a	miR-135a-5p	MTSS1	9788	NPA	increase cell proliferation|increase cell invasion	higher in human CRC samples than in non-tumor control tissue	SW480|SW620	NPA	human CRC samples and non-tumor control tissues	oncogenic
262	23013439	stomach	gastric cancer	NPA	miR-101	miR-101-3p	COX2	5743	NPA	inhibit cell proliferation|induce apoptosis|inhibit tumor growth	significantly lower in gastric cancer tissues than those in the matched normal tissue|negatively associated with increased tumor invasion and lymph node metastasis	NPA	NPA	gastric cancer tissues and the matched normal tissues	tumor-suppressive
263	23013135	esophagus	esophageal squamous cell carcinoma	NPA	miR-150	miR-150-5p	ZEB1	6935	NPA	inhibit epithelial-mesenchymal-transition|inhibit tumor growth	"significantly lower in cancer tissues compared to adjacent non-cancerous tissues|negatively correlated with tumor depth, lymph node metastasis, lymphatic invasion, venous invasion, clinical staging, and poor prognosis"	TE-8	a mouse xenograft model	108 curative resected ESCC samples	tumor-suppressive
264	23012423	lung	non-small cell lung cancer	NPA	miR-494	miR-494-3p	BCL2L11	10018	MAPK3|MAPK1	NPA	NPA	NPA	NPA	NPA	NPA
265	23010597	lung	non-small cell lung cancer	NPA	miR-134	miR-134-5p	FOXM1	2305	NPA	inhibit epithelial-to-mesenchymal transition	NPA	A549	NPA	NPA	tumor-suppressive
266	23006329	brain	glioma	NPA	miR-182	miR-182-5p	CYLD	1540	TGFB1	NPA	overexpressed in a different set of gliomas	NPA	NPA	glioma samples	NPA
267	23001726	stomach	gastric cancer	celecoxib	miR-29c	miR-29c-3p	MCL1	4170	NPA	induce apoptosis	significantly downregulated in gastric cancer tissues relative to nontumor gastric mucosae|negatively associated with progression of gastric cancer|more downregulated in advanced gastric cancers than in gastric adenomas and early gastric cancer	NPA	NPA	"53 gastric tumors including gastric adenomas (atypical epithelia), early gastric cancers and advanced gastric cancers"	tumor-suppressive
268	23001407	pancreas	pancreatic cancer	gemcitabine	miR-17-5p	miR-17-5p	BCL2L11	10018	NPA	increase cell growth|inhibit apoptosis|decrease chemosensitivity to gemcitabine	NPA	Panc-1|BxPC3	NPA	NPA	oncogenic
269	23001043	breast	breast cancer metastasis	NPA	miR-34a	miR-34a-5p	FOSL1	8061	NPA	inhibit cell migration|inhibit cell invasion	significantly decreased in metastatic breast cancer cells and human primary breast tumors with lymph node metastases	NPA	NPA	metastatic breast cancer cells and human primary breast tumors	tumor-suppressive
270	23001043	breast	breast cancer metastasis	NPA	miR-34c	miR-34c-5p	FOSL1	8061	NPA	inhibit cell migration|inhibit cell invasion	significantly decreased in metastatic breast cancer cells and human primary breast tumors with lymph node metastases	NPA	NPA	metastatic breast cancer cells and human primary breast tumors	tumor-suppressive
271	22999819	brain	glioma stem cells	NPA	miR-125b	miR-125b-5p	E2F2	1870	NPA	inhibit cell proliferation	significantly down-regulated in CD133 positive glioma stem cells	NPA	NPA	NPA	tumor-suppressive
272	22996741	lung	lung cancer	cisplatin	miR-155	miR-155-5p	APAF1	317	NPA	decrease sensitivity to cisplate|decrease apoptosis|decrease DNA damage	significantly higher in lung cancer tissues than in paracancerous and normal tissues	A549	NPA	"lung cancer tissues, paracancerous and normal tissues"	NPA
273	22995304	bone and muscle	myxoid liposarcoma	NPA	miR-486	miR-486-5p	SERPINE1	5054	TLS-CHOP	inhibit cell growth	NPA	NPA	NPA	NPA	tumor-suppressive
274	22995297	head and neck	laryngeal squamous cell carcinoma	NPA	miR-1297	miR-1297	PTEN	5728	NPA	promote cell proliferation|promote cell migration|promote tumorgenesis	overexpressed in laryngeal squamous cell carcinomas	Hep-2	NPA	NPA	oncogenic
275	22992343	stomach	gastric cancer	NPA	miR-146a	miR-146a-5p	CARD10|COPS8	29775|10920	lysophosphatidic acid	inhibit NF-kB signaling	up-regulated in 73% of investigated human gastric adenocarcinomas	NPA	mouse model	human gastric adenocarcinomas	NPA
276	22989374	liver	hepatocellular carcinoma	NPA	miR-224	miR-224-5p	NPA	NPA	NPA	promote cell proliferation|promote cell migration|inhibit apoptosis	"the most significantly upregulated in HCC tissues, compared with normal and HCC adjacent non-tumorous liver tissues"	Hek293|Huh7	NPA	"HCC tissues (n?=?18), normal (n?=?9) and HCC adjacent non-tumorous liver tissues (n?=?18)"	oncogenic
277	22986525	prostate	prostate cancer	NPA	miR-106b	miR-106b-5p	CASP7	840	NPA	increase cell adhesion|promote cell growth	NPA	LNCaP|DU145|22Rv1	NPA	NPA	oncogenic
278	22983985	colorectum	colorectal cancer	3-acetyl-11-keto-¦Â-boswellic acid (AKBA)	let-7i	let-7i-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion	NPA	NPA	CRC tumors orthotopically implanted in nude mice	NPA	tumor-suppressive
279	22983984	colorectum	colorectal cancer	rapamycin	miR-144	miR-144-3p	MTOR	2475	NPA	inhibit cell proliferation	"negatively associated with enhanced malignant potential such as venous invasion (P = 0.0013), liver metastasis (P = 0.08), liver recurrence (P = 0.0058) and poor prognosis (P = 0.0041)"	HT29	NPA	137 CRC	tumor-suppressive
280	22983447	blood	multiple myeloma	MLN9708/2238	miR-33b	miR-33b-5p	PIM1	5292	NPA	decrease cell vaibility|decrease cell migration|decrease colony formation|induce apoptosis|increase MNL2238 sensitivity|inhibit tumor growth	constitutively lowly expressed patient MM cells	NPA	NPA	NPA	tumor-suppressive
281	22982443	skin	melanoma	NPA	miR-200c	miR-200c-3p	BMI1	648	NPA	decrease cell proliferation|decrease cell migration|decrease drug resistance|inhibit tumor growth|inhibit metastasis	down-regulated in melanomas (primary and metastatic) compared with melanocytic nevi	NPA	melanoma xenograft	NPA	tumor-suppressive
282	22982144	brain	glioma stem cells	5-aza	miR-23b	miR-23b-3p	NPA	NPA	DNA hypermethylation	induce cell cycle arrest|inhibit cell proliferation	markedly reduced in GSCs	U87	NPA	NPA	tumor-suppressive
283	22981979	breast	breast cancer	NPA	miR-519b	miR-519b-3p	TACR1	6869	NPA	inhibit tumor growth	NPA	T47D|MDA-MB-231	MDA-MB-231 nude BALB/c	NPA	tumor-suppressive
284	22977606	lung	lung cancer	NPA	miR-101	miR-101-3p	EZH2	2146	NPA	inhibit cell invasion	down-regulated in lung cancer	NPA	NPA	NPA	tumor-suppressive
285	22975373	liver	HBV+ hepatocellular carcinoma	NPA	miR-34a	miR-34a-5p	CCL22	6367	TGFB1	inhibit portal vein tumor thrombus (PVTT)	NPA	NPA	NPA	NPA	NPA
286	22971574	stomach	gastric cancer	NPA	miR-181a	miR-181a-5p	MTMR3	8897	NPA	NPA	significantly upregulated in GC tissues	NPA	NPA	gastic cancer tissues	NPA
287	22969930	colorectum	colorectal cancer	NPA	miR-194	miR-194-5p	NPA	NPA	NPA	inhibit cell proliferation	"significantly downregulated in CRC tissues (all p<0.001, paired t-test) and cancer cell lines (all p<0.05) compared to non-tumor counterparts|associated with increased tumor sizes"	HCT116	NPA	107 colorectal cancer tissues	tumor-suppressive
288	22969914	breast	breast cancer	NPA	miR-497	miR-497-5p	BCL2L2	599	NPA	inhibit cell growth|induce apoptosis|induce cell cycle G0/G1 arrest	"relatively decreased in breast cancer specimens|negatively correlated with TNM stage, lymphatic metastasis, tumor size and human epidermal growth factor receptor-2"	MCF-7	NPA	breast cancer and normal breast tissues	tumor-suppressive
289	22969861	lung	non-small cell lung cancer	NPA	miR-99b	miR-99b-5p	FGFR3	2261	NPA	NPA	downregulated in patients with lung cancer	NPA	NPA	NPA	tumor-suppressive
290	22969266	eye	retinoblastoma	NPA	miR-17~92	CLUSTER:miR-17~92	NPA	NPA	EPCAM	increase cell viability|increase cell invasion	highly expressed in retinoblastomas (25 to 220 fold)	Y79	NPA	primary RB tumors	oncogenic
291	22967897	brain	glioma	NPA	miR-136	miR-136-5p	MTDH|BCL2	92140|596	NPa	promote apoptosis induced by chemotherapy	downregulated in human glioma	NPA	NPA	NPA	tumor-suppressive
292	22965940	thyroid	thyroid follicular adenoma and carcinoma	NPA	let-7a	let-7a-5p	FXYD5	53827	NPA	induce epithelial-like phenotype|increase cell adhesion|inhibit cell migratioon	down-regulation in thyroid follicular adenomas compared to normal thyroid|significantly higher down-regulated in follicular carcinomas	WRO	NPA	"10 human thyroid follicular adenomas, 10 normal thyroid tissues and follicular carcinomas"	tumor-suppressive
293	22964640	blood	acute myeloid leukemia	all-trans-retinoic acid (ATRA)	let-7c	let-7c-5p	PBX2	5088	NPA	promote granulocytic differentiation	down-regulated in PML/RAR¦Á-positive blasts from acute promyelocytic leukemia (APL) patients than normal promyelocytes	NPA	NPA	acute promyelocytic leukemia (APL) blasts	NPA
294	22964638	brain	glioma	tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)	miR-21	miR-21-5p	CASP3|TP63	836|8626	NPA	increase TRAIL resistance	NPA	NPA	NPA	NPA	NPA
295	22964638	brain	glioma	tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)	miR-30b	miR-30b-5p	CASP3|TP63	836|8626	NPA	increase TRAIL resistance	NPA	NPA	NPA	NPA	NPA
296	22964638	brain	glioma	tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)	miR-30c	miR-30c-5p	CASP3|TP63	836|8626	NPA	increase TRAIL resistance	NPA	NPA	NPA	NPA	NPA
297	22964582	lung	lung cancer	NPA	miR-34	miR-34a-5p|miR-34b-5p|miR-34c-5p	NPA	NPA	p53	reduce cell proliferation|reduce cell invasion|prevented tumor formation and progression	NPA	NPA	Kras(LSL-G12D)(/+);Trp53(LSL-R172H)(/+) mice lung cancer model	NPA	tumor-suppressive
298	22963810	liver	hepatocellular carcinoma	NPA	miR-1	miR-1	EDN1	1906	NPA	inhibit cell proliferation	reduced both in human liver cancer tissues and in hepatoma cell lines	HepG2|Hep3B	NPA	human liver cancer tissues	tumor-suppressive
299	22962603	liver	hepatocellular carcinoma	NPA	miR-214	miR-214-3p	EZH2|CTNNB1	2146|1499	NPA	inhibit cell growth|inhibit tumorigenicity|inhibit EpCAM(+) stem-like cells	suppressed in HCCs|significantly more suppressed in samples from HCC patients with early recurrent disease compared those from patients with no recurrence	NPA	NPA	20 paired tumor and non-tumor liver tissues of HCC patients and 10 histologically normal liver tissues from colorectal cancer patients with liver metastases|50 HCC tissues from an independent cohort of HCC patients of whom 29 with early recurrent disease (<2 years) and 21 with late recurrent disease	tumor-suppressive
300	22962263	NPA	NPA	hypoxia	miR-210	miR-210-3p	PTPN1|HOXA1|TP53I11	5770|3198|9537	NPA	promote immune escape	NPA	NPA	NPA	NPA	NPA
301	22958893	esophagus	esophageal squamous cell carcinoma	NPA	miR-518b	miR-518b	RAP1B	5908	NPA	inhibit cell proliferation|induce apoptosis|inhibit cell invasion	down-regulated in esophageal squamous cell carcinoma (ESCC) tissues|correlated with metastasis and survival	NPA	NPA	esophageal squamous cell carcinoma (ESCC) tissues	tumor-suppressive
302	22956424	lung	non-small cell lung cancer	NPA	miR-21	miR-21-5p	PTEN	5728	NPA	promote cell growth|promote cell invasion|enhance chemo- or radioresistance	upregulated in NSCLC cell lines and tissues	A549	NPA	NPA	oncogenic
303	22955854	stomach	gastric cancer	NPA	miR-144	miR-144-3p	ZFX	7543	NPA	increae 5-fu sensitivity	"downregulated in stage IV GC patients with respect to stage I GC patients (t-test, P=0.02)"	NPA	NPA	93 cases of primary GCs|stage IV GC patients and stage I GC patients	NPA
304	22952996	NPA	NPA	ergosterol peroxide	miR-378	miR-378-3p	NPA	NPA	NPA	increase cell survival|increase colony formation|increase multiple drug resistance	NPA	NPA	NPA	NPA	NPA
305	22952885	breast	breast cancer	NPA	miR-19a	miR-19a-3p	IMPDH1|NPEPL1	3614|79716	NPA	NPA	NPA	MCF-7	NPA	NPA	NPA
306	22949650	prostate	prostate cancer	NPA	miR-205	miR-205-5p	ZEB1|VIM	6935|7431	TP63|mutant TP53	inhibit epithelial-mesenchymal transition|inhibit cell migration|inhibit lung metastasis	"associated with higher Gleason scores, an increased likelihood of metastatic and infiltration events, and worse prognosis"	NPA	a mouse tail vein model	218 human prostate cancer samples|an independent clinical data set of 281 patients	tumor-suppressive
307	22949171	brain	brain metastasis	NPA	miR-146a	miR-146a-5p	NPA	NPA	NPA	inhibit cell migration|inhibit cell invasion	almost undetectable in LvBr2 cells and highly expressed in the parental cells	NPA	left ventricle (LV) injection of MDA-MB-435 cells into immunodeficiency (NOD/SCID) mice	NPA	tumor-suppressive
308	22948942	prostate	bone metastasis of prostate cancer	NPA	miR-143	miR-143-3p	NPA	NPA	NPA	inhibit cell viability|inhibit colony formation|inhibit tumor sphere formation|inhibit bone invasion	NPA	PC-3	NPA	NPA	tumor-suppressive
309	22948942	prostate	bone metastasis of prostate cancer	NPA	miR-145	miR-145-5p	NPA	NPA	NPA	inhibit cell viability|inhibit colony formation|inhibit tumor sphere formation|inhibit bone invasion	NPA	PC-3	NPA	NPA	tumor-suppressive
310	22948084	skin	melanoma	NPA	miR-31	miR-31-5p	EZH2	2146	EZH2|DNA hypermethylation|EZH2-mediated histone methylation|chromosome 9p21 deletion	inhibit cell migration|inhibit cell invasion	downregulated in melanoma tumors and cell lines	NPA	NPA	NPA	tumor-suppressive
311	22943841	pancreas	pancreatic ductal adenocarcinoma	NPA	miR-101	miR-101-3p	NPA	NPA	NPA	inhibit tumor growth	decreased in pancreatic ductal adenocarcinomas|significantly associated with poor prognosis	PANC-1	SCID mice	archival pancreatic ductal adenocarcinoma tissues	tumor-suppressive
312	22942733	liver	hepatocellular carcinoma	NPA	miR-125b	miR-125b-5p	MCL1|IL6R	4170|3570	NPA	reduce cell proliferation|inhibit cell cycle progression	down-regulated in hepatocellular carcinoma (HCC) tissues	NPA	NPA	hepatocellular carcinoma (HCC) tissues	tumor-suppressive
313	22940702	esophagus	esophageal squamous cell carcinoma	NPA	miR-203	miR-203a	LASP1	3927	NPA	inhibit cell migration|inhibit cell invasion	remarkably downregulated in esophageal squamous cell carcinoma (ESCC) tissues is than that in non-ESCC tissues|significantly correlated with relapse-free survival	NPA	NPA	clinical ESCC specimens	tumor-suppressive
314	22940133	liver	hepatocellular carcinoma	NPA	miR-124	miR-124-3p	PIK3CA	5290	NPA	inhibit cell proliferation|indcue cell cycle G1 arrest|inhibit tumor growth	NPA	HepG2	xenograft model	NPA	tumor-suppressive
315	22935141	breast	breast cancer	NPA	miR-148a	miR-148a-3p	DNMT1|IGF1R|IRS1	1786|3480|3667	DNMT1|DNA hypermethylation	inhibit cell proliferation|inhibit colony formation|inhibit angiogenesis|inhibit AKT and MAPK/ERK signaling	decreased in breast cancer tissues and cell lines	NPA	NPA	breast cancer tissues	tumor-suppressive
316	22935141	breast	breast cancer	NPA	miR-152	miR-152-3p	DNMT1|IGF1R|IRS1	1786|3480|3667	DNMT1|DNA hypermethylation	inhibit cell proliferation|inhibit colony formation|inhibit angiogenesis|inhibit AKT and MAPK/ERK signaling	decreased in breast cancer tissues and cell lines	NPA	NPA	breast cancer tissues	tumor-suppressive
317	22934698	stomach	gastric cancer	NPA	miR-544	miR-544a	IRX1	79192	NPA	promote cell proliferation|promote cell cycle progression	NPA	NPA	NPA	NPA	oncogenic
318	22930392	colorectum	colon cancer	NPA	miR-101	miR-101-3p	NPA	NPA	NPA	inhibit cell growth|inhibit hypoxic survival|inhibit cell invasion|promote Wnt/¦Â-catenin signalling	"downregulated in CRC specimens, depending on tumour grade"	NPA	NPA	CRC specimens	tumor-suppressive
319	22929890	lung	non-small cell lung cancer	radiation|chemotherapy	miR-214	miR-214-3p	NPA	NPA	NPA	increase radio/chemotherapy resistance	upregulated in RT-resistant NSCLC cells	NPA	NPA	NPA	NPA
320	22928040	prostate	prostate cancer	genistein	miR-151	miR-151a-5p	CASZ1|IL1RAPL1|SOX17|N4BP1|ARHGDIA	54897|11141|64321|9683|396	NPA	NPA	NPA	PC3|DU145|RWPE-1	NPA	NPA	oncogenic
321	22927992	skin	melanoma	NPA	miR-16	miR-16-5p	NPA	NPA	NPA	inhibit cell proliferation|decrease cell viability	NPA	A375	NPA	NPA	tumor-suppressive
322	22927992	skin	melanoma	NPA	miR-182	miR-182-5p	NPA	NPA	NPA	inhibit cell proliferation|decrease cell viability	NPA	A375	NPA	NPA	tumor-suppressive
323	22927992	skin	melanoma	NPA	miR-497	miR-497-5p	NPA	NPA	NPA	inhibit cell proliferation|decrease cell viability	NPA	A375	NPA	NPA	tumor-suppressive
324	22927992	skin	melanoma	NPA	miR-96	miR-96-5p	NPA	NPA	NPA	inhibit cell proliferation|decrease cell viability	NPA	A375	NPA	NPA	tumor-suppressive
325	22927443	ovary	ovarian cancer	NPA	miR-214	miR-214-3p	TP53	7157	NPA	increase cancer stem cell population|promote self-renewal	NPA	NPA	NPA	NPA	NPA
326	22923518	liver	hepatocellular carcinoma	NPA	miR-101	miR-101-3p	NPA	NPA	NPA	inhibit cell proliferation|inhibit colony formation	differentially expressed between HCC samples and growth-arrested HepG2 cells	HepG2	NPA	HCC samples	tumor-suppressive
327	22922800	bone and muscle	osteosarcoma	NPA	miR-183	miR-183-5p	EZR	7430	NPA	inhibit cell motility|inhibit cell invasion	NPA	NPA	NPA	NPA	tumor-suppressive
328	22921398	brain	glioma	NPA	miR-138	miR-138-5p	NPA	NPA	NPA	promote tumorsphere formation|increase tumorigenesis	highly expressed in glioma stem cells compared to non-neoplastic tissues|associated with tumor recurrence and survival	NPA	NPA	NPA	oncogenic
329	22912877	colorectum	colorectal cancer	NPA	miR-106a	miR-106a-5p	TGFBR2	7048	NPA	promote cell migration|promote cell invasion	highly expressed in metastatic CRC cells|correlated with clinical cancer progression in primary CRCs	NPA	NPA	primary CRCs	oncogenic
330	22911661	breast	breast cancer	NPA	miR-24-2*	miR-24-2-5p	PRKCA	5578	NPA	reduce cell survival|decrease tumorigenicity	NPA	MCF-7	NPA	NPA	tumor-suppressive
331	22908280	breast	breast cancer stem-like cells	NPA	miR-107	miR-107	SUZ12	23512	ZEB1|ZEB2	inhibit cancer stem cell growth	down-regulated in cancer stem-like cells (CSCs)	NPA	NPA	triple-negative breast cancer patients	tumor-suppressive
332	22908280	breast	breast cancer stem-like cells	NPA	miR-128b	miR-128-3p	BMI1	648	ZEB1|ZEB2	inhibit cancer stem cell growth	down-regulated in cancer stem-like cells (CSCs)	NPA	NPA	triple-negative breast cancer patients	tumor-suppressive
333	22908280	breast	breast cancer stem-like cells	NPA	miR-145	miR-145-5p	ZEB2|KLF4	9839|9314	ZEB1|ZEB2	inhibit cancer stem cell growth	down-regulated in cancer stem-like cells (CSCs)	NPA	NPA	triple-negative breast cancer patients	tumor-suppressive
334	22908280	breast	breast cancer stem-like cells	NPA	miR-15b	miR-15b-5p	SUZ12	23512	ZEB1|ZEB2	inhibit cancer stem cell growth	down-regulated in cancer stem-like cells (CSCs)	NPA	NPA	triple-negative breast cancer patients	tumor-suppressive
335	22908280	breast	breast cancer stem-like cells	NPA	miR-200b	miR-200b-3p	BMI1|SUZ12|ZEB1|ZEB2|KLF4	648|23512|6935|9839|9314	ZEB1|ZEB2	inhibit cancer stem cell growth	down-regulated in cancer stem-like cells (CSCs)	NPA	NPA	triple-negative breast cancer patients	tumor-suppressive
336	22908221	prostate	prostate cancer	NPA	miR-331-3p	miR-331-3p	DOHH	83475	NPA	inhibit cell proliferation	underexpressed in several prostate cancer cell lines compared with normal prostate epithelial cells	DU145	NPA	NPA	tumor-suppressive
337	22908221	prostate	prostate cancer	NPA	miR-642-5p	miR-642-5p	DOHH	83475	NPA	inhibit cell proliferation	underexpressed in several prostate cancer cell lines compared with normal prostate epithelial cells	DU145	NPA	NPA	tumor-suppressive
338	22907300	breast	breast cancer	NPA	miR-129	miR-129-5p	NPA	NPA	NPA	inhibit cell migration|inhibit cell mobility	down-regulated both in breast cancer tissues compared with the paired adjacent normal breast tissues	MDA-MB-231|BT549|MDA-MB-435|MCF10A	NPA	breast cancer tissues and the paired adjacent normal breast tissues	tumor-suppressive
339	22901205	stomach	gastric cancer	Helicobacter pylori	miR-181b	miR-181b-5p	NPA	NPA	NPA	increase cell proliferation|increase cell migration|increase cell invasion|induce apoptosis	aberrantly overexpressed in gastric cancer cells and primary gastric cancer tissues	NPA	NPA	primary gastric cancer tissues	oncogenic
340	22900072	lung	non-small cell lung cancer	NPA	miR-126	miR-126-3p	PIK3R2	5296	NPA	decrease cell proliferation|inhibit tumor growth	decreased in NSCLC lines and tumor tissues	NPA	nude mouse xenograft model	tumor tissues	tumor-suppressive
341	22898998	liver	hepatocellular carcinoma	NPA	miR-140	miR-140-3p	DNMT1	1786	NPA	inhibit hepatocarcinogenesis	NPA	NPA	miRNA-140-knockout mice	NPA	tumor-suppressive
342	22896707	NPA	NPA	NPA	miR-210	miR-210-3p	ISCU|TFRC	23479|7037	HIF1A	increase cell proliferation|promote cell survival	NPA	NPA	xenografted tumors	NPA	oncogenic
343	22895557	colorectum	colorectal cancer	NPA	miR-124	miR-124-3p	NPA	NPA	NPA	inhibit cell growth|inhibit Warburg effect	associated with poor prognosis of colorectal cancer	NPA	NPA	NPA	tumor-suppressive
344	22895557	colorectum	colorectal cancer	NPA	miR-137	miR-137	NPA	NPA	NPA	inhibit cell growth|inhibit Warburg effect	associated with poor prognosis of colorectal cancer	NPA	NPA	NPA	tumor-suppressive
345	22895557	colorectum	colorectal cancer	NPA	miR-340	miR-340-5p	NPA	NPA	NPA	inhibit cell growth|inhibit Warburg effect	associated with poor prognosis of colorectal cancer	NPA	NPA	NPA	tumor-suppressive
346	22892391	nerve	neuroblastoma	cisplatin|etoposide	miR-204	miR-204-5p	BCL2|NTRK2	596|4915	NPA	increase cisplatin and etoposide resistance	expressions in primary neuroblastoma tumours correlated with patient event-free and overall survival	NPA	NPA	primary neuroblastoma tumours	NPA
347	22888524	liver	hepatocellular carcinoma	5-FU	miR-195	miR-195-5p	LATS2	26524	NPA	increase apoptosis	downregulated in resistant BEL-7402/5-FU cells	BEL-7402	NPA	NPA	tumor-suppressive
348	22885155	lung	lung cancer	NPA	miR-26a	miR-26a-5p	PTEN	5728	NPA	enhance cell migration|enhance cell invasion	higher in lymph node metastasis tumor tissues than in primary tumor tissues	NPA	NPA	lymph node metastasis tumor tissues and primary tumor tissues	oncogenic
349	22883469	lung	non-small cell lung cancer	NPA	miR-133b	miR-133b	EGFR	1956	NPA	inhibit cell growth	NPA	NPA	NPA	NPA	tumor-suppressive
350	22876840	lung	non-small cell lung cancer	NPA	miR-196a	miR-196a-5p	HOXA5	3202	NPA	increase cell proliferation|increase cell invasion	highly expressed both in NSCLC samples and cell lines	A549	NPA	34 NSCLC tissues	oncogenic
351	22876288	breast	breast cancer	NPA	miR-7	miR-7-5p	PTK2	5747	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion|inhibit epithelial-mesenchymal transition	decreased in malignant versus normal breast tissue|inversely correlated with metastasis in human breast cancer patients	HBL-100	breast cancer xenografts	malignant and normal breast tissues	tumor-suppressive
352	22876037	liver	hilar cholangiocarcinoma	NPA	miR-373	miR-373-3p	MBD2	8932	MBD2|DNA hypermethylation	NPA	"decreased in cancer tissues|closely associated with poor cell differentiation, advanced clinical stage, and shorter survival"	NPA	NPA	NPA	NPA
353	22871741	NPA	NPA	NPA	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	HAS2	3037	NPA	inhibit cell survival|inhibit cell invasion|inhibit cell adhesion	NPA	MT-1|HeLa	NPA	NPA	tumor-suppressive
354	22871739	skin	melanoma	NPA	miR-205	miR-205-5p	BCL2|ABCA2|ABCA5	596|20|23461	TP73	reduce drug resistance|induce apoptosis|inhibit tumor growth	NPA	NPA	NPA	NPA	tumor-suppressive
355	22871495	brain	glioma	NPA	miR-524-5p	miR-524-5p	JAG1|HES1	182|3280	NPA	inhibit cell proliferation|inhibit cell invasion	downregulated in tumors|associated with the pathological grade and overall survival of gliomas	NPA	NPA	glioma samples	tumor-suppressive
356	22869146	prostate	prostate cancer	NPA	miR-205	miR-205-5p	MED1	5469	DNA hypermethylation	inhibit cell viability	NPA	NPA	NPA	"primary tumor samples (n=14) and matched normal prostate (n=7)|an expanded patient cohort (tumor n=149, matched normal n=30)"	tumor-suppressive
357	22865282	liver	hepatocellular carcinoma	NPA	miR-1271	miR-1271-5p	GPC3	2719	NPA	inhibit cell growth|induce cell death	down-regulated in HCC tumor samples|inversely correlates with GPC3 mRNA expression in a particular subgroup of HCC	HuH7	NPA	21 non-tumoral liver and 112 HCC samples	tumor-suppressive
358	22864815	breast	breast cancer	NPA	miR-29b	miR-29b-3p	C1QTNF6|SPARC|COL4A2	114904|6678|1284	NPA	promote cell invasion	NPA	MCF-7	NPA	NPA	oncogenic
359	22864477	eye	retinoblastoma	NPA	miR-17	miR-17-5p	NPA	NPA	NPA	promote cell viability|promote tumor formation	NPA	NPA	mice	NPA	oncogenic
360	22864477	eye	retinoblastoma	NPA	miR-20a	miR-20a-5p	NPA	NPA	NPA	promote cell viability|promote tumor formation	NPA	NPA	mice	NPA	oncogenic
361	22854542	prostate	prostate cancer	NPA	miR-222	miR-222-3p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell invasion|inhibit cell migration	downregulated in prostate cancer tissues	PC3|DU145	NPA	15 PCa tissues and 17 non-PCa tissues	tumor-suppressive
362	22854542	prostate	prostate cancer	NPA	miR-31	miR-31-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell invasion|inhibit cell migration	downregulated in prostate cancer tissues	PC3|DU145	NPA	15 PCa tissues and 17 non-PCa tissues	tumor-suppressive
363	22854067	head and neck	oral squamous cell carcinoma	NPA	miR-31*	miR-31-3p	RHOA	387	NPA	decrease cell proliferation|decrease cell migration	up-regulated in OSCC tissues	SAS|Fadu 	NPA	oral squamous cell carcinoma tissues	tumor-suppressive
364	22850877	NPA	NPA	NPA	miR-34a	miR-34a-5p	ARHGAP1	392	ZEB1	decrease cell invasion|decrease metastasis|inhibit the formation of promigratory cytoskeletal structures	NPA	NPA	NPA	NPA	tumor-suppressive
365	22849325	colorectum	colorectal cancer	NPA	miR-16	miR-16-5p	CDX2	1045	NPA	NPA	NPA	SW480	NPA	NPA	NPA
366	22849325	colorectum	colorectal cancer	NPA	miR-9	miR-9-5p	CDX2	1045	NPA	NPA	NPA	SW480	NPA	NPA	NPA
367	22847613	uterus	endometrial cancer	NPA	miR-130b	miR-130b-3p	NPA	NPA	p53 mutant	inhibit epithelial-mesenchymal transition	significantly reduced in endometrial cancer tissues|correlated with survival time	NPA	NPA	endometrial cancer tissues	tumor-suppressive
368	22847191	breast	breast cancer	NPA	miR-10b	miR-10b-5p	CDH1	51343	NPA	promote cell invasion	uniquely up-regulated in metastatic cancers	MDA-MB-231	NPA	"benign breast lesions (N=16), primary breast cancers (N=21), and metastatic breast carcinomas (N=23)"	oncogenic
369	22846564	liver	hepatocellular carcinoma	cisplatin	miR-130a	miR-130a-3p	RUNX3	864	NPA	promote cisplatin resistance|activate Wnt/¦Â-catenin signaling	significantly increased in HCC patients treated with cisplatin-based chemotherapy	Huh7	NPA	HCC tissues	oncogenic
370	22843616	blood	non-Hodgkin's lymphoma	radiation	miR-148b	miR-148b-3p	NPA	NPA	NPA	inhibit cell proliferation|increase radition sensitivity|induce apoptosis	NPA	Raji	NPA	NPA	tumor-suppressive
371	22842456	blood	chronic myelogenous leukemia	imatinib	miR-144	miR-144-3p	NPA	NPA	MYC	increase imatinib sensitivity	NPA	K562|K562R	NPA	NPA	NPA
372	22842456	blood	chronic myelogenous leukemia	imatinib	miR-451	miR-451a	NPA	NPA	MYC	increase imatinib sensitivity	NPA	K562|K562R	NPA	NPA	NPA
373	22836756	NPA	NPA	NPA	miR-21	miR-21-5p	SOD3|TNFA	6649|7124	NPA	promote tumorigenesis|regulate reactive oxygen species (ROS)	NPA	NPA	NPA	NPA	oncogenic
374	22829924	breast	HER2+ breast cancer	trastuzumab	miR-194	miR-194-5p	TLN2	83660	NPA	slightly inhibit cell proliferation|inhibit cell migration|inhibit cell invasion	NPA	SKBr3|BT474	NPA	NPA	tumor-suppressive
375	22825752	skin	melanoma	NPA	miR-9	miR-9-5p	NFKB1	4790	NPA	inhibit cell migration|inhibit cell invasion	significantly reduced in highly invasive uveal melanoma cell lines	NPA	NPA	NPA	tumor-suppressive
376	22824797	liver	hepatocellular carcinoma	NPA	miR-125b	miR-125b-5p	MCL1|BCL2L2|IL6R	4170|599|3570	NPA	increase apoptosis	frequently downregulated in hepatocellular carcinoma (HCC) tissues|positively associated with the rate of apoptosis in HCC tissues	NPA	NPA	hepatocellular carcinoma (HCC) tissues	tumor-suppressive
377	22821729	colorectum	colorectal cancer	5-aza-2'-deoxycytidine	miR-149	miR-149-5p	SP1	6667	CpGi DNA hypermethylation	inhibit cell growth|inhibit cell invasion	"markedly reduced in 51.6% of the CRC tissues compared with matched non-cancerous tissues|negatively associated with a greater depth of invasion (p = 0.012), lower 5-year survival rate (p = 0.025)|an independent prognostic factor for overall survival (p = 0.016)"	NPA	NPA	CRC tissues and matched non-cancerous tissues	tumor-suppressive
378	22821565	stomach	gastric cancer	NPA	miR-199a	miR-199a-5p	SMAD4	4089	NPA	block TGF-beta signaling|inhibit cell growth arrest|inhibit apoptosis	NPA	NPA	NPA	NPA	oncogenic
379	22821148	breast	breast cancer	Garcinia	miR-200	miR-200a-3p|miR-200b-3p|miR-200c-3p	NPA	NPA	NPA	increase Garcinia inhibition of cell invasion	NPA	MDA-MB-231|BT-549	xenograft mouse model	NPA	NPA
380	22819824	liver	heptocellular carcinoma	NPA	miR-615-5p	miR-615-5p	IGF2	3481	NPA	inhibit cell growth|inhibit cell migration	"preferentially expressed in HCC, cirrhotic liver tissues and HCC cell lines, but undetected in normal livers"	NPA	NPA	"HCC, cirrhotic liver tissues and normal livers"	tumor-suppressive
381	22819820	liver	HCV+ intrahepatic cholangiocarcinoma	NPA	miR-124	miR-124-3p	SMYD3	64754	NPA	inhibit cell migration|inhibit cell invasion	down-regulated in HCV-related intrahepatic cholangiocarcinomas	NPA	NPA	HCV-related intrahepatic cholangiocarcinoma	tumor-suppressive
382	22812695	ovary	epithelial ovarian carcinoma	paclitaxel	let-7i	let-7i-5p	NPA	NPA	NPA	increase paclitaxel sensitivity|inhibit cell proliferation|induce apoptosis|decrease cell survival	NPA	OVCAR-3	NPA	NPA	tumor-suppressive
383	22811466	pituitary	pituitary adenoma	NPA	miR-107	miR-107	AIP	54998	NPA	inhibit cell proliferation	significantly upregulated in GH-secreting and nonfunctioning pituitary adenomas	NPA	rat model	pituitary adenomas	tumor-suppressive
384	22809628	prostate	prostate cancer	NPA	miR-200	miR-200a-3p|miR-200b-3p|miR-200c-3p	NPA	NPA	NPA	induce integrin activity|promote cell migration	NPA	PC3	NPA	NPA	oncogenic
385	22809510	breast	breast cancer	NPA	miR-224	miR-224-5p	PEBP1	5037	NPA	increase metastasis	significantly upregulated in breast cancer cells compared to human normal breast epithelial cells	MDA-MB-231	NPA	NPA	oncogenic
386	22806311	lung	lung cancer	NPA	miR-21	miR-21-5p	MSH2	4436	NPA	promote cell proliferation|increase cells in S phase	NPA	NPA	NPA	NPA	oncogenic
387	22805767	prostate	prostate cancer	isoflavone	miR-1256	miR-1256	TRIM68	55128	DNA hypermethylation	inhibit cell growth|inhibit cell invasion	lowly expressed both in PCa cells and in human tumor tissues compared with normal epithelial cells and normal human prostate tissues	NPA	NPA	human prostate cancer tissues and normal prostate tissues	tumor-suppressive
388	22805767	prostate	prostate cancer	isoflavone	miR-29a	miR-29a-3p	TRIM68	55128	DNA hypermethylation	inhibit cell growth|inhibit cell invasion	lowly expressed both in PCa cells and in human tumor tissues compared with normal epithelial cells and normal human prostate tissues	NPA	NPA	human prostate cancer tissues and normal prostate tissues	tumor-suppressive
389	22797075	prostate	prostate cancer	NPA	miR-193b	miR-193b-3p	NPA	NPA	CFTR	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion	NPA	NPA	NPA	NPA	tumor-suppressive
390	22797068	skin	melanoma	NPA	miR-125b	miR-125b-5p	JUN	3725	NPA	reduce cell proliferation|reduce cell migration	significantly reduced in malignant melanoma cell lines and tissue samples compared with melanocytes	NPA	NPA	melanoma tissue samples and melanocytes	tumor-suppressive
391	22785209	prostate	prostate cancer	NPA	miR-20a	miR-20a-5p	CX43	2697	NPA	increase cell proliferation|increase colony formation	significantly upregulated in prostate cancer compared with normal prostate tissues	MDA-PCa-2b	NPA	prostate cancer and normal prostate tissues	oncogenic
392	22785131	liver	cholangiocarcinoma	NPA	miR-494	miR-494-3p	PTTG1|TOP2A	9232|7153	NPA	induce cell cycle G2/M arrest	NPA	NPA	NPA	NPA	NPA
393	22783422	uterus	endometrial cancer	NPA	miR-103	miR-103a-3p	TIMP3	7078	NPA	promote cell growth|promote cell invasion	NPA	NPA	NPA	NPA	oncogenic
394	22782903	skin	cutaneous squamous cell carcinoma	NPA	miR-125b	miR-125b-5p	MMP13	4322	NPA	reduce cell proliferation|reduce colony formation|reduce cell migration|reduce cell invasion	downregulated in cutaneous squamous cell carcinomas	UT-SCC-7|A431	NPA	"healthy skins (n = 4) and cutaneous squamous cell carcinomas (n = 4)|40 healthy donors, 13 actinic keratosis, and 74 cSCC patients"	tumor-suppressive
395	22773266	liver	liver cancer	NPA	miR-93	miR-93-5p	NPA	NPA	NPA	promote cell proliferation|promote cell migration|promote colony formation	upregulated in HepG2 cells compared with primary human hepatocytes	HepG2	NPA	NPA	oncogenic
396	22770403	liver	cholangiocarcinoma	NPA	miR-21	miR-21-5p	PTEN|PDCD4	5728|27250	NPA	NPA	up-regulation in human cholangiocarcinoma tissues about 5.6-fold as compared to the matched normal bile duct tissues (P<0.05)	QBC939	NPA	human cholangiocarcinoma tissues and the matched normal bile duct tissues	NPA
397	22768249	liver	heptacellular carcinoma	NPA	miR-125a	miR-125a-5p	MMP11|VEGFA	4320|7422	NPA	inhibit cell proliferation|inhibit metastasis	decreased in both HCC tissues and cell lines|associated with patients' aggressive pathologic features	NPA	NPA	hepatocellular carcinoma tissues	tumor-suppressive
398	22766851	brain	glioblastoma	NPA	miR-218	miR-218-5p	LEF1	51176	NPA	inhibit cell invasion	"low in glioma tissues, especially in glioblastoma multiforme"	NPA	NPA	60 glioblastoma multiforme tissues	tumor-suppressive
399	22766839	kidney	renal cell carcinoma	NPA	miR-138	miR-138-5p	VIM	7431	NPA	inhibit cell migration|inhibit cell invasion|regulate epithelial-mesenchymal transition	NPA	A498|786-O	NPA	NPA	tumor-suppressive
400	22766763	brain	glioma	NPA	miR-10b	miR-10b-5p	NPA	NPA	NPA	promote cell proliferation|promote cell migration|inhibit apoptosis	NPA	U87MG	NPA	NPA	oncogenic
401	22766763	brain	glioma	NPA	miR-21	miR-21-5p	NPA	NPA	NPA	promote cell proliferation|promote cell migration|inhibit apoptosis	NPA	U87MG	NPA	NPA	oncogenic
402	22766504	colorectum	colon cancer	NPA	miR-145	miR-145-5p	PAK4	10298	NPA	inhibit cell growth	markedly decreased in human colon cancer cells compared to normal epithelial cells	SW620	NPA	NPA	tumor-suppressive
403	22761812	breast	breast cancer	NPA	miR-21	miR-21-5p	NPA	NPA	NPA	promote epithelial-mesenchymal transition|promote cancer stem-like cell phenotype	NPA	MDA-MB-231	NPA	NPA	oncogenic
404	22761738	NPA	NPA	NPA	let-7b	let-7b-5p	CYP2J2	1573	NPA	inhibit cell proliferation|induce apoptosis	NPA	MDA-MB-435	nude mice xenografts with MDA-MB-435 cells	18 matched lung squamous cell cancer and adjacent normal lung tissues	tumor-suppressive
405	22761433	breast	breast cancer	NPA	miR-9	miR-9-5p	AP3B1|CCNG1|LARP1|MTHFD1L|MTHFD2|SRPK1	8546|900|23367|25902|10797|6732	NPA	inhibit cell proliferation|inhibit cell invasion|promote apoptosis	downregulated in primary breast tumor samples compared with normal breast samples	MCF-7|MDA-MB-231|MCF-10-2A	NPA	primary breast tumor samples and normal breast samples	tumor-suppressive
406	22761427	head and neck	oral squamous cell carcinoma	NPA	miR-21	miR-21-5p	RECK	8434	NPA	NPA	highly expressed in a majority of the keratinized tumors	CAL 27	CAL 27 orthotopic xenograft tumors	NPA	NPA
407	22761427	head and neck	oral squamous cell carcinoma	NPA	miR-7	miR-7-5p	RECK	8434	NPA	NPA	highly expressed in a majority of the keratinized tumors	CAL 27	CAL 27 orthotopic xenograft tumors	NPA	NPA
408	22761336	NPA	NPA	cisplatin|AZD2281	miR-96	miR-96-5p	RAD51|REV1	5888|51455	NPA	increase drug sensitivity|decrease homologous recombination	NPA	NPA	NPA	NPA	NPA
409	22753745	brain	glioblastoma	temozolomide	miR-21	miR-21-5p	NPA	NPA	NPA	increase temozolomide resistance|inhibit apoptosis	NPA	D54MG	NPA	NPA	oncogenic
410	22752005	lung	non-small cell lung cancer	NPA	miR-23a	miR-23a-3p	CDH1	51343	TGFB1	promote epithelial-mesenchymal transition|increae resistance to gefitinib	NPA	A549	NPA	NPA	oncogenic
411	22751686	head and neck	oral squamous cell carcinoma	NPA	miR-99a	miR-99a-5p	MTOR	2475	NPA	inhibit cell proliferation|induce apoptosis	markedly decreased in OSCC tissues compared with the adjacent non-tumor tissues	Tca-8113	NPA	25 cases of primary OSCC tissues	tumor-suppressive
412	22751119	breast	breast cancer	progesterone	miR-29	miR-29a-3p|miR-29b-3p|miR-29c-3p	KLF4	9314	PGR	inhibit stem-like properties|inhibit dedifferentiation	NPA	NPA	NPA	NPA	NPA
413	22750848	brain	proneural subtype glioblastoma	NPA	miR-34a	miR-34a-5p	PDGFRA	5156	NPA	NPA	correlated with overall survival	NPA	NPA	TCGA glioblastoma samples	NPA
414	22749944	lung	non-small cell lung cancer	cisplatin	miR-513a-3p	miR-513a-3p	GSTP1	2950	NPA	increase cisplatin sensitivity	downregulated in resistant cells	A549|A549/CDDP	NPA	NPA	NPA
415	22747855	skin	melanoma	NPA	miR-376a	miR-376a-3p	IGF1R	3480	NPA	slightly inhibit cell growth|inhibit cell migration	"significantly down-regulated in melanoma cell lines, benign nevi and melanoma samples relative to normal melanocytes"	NPA	NPA	benign nevi and melanoma samples and normal melanocytes	tumor-suppressive
416	22747855	skin	melanoma	NPA	miR-376c	miR-376c-3p	IGF1R	3480	NPA	slightly inhibit cell growth|inhibit cell migration	"significantly down-regulated in melanoma cell lines, benign nevi and melanoma samples relative to normal melanocytes"	NPA	NPA	benign nevi and melanoma samples and normal melanocytes	tumor-suppressive
417	22745829	brain	glioma	NPA	miR-23b	miR-23b-3p	PYK2	2185	NPA	inhibit cell migration|inhibit cell invasion	significantly down regulated in the migrating cell population relative to cells in the migration-restricted population	NPA	NPA	NPA	tumor-suppressive
418	22739938	head and neck	nasopharyngeal carcinoma	NPA	miR-138	miR-138-5p	CCND1	595	NPA	inhibit cell proliferation|inhibit colony formation|inhibit tumorigenesis|inhibit cell cycle progression	commonly underexpressed in nasopharyngeal carcinoma (NPC) specimens and NPC cell lines	NPA	NPA	nasopharyngeal carcinoma (NPC) specimens	tumor-suppressive
419	22736761	brain	glioma stem-like cell	3-deazaneplanocin A	miR-1275	miR-1275	CLDN11	5010	promote H3K27me3	increase cell growth	consistently down-regulated during GSC differentiation	NPA	NPA	NPA	oncogenic
420	22735571	colorectum	colorectal cancer	NPA	miR-200	miR-200a-3p|miR-200b-3p|miR-200c-3p	NPA	NPA	NPA	increase cell proliferation|reduce cell invasion|reduce cell migration	upregulated in liver metastasis tissues than primary CRCs	NPA	NPA	fifty-four pairs of primary CRC and corresponding matched liver metastasis tissue specimens	oncogenic/tumor-suppersive
421	22733138	NPA	NPA	NPA	miR-24	miR-24-3p	XIAP	331	NPA	reduce apoptosis resistance	NPA	NPA	NPA	NPA	NPA
422	22730212	cervix	cervical cancer	NPA	miR-17-5p	miR-17-5p	TP53INP1	94241	NPA	inhibit cell growth|promote apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
423	22723956	lung	non-small cell lung cancer	taxane	miR-337-3p	miR-337-3p	STAT3|RAP1A	6774|5907	NPA	increase taxane sensitivity	NPA	NCI-H1155	NPA	NPA	NPA
424	22723937	breast	breast cancer	NPA	miR-137	miR-137	ESRRA	2101	NPA	inhibit cell proliferation|inhibit cell migration	NPA	NPA	NPA	NPA	tumor-suppressive
425	22723551	blood	chronic lymphocytic leukemia	NPA	miR-125b	miR-125b-5p	NPA	NPA	NPA	"modulate glucose, glutathione, lipid, and glycerolipid metabolism"	underexpressed in both aggressive and indolent CLL patients	NPA	NPA	NPA	NPA
426	22719071	prostate	prostate cancer	NPA	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit clonal expansion|induce cell cycle G2/M arrest without senescencee	downregulated coordinately in several prostate cancer stem/progenitor cell populations	NPA	NPA	NPA	tumor-suppressive
427	22719071	prostate	prostate cancer	NPA	miR-34a	miR-34a-5p	NPA	NPA	NPA	induce cell cycle G1 arrest|induce senescencee	downregulated coordinately in several prostate cancer stem/progenitor cell populations	NPA	NPA	NPA	tumor-suppressive
428	22718995	nerve	malignant peripheral nerve sheath tumor	NPA	miR-204	miR-204-5p	NPA	NPA	NPA	reduce cell proliferation|reduce cell migration|reduce cell invasion	downregulated in NF1 and non-NF1 MPNST tumor tissues and in tumor cell lines	STS26T|ST88-14|T265p21	NPA	NF1 and non-NF1 MPNST tumor tissues	tumor-suppressive
429	22713668	breast	triple-negative breast cancer	NPA	miR-203	miR-203a	BIRC5|LASP1	332|3927	NPA	inhibit cell proliferation|inhibit cell migration	NPA	NPA	NPA	NPA	tumor-suppressive
430	22713463	liver	hepatocellular carcinoma	cisplatin	miR-199a-5p	miR-199a-5p	ATG7	10533	NPA	inhibit cell proliferation|inhibit autophagy	significantly reduced in HCC patients and cell lines treated with cisplatin-based chemotherapy	Huh7|HepG2	NPA	HCC patients treated with cisplatin-based chemotherapy	tumor-suppressive
431	22711166	stomach	gastric cancer	NPA	miR-146a	miR-146a-5p	L1CAM	3897	NPA	inhibit cell invasion|inhibit metastasis	NPA	MKN-45	nude mice	NPA	tumor-suppressive
432	22710984	breast	breast cancer	NPA	miR-632	miR-632	NPA	NPA	NPA	promote cell invasion	upregulated in invasive and metastatic breast cancer cells compared with mammary epithelial cells	NPA	NPA	NPA	oncogenic
433	22710713	colorectum	colorectal cancer	cisplatin|5-fluorouracil	miR-497	miR-497-5p	IGF1R	3480	NPA	reduce cell survival|inhibit cell proliferation|inhibit cell invasion|increase apoptosis sensitivity	downregulated in the majority of CRC tissues relative to paired adjacent normal mucosa	NPA	NPA	CRC tissues and paired adjacent normal mucosa	tumor-suppressive
434	22709411	brain	glioblastoma	NPA	miR-21	miR-21-5p	NPA	NPA	NPA	promote cell growth	NPA	U87|LN229	NPA	NPA	oncogenic
435	22707408	liver	intrahepatic cholangiocarcinoma	NPA	miR-200c	miR-200c-3p	NCAM1	4684	NPA	reduce epithelial-mesenchymal transition	NPA	NPA	NPA	23 ICC and combined hepatocellular cholangiocarcinoma tumor specimens from Asian patients|additional 68 ICC cases derived from Caucasian patients	tumor-suppressive
436	22706599	esophagus	oesophageal adenocarcinoma	chemoradiation therapy (CRT)	miR-31	miR-31-5p	NPA	NPA	NPA	increase radiation sensitivity	significantly reduced in patients demonstrating poor histomorphologic response to neoadjuvant CRT	NPA	NPA	oesophageal tumours	NPA
437	22705304	breast	breast cancer	NPA	miR-218	miR-218-5p	NPA	NPA	NPA	inhibit cell cycle|inhibit clonony formation	NPA	NPA	NPA	NPA	tumor-suppressive
438	22705304	breast	breast cancer	NPA	miR-7	miR-7-5p	NPA	NPA	NPA	inhibit cell cycle|inhibit clonony formation	NPA	NPA	NPA	NPA	tumor-suppressive
439	22703967	nerve	neuroblastoma	NPA	miR-34a	miR-34a-5p	NPA	NPA	CDK1	induce apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
440	22701724	breast	breast cancer	NPA	miR-30c	miR-30c-5p	KRAS	3845	NPA	inhibit cell proliferation	underexpressed in tumor tissues than their normal breast tissue counterparts	NPA	NPA	22 hereditary breast tumors and 15 non-tumoral breast tissues|additional 18 sporadic breast tumors and their normal breast tissue counterparts	tumor-suppressive
441	22698405	bone and muscle	Ewing sarcoma family tumor	NPA	miR-143	miR-143-3p	NPA	NPA	TARBP2	inhibit cancer stem cell colongenicity|inhibit tumor grwoth	NPA	NPA	NPA	NPA	tumor-suppressive
442	22698405	bone and muscle	Ewing sarcoma family tumor	NPA	miR-145	miR-145-5p	NPA	NPA	TARBP2	inhibit cancer stem cell colongenicity|inhibit tumor grwoth	NPA	NPA	NPA	NPA	tumor-suppressive
443	22693547	breast	breast cancer	NPA	miR-125b	miR-125b-5p	STARD13	90627	NPA	induce metastasis	NPA	MCF-7|MDA-MB-231	NPA	NPA	oncogenic
444	22691140	colorectum	colon cancer	NPA	miR-143	miR-143-3p	HK2	3796	NPA	reduce glucose metabolism	NPA	DLD-1	NPA	NPA	NPA
445	22685542	kidney	renal cell carcinoma	NPA	miR-21	miR-21-5p	PDCD4	27250	NPA	increase cell proliferation|increase cell migration|increase cell invasion	NPA	NPA	NPA	NPA	oncogenic
446	22685420	breast	breast cancer	NPA	miR-93	miR-93-5p	NPA	NPA	NPA	induce mesenchymal-epithelial transition|inhibit TGF-beta signaling|reduce cancer stem cells|block tumor development	NPA	SUM159|MCF7	mouse xenograft models	NPA	tumor-suppressive
447	22685266	uterus	leiomyoma	NPA	miR-200c	miR-200c-3p	ZEB1|ZEB2|TIMP2|FBLN5|VEGFA	6935|9839|7077|10516|7422	NPA	NPA	significantly down-regulated in leiomyomas than matched myometrium	NPA	NPA	76 leiomyomas and matched myometrium	NPA
448	22684895	liver	hepatocellular carcinoma	NPA	miR-590-5p	miR-590-5p	TGFBR2	7048	NPA	promote proliferation|promote invasion	higher in the human hepatocellular carcinoma cell line HepG2 than in the normal hepatocellular cell line L02	HepG2|L02	NPA	NPA	oncogenic
449	22684561	bladder	invasive urothelial bladder carcinoma	NPA	miR-34a	miR-34a-5p	NOTCH1	4851	NPA	inhibit cell migration|inhibit cell invasion	aberrantly expressed in cancer tissues	253J|J82	NPA	NPA	tumor-suppressive
450	22684007	liver	hepatocellular carcinoma	NPA	miR-376a	miR-376a-3p	PIK3R1	5295	NPA	inhibit cell proliferation|induce apoptosis	frequently down-regulated in HCC cell lines and HCC tissues|positively significantly associated with high serum AFP level|inversely correlated with PIK3R1 expression in HCC	Huh7	NPA	HCC tissues	tumor-suppressive
451	22683924	liver	hepatocellular carcinoma	LBH589	let-7b	let-7b-5p	NPA	NPA	NPA	inhibit cell proliferation|induce apoptosis 	NPA	HepG2|Hep3B	xenografts	NPA	tumor-suppressive
452	22683180	stomach	gastric cancer	NPA	miR-574-3p	miR-574-3p	CUL2	8453	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion	downregulated mainly in the early stages of gastric cancer or in cancers with high level of differentiation	SGC7901	NPA	gastric cancer tissues and the normal gastric tissues	tumor-suppressive
453	22681957	brain	glioma	NPA	miR-221	miR-221-3p	TIMP3	7078	NPA	increase cell invasion	significantly increased in high-grade gliomas compared with low-grade gliomas|positively correlated with the degree of glioma infiltration|correlated with poorer overall survival	NPA	xenograft model	fifty glioma patients	oncogenic
454	22681957	brain	glioma	NPA	miR-222	miR-222-3p	TIMP3	7078	NPA	increase cell invasion	significantly increased in high-grade gliomas compared with low-grade gliomas|positively correlated with the degree of glioma infiltration|correlated with poorer overall survival	NPA	xenograft model	fifty glioma patients	oncogenic
455	22681717	liver	hepatocellular carcinoma	NPA	miR-182	miR-182-5p	MTSS1	9788	NPA	increase cell invasion	up-regulated in HCC tissues compared with normal tissue|correlated with intrahepatic metastasis (p = 0.034) and poor prognosis (p = 0.039) of HCC patient	HUH-1	NPA	86 cases of paired HCC and normal tissues	oncogenic
456	22678116	breast	breast cancer	docosahexaenoic acid (DHA)	miR-21	miR-21-5p	PTEN	5728	NPA	increase cell growth|increase metastasis	NPA	MDA-MB-231|MCF-7	breast tumors of mice	NPA	oncogenic
457	22677902	colorectum	colon cancer	NPA	miR-17	miR-17-5p	NPA	NPA	PTP4A3	increase cell proliferation|increase cell invasion	NPA	NPA	NPA	matched primary colon cancer tissues and metastatic lesions	oncogenic
458	22677902	colorectum	colon cancer	NPA	miR-19a	miR-19a-3p	NPA	NPA	PTP4A3	increase cell proliferation|increase cell invasion	NPA	NPA	NPA	matched primary colon cancer tissues and metastatic lesions	oncogenic
459	22677902	colorectum	colon cancer	NPA	miR-21	miR-21-5p	NPA	NPA	PTP4A3	increase cell proliferation|increase cell invasion	NPA	NPA	NPA	matched primary colon cancer tissues and metastatic lesions	oncogenic
460	22677230	blood	childhood acute lymphoblastic leukemia	NPA	miR-101	miR-101-3p	PTGES3	10728	NPA	NPA	down-regulated in childhood ALL cases	NPA	NPA	100 childhood acute lymphoblastic leukemia (ALL) bone marrow (BM) samples	NPA
461	22677169	stomach	gastric cancer	NPA	miR-625	miR-625-5p	ILK	3611	NPA	inhibit cell invasion|inhibit metastasis	significantly down-regulated in gastric cancer|negatively correlated with lymph node metastasis	NPA	NPA	gastric cancer tissues	tumor-suppressive
462	22677042	colorectum	colorectal carcinoma	L-OHP|VCR	miR-222	miR-222-3p	ADAM17	6868	NPA	reduce multidrug-resistance	NPA	HCT116|HCT-8	NPA	NPA	NPA
463	22676135	colorectum	colorectal carcinoma	L-OHP	miR-297	miR-297	ABCC2	1244	NPA	reduce multidrug-resistance	down-regulated in a panel of human colorectal carcinoma tissues	HCT116	NPA	human colorectal carcinoma tissues	NPA
464	22672828	pancreas	pancreatic cancer	hypoxia	miR-210	miR-210-3p	E2F3|EFNA3|GIT2|MNT|ZNF462|EGR3	1871|1944|9815|4335|58499|1960	HIF1A	NPA	NPA	AsPC-1|BxPC-3|MIAPaCa-2|PANC-1|Su86.86|SW1990|Capan-1|T3M4	NPA	NPA	NPA
465	22664953	liver	hepatocellular carcinoma	NPA	miR-1	miR-1	ETS1	2113	NPA	inhibit cell migration|inhibit cell invasion	NPA	HepG2	NPA	NPA	tumor-suppressive
466	22664953	liver	hepatocellular carcinoma	NPA	miR-499	miR-499a-5p	ETS1	2113	NPA	inhibit cell migration|inhibit cell invasion	NPA	HepG2	NPA	NPA	tumor-suppressive
467	22649212	brain	glioma	NPA	miR-23b	miR-23b-3p	VHL	7428	NPA	increase cell growth|ihibit apoptosis|increase cell invasion|promote beta-catenin/Tcf-4 and HIF-1alpha/VEGF signaling	elevated in both glioma samples and glioma cells	NPA	NPA	NPA	oncogenic
468	22642900	colorectum	colorectal cancer	NPA	miR-139	miR-139-5p	RAP1B	5908	NPA	inhibit cell growth|inhibit tumorigenicity	down-regulated in colorectal carcinoma (CRC) tissues|negatively correlated with advanced CRC and lower overall survival of patients with CRC	SW480|SW620|LS174T|HCT116	NPA	colorectal carcinoma (CRC) tissues	tumor-suppressive
469	22641236	esophagus	esophageal squamous cell carcinoma	NPA	miR-133a	miR-133a-3p	CD47	961	NPA	inhibit tumorigenesis	significantly lower in cancer tissues compared to adjacent non-cancerous tissues (P<0.001)	NPA	mouse xenograft model	102 cases of curative resected ESCC and adjacent non-cancerous tissue	tumor-suppressive
470	22641068	liver	hepatocellular carcinoma	trichostatin A	miR-449	miR-449a	MET	4233	HDAC1|HDAC2|HDAC3	promote apoptosis|reduce proliferation	expressed lower in HCC samples from patients	HepG2|HLE|HLF|Huh7|THLE-2|THLE-3	xenograft tumors from modified cells in nude mice	HCC samples from 23 patients	tumor-suppressive
471	22637745	pancreas	pancreatic cancer	CDF|BR-DIM	miR-200c	miR-200c-3p	NPA	NPA	NPA	alter cell morphology|inhibit would-healing capacity|inhibit colony formation	NPA	BxPC-3|MIAPaCa-2|MIAPaCa-2-GR	NPA	NPA	NPA
472	22634495	cervix	cervical cancer	NPA	miR-10a	miR-10a-5p	CHL1	1663	NPA	promote colony formation|promote cell migration|promote cell invasion	upregulated in human cervical cancer	HeLa|C33A	NPA	cervical cancer tissues	oncogenic
473	22634383	blood	leukemic Jurkat cells	NPA	miR-23a	miR-23a-3p	NPA	NPA	NFKB1	inhibit glutamine metabolism	NPA	NPA	NPA	NPA	NPA
474	22629428	head and neck	head and neck squamous cell carcinoma	NPA	miR-34a	miR-34a-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit colony formation|inhibit cell migration|inhibit tumor growth|inhibit angiogenesis	NPA	NPA	SCID mouse xenograft	NPA	tumor-suppressive
475	22629385	breast	breast cancer	NPA	miR-204	miR-204-5p	IL11	3589	NPA	NPA	NPA	MDA-MB-231|MDA-MB-231(SA)	NPA	NPA	NPA
476	22629385	breast	breast cancer	NPA	miR-211	miR-211-5p	IL11	3589	NPA	NPA	NPA	MDA-MB-231|MDA-MB-231(SA)	NPA	NPA	NPA
477	22629385	breast	breast cancer	NPA	miR-379	miR-379-5p	IL11	3589	NPA	NPA	NPA	MDA-MB-231|MDA-MB-231(SA)	NPA	NPA	NPA
478	22629365	liver	hepatocelluar carcinoma	NPA	miR-155	miR-155-5p	NPA	NPA	NPA	increase cell growth|inhibit cell death	significantly associated with recurrence-free (RFS)	J7|Mahlavu	xenograft tumors	paraneoplastic liver tissues of 12 HCC patients	oncogenic
479	22628407	colorectum	colorectal cancer	NPA	miR-23a	miR-23a-3p	MTSS1	9788	NPA	promote cell migration|promote cell invasion	upregulated in primary tumors from patients with stage I/II colorectal cancers	NPA	DNA mismatch repair (MMR) mutant mouse models	primary tumors from patients with stage I/II colorectal cancers	oncogenic
480	22628407	colorectum	colorectal cancer	NPA	miR-27a	miR-27a-3p	FBXW7	55294	NPA	promote cell proliferation	upregulated in primary tumors from patients with stage I/II colorectal cancers	NPA	DNA mismatch repair (MMR) mutant mouse models	primary tumors from patients with stage I/II colorectal cancers	oncogenic
481	22628193	pancreas	pancreatic cancer	NPA	miR-301a	miR-301a-3p	BMI1	648	NPA	promote cell proliferation	significantly increased in PC tissues	NPA	NPA	PC tissues	oncogenic
482	22623155	breast	breast cancer	5-FU	miR-34a	miR-34a-5p	BCL2|SIRT1	596|23411	NPA	inhibit cell proliferation|inhibit cell invasion|induce apoptosis	down-regulated by almost 50?% in breast cancer samples compared with their corresponding adjacent non-malignant breast tissues	184A1	NPA	breast cancer samples and their corresponding adjacent non-malignant breast tissues	tumor-suppressive
483	22618231	breast	breast cancer	17beta-estradiol (E2)	miR-21	miR-21-5p	JAG1	182	NPA	NPA	NPA	MCF-7|MDA-MB-231	NPA	NPA	NPA
484	22617440	blood	chronic myelogenous leukemia	imatinib	miR-30a	miR-30a-5p	NPA	NPA	NPA	inhibit autophagy|increase apoptosis|reduce imatinib resistance	NPA	NPA	NPA	NPA	tumor-suppressive
485	22614869	ovary	ovarian cancer	cisplatin	miR-130a	miR-130a-3p	NPA	NPA	NPA	increase cisplatin resistance	NPA	SKOV3	NPA	NPA	NPA
486	22614734	brain	glioma	NPA	miR-27a	miR-27a-3p	NPA	NPA	NPA	promote cell proliferation|reduce the cell cycle G1 arrest|promote cell invasion	NPA	U87	NPA	NPA	oncogenic
487	22614013	pituitary	pituitary somatomammotrophic tumor	NPA	miR-128	miR-128-3p	BMI1	648	NPA	inhibit colony formation|inhibit cell invasion|inhibit tumor growth	NPA	NPA	GH3 tumor growth in xenografts	NPA	tumor-suppressive
488	22614013	pituitary	pituitary somatomammotrophic tumor	NPA	miR-26b	miR-26b-5p	PTEN	5728	NPA	increase colony formation|increase cell invasion|promote tumor growth	NPA	NPA	GH3 tumor growth in xenografts	NPA	oncogenic
489	22614007	prostate	prostate cancer	NPA	miR-21	miR-21-5p	BTG2	7832	NPA	promote epithelial-mesenchymal transition	NPA	NPA	NPA	NPA	oncogenic
490	22614005	stomach	gastric cancer	NPA	miR-7	miR-7-5p	IGF1R	3480	NPA	reduce cell migration|reduce cell invasion	significantly downregulated in highly metastatic GC cell lines and metastatic tissues	NPA	NPA	human primary GC with matched lymph node metastasis tissue	tumor-suppressive
491	22613005	liver	hepatocellular carcinoma	NPA	miR-214	miR-214-3p	HDGF	3068	NPA	inhibit tumor growth|inhibit angiogenesis	negatively associated with higher tumor recurrence and worse clinical outcomes	NPA	xenograft tumor	HCC tissues	tumor-suppressive
492	22610076	blood	chronic lymphocytic leukemia	NPA	miR-181a	miR-181a-5p	BCL2|MCL1|XIAP	596|4170|331	NPA	increase apoptosis	frequently down-regulated in chronic lymphocytic leukemia cells|significantly lower in poor prognostic subgroups defined by unmutated immunoglobulin heavy chain variable status and p53 aberrations|negatively associated with shorter overall survival and treatment-free survival in CLL patients	NPA	NPA	"six Chinese patients with chronic lymphocytic leukemia (CLL), and in peripheral B cells from pooled 30 healthy donors|primary CLL cells from 40 patients"	tumor-suppressive
493	22610076	blood	chronic lymphocytic leukemia	NPA	miR-181b	miR-181b-5p	BCL2|MCL1|XIAP	596|4170|331	NPA	increase apoptosis	frequently down-regulated in chronic lymphocytic leukemia cells|significantly lower in poor prognostic subgroups defined by unmutated immunoglobulin heavy chain variable status and p53 aberrations|negatively associated with shorter overall survival and treatment-free survival in CLL patients	NPA	NPA	"six Chinese patients with chronic lymphocytic leukemia (CLL), and in peripheral B cells from pooled 30 healthy donors|primary CLL cells from 40 patients"	tumor-suppressive
494	22609199	kidney	renal cell carcinoma	NPA	miR-101	miR-101-3p	NPA	NPA	NPA	inhibit cell proliferation	decreased in 15 of 54 RCCs	NPA	NPA	54 RCCs	tumor-suppressive
495	22609116	blood	diffuse large B-cell lymphoma	NPA	miR-155	miR-155-5p	PIK3R1	5295	NPA	promote PI3K-AKT signaling	NPA	DHL16|OCI-Ly3	NPA	NPA	NPA
496	22593586	NPA	NPA	rapamycin	miR-143	miR-143-3p	HK2	3796	NPA	reduce glucose metabolism|inhibit cell proliferation|inhibit tumor formation	NPA	NPA	NPA	NPA	tumor-suppressive
497	22593189	colorectum	colorectal cancer	NPA	miR-103	miR-103a-3p	DAPK1|KLF4	1612|9314	NPA	increase cell motility|increase cell-matrix adhesion|decrease cell-cell adhesion	associated with metastasis potential of CRC cell lines and poor prognosis in patients with CRC	NPA	mouse models of CRC	CRC patients	oncogenic
498	22593189	colorectum	colorectal cancer	NPA	miR-107	miR-107	DAPK1|KLF4	1612|9314	NPA	increase cell motility|increase cell-matrix adhesion|decrease cell-cell adhesion	associated with metastasis potential of CRC cell lines and poor prognosis in patients with CRC	NPA	mouse models of CRC	CRC patients	oncogenic
499	22592534	breast	breast cancer	NPA	miR-145	miR-145-5p	NRAS|VEGFA	4893|7422	NPA	inhibit angiogeneis|inhibit cell growth|inhibit cell invasion|inhibit tumor growth	significantly downregulated in breast cancer tissues|inversely correlated with malignancy stages of breast tumors	NPA	NPA	106 cases of normal and cancer tissues	tumor-suppressive
500	22592211	lung	lung cancer	NPA	miR-381	miR-381-3p	ID1	3397	NPA	inhibit cell migration|inhibit cell invasion	significantly downregulated in human lung adenocarcinomas	NPA	NPA	18 human lung adenocarcinomas and corresponding normal lung tissue	tumor-suppressive
501	22581829	colorectum	colorectal cancer	NPA	miR-93	miR-93-5p	CCNB1|ERBB2	891|2064	NPA	inhibit cell proliferation|inhibit cell migration|induce cell cycle G2 arrest	downregulated in early (recurrence within 12 months after surgery) and non-early relapse CRC patients	NPA	xenograft in null mice	35 early relapse and 42 non-early relapse subjects	tumor-suppressive
502	22581522	stomach	gastric cancer	NPA	miR-181a	miR-181a-5p	KLF6	1316	NPA	promote cell proliferation|promote colony formation|promote cell migration|promote cell invasion|inhibit apoptosis	overexpressed in human gastric cancer tissues	SGC-7901	NPA	human gastric cancer tissues	oncogenic
503	22580605	colorectum	colorectal cancer	NPA	miR-502-5p	miR-502-5p	RAB1B	81876	NPA	inhibit autophagy|inhibit cell growth|inhibit cell cycle progression|inhibit tumor growth	downregulated in colon cancer patient specimens compared with the paired normal control samples	NPA	mouse tumor xenografts	colon cancer patient specimens and the paired normal control samples	tumor-suppressive
504	22580051	colorectum	colorectal cancer	NPA	miR-139	miR-139-5p	IGF1R	3480	NPA	inhibit metastasis|inhibit cell invasion	underexpressed in 34 CRC tissues compared to their corresponding nontumor tissues|negatively associated with disease progression and metastasis	NPA	NPA	34 CRC tissues and their corresponding nontumor tissues	tumor-suppressive
505	22578566	breast	triple negative breast cancer	NPA	miR-205	miR-205-5p	E2F1|LAMC1	1869|3915	TP53	reduce cell proliferation|inhibit cell cycle progression|inhibit clonogenic potential|inhibit tumor growth	critically down-expressed in highly aggressive triple negative breast cancer cells compared to a normal-like cell line	NPA	NPA	NPA	tumor-suppressive
506	22574716	colorectum	colon cancer	NPA	miR-15	miR-15a-5p|miR-15b-5p	NPA	NPA	NPA	inhibit tumor growth|inhibit angiogenesis	NPA	HCT116|SW620	NPA	NPA	tumor-suppressive
507	22574716	colorectum	colon cancer	NPA	miR-16	miR-16-5p	NPA	NPA	NPA	inhibit tumor growth|inhibit angiogenesis	NPA	HCT116|SW620	NPA	NPA	tumor-suppressive
508	22573479	breast	breast cancer	NPA	miR-10b	miR-10b-5p	SDC1	6382	NPA	increase cell migration|increase cell invasion	NPA	MDA-MB-231|MCF-7	NPA	NPA	oncogenic
509	22573352	lung	non-small cell lung cancer	NPA	miR-708	miR-708-5p	TMEM88	92162	NPA	increase cell proliferation|increase cell invasion|increase cell migration	significantly higher in tumor samples	NPA	NPA	"56 pairs of fresh-frozen (FF) and 47 pairs of formalin-fixed, paraffin-embedded (FFPE) samples from never smokers"	oncogenic
510	22570426	brain	glioblastoma	temozolomide	miR-181d	miR-181d-5p	MGMT	4255	NPA	NPA	"inversely associated with patient overall survival after correcting for age, Karnofsky performance status, extent of resection, and temozolomide (TMZ) treatment"	NPA	NPA	82 glioblastomas|an independent cohort (n= 35)|TCGA dataset (n= 424)	NPA
511	22569286	uterus	endometrial cancer	NPA	miR-200c	miR-200c-3p	ZEB1|ZEB2|VEGFA|FLT1|IKBKB|KLF9	6935|9839|7422|2321|3551|687	NPA	increase cell proliferation	upregulated in endometrial tumors as compared to endometrial tissues from peri- and postmenopausal period	NPA	NPA	"endometrial tissues (N = 52) from normal endometrial biopsies (N = 15), endometrial tissues including those exposed to hormonal therapies (N = 20), and grade I-III endometrial cancer (N = 17)"	oncogenic
512	22569260	NPA	NPA	NPA	miR-223	miR-223-3p	FOXO1	2308	NPA	inhibit cell proliferation	NPA	HCT116|HeLa|HuH-7	NPA	NPA	tumor-suppressive
513	22568628	brain	glioma CD133+ cancer stem cells	NPA	miR-34a	miR-34a-5p	NPA	NPA	NPA	inhibit cell proliferation|induce apoptosis	down-regulated in CD133-positive U87 cells	U87	NPA	NPA	tumor-suppressive
514	22564856	NPA	NPA	NPA	miR-328	miR-328-3p	PTPRJ	5795	NPA	increase cell proliferation	NPA	HeLa|SKBr3	NPA	NPA	oncogenic
515	22564723	nerve	neuroblastoma	NPA	miR-9	miR-9-5p	MMP14	4323	NPA	inhibit cell invasion|inhibit migration|inhibit angiogenesis	downregulated in subtotal 20 neuroblastoma cases	SH-SY5Y|SK-N-SH	NPA	42 neuroblastoma tissues	tumor-suppressive
516	22563438	breast	invasive breast cancer	NPA	miR-92	miR-92a-3p|miR-92b-3p	NPA	NPA	NPA	inhibit cell migration	inversely correlated to tumour grade and recurrence-free survival	NPA	NPA	144 invasive breast cancer samples	tumor-suppressive
517	22561557	cervix	cervical carcinoma	NPA	miR-19a	miR-19a-3p	CUL5	8065	NPA	promote cell growth|promote cell invasion	highly expressed in human cervical cancer cells	HeLa|C33A	NPA	NPA	oncogenic
518	22561557	cervix	cervical carcinoma	NPA	miR-19b	miR-19b-3p	CUL5	8065	NPA	promote cell growth|promote cell invasion	highly expressed in human cervical cancer cells	HeLa|C33A	NPA	NPA	oncogenic
519	22558405	brain	glioblastoma stem cells	NPA	miR-10a	miR-10a-5p	CSMD1	64478	NPA	NPA	increased in glioblastoma stem cells than normal neural stem cells	NPA	NPA	NPA	NPA
520	22558405	brain	glioblastoma stem cells	NPA	miR-10b	miR-10b-5p	CSMD1	64478	NPA	NPA	increased in glioblastoma stem cells than normal neural stem cells	NPA	NPA	NPA	NPA
521	22558405	brain	glioblastoma stem cells	NPA	miR-124	miR-124-3p	NRAS|PIM3	4893|415116	NPA	NPA	decreased in glioblastoma stem cells than normal neural stem cells|reduced in tumor tissues	NPA	NPA	NPA	NPA
522	22558167	NPA	NPA	NPA	miR-6165	miR-6165	NPA	NPA	NGFR_intron	induce apoptosis	NPA	U87|HeLa	NPA	NPA	tumor-suppressive
523	22556343	uterus	leiomyoma	NPA	miR-106b	miR-106b-5p	F3|IL8	2152|3576	MCM7_intron	inhibit cell proliferation	significantly downregulated in leiomyomas compared with myometrium	NPA	NPA	63 leiomyoma and paired myometrium	tumor-suppressive
524	22556343	uterus	leiomyoma	NPA	miR-93	miR-93-5p	F3|IL8	2152|3576	MCM7_intron	inhibit cell proliferation	significantly downregulated in leiomyomas compared with myometrium	NPA	NPA	63 leiomyoma and paired myometrium	tumor-suppressive
525	22555458	prostate	prostate cancer	NPA	miR-205	miR-205-5p	NPA	NPA	TP63	regulate basement membrane deposition|inhibit tumor progression	reduced in prostate cancer	NPA	NPA	NPA	tumor-suppressive
526	22553926	colorectum	colorectal cancer	NPA	miR-21	miR-21-5p	NPA	NPA	EGF|RAS|ETS transcription factors|ETV4	NPA	NPA	NPA	NPA	NPA	NPA
527	22552290	prostate	prostate cancer CD44+ tumor-initiating cells	NPA	miR-708	miR-708-5p	CD44|AKT2	960|208	NPA	inhibit tumor growth	"negatively associated significantly with poor survival outcome, tumor progression, and recurrence in patients with prostate cancer"	NPA	a murine xenograft model of human prostate cancer	prostate cancer tissues	tumor-suppressive
528	22550173	blood	diffuse large B-cell lymphoma	NPA	miR-125a	miR-125a-5p	TNFAIP3	7128	NF-kB	promote NF-kB signaling	NPA	NPA	NPA	primary diffuse large B-cell lymphomas	NPA
529	22550173	blood	diffuse large B-cell lymphoma	NPA	miR-125b	miR-125b-5p	TNFAIP3	7128	NF-kB	promote NF-kB signaling	NPA	NPA	NPA	primary diffuse large B-cell lymphomas	NPA
530	22547075	breast	breast cancer	genotoxic treatment	miR-21	miR-21-5p	NPA	NPA	NF-kB|STAT3|IL6	promote DNA damage-induced apoptosis|increase the metastatic potential	NPA	NPA	NPA	NPA	oncogenic
531	22540680	liver	intrahepatic cholangiocarcinoma	NPA	miR-214	miR-214-3p	TWIST1	7291	NPA	inhibit epithelial-mesenchymal transition|ihibit metastasis	remarkably decreased in metastatic intrahepatic cholangiocarcinoma tissues compared to non-metastatic tissues	NPA	NPA	metastatic intrahepatic cholangiocarcinoma tissues and non-metastatic tissues	tumor-suppressive
532	22539488	stomach	gastric cancer	NPA	miR-181b	miR-181b-5p	CREB1	1385	NPA	inhibit cell proliferation|inhibit colony formation	significantly downregulated in human gastric cancer cell lines versus the gastric epithelial cells	NPA	NPA	NPA	tumor-suppressive
533	22536440	liver	hepatocellular carcinoma	NPA	miR-129-5p	miR-129-5p	VCP	7415	NPA	inhibit tumor growth|increase apoptosis|inhibit cell migration	negatively associated with the level of VCP in HCC tissues	NPA	NPA	HCC tissues	tumor-suppressive
534	22533346	colorectum	colorectal cancer	NPA	miR-143	miR-143-3p	MACC1	346389	NPA	inhibit cell growth|inhibit cell migration|inhibit cell invasion	NPA	SW620	NPA	NPA	tumor-suppressive
535	22532850	prostate	prostate cancer	TNF-related apoptosis-inducing ligand	miR-133b	miR-133b	FAIM	55179	NPA	inhibit cell proliferation|increase apoptosis sensitivity	"significantly downregulated in 75% of tumor specimens of prostate cancer patients, when compared with matched healthy tissue"	PC3|HeLa	ex-vivo model of prostate cancer	tumor specimens of prostate cancer patients and matched healthy tissue	tumor-suppressive
536	22531314	bone and muscle	fibrosarcoma	NPA	miR-409-3p	miR-409-3p	ANG	283	NPA	inhibit cell proliferation|inhibit angiogenesis|inhibit metastasis	NPA	HT1080	mouse tumor xenografts	NPA	tumor-suppressive
537	22528944	liver	hepatocellular carcinoma	NPA	miR-10b	miR-10b-5p	CADM1	23705	NPA	increase cell migration|increase cell invasion	highly expressed in metastatic HCC tissues and in metastatic HCC cell lines|correlated with poorer overall survival|an independent predictor of poor prognosis	HepG2|MHCC97H	NPA	metastatic HCC tissues	oncogenic
538	22526161	nerve	malignant peripheral nerve sheath tumor	NPA	miR-21	miR-21-5p	NPA	NPA	NPA	increase cell growth|reduce apoptosis	significantly higher in malignant peripheral nerve sheath tumors than that in neurofibromas	NPA	NPA	"6 malignant peripheral nerve sheath tumors (MPNSTs) and 6 neurofibroma (NFs)|12 MPNSTs, 11 NFs, and 5 normal nerves"	oncogenic
539	22525818	uterus	endometrial cancer	NPA	miR-155	miR-155-5p	NPA	NPA	NPA	increase cell survival	overexpressed in endometrial carcinoma tissues	NPA	NPA	endometrial carcinoma tissues	NPA
540	22525461	bone and muscle	osteosarcoma	NPA	miR-183	miR-183-5p	EZR	7430	NPA	inhibit cell migration|inhibit cell invasion	markedly down-regulated in osteosarcoma cells and tissues compared with matching normal bone tissues|significantly correlated with lung metastasis as well as with local recurrence	NPA	NPA	osteosarcoma tissues and the matching normal bone tissues	tumor-suppressive
541	22525428	skin	melanoma	NPA	miR-205	miR-205-5p	ZEB2	9839	NPA	inhibit cell motility|inhibit cell migration|modestly reduce cell proliferation	significantly and progressively downregulated from nevi to primary melanomas to metastatic melanomas	NPA	xenograft model	"nevi, primary melanomas and metastatic melanomas"	tumor-suppressive
542	22521303	breast	breast cancer	doxorubicin	miR-298	miR-298	MDR1	23158	NPA	reduce doxorubicin resistance	down-regulated in doxorubicin-resistant human breast cancer cells	MDA-MB-231	NPA	NPA	NPA
543	22516261	kidney	renal clear cell carcinoma	NPA	miR-204	miR-204-5p	MAP1LC3B	81631	VHL	inhibit macro-autophagy	concomitantly decreased in higher tumor grade of human ccRCCs	NPA	xenograft models	clear cell renal cell carcinomas (ccRCCs)	tumor-suppressive
544	22514743	breast	breast cancer	NPA	miR-203	miR-203a	SNAI1	6615	SNAI1	NPA	NPA	MCF7	NPA	NPA	NPA
545	22510476	lung	non-small cell lung cancer	chemotherapy	miR-126	miR-126-3p	VEGFA	7422	NPA	suppress tumor growth|increase chemotherapy sensitivity	NPA	A549	A549 xenograft	NPA	tumor-suppressive
546	22508479	breast	breast cancer	tamoxifen	miR-375	miR-375	MTDH	92140	NPA	reduce tamoxifen resistance|inhibit epithelial-mesenchymal transition	downregulated in tamoxifen-resistant cancer cells	MCF-7	NPA	NPA	tumor-suppressive
547	22508046	nerve	neuroblastoma	NPA	miR-206	miR-206	OTX2	5015	NPA	inhibit cell proliferation|induce apoptosis	NPA	U343|SK-N-SH	NPA	NPA	tumor-suppressive
548	22505583	prostate	prostate cancer	NPA	miR-27a	miR-27a-3p	PHB	5245	AR	increase cell growth	NPA	NPA	NPA	NPA	oncogenic
549	22504094	liver	hepatocellular carcinoma	hypoxia	miR-375	miR-375	ATG7	10533	NPA	inhibit autophagy under hypoxic conditions	down-regulated in HCC cells and tissues	Huh7|HepG2	HCC xenograft tumors in nude mice	HCC tissues	tumor-suppressive
550	22502680	lung	non-small cell lung cancer	gefitinib	miR-214	miR-214-3p	NPA	NPA	NPA	increase gefitinib resistance	significantly up-regulated in resistant cells	HCC827|HCC827/GR	NPA	NPA	NPA
551	22498306	ovary	CD44+/CD117+ ovarian cancer stem cells	cisplatin|pacitaxel|adriamycin	miR-199a	miR-199a-5p	CD44	960	NPA	inhibit cell cycle progression|inhibit cell proliferation|inhibit cell invasion|reduce multi-drug resistance	NPA	NPA	xenograft tumors formed by ovarian CICs	NPA	tumor-suppressive
552	22496917	liver	HBV+ hepatocellular carcinoma	Hepatitis B virus encoded X antigen (HBx)	miR-148a	miR-148a-3p	PTEN	5728	URG11	promote cell proliferation|promote cell cycle progression|promote cell migration|inhibit Akt signaling	elevated in HBx positive liver samples from infected patients	HepG2|Hep3B	SCID mice	NPA	oncogenic
553	22495929	NPA	NPA	NPA	miR-145	miR-145-5p	NPA	NPA	CEBPB	NPA	NPA	NPA	NPA	NPA	NPA
554	22493297	blood	acute myeloid leukemia	NPA	miR-142-3p	miR-142-3p	CCNT2|MAP3K7	905|6885	NPA	promote myeloid differentiation	upregulated during myeloid differentiation in leukemia cell lines	HL-60|THP-1|NB4	NPA	NPA	NPA
555	22493297	blood	acute myeloid leukemia	NPA	miR-29a	miR-29a-3p	CCNT2|CDK6	905|1021	NPA	promote myeloid differentiation	upregulated during myeloid differentiation in leukemia cell lines	HL-60|THP-1|NB4	NPA	NPA	NPA
556	22492871	uterus	endometrial cancer	17¦Â-estradiol|P4|medroxyprogesterone acetate	miR-181a	miR-181a-5p	PGR|DDX3X|TIMP3	5241|1654|7078	NPA	inhibit cell proliferation	associated with endometrial transition from normal into cancerous states	Ishikawa	NPA	endometrial biopsies and endometrial tissues from follicular and luteal phases with and without exposure to hormonal therapies and grade I-III endometrial cancer (n = 52)	tumor-suppressive
557	22492871	uterus	endometrial cancer	17¦Â-estradiol|P4|medroxyprogesterone acetate	miR-98	miR-98-5p	PGRMC1|CYP19A1	10857|1588	NPA	inhibit cell proliferation	associated with endometrial transition from normal into cancerous states	Ishikawa	NPA	endometrial biopsies and endometrial tissues from follicular and luteal phases with and without exposure to hormonal therapies and grade I-III endometrial cancer (n = 52)	tumor-suppressive
558	22492316	NPA	NPA	NPA	miR-7	miR-7-5p	EGFR	1956	E2F1	reduce cell viability|induce autophagy	NPA	NPA	NPA	NPA	tumor-suppressive
559	22491710	lung	non-small cell lung cancer	NPA	miR-193b	miR-193b-3p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion	markedly down-regulated in NSCLC cancer tissues	A549	NPA	NSCLC cancer tissues and adjacent normal tissues	tumor-suppressive
560	22491216	head and neck	head and neck squamous cell carcinoma	NPA	miR-107	miR-107	NPA	NPA	NPA	reduce clonogenic survival|inhibit cell invasion|inhibit cell migration|reduce the cancer-initiating cell population|inhibit tumor growth	NPA	NPA	NPA	NPA	tumor-suppressive
561	22490015	brain	glioblastoma	NPA	miR-143	miR-143-3p	NPA	NPA	NPA	promote cell invasion	over-expressed in invasive subpopulations of glioblastoma cells	IM3	NPA	NPA	oncogenic
562	22490015	brain	glioblastoma	NPA	miR-145	miR-145-5p	NPA	NPA	NPA	promote cell invasion	over-expressed in invasive subpopulations of glioblastoma cells	IM3	NPA	NPA	oncogenic
563	22488243	lung	non-small cell lung cancer	NPA	miR-1258	miR-1258	NPA	NPA	NPA	inhibit cell invasion	NPA	A549	NPA	cancer tissues and its adjacent tissue of 53 patients with NSCLC	tumor-suppressive
564	22484852	lung	lung cancer	NPA	miR-22	miR-22-3p	ERBB3	2065	NPA	inhibit cell proliferation|inhibit cell migration	lower in lung cancer tissues	A549|H1299	nude mice	lung cancer tissues and normal tissues	tumor-suppressive
565	22484120	liver	cholangiocarcinoma	NPA	miR-26a	miR-26a-5p	GSK3B	2932	NPA	increase cell proliferation|increase colony formation|increase tumor growth	incrased in human cholangiocarcinoma tissues and cell lines compared with the noncancerous biliary epithelial cells	CCLP1|SG231|HuCCT1|TFK1	severe combined immune-deficient mice	human cholangiocarcinoma tissues and the noncancerous biliary epithelial cells	oncogenic
566	22479643	ovary	high-grade serous ovarian carcinoma	NPA	miR-29a	miR-29a-3p	NPA	NPA	NPA	decrease cell viability	NPA	NPA	NPA	TCGA 487 high-grade serous ovarian cancers	tumor-suppressive
567	22479456	brain	proneural malignant glioma	NPA	miR-34a	miR-34a-5p	PDGFRA	5156	PDGF	inhibit cell growth	significantly lower in proneural gliomas compared to other tumor subtypes	NPA	NPA	TCGA glioblastoma samples	tumor-suppressive
568	22479342	prostate	prostate cancer	castration	let-7c	let-7c-5p	NPA	NPA	NPA	decrease cell proliferation|decrease clonogenicity|decrease anchorage-independent cell growth	downregulated in clinical PCa specimens compared to their matched benign tissues|downregulated in castration-resistant prostate cancer cells	NPA	xenografts of human PCa cells	clinical PCa specimens and their matched benign tissues	tumor-suppressive
569	22476851	breast	breast cancer	NPA	miR-30a	miR-30a-5p	VIM	7431	NPA	inhibit cell migration|inhibit cell invasion	"negatively associated with late tumor stage, lymph node metastasis, and worse progression of cancer patients"	NPA	NPA	breast cancer patients	tumor-suppressive
570	22476768	colorectum	colorectal cancer	5-FU|L-OHP|SN38	miR-21	miR-21-5p	NPA	NPA	NPA	promote cell migration|increase cell viability	significantly increased in CRC tumor tissues|significantly differentially expressed between CRC tissues of patients with CRC in different clinical stages|correlated to shorter overall survival of CRC patients	DLD-1	NPA	44 paired samples of tumoral and non-tumoral colon tissues diagnosed for CRCs	oncogenic
571	22472569	bone and muscle	osteosarcoma	NPA	miR-145	miR-145-5p	VEGFA	7422	NPA	inhibit cell invasion|inhibit angiogenesis	significantly under-expressed in osteosarcoma tissues	NPA	NPA	NPA	tumor-suppressive
572	22470493	stomach	gastric cancer	NPA	miR-223	miR-223-3p	STMN1	3925	NPA	NPA	NPA	AGS|MKN7	NPA	NPA	NPA
573	22470130	brain	glioblastoma	NPA	miR-155	miR-155-5p	NPA	NPA	NPA	increase cell proliferation	elevated in primary and secondary glioblastoma tissues as well as in glioblastoma primary cultures	NPA	NPA	93 cases of multiform glioblastoma (primary and secondary glioblastoma tumours)	oncogenic
574	22469988	head and neck	head and neck squamous cell carcinoma	NPA	miR-143	miR-143-3p	HK2	3796	NPA	NPA	NPA	NPA	NPA	NPA	NPA
575	22469983	cervix	cervical cancer	NPA	miR-424	miR-424-5p	CHEK1	1111	NPA	inhibit cell growth|increase apoptosis|block cell cycle G1/S transition|inhibit cell migration|inhibit cell invasion	"significantly decreased in 147 cervical cancer tissues versus 74 cervical normal tissues|positively correlated with poor tumor differentiation, advanced clinical stage, lymph node metastasis and other poor prognostic clinicopathological parameters"	SiHa|CaSki	NPA	147 cervical cancer tissues and 74 cervical normal tissues	tumor-suppressive
576	22469786	stomach	gastric cancer	NPA	miR-495	miR-495-3p	PTP4A3	11156	NPA	inhibit cell migration|inhibit cell invasion	downregulated in gastric carcinoma samples	NPA	NPA	gastric carcinoma samples	tumor-suppressive
577	22469786	stomach	gastric cancer	NPA	miR-551a	miR-551a	PTP4A3	11156	NPA	inhibit cell migration|inhibit cell invasion	downregulated in gastric carcinoma samples	NPA	NPA	gastric carcinoma samples	tumor-suppressive
578	22469780	blood	B-cell acute lymphoblastic leukemia	NPA	miR-125b	miR-125b-5p	ARID3A	1820	NPA	promote cell proliferation|inhibit apoptosis	overexpressed in B-ALL cases with the t(11;14)(q24;q32) translocation	NPA	NPA	NPA	oncogenic
579	22469510	lung	lung cancer	NPA	miR-26a	miR-26a-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell cycle G1/S transition|induce apoptosis|inhibit cell migration|inhibit cell invasion	down-regulated in human lung cancer tissues	A549	NPA	human lung cancer tissues and normal tissues	tumor-suppressive
580	22469014	colorectum	colorectal cancer	NPA	miR-135b	miR-135b-5p	NPA	NPA	NPA	increase cell viability	increased in CRC tumour tissues	DLD-1|HCT-116	NPA	colorectal cancer (CRC) tissues and paired non-tumoural tissues|an independent cohort of 125 clinically characterized CRC patients	oncogenic
581	22469014	colorectum	colorectal cancer	NPA	miR-215	miR-215-5p	NPA	NPA	NPA	decrease cell viability|decrease cell migration|increase apoptosis|induce cell cycle arrest	significantly decreased in colorectal cancer (CRC) tissues than paired non-tumoural tissues|correlated with clinical stage	DLD-1|HCT-116	NPA	colorectal cancer (CRC) tissues and paired non-tumoural tissues|an independent cohort of 125 clinically characterized CRC patients	tumor-suppressive
582	22469014	colorectum	colorectal cancer	NPA	miR-375	miR-375	NPA	NPA	NPA	decrease cell viability|inhibit cell cycle G1/S transition	significantly decreased in colorectal cancer (CRC) tissues than paired non-tumoural tissues	DLD-1|HCT-116	NPA	colorectal cancer (CRC) tissues and paired non-tumoural tissues|an independent cohort of 125 clinically characterized CRC patients	tumor-suppressive
583	22469014	colorectum	colorectal cancer	NPA	miR-378	miR-378-3p	NPA	NPA	NPA	inhibit cell cycle G1/S transition	significantly decreased in colorectal cancer (CRC) tissues than paired non-tumoural tissues|correlated with clinical stage	DLD-1|HCT-116	NPA	colorectal cancer (CRC) tissues and paired non-tumoural tissues|an independent cohort of 125 clinically characterized CRC patients	tumor-suppressive
584	22469014	colorectum	colorectal cancer	NPA	miR-422a	miR-422a	NPA	NPA	NPA	inhibit cell cycle G1/S transition	significantly decreased in colorectal cancer (CRC) tissues than paired non-tumoural tissues|correlated with clinical stage	DLD-1|HCT-116	NPA	colorectal cancer (CRC) tissues and paired non-tumoural tissues|an independent cohort of 125 clinically characterized CRC patients	tumor-suppressive
585	22465665	ovary	ovarian cancer	cisplatin	miR-93	miR-93-5p	PTEN	5728	NPA	inhibit apoptosis|reduce cisplatin chemosensitivity	significantly up-regulated in cisplatin-resistant ovarian cancer cells	NPA	NPA	NPA	oncogenic
586	22465663	brain	glioma	NPA	miR-483-5p	miR-483-5p	MAPK3	5595	NPA	inhibit cell proliferation|induce cell cycle G0/G1 arrest	significantly down-regulated in gliomas	NPA	NPA	human glioblastoma tissues and the adjacent normal brain tissues	tumor-suppressive
587	22464652	stomach	gastric cancer	NPA	miR-21	miR-21-5p	SERPINI1	5274	NPA	NPA	NPA	NPA	NPA	NPA	oncogenic
588	22460089	uterus	endometrioid endometrial cancer	NPA	miR-125b	miR-125b-5p	ERBB2	2064	NPA	inhibit cell invasion	down-regulated in human endometrioid endometrial cancer (EEC) specimens compared to that in NC specimens	HEC1B	NPA	human endometrioid endometrial cancer (EEC) and normal endometrium (NE) samples	tumor-suppressive
589	22459450	colorectum	colon cancer	NPA	miR-320a	miR-320a	CTNNB1	1499	NPA	inhibit cell proliferation	frequently downregulated in cancer cell lines and colon cancer tissues	NPA	NPA	colon cancer tissues	tumor-suppressive
590	22457808	esophagus	esophageal squamous cell carcinoma	NPA	miR-143	miR-143-3p	FSCN1	6624	NPA	NPA	statistically different between cancer tissues and matched controls|significantly associated with the risk for esophageal cancer|negatively correlated with a trend of lymph node metastases	NPA	NPA	110 pairs of esophageal cancer tissues and adjacent normal tissues	NPA
591	22457808	esophagus	esophageal squamous cell carcinoma	NPA	miR-145	miR-145-5p	FSCN1	6624	NPA	NPA	statistically different between cancer tissues and matched controls|significantly associated with the risk for esophageal cancer|negatively correlated with a trend of lymph node metastases	NPA	NPA	110 pairs of esophageal cancer tissues and adjacent normal tissues	NPA
592	22457788	bone and muscle	osteosarcoma	NPA	miR-34a	miR-34a-5p	MET	4233	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion|inhibit tumor growth|inhibit pulmonary metastasis	NPA	NPA	NPA	NPA	tumor-suppressive
593	22456107	colorectum	colorectal cancer	NPA	miR-372	miR-372-3p	NPA	NPA	NPA	promote cell proliferation	an independent prognostic factor|associated with synchronous liver metastasis	LoVo	NPA	144 CRC patients	oncogenic
594	22453125	colorectum	colorectal cancer stem-like cells	NPA	miR-328	miR-328-3p	ABCG2|MMP16	9429|4325	NPA	reduce the number of SP cells|reduce drug resistance|inhibit cell invasion	significantly reduced in side population (SP) cells compared with Non-SP cells	NPA	NPA	NPA	tumor-suppressive
595	22450781	stomach	gastric cancer	NPA	miR-101	miR-101-3p	NPA	NPA	genomic_deletion	cause E-cadherin dysfunction	significantly down-regulated in gastric cancer (p < 0.0089) in comparison with normal gastric mucosas	Kato III	NPA	gastric cancer tissues and normal gastric mucosas	NPA
596	22450659	stomach	gastric cancer	NPA	miR-124	miR-124-3p	SPHK1	8877	NPA	inhibit cell proliferation|inhibit tumorigenicity|inhibit AKT signaling	NPA	NPA	NPA	NPA	tumor-suppressive
597	22450326	esophagus	esophageal squamous cell carcinoma	NPA	miR-25	miR-25-3p	CDH1	51343	NPA	promote cell migration|promote cell invasion	"up-regulated in 60 esophageal squamous cell carcinoma (ESCC) tissues compared with matched adjacent non-cancer tissues|correlated with the status of lymph node metastasis and TNM (Tumor, Node and Metastasis) stage"	NPA	NPA	60 esophageal squamous cell carcinoma (ESCC) tissues and matched adjacent non-cancer tissues	oncogenic
598	22449978	cervix	cervical cancer	NPA	miR-20a	miR-20a-5p	TNKS2	80351	NPA	increase long-term cell proliferation|increase cell migration|increase cell invasion	upregulated in cervical cancer tissues	HeLa|C-33A	NPA	cervical cancer tissues	oncogenic
599	22449976	liver	hepatocellular carcinoma	NPA	miR-219-5p	miR-219-5p	GPC3	2719	NPA	inhibit cell proliferation|block cell cycle G1/S transition	"significantly downregulated in 83 HCC tissues and three HCC cell lines, compared to their non-tumor counterparts|correlated with tumor size, histological differentiation, and overall survival time in HCC patients"	NPA	NPA	83 HCC tissues	tumor-suppressive
600	22448917	blood	leukemia	NPA	miR-297b-3p	NO_RECORD	MLLT3	4300	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion|induce cell cycle arrest|inhibit tumor growth	NPA	NPA	xenograft tumor in the nude mouse	NPA	tumor-suppressive
601	22448917	blood	leukemia	NPA	miR-297b-5p	NO_RECORD	MLLT3	4300	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion|induce cell cycle arrest|inhibit tumor growth	NPA	NPA	xenograft tumor in the nude mouse	NPA	tumor-suppressive
602	22446874	liver	hepatocellular carcinoma	NPA	miR-421	miR-421	FXR	9971	NPA	promote cell proliferation|promote cell migration|promote invasion of HCC cells	inversely correlated with FXR protein level in HCC cell lines	NPA	NPA	NPA	oncogenic
603	22442719	prostate	prostate cancer	"3,3'-diindolylmethane"	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	EZH2	2146	NPA	reduce clonogenic abilit|reduce sphere-forming capacity	"downregulated in human prostate cancer tissue specimens, especially in higher Gleason grade tumors"	NPA	NPA	prostate cancer tissues	tumor-suppressive
604	22442671	blood	chronic myelogenous leukemia	NPA	miR-181a	miR-181a-5p	RALA	5898	NPA	inhibit cell growth|induce cell cycle G2 arrest|induce apoptosis	NPA	K562	NPA	NPA	tumor-suppressive
605	22442669	brain	glioma	NPA	miR-128	miR-128-3p	RPS6KB1	6198	NPA	inhibit cell proliferation|inhibit tumor growth|inhibit angiogenesis	decreased in glioma	NPA	NPA	glioma samples	tumor-suppressive
606	22439757	breast	breast cancer	NPA	miR-135a	miR-135a-5p	HOXA10	3206	NPA	promote cell migration|promote cell invasion	highly expressed in metastatic breast tumors	NPA	NPA	breast cancer tissues	oncogenic
607	22438124	lung	lung cancer	delta-tocotrienol	miR-34a	miR-34a-5p	NPA	NPA	NOTCH1	inhibit cell growth|inhibit cell invasiveness|induce apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
608	22435731	breast	third-sphere forming breast cancer stem cell-like cells	NPA	miR-21	miR-21-5p	NPA	NPA	NPA	promote epithelial-mesenchymal transition|promote cell invasion|promote cell migration	upregulated in the cancer stem cell-like cells	NPA	NPA	NPA	oncogenic
609	22433310	liver	hepatocellular carcinoma	HBx	miR-192	miR-192-5p	NPA	NPA	NPA	induce apoptosis	NPA	HepG2	NPA	NPA	tumor-suppressive
610	22433309	liver	hepatocellular carcinoma	NPA	let-7c	let-7c-5p	NPA	NPA	NPA	inhibit cell proliferation|induce cell cycle G1 arrest	NPA	HCCLM3	NPA	NPA	tumor-suppressive
611	22431721	kidney	renal childhood neoplasms	NPA	miR-141	miR-141-3p	ACVR2B	93	NPA	NPA	significantly downregulated in nephroblastomas	NPA	NPA	55 nephroblastomas	NPA
612	22431721	kidney	renal childhood neoplasms	NPA	miR-192	miR-192-5p	ACVR2B	93	NPA	NPA	significantly downregulated in nephroblastomas	NPA	NPA	55 nephroblastomas	NPA
613	22431721	kidney	renal childhood neoplasms	NPA	miR-194	miR-194-5p	ACVR2B	93	NPA	NPA	significantly downregulated in nephroblastomas	NPA	NPA	55 nephroblastomas	NPA
614	22431721	kidney	renal childhood neoplasms	NPA	miR-200c	miR-200c-3p	ACVR2B	93	NPA	NPA	significantly downregulated in nephroblastomas	NPA	NPA	55 nephroblastomas	NPA
615	22431721	kidney	renal childhood neoplasms	NPA	miR-215	miR-215-5p	ACVR2B	93	NPA	NPA	significantly downregulated in nephroblastomas	NPA	NPA	55 nephroblastomas	NPA
616	22431718	liver	hepatocellular carcinoma	NPA	miR-145	miR-145-5p	IRS1|IRS2	3667|8660	NPA	induce G(2)-M cell cycle arrest|induce apoptosis|inhibit cell viability|inhibit cell proliferation	reduced in 50% tumor|negatively correlated with a shorter disease-free survival of patients	HKCI-C2	NPA	80 HCC patients	tumor-suppressive
617	22431589	brain	glioblastoma multiforme	NPA	miR-25	miR-25-3p	MDM2|TSC1	4193|7248	TP53|E2F1|MYC	inhibit cell proliferation|induce cell cycle arrest	NPA	NPA	glioblastoma multiforme cells in mouse brain	NPA	tumor-suppressive
618	22431589	brain	glioblastoma multiforme	NPA	miR-32	miR-32-5p	MDM2|TSC1	4193|7248	TP53|E2F1|MYC	inhibit cell proliferation|induce cell cycle arrest	NPA	NPA	glioblastoma multiforme cells in mouse brain	NPA	tumor-suppressive
619	22426647	stomach	gastric cancer	5-Aza-2-deoxycytidine	miR-155	miR-155-5p	SMAD2	4087	NPA	inhibit cell migration|inhibit cell invasion|reduce cell adhesion	significantly downregulated in gastric cancer cell lines compared with an immortalized gastric epithelial cell line	SGC-7901|MKN-45|GES-1	NPA	NPA	tumor-suppressive
620	22426479	lung	lung cancer	NPA	miR-542-5p	miR-542-5p	EGFR	1956	NPA	inhibit cell growth	NPA	H3255|A549|Hcc827	NPA	human lung cancer tissue samples	tumor-suppressive
621	22425712	head and neck	head and neck squamous cell carcinoma	NPA	miR-100	miR-100-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell migration|induce apoptosis	downregulated in cancer tissues	NPA	NPA	a set of HNSCC cases	tumor-suppressive
622	22420029	stomach	gastric cancer	NPA	miR-196a	miR-196a-5p	NPA	NPA	NPA	promote epithelial-mesenchymal transition|increase cell migration|increase cell invasion	significantly increased in primary gastric cancer tissues versus adjacent normal tissues	NPA	NPA	72 gastric cancer samples	oncogenic
623	22419847	skin	uveal melanoma	doxorubicin	miR-34b	miR-34b-5p	MET	4233	NPA	reduce cell growth|reduce cell migration|induce cell cycle G1 arrest	dramatically decreased in uveal melanoma cells and clinical samples	NPA	NPA	uveal melanoma clinical samples	tumor-suppressive
624	22419847	skin	uveal melanoma	doxorubicin	miR-34c	miR-34c-5p	MET	4233	NPA	reduce cell growth|reduce cell migration|induce cell cycle G1 arrest	dramatically decreased in uveal melanoma cells and clinical samples	NPA	NPA	uveal melanoma clinical samples	tumor-suppressive
625	22414602	NPA	NPA	NPA	miR-96	miR-96-5p	ALK	238	NPA	reduce cell proliferation|reduce colony formation|reduce cell migration	markedly decreased in ALK-expressing cancer cell lines and primary human tumors compared with their normal cellular and tissue counterparts	NPA	NPA	primary human tumors and their normal tissue counterparts	tumor-suppressive
626	22411914	brain	medulloblastoma	NPA	miR-199b-5p	miR-199b-5p	FUT4	2526	HES1	NPA	significantly decreased in metastatic cases	NPA	NPA	medulloblastoma tissues	NPA
627	22407818	breast	oestrogen receptor-positive postmenopausal breast cancer	letrozole	let-7f	let-7f-5p	CYP19A1	1588	NPA	reduce cell proliferation|reduce cell migration	NPA	MCF-7|SK-BR-3	NPA	NPA	tumor-suppressive
628	22407312	pancreas	pancreatic cancer	NPA	miR-10a	miR-10a-5p	NPA	NPA	NPA	promote cell invasion	overexpressed in pancreatic cancer cells isolated from a subset of primary tumors compared with precursor lesions and normal ducts	NPA	NPA	20 primary pancreatic cancer tissues	oncogenic
629	22407310	colorectum	colon cancer	NPA	miR-200c	miR-200c-3p	ZEB1	6935	NPA	inhibit cell migration|inhibit cell invasion	NPA	SW480|SW620	NPA	NPA	tumor-suppressive
630	22407299	prostate	prostate cancer	NPA	miR-133a	miR-133a-3p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion	NPA	Du145|PC3	NPA	NPA	tumor-suppressive
631	22407299	prostate	prostate cancer	NPA	miR-133b	miR-133b	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion	NPA	Du145|PC3	NPA	NPA	tumor-suppressive
632	22406049	brain	glioma	NPA	miR-137	miR-137	COX2	5743	NPA	inhibit cell proliferation|inhibit cell invasion	downregulated in glioma samples and glioma cells	NPA	NPA	glioma samples	tumor-suppressive
633	22402744	brain	medulloblastoma	rapamycin	miR-183~96~182	CLUSTER:miR-183~96~182	NPA	NPA	NPA	inhibit apoptosis|incease cell migration	NPA	NPA	NPA	NPA	oncogenic
634	22402125	prostate	prostate cancer	NPA	miR-29b	miR-29b-3p	NPA	NPA	NPA	inhibit wound healing|inhibit cell invasion|inhibit colony formation	significant downregulated in human prostate cancer tissues as compared with patient-matched nontumor tissues	PC3|LNCaP	severe combined immunodeficient mice	human prostate cancer tissues and patient-matched nontumor tissues	tumor-suppressive
635	22399519	thyroid	anaplastic thyroid carcinoma	NPA	miR-25	miR-25-3p	EZH2	2146	NPA	inhibit cell proliferation|inhibit colony formation|induce cell cycle G2/M arrest	NPA	ACT-1|8505c|FRO	NPA	NPA	tumor-suppressive
636	22399519	thyroid	anaplastic thyroid carcinoma	NPA	miR-30d	miR-30d-5p	EZH2	2146	NPA	inhibit cell proliferation|inhibit colony formation|induce cell cycle G2/M arrest	NPA	ACT-1|8505c|FRO	NPA	NPA	tumor-suppressive
637	22399294	cervix	cervical cancer	NPA	miR-214	miR-214-3p	GALNT7	117248	NPA	reduce cell proliferation|reduce cell migration|reduce cell invasion	frequently down-regulated in cervical cancer	NPA	NPA	cervical cancer tissues	tumor-suppressive
638	22395361	blood	chronic myeloid leukemia	imatinib	miR-30a	miR-30a-5p	NPA	NPA	NPA	increase imatinib induced cytotoxicity|induce apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
639	22393463	breast	breast cancer	NPA	miR-203	miR-203a	SNAI2	6591	promoter DNA hypermethylation	induce cell cycle arrest|induce apoptosis|inhibit cell invasion|inhibit cell migration	upregulated in primary tumors and some nonmetastatic cell lines|downregulated in metastatic cell lines	BT549|Hs578T|MDA-MB-231	NPA	primary breast cancer tissues	tumor-suppressive
640	22392644	liver	hepatocellular carcinoma	Hepatitis B virus X protein (HBx)	miR-216a	miR-216a-5p	CADM1	23705	AR	NPA	upregulated starting from the precancerous stage|elevated mainly in male patients	NPA	NPA	precancerous and cancerous liver tissues	oncogenic
641	22391564	prostate	prostate carcinoma	castration	miR-130a	miR-130a-3p	NPA	NPA	NPA	repress MAPK signaling|repress AR signaling|induce morphological changes|inhibit tumor growth|induce apoptosis|induce cell cycle arrest	downregulated in cancer tissue	LNCaP	NPA	prostate cancer tissue	tumor-suppressive
642	22391564	prostate	prostate carcinoma	castration	miR-203	miR-203a	NPA	NPA	NPA	repress MAPK signaling|repress AR signaling|induce morphological changes|inhibit tumor growth|induce apoptosis|induce cell cycle arrest	downregulated in cancer tissue	LNCaP	NPA	prostate cancer tissue	tumor-suppressive
643	22391564	prostate	prostate carcinoma	castration	miR-205	miR-205-5p	NPA	NPA	NPA	repress MAPK signaling|repress AR signaling|induce morphological changes|inhibit tumor growth|induce apoptosis|induce cell cycle arrest	downregulated in cancer tissue	LNCaP	NPA	prostate cancer tissue	tumor-suppressive
644	22388101	stomach	gastric cancer	NPA	miR-409-3p	miR-409-3p	PHF10	55274	NPA	inhibit cell proliferation|induce cell apoptosis	significantly downregulated in gastric cancer (GC) cell lines and tissues	SGC-7901	NPA	gastric cancer tissues	tumor-suppressive
645	22387901	liver	hepatocellular carcinoma	hypoxia	miR-210	miR-210-3p	AIFM3	150209	NPA	increase cell viability|reduce G0/G1 cell cycle arrest|reduce apoptosis|reduce radiosensitivity	upregulated in hypoxia cancer cell lines	SMMC-7721|HepG2|Huh7	NPA	NPA	oncogenic
646	22384170	colorectum	colon cancer progenitor cells (CD133+)	NPA	miR-302b	miR-302b-3p	NPA	NPA	ASCL2	restore stemness characteristics|increase tumorsphere formation|increase colony formation|increase cell invasion|increase cell migration	NPA	HT-29|LS174T	NPA	NPA	oncogenic
647	22384141	pancreas	pancreatic ductal adenocarcinoma	NPA	miR-126	miR-126-3p	KRAS	3845	NPA	NPA	downregulated in pancreatic ductal adenocarcinomas (PDAC) compared to low malignant potential pancreatic benign cystic tumors (BCT)	NPA	NPA	pancreatic ductal adenocarcinomas (PDAC) and pancreatic benign cystic tumors (BCT)	NPA
648	22384020	breast	breast cancer	trastuzumab	miR-26a	miR-26a-5p	NPA	NPA	NPA	inhibit cell growth|induce cell cycle G1 arrest in HER2+ cancer cells|induce apoptosis in HER2+ cancer cells	NPA	MCF7|MDA-MB-231	NPA	NPA	tumor-suppressive
649	22384020	breast	breast cancer	trastuzumab	miR-30b	miR-30b-5p	CCNE2	9134	NPA	inhibit cell growth|induce cell cycle G1 arrest in HER2+ cancer cells	NPA	MCF7|MDA-MB-231	NPA	NPA	tumor-suppressive
650	22382496	nerve	neuroblastoma	NPA	miR-335	miR-335-5p	ROCK1|MAPK1|LRG1	6093|5594|116844	MYCN	inhibit cell invasion|inhibit cell migration	NPA	NPA	NPA	NPA	tumor-suppressive
651	22378464	bladder	bladder cancer	NPA	miR-1	miR-1	PTMA|PNP	5757|5539	NPA	inhibit cell proliferation|inhibit cell invasion|induce apoptosis	significantly reduced in cancer cells	NPA	NPA	NPA	tumor-suppressive
652	22378464	bladder	bladder cancer	NPA	miR-133a	miR-133a-3p	PTMA|PNP	5757|5539	NPA	inhibit cell proliferation|inhibit cell invasion|induce apoptosis	significantly reduced in cancer cells	NPA	NPA	NPA	tumor-suppressive
653	22378351	head and neck	head and neck squamous cell carcinoma	NPA	miR-133a	miR-133a-3p	ARPC5	10092	NPA	"actin cytoskeleton reorganization|change cell morphology to a round, bleb-like shape"	NPA	SAS|HSC3|IMC-3	NPA	NPA	tumor-suppressive
654	22378186	liver	hepatocellular carcinoma stem-like cells	NPA	miR-145	miR-145-5p	NPA	NPA	NPA	induce senescence-like cell cycle G1 arrest|inhibit clonogenic cell expansion|inhibit xenograft tumor growth|inhibit tumorsphere growth	expressed lower in cancer stem-like cells than the other cell lines	T3A-A3|BEL-7402|LSEC	nude mice xenograft tumor	NPA	tumor-suppressive
655	22374871	blood	acute myeloid leukemia	NPA	miR-199b-5p	miR-199b-5p	PODXL|DDR1	5420|780	NPA	inhibit in collagen IV induced migration	significantly decreased in most AML patients	K562	NPA	"M2, M4, and M1 FAB-subtype patients"	tumor-suppressive
656	22374676	head and neck	nasopharyngeal carcinoma	radiation	miR-205	miR-205-5p	PTEN	5728	NPA	increase foci formation|reduce apoptosis	significantly elevated followed the radiotherapy in NPC patients	CNE-2	NPA	NPA	oncogenic
657	22373864	liver	hepatocellular carcinoma	NPA	miR-301a	miR-301a-3p	MEOX2	4223	NPA	increasing cell proliferation|increase cell migration|increase cell invasion|inhibit apoptosis|activate NF-¦ÊB signaling	significantly upregulated in HCC samples compared with in the matching nontumoral tissues	NPA	NPA	HCC tissues and adjacent non-tumorous tissues	oncogenic
658	22373578	colorectum	colon cancer liver metastasis	NPA	miR-493	miR-493-3p	IGF1R	3480	NPA	inhibit retention of metastasized cells|indce cell death	inversely related to the presence of liver metastasis	NPA	NPA	primary colon cancer tissues	tumor-suppressive
659	22370644	stomach	gastric cancer	NPA	miR-145	miR-145-5p	CDH2	1000	NPA	inhibit cell migration|inhibit cell invasion|inhibit metastasis|impair local invasion	"stepwise downregulated in nontumorous gastric mucosa, primary gastric cancers and their secondary metastases"	NPA	NPA	"nontumorous gastric mucosa, primary gastric cancers and their secondary metastases"	tumor-suppressive
660	22370643	prostate	prostate adenocarcinoma	NPA	miR-1	miR-1	SNAI2	6591	SNAI2	inhibit epithelial-mesenchymal transition	reduced with progression of prostate adenocarcinoma	NPA	mouse model	prostate adenocarcinoma tissues	tumor-suppressive
661	22370643	prostate	prostate adenocarcinoma	NPA	miR-200	miR-200a-3p|miR-200b-3p|miR-200c-3p	SNAI2	6591	SNAI2	inhibit epithelial-mesenchymal transition	reduced with progression of prostate adenocarcinoma	NPA	mouse model	prostate adenocarcinoma tissues	tumor-suppressive
662	22370637	lung	non-small cell lung cancer	paclitaxel	miR-34c-5p	miR-34c-5p	BMF|MYC	90427|4609	NPA	increase the resistance of paclitaxel-induced apoptosis	NPA	A549	NPA	NPA	NPA
663	22369946	kidney	renal cell carcinoma	NPA	miR-508-3p	miR-508-3p	NPA	NPA	NPA	inhibit cell proliferation|induce apoptosis|inhibit cell migration	down-regulated in renal cancer tissues	786-0	NPA	renal cancer tissues	tumor-suppressive
664	22369946	kidney	renal cell carcinoma	NPA	miR-509-3p	miR-509-3p	NPA	NPA	NPA	inhibit cell proliferation|induce apoptosis|inhibit cell migration	down-regulated in renal cancer tissues	786-0	NPA	renal cancer tissues	tumor-suppressive
665	22362744	blood	T-cell acute lymphoblastic leukemia	NPA	miR-19	miR-19a-3p	CYLD	1540	NPA	NPA	highly expressed in T-ALL patients and cell lines	NPA	NPA	T-ALL patients	NPA
666	22362728	liver	hepatocellular carcinoma	NPA	miR-138	miR-138-5p	CCND3	896	NPA	reduce cell viability|reduce colony formation|inhibit tumor cell growth in xenograft nude mice	downregulated in 77.8%(14/18) of HCC tissues compared with adjacent non-tumor tissues	NPA	xenograft nude mice	18 HCC tissues and adjacent non-tumor tissues	tumor-suppressive
667	22359598	liver	hepatocellular carcinoma	thapsigargin|tunicamycin|hypoxia	miR-214	miR-214-3p	XBP1	7495	NF-kB	inhibit cell proliferation|induce apoptosis|inhibit colony formation|reduce tumor in nude mice	"significantly reduced in the majority of examined 23 HCC tissues and HepG2 and SMMC-7721 cell lines, compared with their nontumor counterparts"	SMMC-7721|HepG2	xenotransplantation model of the BALB/c athymic nude mice	23 HCC tissues and nontumor counterparts	tumor-suppressive
668	22357618	lung	non-small cell lung cancer	4'-12-O-tetradecanoylphorbol-13-acetate (TPA)	miR-212	miR-212-3p	PTCH1	5727	NPA	promote cell cycle progression|promote cell proliferation|promote cell migration|promote cell invasion	NPA	NPA	NPA	NPA	oncogenic
669	22354972	skin	melanoma	NPA	miR-203	miR-203a	E2F3|ZNF148	1871|7707	NPA	induce cell cycle arrest|induce cell senescence	NPA	Mewo	NPA	NPA	tumor-suppressive
670	22353936	colorectum	colon cancer	NPA	miR-101	miR-101-3p	PTGER4	5734	NPA	reduce cell proliferation|inhibit cell motility	NPA	LS174T	NPA	26 colon cancers (i.e. 15 adenocarcinomas and 9 adenomas) and 16 normal colon specimens	tumor-suppressive
671	22353710	blood	mixed lineage leukaemia (MLL)-rearranged leukaemia	NPA	miR-196b	miR-196b-5p	HOXA9|MEIS1	3205|4211	NPA	NPA	NPA	NPA	NPA	NPA	NPA
672	22350415	blood	chronic lymphocytic leukemia	NPA	miR-130a	miR-130a-3p	ATG2B|DICER1	55102|23405	NPA	inhibit autophagy|reduce autophagosome formation|modulate cell survival	NPA	NPA	NPA	NPA	NPA
673	22350414	bone and muscle	liposarcoma	NPA	miR-155	miR-155-5p	CSNK1A1	1452	NPA	increase cell growth|increase colony foramtion|reduce cell cycle G1/S arrest|promote tumor growth	most overexpressed in liposarcoma samples	NPA	murine xenografts	human liposarcomas and normal fat specimens	oncogenic
674	22348345	blood	Nucleophosmin1 mutated acute myeloid leukaemia	NPA	miR-10a	miR-10a-5p	KLF4|RB1CC1	9314|9821	NPA	inhibit cell death|increase clonogenic capacity	most differentially overexpressed in NPM1mut-AML versus NPM1wildtype-AML (> 10 fold higher as confirmed by qRT-PCR)	OCI-AML3	NPA	NPM1mut-AML and NPM1wildtype-AML	oncogenic
675	22348245	colorectum	colorectal cancer	NPA	miR-146a	miR-146a-5p	MMP16	4325	NPA	reduce cell invasion	increased in the course of differentiating Caco-2 cell line	Caco-2|HT-29	NPA	NPA	tumor-suppressive
676	22347428	kidney	renal cancer	genistein	miR-21	miR-21-5p	NPA	NPA	NPA	promote cell cycle|inhibit apoptosis|increase cell invasion|increase cell migration	increased in cancer tissues (in 48/90% cases)	A-498	A-498 cells in nude mice	54 pairs of kidney cancers and their normal matched tissues	oncogenic
677	22344632	pancreas	pancreatic cancer	NPA	miR-31	miR-31-5p	NPA	NPA	NPA	reduce cell proliferation|reduce cell migration|reduce cell invasion	NPA	AsPC-1|HPAF-II	NPA	16 pancreatic cancer cell lines and four normal pancreatic samples	tumor-suppressive
678	22343731	stomach	gastric cancer	NPA	miR-196a	miR-196a-5p	CDKN1B	1027	NPA	increase cell cycle progression|increase cell proliferation|increase colony formation|increase tumor growth	"positively associated with tumor size, a higher clinical stage, and shorter overall survival of patients"	SGC7901	nude mice	gastric cancer tissues	oncogenic
679	22343615	colorectum	colorectal cancer	NPA	miR-1	miR-1	MET	4233	NPA	reduce cell proliferation|reduce motility	significantly downregulated in cancer tissues	NPA	NPA	40 colorectal cancers and their paired normal tissues	tumor-suppressive
680	22335905	lung	non-small cell lung cancer	NPA	miR-21	miR-21-5p	PDCD4	27250	NPA	increase cell proliferation|reduce apoptosis	2.24-fold higher in the NSCLC and 3.06-fold higher in the A549 cells than that in the adjacent normal tissues	A549	NPA	NSCLC and adjacent normal tissues	oncogenic
681	22333974	breast	breast cancer	NPA	miR-124	miR-124-3p	NPA	NPA	NPA	regulate EGFR signaling|inhibit cell cycle progression|inhibit cell proliferation	NPA	NPA	NPA	NPA	tumor-suppressive
682	22333974	breast	breast cancer	NPA	miR-147	miR-147a|miR-147b	NPA	NPA	NPA	regulate EGFR signaling|inhibit cell cycle progression|inhibit cell proliferation	NPA	NPA	NPA	NPA	tumor-suppressive
683	22333974	breast	breast cancer	NPA	miR-193a-3p	miR-193a-3p	NPA	NPA	NPA	regulate EGFR signaling|inhibit cell cycle progression|inhibit cell proliferation	NPA	NPA	NPA	NPA	tumor-suppressive
684	22330340	bone and muscle	rhabdomyosarcoma	NPA	miR-29	miR-29a-3p|miR-29b-3p|miR-29c-3p	CCND2|E2F7	894|144455	NPA	induce cell cycle G1 arrest|decrease cell proliferation	NPA	JR1|Rh30	NPA	NPA	tumor-suppressive
685	22330141	cervix	cervical cancer	NPA	miR-9	miR-9-5p	NPA	NPA	NPA	increase cell viability|increase cell growth|increase cell migration	significantly differentially expressed during the consecutive stages of cervical SCC development	NPA	NPA	"normal cervical squamous epithelium, high-grade precancerous lesions (cervical intraepithelial neoplasia (CIN2-3)), squamous cell carcinomas (SCCs) and adenocarcinomas"	oncogenic
686	22330136	NPA	NPA	NPA	miR-143	miR-143-3p	MDM2	4193	TP53	inhibit cell growth|induce apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
687	22330136	NPA	NPA	NPA	miR-145	miR-145-5p	MDM2	4193	TP53	inhibit cell growth|induce apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
688	22328083	colorectum	colon cancer	vitamin D	miR-22	miR-22-3p	NPA	NPA	VDR	inhibit cell migration|inhibit cell proliferation	lower in the tumour than in the matched normal tissue	HCT116|SW480	NPA	50 human colon cancer patients	tumor-suppressive
689	22326755	kidney	renal cell carcinoma	NPA	miR-17-5p	miR-17-5p	VHL|HIF1A	7428|3091	NPA	NPA	NPA	NPA	NPA	NPA	NPA
690	22326755	kidney	renal cell carcinoma	NPA	miR-224	miR-224-5p	VHL|HIF1A	7428|3091	NPA	NPA	NPA	NPA	NPA	NPA	NPA
691	22326282	bone and muscle	giant cell tumor	NPA	miR-224	miR-224-5p	API5|SMAD5|SLMAP|H3F3B	8539|4090|7871|3021	NPA	NPA	significantly differentially expressed in GCTSCs and MSCs	NPA	NPA	giant cell tumor derived stromal cells and mesenchymal stem cells	NPA
692	22325466	stomach	gastric adenocarcinoma	NPA	miR-182	miR-182-5p	CREB1	1385	NPA	inhibit cell proliferation|inhibit colony formation	significantly downregulated in human gastric adenocarcinoma tissue samples	NPA	NPA	a large sample of gastric tissue samples	tumor-suppressive
693	22322955	colorectum	colorectal cancer	5-fluorouracil	miR-10b	miR-10b-5p	BCL2L11	10018	NPA	induce 5-FU chemoresistance	significantly associated with high incidence of lymphatic invasion (P = 0.0257) and poor prognosis (P = 0.0057)	NPA	NPA	88 colorectal cancer cases	NPA
694	22322911	stomach	gastric cancer	NPA	miR-125a-3p	miR-125a-3p	NPA	NPA	NPA	inhibit cell proliferation	"negatively correlated tumor size (p=0.0002), tumor invasion (p=0.0149), lymph node metastasis (p=0.018), liver metastasis (p=0.016), peritoneal dissemination (p=0.03), advanced clinical stage (p=0.0037) and poor prognosis (p=0.0083)"	NPA	NPA	70 gastric cancer cases	tumor-suppressive
695	22322863	ovary	high-grade serous ovarian carcinoma	NPA	miR-182	miR-182-5p	NPA	NPA	NPA	increase tumor transformation|increase cell invasion|increase metastasis	significantly higher in serious tubal intraepithelial carcinoma (STIC) than in matched normal Fallopian tube	NPA	NPA	serious tubal intraepithelial carcinoma (STIC) and matched normal Fallopian tube	oncogenic
696	22322403	liver	hepatocellular carcinoma	NPA	miR-21	miR-21-5p	PDCD4	27250	AP-1	increase cell migration|increase cell invasion	"significantly upregulated in HCC tissues and cell lines, compared with adjacent non-tumor tissues and normal hepatic cells"	NPA	NPA	"HCC tissues, adjacent non-tumor tissues and normal hepatic cells"	oncogenic
697	22321642	stomach	gastric cancer	NPA	miR-222	miR-222-3p	RECK	8434	NPA	promote cell proliferation|promote colony formation	up-regulated in H.pylori-infected gastric mucosa and gastric cancer	NPA	NPA	H.pylori-infected gastric mucosa and gastric cancer	oncogenic
698	22320217	liver	hepatocellular carcinoma	NPA	miR-30c-1*	miR-30c-1-3p	HMBOX1	79618	NPA	promote NK cell cytotoxicity	NPA	SMMC-7721|HepG2	NPA	NPA	NPA
699	22319632	liver	hepatocellular carcinoma	NPA	miR-520b	miR-520b	MEKK2|CCND1	10746|595	NPA	suppress cell growth	significantly reduced in clinical HCC tissues and hepatoma cell lines	NPA	NPA	clinical HCC tissues 	tumor-suppressive
700	22318941	liver	hepatocellular carcinoma	NPA	miR-23a	miR-23a-3p	PPARGC1A|G6PC	10891|2538	IL6|STAT3	NPA	up-regulated in the mouse liver tumors as well as in primary human HCC	"mouse model (mice fed a choline-deficient diet) that develops nonalcoholic steatohepatitis (NASH), preneoplastic nodules, and hepatocellular carcinoma (HCC)"	NPA	human primary HCCs	NPA
701	22316494	blood	multiple myeloma	NPA	miR-21	miR-21-5p	PIAS3	10401	NPA	increase STAT3 signaling|increase cell growth|increase cell cycle progression|inhibit apoptosis	NPA	U266	NPA	NPA	oncogenic
702	22315007	esophagus	esophageal squamous cell carcinoma	NPA	miR-1322	miR-1322	SPINK7	84651	NPA	NPA	significantly upregulated in ESCC tissue and serum samples than in controls	NPA	NPA	44 paired ESCC and adjacent normal tissues and 402 case-controlled serum samples	NPA
703	22314666	prostate	prostate cancer	phenethyl isothiocyanate	miR-141	miR-141-3p	NR0B2	8431	NPA	NPA	upregulated in PCa cells	LNCaP	NPA	NPA	NPA
704	22311119	stomach	gastric carcinoma	NPA	miR-200b	miR-200b-3p	NPA	NPA	NPA	change the cell morphology from fibroblast- to epithelial-like|inhibit cell proliferation|inhibit cell migration|inhibit cell invasion	"negatively associated with diffuse histologic type, depth of tumor, tumor size, lymph node metastasis, and lymphatic invasion"	NPA	NPA	40 gastric cancer patients who underwent gastrectomy from 2008 to 2010	tumor-suppressive
705	22310976	stomach	gastric cancer	NPA	miR-135a	miR-135a-5p	JAK2	3717	NPA	reduce cell proliferation|reduce colony formation	"downregulated in the majority of human primary gastric cancer tissues (8/11; 73%), compared with pair-matched adjacent non-tumor tissues"	GES-1	NPA	11 human primary gastric cancer tissues and pair-matched adjacent non-tumor tissues	tumor-suppressive
706	22310293	blood	Hodgkin lymphoma	NPA	miR-9	miR-9-5p	DICER1|ELAVL1	23405|1994	NPA	increase tumor outgrowth	NPA	NPA	a xenograft model of HL	NPA	oncogenic
707	22310291	prostate	prostate cancer	5-aza-2'-deoxycytidine	miR-132	miR-132-3p	TLN2|HBEGF	83660|1839	DNA hypermethylation	induce cell detachment|induce cell death (anoikis)	downregulated in methylated prostate cancer samples	PC3	NPA	50 human prostate carcinoma specimens and 24 normal controls	tumor-suppressive
708	22308110	colorectum	colorectal cancer	butyrate|suberoylanilide hydroxamic acid (SAHA)|trichostatin A (TSA)	miR-18a	miR-18a-5p	CDK19|NEDD9	23097|4739	NPA	inhibit cell growth	NPA	HT29|HCT116	NPA	NPA	tumor-suppressive
709	22307849	kidney	renal cell carcinoma	NPA	miR-155	miR-155-5p	NPA	NPA	NPA	promote cell proliferation|promote cell migration|inhibit apoptosis	upregulated in clear cell RCC (ccRCC) tissue and renal cancer cell lines	NPA	NPA	renal cancers and matched adjacent non-tumor tissues	oncogenic
710	22307404	breast	breast cancer	NPA	miR-125b	miR-125b-5p	ARID3B	10620	NPA	reduce cell motility|reduce cell migration	decreased in 14 out of 19 breast cancer cell lines	MCF7	NPA	NPA	tumor-suppressive
711	22306317	head and neck	laryngeal carcinoma	NPA	miR-203	miR-203a	BIRC5	332	NPA	inhibit cell growth|induce cell cycle G1 arrest	NPA	NPA	NPA	NPA	tumor-suppressive
712	22306127	NPA	NPA	NPA	miR-134	miR-134-5p	DPYD	1806	NPA	NPA	significantly lower in the tumors than normal lung tissue	HepG2|MIAPaca-2	NPA	lung tumors and normal tissue	NPA
713	22306127	NPA	NPA	NPA	miR-27a	miR-27a-3p	DPYD	1806	NPA	NPA	NPA	HepG2|MIAPaca-2	NPA	lung tumors and normal tissue	NPA
714	22306127	NPA	NPA	NPA	miR-27b	miR-27b-3p	DPYD	1806	NPA	NPA	significantly lower in the tumors than normal lung tissue	HepG2|MIAPaca-2	NPA	lung tumors and normal tissue	NPA
715	22306127	NPA	NPA	NPA	miR-582-5p	miR-582-5p	DPYD	1806	NPA	NPA	NPA	HepG2|MIAPaca-2	NPA	lung tumors and normal tissue	NPA
716	22301433	lung	lung cancer side population (SP) cells	NPA	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	NPA	NPA	NPA	inhibit cell proliferation|induce cell cycle G1/S arrest	NPA	NPA	NPA	NPA	tumor-suppressive
717	22301433	lung	lung cancer side population (SP) cells	NPA	miR-31	miR-31-5p	NPA	NPA	NPA	promote cell growth|promote cell cycle G0/G1 transition	NPA	NPA	NPA	NPA	oncogenic
718	22301190	NPA	NPA	NPA	miR-34a	miR-34a-5p	IMPDH1	3614	TP53	NPA	NPA	NPA	NPA	NPA	NPA
719	22298639	stomach	gastric cancer	NPA	miR-196b	miR-196b-5p	NPA	NPA	ETS2	increase cell migration|increase cell invasion	NPA	NPA	NPA	NPA	oncogenic
720	22294552	kidney	renal cell carcinoma	NPA	miR-1285	miR-1285-3p	TGM2	7052	NPA	inhibit cell proliferation|inhibit cell invasion|inhibit cell migration	downregulated in renal cell carcinoma (RCC) specimens	NPA	NPA	RCC clinical specimens	tumor-suppressive
721	22294051	brain	glioblastoma	NPA	miR-221	miR-221-3p	GJA1	2697	NPA	promote cell proliferation|promote cell invasion|inhibit apoptosis	NPA	U251	NPA	NPA	oncogenic
722	22294051	brain	glioblastoma	NPA	miR-222	miR-222-3p	GJA1	2697	NPA	promote cell proliferation|promote cell invasion|inhibit apoptosis	NPA	U251	NPA	NPA	oncogenic
723	22293682	stomach	gastric cancer	NPA	miR-10b	miR-10b-5p	HOXD10	3236	NPA	increase cell invasion	dramatically elevated in lymphoma node metastasis-positive tumor tissues compared with lymphoma node metastasis-free tumor tissues	MNK45|GES-1	NPA	lymphoma node metastasis-positive tumor tissues compared and lymphoma node metastasis-free tumor tissues	oncogenic
724	22293115	liver	hepatocellular carcinoma	NPA	miR-125b	miR-125b-5p	BCL2	596	NPA	inhibit cell proliferation|induce apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
725	22292984	breast	breast cancer	NPA	miR-133a	miR-133a-3p	FSCN1	6624	NPA	slightly inhibit cell growth|decrease cell migration|decrease cell invasion	"downregulated from normal through benign to cancerous breast tissues|negatively associated with lymph nodesmetastasis, high clinical stages, and shorter relapse-free survivals of patients with breast cancer"	NPA	NPA	"26 benign, 34 pericancerously normal and 90 cancerous tissues"	tumor-suppressive
726	22292433	esophagus	esophageal squamous cancer	NPA	miR-34a	miR-34a-5p	NPA	NPA	RELA|TP53	NPA	NPA	NPA	NPA	NPA	NPA
727	22289176	bladder	bladder cancer	NPA	miR-195	miR-195-5p	CDK4	1019	NPA	induce cell cycle G1 arrest|inhibit cell growth	down-regulated in human bladder cancer tissue versus normal adjacent tissue	T24	NPA	human bladder cancer tissue and normal adjacent tissue	tumor-suppressive
728	22287560	colorectum	colon carcinoma	NPA	miR-30a-5p	miR-30a-5p	DTL	51514	NPA	inhibit cell growth|induce cell cycle G1 arrest|induce apoptosis	NPA	HCT116	NPA	NPA	tumor-suppressive
729	22286770	breast	breast cancer	NPA	miR-106b~25	CLUSTER:miR-106b~25	SMAD7	4092	SIX1	activate TGF-beta signaling|induce epithelial-mesenchymal transition|induce a tumor initiating cell phenotype	significantly associated with shortened time to relapse	NPA	NPA	human breast cancers	oncogenic
730	22286762	NPA	NPA	sulindac sulfide	miR-10b	miR-10b-5p	NPA	NPA	NF-kB	promote cell invasion	NPA	MDA-MB-231|HCT116	NPA	NPA	oncogenic
731	22286762	NPA	NPA	sulindac sulfide	miR-17	miR-17-5p	NPA	NPA	NF-kB	promote cell invasion	NPA	MDA-MB-231|HCT116	NPA	NPA	oncogenic
732	22286762	NPA	NPA	sulindac sulfide	miR-21	miR-21-5p	NPA	NPA	NF-kB	promote cell invasion	NPA	MDA-MB-231|HCT116	NPA	NPA	oncogenic
733	22286762	NPA	NPA	sulindac sulfide	miR-9	miR-9-5p	NPA	NPA	NF-kB	promote cell invasion	NPA	MDA-MB-231|HCT116	NPA	NPA	oncogenic
734	22285547	lung	lung adenocarcinoma	NPA	miR-145	miR-145-5p	POU5F1|SOX2|FSCN1	5460|6657|6624	NPA	reduce CSC-like properties|improve chemoradioresistance|inhibit epithelial-mesenchymal transition|inhibit metastastic ability|inhibit tumor growth	NPA	NPA	mouse xenograft tumors	NPA	tumor-suppressive
735	22276989	liver	hepatocellular carcinoma	NPA	miR-122	miR-122-5p	WNT1	7471	NPA	inhibit cell growth|promote cell apoptosis	significantly reduced in  HCC tissues or varied hepatoma cells compared to para-cancerous tissues or Chang liver cell	HepG2|Hep3B|Chang	NPA	para-cancerous tissues and HCC tissues	tumor-suppressive
736	22276743	brain	glioblastoma multiforme	taxol	miR-155	miR-155-5p	NPA	NPA	NPA	inhibit apoptosis|induce taxol resistance	NPA	U251	NPA	NPA	oncogenic
737	22270966	stomach	gastric cancer	NPA	miR-223	miR-223-3p	FBXW7	55294	NPA	inhibit apoptosis|increase cell proliferation|increase cell invasion	highly expressed in 19 of 22 cancer tissue samples compared with patient-matched normal gastric mucosa	SGC7901	nude mice	22 gastric cancer tissue and corresponding gastric mucosa tissues	oncogenic
738	22267008	stomach	gastric cancer	NPA	miR-21	miR-21-5p	PTEN	5728	NPA	promote cell growth|promote cell invasion|promote cell migration	"highly expressed in gastric cancer tissues compared to the adjacent non-tumor tissues|significantly associated with the degree of differentiation of the tumour tissues (P=0.004), as well as local invasion and lymph node metastasis (P<0.01)"	BGC-823	NPA	gastric cancer tissues and the adjacent non-tumor tissues	oncogenic
739	22266859	prostate	castration-resistant prostate cancer	NPA	miR-148a	miR-148a-3p	PIK3IP1	113791	AR	promote cell proliferation	differentially expressed in CRPC compared with benign prostate hyperplasia	LNCaP	NPA	CRPC and benign prostate hyperplasia	oncogenic
740	22266859	prostate	castration-resistant prostate cancer	NPA	miR-32	miR-32-5p	BTG2	7832	AR	reduce apoptosis	differentially expressed in CRPC compared with benign prostate hyperplasia	LNCaP	NPA	CRPC and benign prostate hyperplasia	oncogenic
741	22266852	breast	breast cancer	NPA	miR-580	miR-580-3p	TWIST1	7291	NPA	NPA	NPA	MCF-10A	NPA	NPA	NPA
742	22266319	head and neck	head and neck squamous cell carcinoma	NPA	miR-133a	miR-133a-3p	MSN	4478	NPA	NPA	NPA	FaDu|HSC3|IMC-3|SAS	NPA	NPA	tumor-suppressive
743	22266187	bladder	bladder cancer	NPA	miR-449a	miR-449a	NPA	NPA	NPA	inhibit cell growth|induce cell cycle G1 arrest|reduce tumor growth	frequently downregulated in bladder cancer tissues	T24|5637	T24 tumor xenografts	14 human bladder cancer tissues	tumor-suppressive
744	22265971	bladder	bladder cancer	NPA	miR-195-5p	miR-195-5p	SLC2A3	6515	NPA	decrease cell glucose uptake|inhibit cell growth|promote apoptosis	NPA	T24	NPA	NPA	tumor-suppressive
745	22264793	blood	adult T cell leukemia	NPA	miR-31	miR-31-5p	MAP3K14	9020	Polycomb	inhibit noncanonical NF-kB signaling	downregulated in primary adult T cell leukemia (ATL) cells	NPA	NPA	primary ATL cells	tumor-suppressive
746	22262409	liver	hepatocellular carcinoma	NPA	miR-519d	miR-519d-3p	CDKN1A|PTEN|AKT3|TIMP2	1026|5728|10000|7077	TP53|DNA hypomethylation	promote cell proliferation|promote invasion|inhibit apoptosis	over-expressed in hepatocellular carcinoma (HCC)	NPA	NPA	NPA	oncogenic
747	22260523	breast	breast cancer	estradiol	miR-143	miR-143-3p	BCL2|BIRC5	596|332	NPA	inhibit cell proliferation	highly expressed in triple positive breast cancer tissues	MCF-7	NPA	breast cancer tissues	tumor-suppressive
748	22260523	breast	breast cancer	estradiol	miR-16	miR-16-5p	BCL2|CCND1|BIRC5	596|595|332	NPA	inhibit cell proliferation	highly expressed in triple positive breast cancer tissues	MCF-7	NPA	breast cancer tissues	tumor-suppressive
749	22260523	breast	breast cancer	estradiol	miR-203	miR-203a	BIRC5	332	NPA	inhibit cell proliferation	highly expressed in triple positive breast cancer tissues	MCF-7	NPA	breast cancer tissues	tumor-suppressive
750	22253443	brain	glioma	NPA	miR-124	miR-124-3p	SNAI2	6591	NPA	reduce neurosphere formation|reduce CD133(+) cell subpopulation|inhibit cell invasion	down-regulated in a panel of different grades of glioma tissues and in all of the human glioma cell lines	NPA	NPA	a panel of different grades of glioma tissues	tumor-suppressive
751	22251626	breast	breast cancer	NPA	let-7a	let-7a-5p	CCR7	1236	NPA	decrease cell proliferation|decrease cell migration|decrease cell invasion	NPA	MDA-MB-231|MCF-7	transparent zebrafish embryos	breast cancer patient tissues	tumor-suppressive
752	22251480	blood	cytogenetically abnormal acute myeloid leukemia	NPA	miR-181b	miR-181b-5p	NPA	NPA	NPA	promote apoptosis|reduce cell viability|inhibit cell proliferation|delay leukemogenesis	significantly associated with favorable overall survival	NPA	NPA	183 CA-AML patients|a validation set of 271 CA-AML patients	tumor-suppressive
753	22249446	head and neck	oral squamous cell carcinoma	cisplatin	miR-21	miR-21-5p	NPA	NPA	NPA	promote cell growth|inhibit apoptosis|reduce cisplatin sensitivity	significantly overexpressed in OSCC tissues than in corresponding noncancerous tissues	CA-27	NPA	10 pairs of OSCC and noncancerous tissue samples	oncogenic
754	22249270	head and neck	nasopharyngeal carcinoma	NPA	miR-663	miR-663a	CDKN1A	1026	NPA	promote cell proliferation	upregulated in nasopharyngeal carcinoma tissues	NPA	xenografts in nude mice	nasopharyngeal carcinoma tissues	oncogenic
755	22249264	lung	lung adenocarcinoma	src inhibitor saracatinib	miR-29b	miR-29b-3p	ID1	3397	MYC	reduce cell migration|reduce cell invasion	significantly downregulated in primary lung adenocarcinoma samples compared with matched alveolar lung tissue	NPA	NPA	primary lung adenocarcinoma samples and matched alveolar lung tissue	tumor-suppressive
756	22249248	liver	hepatocellular carcinoma	NPA	miR-100	miR-100-5p	PLK1	5347	NPA	inhibit cell growth|inhibit colony formation	downregulated in human HCCs	NPA	rat model	human HCCs	tumor-suppressive
757	22248718	NPA	NPA	NPA	miR-376b	miR-376b-3p	ATG4C|BECN1	84938|8678	NPA	reduce autophagy	NPA	MCF-7|Huh-7	NPA	NPA	NPA
758	22246523	head and neck	laryngeal squamous cell carcinoma	NPA	miR-34a	miR-34a-5p	NPA	NPA	NPA	inhibit cell proliferation|ihibit cell cycle G0/G1 transition	downregulated in LSCC tissue samples|negatively correlated with histologic differentiation and were positively correlated with survival rate	Hep-2	NPA	LSCC tissue samples	tumor-suppressive
759	22246341	ovary	epithelial ovarian cancer	NPA	miR-100	miR-100-5p	PLK1	5347	NPA	inhibit cell growth	significantly reduced in EOC tissues compared to adjacent normal tissues|correlated with shorter overall survival of EOC patients	NPA	NPA	98 EOC tissues and 15 adjacent normal epithelial tissues	tumor-suppressive
760	22245693	pancreas	pancreatic cancer	metformin	miR-26a	miR-26a-5p	HMGA1	3159	NPA	inhibit cell proliferation|inhibit cell invasion|inhibit cell migration|increase apoptosis	NPA	Sw1990|Panc-1	nude mice xenograft models	NPA	tumor-suppressive
761	22241070	blood	chronic myeloid leukemia	imatinib	miR-212	miR-212-3p	ABCG2	9429	NPA	NPA	NPA	K-562	NPA	NPA	NPA
762	22240480	colorectum	colorectal cancer	NPA	miR-28-3p	miR-28-3p	NME1	6023	NPA	increase cell migration|increase cell invasion|promote metastasis	down-regulated in CRC samples compared with normal colon samples	HCT116|RKO|SW480	tumor xenograft in immunodeficient mice	108 CRC and 49 normal colorectal samples (47 paired)	oncogenic
763	22240480	colorectum	colorectal cancer	NPA	miR-28-5p	miR-28-5p	CCND1|HOXB3	595|3213	NPA	reduce cell proliferation|reduce cell migration|reduce cell invasion	down-regulated in CRC samples compared with normal colon samples	HCT116|RKO|SW480	tumor xenograft in immunodeficient mice	108 CRC and 49 normal colorectal samples (47 paired)	tumor-suppressive
764	22235338	colorectum	colorectal cancer	NPA	miR-211	miR-211-5p	CHD5	7485	NPA	increase cell proliferation|increase tumor growth|incease cell migration	NPA	HCT-116	tumor xenografts	NPA	oncogenic
765	22235332	prostate	prostate cancer	NPA	miR-34a	miR-34a-5p	MYC	4609	NPA	inhibit cell proliferation|inhibit cell invasion|promote apoptosis|inhibit tumor growth	NPA	PC-3	xenograft tumor growth in nude mice	NPA	tumor-suppressive
766	22235305	blood	cutaneous T-cell lymphoma	chemotherapy	miR-122	miR-122-5p	NPA	NPA	NPA	decrease chemotherapy-induced apoptosis|activate Akt signaling	NPA	NPA	NPA	NPA	NPA
767	22234835	liver	hepatocellular carcinoma	NPA	miR-7	miR-7-5p	PIK3CD|MTOR|RPS6KB1	5293|2475|6198	NPA	inhibit cell proliferation|induce cell cycle arrest|inhibit cell migration|inhibit metastasis	NPA	NPA	xenograft mouse model	clinical HCC samples	tumor-suppressive
768	22234685	blood	chronic lymphocytic leukemia	NPA	miR-650	miR-650	CDK1|CDKN2A|EBF3	983|1029|253738	IGL(host gene)	influence cell proliferation	associated with a favorable CLL prognosis	NPA	NPA	chronic lymphocytic leukemia samples	NPA
769	22234174	head and neck	head and neck squamous cell carcinoma	NPA	miR-375	miR-375	NPA	NPA	NPA	inhibit cell invasion	most significantly down-regulated in tumors relative to matched adjacent nonmalignant tissue|correlated significantly with cancer survival and distant metastasis	UMSCC1|UMSCC47	NPA	123 primary HNSCC patients	tumor-suppressive
770	22223089	skin	melanoma	NPA	miR-200c	miR-200c-3p	NPA	NPA	NPA	inhibit colony formation	downregulated in primary or metastatic melanomas than in benign naevi	NPA	NPA	"benign naevi, primary and metastatic melanomas"	tumor-suppressive
771	22223089	skin	melanoma	NPA	miR-205	miR-205-5p	NPA	NPA	NPA	inhibit colony formation	downregulated in primary or metastatic melanomas than in benign naevi|differentially expressed between primary and metastatic melanomas	NPA	NPA	"benign naevi, primary and metastatic melanomas"	tumor-suppressive
772	22223089	skin	melanoma	NPA	miR-211	miR-211-5p	NPA	NPA	NPA	inhibit colony formation|inhibit cell invasion	downregulated in primary or metastatic melanomas than in benign naevi	NPA	NPA	"benign naevi, primary and metastatic melanomas"	tumor-suppressive
773	22217655	brain	glioblastoma	NPA	miR-195	miR-195-5p	NPA	NPA	NPA	inhibit cell cycle progression|inhibit cell invasion	NPA	NPA	NPA	NPA	tumor-suppressive
774	22211245	NPA	NPA	NPA	miR-200a	miR-200a-3p	CTNNB1	1499	NPA	regulate Wnt/¦Â-catenin signaling	NPA	SGC790|U251	NPA	NPA	NPA
775	22210897	liver	hepatocellular carcinoma	NPA	miR-26a	miR-26a-5p	CDK6|CCNE1	1021|898	MYC	block cell cycle G1/S transition	frequently downregulated in hepatocellular carcinoma (HCC) tissues	NPA	two-thirds partial-hepatectomies in mice	hepatocellular carcinoma (HCC) tissues	tumor-suppressive
776	22210897	liver	hepatocellular carcinoma	NPA	miR-26b	miR-26b-5p	CDK6|CCNE1	1021|898	MYC	block cell cycle G1/S transition	frequently downregulated in hepatocellular carcinoma (HCC) tissues	NPA	two-thirds partial-hepatectomies in mice	hepatocellular carcinoma (HCC) tissues	tumor-suppressive
777	22210864	prostate	prostate cancer	NPA	miR-1	miR-1	NPA	NPA	NPA	inhibit cell growth	most consistently down-regulated in primary human prostate tumors|further reduced in distant metastasis|correlated with disease recurrence	NPA	NPA	primary prostate tumors and distant metastasis	tumor-suppressive
778	22209977	blood	acute myeloid leukemia	Ara-C	miR-181a	miR-181a-5p	BCL2	596	NPA	increase Ara-C sensitivity|reduce cell viability|activate apoptosis pathway	NPA	HL-60	NPA	NPA	tumor-suppressive
779	22207897	breast	breast cancer	cisplatin	miR-203	miR-203a	SOCS3	9021	NPA	increase cisplatin-mediated apoptosis	significant upregulated in human breast cancer tissues as compared to patient-matched nontumor breast tissues	MCF-7	NPA	human breast cancer tissues and patient-matched nontumor breast tissues	NPA
780	22207524	brain	glioma	NPA	miR-181d	miR-181d-5p	KRAS|BCL2	3845|596	NPA	inhibit cell proliferation|induce cell cycle arrest|induce apoptosis	down-regulated in human glioma samples	NPA	NPA	human glioma samples	tumor-suppressive
781	22198213	colorectum	colon cancer	NPA	miR-34a	miR-34a-5p	FOSL1	8061	TP53	inhibit cell migration|inhibit cell invasion	"downregulated in 25 of 40 (62.5%) colon cancer tissues, as compared with the adjacent normal colon tissues"	NPA	NPA	40 colon cancer tissues and the adjacent normal colon tissues	tumor-suppressive
782	22193543	lung	non-small cell lung cancer	cisplatin|doxorubicin|5-fluorouracyl	miR-128	miR-128-3p	E2F5	1875	p53R175H	inhibit apoptosis|increase chemotherapy resistance	NPA	NPA	NPA	NPA	oncogenic
783	22189055	stomach	gastric cancer	NPA	miR-610	miR-610	VASP	7408	NPA	reduce cell migration|reduce cell invasion	down-regulated in gastric cancer tissues compared with their adjacent non-tumour gastric tissues	NPA	NPA	paired gastric cancer tissues and their adjacent non-tumour gastric tissues	tumor-suppressive
784	22188669	pancreas	pancreatic cancer	NPA	miR-193b	miR-193b-3p	CCND1|NT5E|PLAU|STARD7|STMN1|YWHAZ	595|4907|5328|56910|3925|7534	NPA	inhibit cell proliferation	NPA	HEK293	NPA	NPA	tumor-suppressive
785	22187223	breast	breast cancer	NPA	miR-21	miR-21-5p	NPA	NPA	NPA	increase cell growth|increase cell migration|increase cell invasion|increase self-renewal|increase clonogenicity	NPA	MCF-7	NPA	NPA	oncogenic
786	22186140	bone and muscle	osteosarcoma	NPA	miR-20a	miR-20a-5p	FAS	2194	NPA	increase metastases	NPA	LM7|SAOS-2	mice injected with LM7	NPA	oncogenic
787	22185756	lung	lung cancer	NPA	miR-365	miR-365a-3p	NKX2-1|HMGA2	7080|8091	NPA	NPA	NPA	NPA	NPA	NPA	NPA
788	22183793	blood	mucosa-associated lymphoid tissue lymphoma	NPA	miR-200a	miR-200a-3p	CCNE2	9134	NPA	NPA	downregulated in conjunctival MALT lymphoma than in normal adjacent tissues	NPA	NPA	14 paired conjunctival MALT lymphoma samples	tumor-suppressive
789	22183793	blood	mucosa-associated lymphoid tissue lymphoma	NPA	miR-200b	miR-200b-3p	CCNE2	9134	NPA	NPA	downregulated in conjunctival MALT lymphoma than in normal adjacent tissues	NPA	NPA	14 paired conjunctival MALT lymphoma samples	tumor-suppressive
790	22183793	blood	mucosa-associated lymphoid tissue lymphoma	NPA	miR-200c	miR-200c-3p	CCNE2	9134	NPA	NPA	downregulated in conjunctival MALT lymphoma than in normal adjacent tissues	NPA	NPA	14 paired conjunctival MALT lymphoma samples	tumor-suppressive
791	22180714	colorectum	colon cancer stems cells	NPA	miR-93	miR-93-5p	HDAC8|TLE4	55869|7091	NPA	inhibit cell proliferation|inhibit colony formation	downregulated in cancer stem cells	SW1116	NPA	NPA	tumor-suppressive
792	22180573	kidney	VHL-inactivated renal cancer	NPA	miR-1826	DEAD_ENTRY	CTNNB1|MEK1	1499|5604	NPA	inhibit cell proliferation|inhibit cell invasion|inhibit cell migration	significantly lower in renal cancer tissues compared with non-neoplastic areas| significantly negatively associated with overall shorter survival and earlier recurrence after radical nephrectomy	NPA	NPA	renal cancer tissues and non-neoplastic areas	tumor-suppressive
793	22179829	cervix	cervical carcinoma	NPA	miR-133b	miR-133b	STK3	8428	NPA	promote cell proliferation|promote colony formation|promote tumorigenesis|promote lung metastasis	elevated in human cervical carcinomas|progressively elevated throughout advancing stages	NPA	mouse	human cervical carcinoma tissues	oncogenic
794	22179828	stomach	gastric cancer	NPA	miR-409-3p	miR-409-3p	RDX	5962	NPA	reduce cell migration|reduce cell invasion|reduce distal pulmonary metastases|reduce peritoneal dissemination	downregulated frequently in human GCs|significantly associated with tumor-node-metastasis (TNM) stage and lymph node metastasis	NPA	NPA	human GCs	tumor-suppressive
795	22179665	colorectum	colon cancer	NPA	miR-1	miR-1	NPA	NPA	NPA	inhibit MET-induced cell invasion	downregulated in 84.6% of the tumors	NPA	NPA	52 matched pairs of colorectal cancers and nontumoral surrounding tissues	tumor-suppressive
796	22179486	bladder	bladder cancer	NPA	miR-574-3p	miR-574-3p	MESDC1	59274	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion|induce apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
797	22179124	brain	glioma	NPA	miR-451	miR-451a	CAB39	51719	NPA	inhibit PI3K/AKT signaling|inhibit tumor growth	downregulated in glioma samples|inversely correlated with WHO grades of gliomas	U251|U87|LN229|A172	nude mice	glioma samples	tumor-suppressive
798	22178270	liver	hepatocellular carcinoma	NPA	miR-224	miR-224-5p	API5	8539	NF¦ÊB|LPS|TNF¦Á|LT¦Á	promote cell migration|promote cell invasion	strongly up-regulated in both peri-tumoral cirrhotic livers and HCC samples as compared to normal livers	NPA	NPA	"peri-tumoral cirrhotic livers, HCC samples and normal livers"	oncogenic
799	22178073	bladder	bladder cancer	NPA	miR-1	miR-1	SRSF9	8683	NPA	induce apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
800	22172490	lung	small cell lung cancer	NPA	miR-375	miR-375	NPA	NPA	ASCL1	NPA	dramatically elevated in all SCLC cell lines examined	NCI-H209	mouse SCLC-like tumors	NPA	NPA
801	22167392	stomach	gastric cancer	5-aza-2'-deoxycytidine	miR-148a	miR-148a-3p	NPA	NPA	DNMT1|DNA hypermethylation	inhibit cell proliferation	downregulated in gastric cancer tissues	NPA	NPA	gastric cancer tissues	tumor-suppressive
802	22167321	breast	breast cancer	NPA	miR-146a	miR-146a-5p	TRAF2	7186	BRCA1	NPA	NPA	HCC1937	NPA	NPA	NPA
803	22167321	breast	breast cancer	NPA	miR-205	miR-205-5p	TRAF2	7186	BRCA1	NPA	NPA	HCC1937	NPA	NPA	NPA
804	22167321	breast	breast cancer	NPA	miR-99b	miR-99b-5p	TRAF2	7186	BRCA1	NPA	NPA	HCC1937	NPA	NPA	NPA
805	22161865	prostate	castration-resistant prostate cancer	NPA	miR-146a	miR-146a-5p	EGFR	1956	NPA	inhibit cell growth|inhibit colony formation|inhibit cell migration|reduce tumorigenicity|reduce angiogenesis	significantly decreased in CRPC tissues compared to ADPC tissues	NPA	NPA	15 androgen-dependent prostate cancer (ADPC) tissues and 5 CRPC tissues	tumor-suppressive
806	22160209	cervix	cervical cancer	NPA	miR-143	miR-143-3p	BCL2	596	NPA	inhibit cell proliferation|induce apoptosis|inhibit tumor formation	most significantly down-regulated in human cervical cancer compared with normal cervical tissues	HeLa	female athymic nude mice	human cervical cancer and normal cervical tissues	tumor-suppressive
807	22160187	liver	hepatocellular carcinoma	NPA	miR-96	miR-96-5p	NPA	NPA	NPA	promote cell migration|promote cell invasion	significantly increased in highly metastatic HCCLM6 cells	HCCLM6	NPA	NPA	oncogenic
808	22159405	liver	liver cancer	NPA	miR-1301	miR-1301-3p	NPA	NPA	NPA	inhibit cell migration|inhibit cell invasion|promote apoptosis	NPA	HepG2	NPA	NPA	tumor-suppressive
809	22159356	brain	glioma	NPA	miR-205	miR-205-5p	VEGFA	7422	NPA	induce apoptosis|induce cell cycle arrest|reduce cell viability|reduce clonability|inhibit cell invasion	NPA	NPA	NPA	NPA	tumor-suppressive
810	22159222	kidney	renal cell carcinoma	NPA	miR-34a	miR-34a-5p	MYC	4609	NPA	inhibit cell invasion	NPA	NPA	NPA	NPA	tumor-suppressive
811	22158050	breast	ER- breast cancer	NPA	miR-373	miR-373-3p	RELA|TGFBR2	5970|7048	NPA	inhibit cell invasion|inhibit intravasation	negatively correlated with lymph node metastasis specifically in ER(-) tumors	MDA-MB-231	NPA	ER+/ER- breast cancer patients	tumor-suppressive
812	22158050	breast	ER- breast cancer	NPA	miR-520c	miR-520c-3p	RELA|TGFBR2	5970|7048	NPA	inhibit cell invasion|inhibit intravasation	negatively correlated with lymph node metastasis specifically in ER(-) tumors	MDA-MB-231	NPA	ER+/ER- breast cancer patients	tumor-suppressive
813	22158047	head and neck	head and neck squamous cell carcinoma	NPA	miR-107	miR-107	PRKCE	5581	NPA	inhibit cell proliferation|inhibit DNA replication|inhibit colony formation|inhibit cell invasion	reduced in human primary HNSCC tumors	SCC15|SCC25|CAL27	nude mice	human primary HNSCC tumors	tumor-suppressive
814	22157765	NPA	NPA	cis-dichloro-diamine platinum|taxol	miR-30a	miR-30a-5p	BECN1	8678	NPA	reduce autophagy|induce apoptosis	significantly reduced in tumor cells by cis-DDP treatment	LC3	tumor implantation mouse model	NPA	NPA
815	22157681	lung	non-small cell lung cancer	gefitinib	miR-103	miR-103a-3p	PRKCE	5581	MET	promote epithelial-mesenchymal transition	NPA	NPA	NPA	NPA	NPA
816	22157681	lung	non-small cell lung cancer	gefitinib	miR-203	miR-203a	SRC	6714	MET	promote epithelial-mesenchymal transition	NPA	NPA	NPA	NPA	NPA
817	22157681	lung	non-small cell lung cancer	gefitinib	miR-221	miR-221-3p	APAF1	317	EGFR|MET	NPA	NPA	NPA	NPA	NPA	NPA
818	22157681	lung	non-small cell lung cancer	gefitinib	miR-222	miR-222-3p	APAF1	317	EGFR|MET	NPA	NPA	NPA	NPA	NPA	NPA
819	22157681	lung	non-small cell lung cancer	gefitinib	miR-30b	miR-30b-5p	BCL2L11	10018	EGFR|MET	NPA	NPA	NPA	NPA	NPA	NPA
820	22157681	lung	non-small cell lung cancer	gefitinib	miR-30c	miR-30c-5p	BCL2L11	10018	EGFR|MET	NPA	NPA	NPA	NPA	NPA	NPA
821	22156201	brain	glioma	NPA	miR-30e*	miR-30e-3p	NFKBIA	4792	NPA	activate NF-kB signaling|increase cell invasion	upregulated in primary human glioma cells|correlated with malignant progression and poor survival	NPA	orthotopic xenotransplantation model	primary human glioma cells	oncogenic
822	22155254	kidney	renal cell carcinoma	NPA	let-7a	let-7a-5p	NPA	NPA	NPA	inhibit cell proliferation|induce cell cycle arrest	NPA	769P|Caki-1|786O	NPA	NPA	tumor-suppressive
823	22153071	liver	hepatocellular carcinoma	NPA	miR-124	miR-124-3p	IL6R	3570	HNF4A	inhibit carcinogenesis|induce apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
824	22153071	liver	hepatocellular carcinoma	NPA	miR-24	miR-24-3p	HNF4A	3172	IL6R|STAT3	NPA	NPA	NPA	NPA	NPA	NPA
825	22153071	liver	hepatocellular carcinoma	NPA	miR-629	miR-629-5p	HNF4A	3172	IL6R|STAT3	NPA	NPA	NPA	NPA	NPA	NPA
826	22151897	lung	lung cancer	NPA	miR-494	miR-494-3p	IGF2BP1	10642	NPA	inhibit cell proliferation|reduce colony forming|induce senescence	NPA	A549	NPA	NPA	tumor-suppressive
827	22146319	liver	biliary tract cancer	NPA	miR-421	miR-421	NR1H4	9971	NPA	promote cell proliferation|promote colony formation|promote cell migration|reduce cell cycle G0/G1 arrest	significantly up-regulated in both primary tumor specimens and cell lines	NPA	NPA	primary biliary tract cancer tissues	oncogenic
828	22144583	breast	breast cancer	NPA	miR-200c	miR-200c-3p	FHOD1|PPM1F	29109|9647	NPA	inhibit cell elongation|inhibit stress fiber formation|inhibit cell migration|inhibit cell invasion	"inversely correlated with expression levels of FHOD1 and PPM1F in breast cancer cell lines, breast cancer patient samples, and 58 cancer cell lines of various origins"	NPA	NPA	breast cancer patient samples	tumor-suppressive
829	22144109	liver	hepatocellular carcinoma	hypoxia	miR-210	miR-210-3p	VMP1	81671	NPA	promote cell migration|promote cell invasion	frequently up-regulated in hepatocellular carcinoma (HCC) samples|negatively correlated with VMP1 in HCC tissues	NPA	NPA	hepatocellular carcinoma (HCC) samples	oncogenic
830	22139839	blood	leukemic B-cells	NPA	miR-125b	miR-125b-5p	BCL2	596	CD40LG	increase cell proliferation	NPA	MEC1	NPA	NPA	oncogenic
831	22139839	blood	leukemic B-cells	NPA	miR-155	miR-155-5p	BCL2	596	CD40LG	increase cell proliferation	NPA	MEC1	NPA	NPA	oncogenic
832	22139708	lung	lung adenocarcinoma	docetaxel	miR-200b	miR-200b-3p	E2F3	1871	NPA	reduce docetaxel chemoresistance|inhibit cell proliferation|induce cell cycle G2/M arrest|induce apoptosis	"down-regulated in docetaxel-resistant SPC-A1/DTX cells|negatively correlated with high expression of E2F3|negatively correlated with decreased sensitivity to docetaxel, and poor prognosis|decreased in tumor tissues sampled from lung adenocarcinoma patients treated with docetaxel-based chemotherapy"	SPC-A1	nude mouse xenograft model	tumor tissues sampled from lung adenocarcinoma patients treated with docetaxel-based chemotherapy	tumor-suppressive
833	22139444	uterus	endometrial cancer	NPA	miR-30c	miR-30c-5p	MTA1	9112	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion	NPA	Ishikawa|HEC-1-B	NPA	NPA	tumor-suppressive
834	22139384	head and neck	laryngeal squamous cell carcinoma	NPA	miR-24	miR-24-3p	S100A8	6279	NPA	induce cell morphology change|inhibit cell proliferation|reduce cell invasion	down-regulated in human LSCC tissues	Hep2	NPA	human LSCC tissues	tumor-suppressive
835	22139078	stomach	gastric cancer	NPA	miR-7	miR-7-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit colony formation	NPA	NPA	K19-C2mE and Gan mouse models that develop gastritis and gastritis-associated tumors	NPA	tumor-suppressive
836	22139076	brain	malignant glioma	NPA	miR-135a	miR-135a-5p	STAT6|SMAD5|BMPR2	6778|4090|659	NPA	induce mitochondria-dependent apoptosis	dramatically downregulated in malignant glioma|correlated with the pathological grading	NPA	NPA	malignant glioma tissues	tumor-suppressive
837	22134538	brain	non-sonic hedgehog-medulloblastoma	NPA	miR-182	miR-182-5p	NPA	NPA	NPA	increase cell migration|promote leptomeningeal metastatic dissemination	significantly overexpressed in metastatic MB as compared to non-metastatic tumors|highly overexpressed in non-sonic hedgehog MBs (non-SHH-MBs)	NPA	xenografts	metastatic MB and non-metastatic tumors	oncogenic
838	22134529	colorectum	colorectal cancer	NPA	miR-320a	miR-320a	NRP1	8829	NPA	inhibit cell migration|inhibit cell invasion	significantly decreased in the liver metastasis tissues than matched primary CRC tissues	NPA	NPA	62 CRC patients with paired liver metastasis tissues and primary CRC tissues	tumor-suppressive
839	22134354	NPA	NPA	NPA	miR-34a	miR-34a-5p	SNAI1	6615	ZEB1|SNAI1	inhibit epithelial-mesenchymal transition|inhibit cell migration|inhibit cell invasion	NPA	NPA	NPA	NPA	tumor-suppressive
840	22134354	NPA	NPA	NPA	miR-34b	miR-34b-5p	SNAI1	6615	ZEB1|SNAI1	inhibit epithelial-mesenchymal transition|inhibit cell migration|inhibit cell invasion	NPA	NPA	NPA	NPA	tumor-suppressive
841	22134354	NPA	NPA	NPA	miR-34c	miR-34c-5p	SNAI1	6615	ZEB1|SNAI1	inhibit epithelial-mesenchymal transition|inhibit cell migration|inhibit cell invasion	NPA	NPA	NPA	NPA	tumor-suppressive
842	22132820	colorectum	colorectal carcinoma	NPA	miR-17	miR-17-5p	RND3	390	NPA	promote cell migration|reduce cell cycle G0/G1 arrest	upregulated in CRC tissues than in normal tissues|negatively correlated with RND3 expression in CRC tissues	NPA	a nude mouse xenograft model	CRC tissues and normal tissues	oncogenic
843	22131135	skin	melanoma	NPA	miR-9	miR-9-5p	NFKB1	4790	NPA	reduce cell proliferation|reduce cell migration	down-regulated in metastatic melanomas compared to primary melanomas	NPA	NPA	metastatic melanomas and primary melanomas	tumor-suppressive
844	22128178	prostate	prostate cancer	NPA	let-7c	let-7c-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit AR signaling	downregulated in prostate cancer specimens	NPA	NPA	prostate cancer specimens	tumor-suppressive
845	22121083	colorectum	colorectal carcinoma	L-OHP	miR-1915	miR-1915-3p	BCL2	596	NPA	reduce multidrug-resistance	NPA	HCT116	NPA	NPA	NPA
846	22120825	brain	glioma	NPA	miR-7	miR-7-5p	NPA	NPA	NPA	inhibit cell migration|inhibit cell invasion|inhibit tumorigenesis|inhibit lung metastases	NPA	NPA	NPA	NPA	tumor-suppressive
847	22120719	nerve	neuroblastoma	NPA	miR-27b	miR-27b-3p	PPARG	5468	NPA	inhibit cell growth|inhibit tumor growth	NPA	NPA	mouse xenografts	NPA	tumor-suppressive
848	22120675	lung	lung adenocarcinoma	docetaxel	miR-100	miR-100-5p	PLK1	5347	NPA	reduce docetaxel chemoresistance|inhibit cell proliferation|induce cell cycle G2/M arrest|induce apoptosis	significantly down-regulated in docetaxel-resistant SPC-A1/DTX cells|inverse correlated with PLK1 expression in clinical lung adenocarcinoma tissues	SPC-A1|SPC-A1/DTX	nude mice SPC-A1/DTX tumor xenografts	clinical lung adenocarcinoma tissues	tumor-suppressive
849	22117060	liver	hepatocellular carcinoma	5-fluorouracil (5-FU)	miR-193a-3p	miR-193a-3p	SRSF2	6427	DNA methylation	promote cell proliferation|increase cell cycle|increase 5-FU resistance	NPA	QGY-7703|SMMC-7721	nude mice	NPA	oncogenic
850	22116552	blood	mantle cell lymphoma	chemotherapy	miR-17~92	CLUSTER:miR-17~92	PHLPP2	23035	NPA	activate PI3K/AKT signaling|inhibit chemotherapy-induced apoptosis|promote tumor growth	positively associated with poorer survival in patients with MCL (P=0.021)	NPA	a xenograft MCL mouse model	mantle cell lymphomas	oncogenic
851	22113133	breast	ER+ breast cancer	NPA	miR-34b	miR-34b-5p	CCND1|JAG1	595|182	ESR1|TP53	inhibit cell proliferation|inhibit tumor growth	NPA	MCF-7|T47D|MBA-MB-361|MDA-MB-435	Tet-On system orthotopic mammary fat pad xenograft mouse model	NPA	tumor-suppressive
852	22110210	head and neck	laryngeal suamous cell carcinoma	NPA	miR-206	miR-206	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion|inhibit tumorigenesis|induce apoptosis	"significantly down-regulated in the LSCC tissues|negatively correlated with T grade, nodal metastasis and clinical stage of LSCC"	NPA	a mouse model	primary LSCC tissues and corresponding adjacent non-neoplastic tissues	tumor-suppressive
853	22109528	colorectum	colon cancer	NPA	miR-23b	miR-23b-3p	FZD7|MAP3K1	8324|4214	NPA	inhibit tumor growth|inhibit angiogenesis|inhibit metastasis|inhibit cell migration	downregulated in human colon cancer samples	NPA	NPA	human colon cancer samples	tumor-suppressive
854	22108521	esophagus	oesophageal squamous cell carcinoma	NPA	miR-223	miR-223-3p	FBXW7	55294	NPA	NPA	significantly higher in cancerous tissues than in the corresponding normal tissues|significantly inversely correlated with FBXW7 protein	NPA	NPA	109 resected ESCC specimens	NPA
855	22108519	bladder	bladder cancer	NPA	miR-143	miR-143-3p	SERPINE1	5054	NPA	NPA	downregulated in all stages of bladder cancer|inversely correlated with SERPINE1 expression	NPA	NPA	"a panel of normal bladder urothelial biopsies, superficial Ta bladder tumours and invasive T1-T4 tumours"	NPA
856	22108519	bladder	bladder cancer	NPA	miR-145	miR-145-5p	SERPINE1	5054	NPA	NPA	downregulated in all stages of bladder cancer|inversely correlated with SERPINE1 expression	NPA	NPA	"a panel of normal bladder urothelial biopsies, superficial Ta bladder tumours and invasive T1-T4 tumours"	NPA
857	22105810	breast	breast cancer	NPA	miR-155	miR-155-5p	NPA	NPA	NPA	promote cell growth|increase cell cycle progression|inhibit apoptosis|reduce radiosensitivity	"significantly higher in breast cancer tissues than in corresponding nontumor tissues|correlated with higher tumor grade, advanced tumor stage and lymph node metastasis"	NPA	NPA	breast cancer tissues and corresponding nontumor tissues	oncogenic
858	22105365	liver	hepatocellular carcinoma	NPA	miR-520e	miR-520e	NIK	9448	DNA hypermethylation	suppress cell proliferation	dramatically decreased in examined hepatoma cell lines and clinical hepatocellular carcinoma (HCC) tissues	NPA	nude mice	clinical hepatocellular carcinoma (HCC) tissues	tumor-suppressive
859	22102825	NPA	NPA	NPA	miR-34a	miR-34a-5p	ARAF|PIK3R2|CCND3|CCNG2|MCM2|MCM5|PLK1|SMAD4	369|5296|896|901|4176|4174|5347|4089	NPA	NPA	NPA	K562|HCT116	NPA	NPA	NPA
860	22101765	ovary	ovarian adenocarcinoma	NPA	miR-141	miR-141-3p	MAPK14	1432	NPA	modulate the oxidative stress response|increase tumor growth|increase chemotherapeutic response	NPA	NPA	mouse models	NPA	oncogenic
861	22101765	ovary	ovarian adenocarcinoma	NPA	miR-200a	miR-200a-3p	MAPK14	1432	NPA	modulate the oxidative stress response|increase tumor growth|increase chemotherapeutic response	NPA	NPA	mouse models	NPA	oncogenic
862	22101269	breast	ER+ breast cancer	NPA	miR-200b	miR-200b-3p	MYBL2	4605	NPA	NPA	NPA	NPA	NPA	NPA	NPA
863	22101269	breast	ER+ breast cancer	NPA	miR-200c	miR-200c-3p	MYBL2	4605	NPA	NPA	NPA	NPA	NPA	NPA	NPA
864	22101269	breast	ER+ breast cancer	NPA	miR-429	miR-429	MYBL2	4605	NPA	NPA	NPA	NPA	NPA	NPA	NPA
865	22099878	colorectum	colorectal cancer	NPA	miR-21	miR-21-5p	CCL20	6364	NPA	NPA	NPA	Caco-2|SW480|SW620	NPA	NPA	NPA
866	22096245	blood	lymphoma	NPA	miR-155	miR-155-5p	GCSAM	257144	NPA	increase cell motility	NPA	NPA	NPA	NPA	oncogenic
867	22094257	skin	squamous cell carcinoma	NPA	miR-21	miR-21-5p	GRHL3	57822	NPA	NPA	"increased in human skin, and head and neck SCC|negatively associated with GRHL3 expression"	NPA	NPA	"human skin, and head and neck SCC"	NPA
868	22093834	bone and muscle	osteosarcoma	NPA	miR-125b	miR-125b-5p	STAT3	6774	STAT3	inhibit cell proliferation|inhibit cell migration|inhibit tumor formation	frequently down-regulated in osteosarcoma samples and human osteosarcoma cell lines	NPA	NPA	osteosarcoma samples	tumor-suppressive
869	22093618	kidney	renal cancer	NPA	miR-199a	miR-199a-5p	GSK3B	2932	NPA	inhibit cell growth	decreased in 59% (32 of 54) of RCCs|negatively correlated with higher tumor stage (p < 0.05)|negatively correlated with nuclear overexpression of GSK3B (p < 0.05)	NPA	NPA	54 RCCs	tumor-suppressive
870	22093444	blood	acute myeloid leukemia	NPA	miR-143	miR-143-3p	NPA	NPA	TP73	inhibit neutrophil differentiation	significantly repressed in primary AML patient samples as compared to neutrophils of healthy donors	NPA	NPA	primary AML patient samples and neutrophils of healthy donors	tumor-suppressive
871	22093444	blood	acute myeloid leukemia	NPA	miR-145	miR-145-5p	NPA	NPA	TP73	inhibit neutrophil differentiation	significantly repressed in primary AML patient samples as compared to neutrophils of healthy donors	NPA	NPA	primary AML patient samples and neutrophils of healthy donors	tumor-suppressive
872	22089643	lung	lung squamous cell carcinoma	NPA	miR-133a	miR-133a-3p	GSTP1|ARPC5	2950|10092	NPA	inhibit cell proliferation	significantly reduced in cancer tissues compared with normal tissues	PC10|H157	NPA	lung-SCC clinical specimens	tumor-suppressive
873	22089331	brain	glioblastoma	NPA	miR-31	miR-31-5p	RDX	5962	NPA	inhibit cell migration|inhibit cell invasion	down-regulated in glioblastoma compared with normal brain tissues	U251	NPA	10 glioblastoma and 7 normal brain tissues	tumor-suppressive
874	22085528	breast	breast cancer	NPA	miR-124	miR-124-3p	NPA	NPA	DNA hypermethylation in cancer	inhibit metastasis	reduced in aggressive MDA-MB-231 and SK-3rd breast cancer cells	MDA-MB-231|SK-3rd	NPA	NPA	tumor-suppressive
875	22078727	lung	lung cancer	NPA	miR-449a	miR-449a	HDAC1	3065	NPA	inhibit cell growth	down-regulated in primary lung cancer	NPA	NPA	primary lung cancer	tumor-suppressive
876	22078727	lung	lung cancer	NPA	miR-449b	miR-449b-5p	HDAC1	3065	NPA	inhibit cell growth	down-regulated in primary lung cancer	NPA	NPA	primary lung cancer	tumor-suppressive
877	22076535	ovary	ovarian cancer	NPA	miR-25	miR-25-3p	BCL2L11	10018	NPA	promote cell proliferation|induce apoptosis	highly expressed both in clinical ovarian cancer samples and cell lines|inversely correlated with BCL2L11 in ovarian cancer tissues	NPA	NPA	clinical ovarian cancer samples	oncogenic
878	22075712	brain	glioma	temozolomide	miR-221	miR-221-3p	NPA	NPA	NPA	inhibit apoptosis|reduce temozolomide sensitivity	NPA	U251|LN308|U87	NPA	NPA	oncogenic
879	22075712	brain	glioma	temozolomide	miR-222	miR-222-3p	NPA	NPA	NPA	inhibit apoptosis|reduce temozolomide sensitivity	NPA	U251|LN308|U87	NPA	NPA	oncogenic
880	22074923	breast	breast tumor-initiating cells	NPA	miR-34c	miR-34c-5p	NOTCH4	4855	SP1|DNA hypermethylation	reduce cell self-renewal|inhibit epithelial-mesenchymal transition|inhibit cell migration	reduced in the BT-ICs of MCF-7 and SK-3rd cells	MCF-7|SK-3rd	NPA	NPA	tumor-suppressive
881	22072622	colorectum	colon cancer	NPA	miR-21	miR-21-5p	TGFBR2	7048	NPA	increase sphere forming ability|increase tumor formation	NPA	HCT-116|HT-29	SCID mice	NPA	oncogenic
882	22072615	colorectum	colon cancer	5-fluorouracil	miR-365	miR-365a-3p	CCND1|BCL2	595|596	NPA	inhibit cell cycle progression|promote 5-fluorouracil-induced apoptosis|repress tumorigenicity	downregulated in human colon cancer tissues as compared with that in matched non-neoplastic mucosa tissues|negatively correlated with cancer progression and poor survival in colon cancer patients	NPA	NPA	human colon cancer tissuesand matched non-neoplastic mucosa tissues	tumor-suppressive
883	22069160	ovary	epithelial ovarian cancer	paclitaxel	miR-433	miR-433-3p	MAD2L1	4085	NPA	NPA	NPA	A2780	NPA	NPA	NPA
884	22068816	prostate	prostate cancer	NPA	miR-1	miR-1	PNP	5539	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion	significantly downregulated in PCa compared with non-PCa tissues	PC3|DU145	NPA	PCa compared and non-PCa tissues	tumor-suppressive
885	22068816	prostate	prostate cancer	NPA	miR-133a	miR-133a-3p	PNP	5539	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion	significantly downregulated in PCa compared with non-PCa tissues	PC3|DU145	NPA	PCa compared and non-PCa tissues	tumor-suppressive
886	22064652	pancreas	pancreatic cancer	NPA	miR-126	miR-126-3p	ADAM9	8754	NPA	reduce cell migration|reduce cell invasion	reduced in invasive ductal adenocarcinoma (IDA)	NPA	NPA	"invasive ductal adenocarcinoma (IDA), intraductal papillary mucinous adenoma, intraductal papillary mucinous carcinoma"	tumor-suppressive
887	22059741	head and neck	nasopharyngeal carcinoma	NPA	miR-1	miR-1	PTMA	5757	NPA	induce apoptosis	NPA	HeLa|Cal-27|KYSE30|NPC-TW06|SW620|HepG2|HEK-293T|SAS|PC-13	NPA	NPA	tumor-suppressive
888	22058146	NPA	NPA	NPA	miR-30d	miR-30d-5p	NPA	NPA	NPA	regulate cell proliferation|regulate apoptosis|regulate senescence|regulate cell migration	associated significantly with poor clinical outcomes in ovarian cancer patients	NPA	NPA	ovarian cancer patients	NPA
889	22057916	bladder	bladder cancer	NPA	miR-493	miR-493-3p	FZD4|RHOC	8322|389	NPA	inhibit cell growth|inhibit cell migration	significantly lower in bladder cancer tissues than in their corresponding noncancerous tissues	SV-HUC-1|T24|J82|TCCSUP	NPA	bladder cancer tissues and their corresponding noncancerous tissues	tumor-suppressive
890	22056881	liver	hepatocellular carcinoma	NPA	miR-375	miR-375	MTDH	92140	NPA	inhibit cell proliferation|inhibit clonogenicity|inhibit cell migration|inhibit invasion|induce cell cycle G1 arrest|induce apoptosis	significantly downregulated in hepatocellular carcinoma (HCC) tissues and cell lines|inversely correlated with MTDH expression in HCC tissues	NPA	hepatoma xenografts in nude mice	cancerous hepatocytes and normal primary human hepatocytes	tumor-suppressive
891	22052540	uterus	endometrial serous adenocarcinoma	5-aza-2'deoxycytidine (DAC)	miR-34b	miR-34b-5p	NPA	NPA	promoter DNA hypermethylation in cancer	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion	down-regulated in endometrial serous adenocarcinoma than normal endometria	NPA	NPA	ESC with the levels in endometrial endometrioid adenocarcinoma (EEC) and normal endometria	tumor-suppressive
892	22052201	liver	hepatocellular carcinoma	NPA	miR-483	miR-483-3p	SOCS3	9021	IGF2_intron	promote cell proliferation	NPA	NPA	NPA	NPA	oncogenic
893	22052152	lung	non-small cell lung cancer	NPA	miR-378	miR-378-3p	NPA	NPA	NPA	promote cell migration|promote cell invasion|promote tumor angiogenesis|promote brain metastasis	significantly higher in brain metastasis NSCLCs	NPA	NPA	matched NSCLC from 8 patients with brain metastasis and 21 without brain metastasis	oncogenic
894	22049531	bladder	bladder cancer	NPA	miR-1826	DEAD_ENTRY	CTNNB1|VEGFC|MEK1	1499|7424|5604	NPA	inhibit cell viability|inhibit cell invasion|inhibit cell migration|induce apoptosis|induce cell cycle G1 arrest	"lower in BC tissues|inversely correlated with several clinical parameters (pT, grade)"	J82|T24|SV-HUC-1|TCCSUP	NPA	BC tissues	tumor-suppressive
895	22047961	lung	small cell lung cancer	5-aza-2'-deoxycytidine	miR-34b	miR-34b-5p	NPA	NPA	DNA hypermethylation	inhibit cell growth|inhibit cell migration|inhibit cell invasion	reduced in methylated cell lines and tumors	H1048|SBC5	NPA	27 SCLC clinical specimens and 47 NSCLC primary tumors	tumor-suppressive
896	22047961	lung	small cell lung cancer	5-aza-2'-deoxycytidine	miR-34c	miR-34c-5p	NPA	NPA	DNA hypermethylation	inhibit cell growth|inhibit cell migration|inhibit cell invasion	reduced in methylated cell lines and tumors	H1048|SBC5	NPA	27 SCLC clinical specimens and 47 NSCLC primary tumors	tumor-suppressive
897	22042971	stomach	gastrointestinal stromal tumor	NPA	miR-494	miR-494-3p	KIT	3815	NPA	induce apoptosis|inhibit cell growth|affect cell cycle progression	inversely correlated with KIT expression in GISTs	GIST882	NPA	fresh-frozen gastrointestinal stromal tumors from 31 patients	tumor-suppressive
898	22042699	blood	anaplastic large cell lymphoma	NPA	miR-135b	miR-135b-5p	FOXO1|STAT6|GATA3	2308|6778|2625	NPM-ALK|STAT3	promote angiogenesis|promote tumor growth	NPA	NPA	NPA	NPA	oncogenic
899	22040413	brain	glioblastoma	NPA	miR-7	miR-7-5p	PTK2	5747	NPA	inhibit cell migration|inhibit cell invasion	inversely correlated with PTK2 expression in human glioma tissues	U87|U251	NPA	human glioma tissues	tumor-suppressive
900	22036718	colorectum	colon cancer	hydroxycamptothecin (HCPT)	miR-506	miR-506-3p	PPARA	5465	NPA	increase HPCT resistance	NPA	SW1116	NPA	NPA	NPA
901	22033921	liver	hepatocellular carcinoma	NPA	miR-15a	miR-15a-5p	PCMT1	5110	NPA	promote apoptosis 	NPA	HepG2	NPA	NPA	tumor-suppressive
902	22033921	liver	hepatocellular carcinoma	NPA	miR-16	miR-16-5p	PCMT1	5110	NPA	promote apoptosis 	NPA	HepG2	NPA	NPA	tumor-suppressive
903	22033272	kidney	renal cell carcinoma	NPA	miR-215	miR-215-5p	NPA	NPA	NPA	reduce cell migration|reduce cell invasion	significantly downregulated in metastatic compared with primary RCCs	NPA	NPA	metastatic and primary RCCs	tumor-suppressive
904	22031094	head and neck	head and neck cancer	NPA	miR-375	miR-375	MTDH	92140	NPA	reduce cell viability|reduce clonogenic survival|inhibit cell migration|inhibit cell invasion	significantly reduced in nasopharyngeal carcinoma (NPC) patients	NPA	NPA	head and neck cancers (HNC) patient samples	tumor-suppressive
905	22028325	colorectum	colon cancer	NPA	miR-194	miR-194-5p	THBS1	7057	TP53	promote angiogenesis	NPA	HCT116	Ras-induced murine colon carcinomas	NPA	oncogenic
906	22025269	liver	CD133+ hepatocellular carcinoma cancer stem-like cells	NPA	miR-150	miR-150-5p	MYB	4602	NPA	inhibit tumorsphere formation|inhibit tumor growth|induce cell cycle arrest|induce apoptosis	downregulated in CD133+ HCC CSCs	NPA	NPA	NPA	tumor-suppressive
907	22024689	ovary	ovarian cancer	lysophosphatidic acid (LPA)|cisplatin	miR-30c-2*	miR-30c-2-3p	BCL9	607	EGF|PDGF	reduce cell proliferation|reduce cell viability|reduce cisplatin resistance	NPA	SKOV-3|OVCAR-3|HeyA8-MDR	NPA	NPA	tumor-suppressive
908	22024478	nerve	neuroblastoma	NPA	miR-124	miR-124-3p	AHR	196	NPA	inhibit cell differentiation|reduce cell cycle arrest|reduce apoptosis	NPA	SK-N-SH	NPA	NPA	oncogenic
909	22024162	NPA	NPA	NPA	miR-34	miR-34a-5p|miR-34b-5p|miR-34c-5p	SNAI1|LEF1|CTNNB1|AXIN2	6615|51176|1499|8313	TP53	inhibit epithelial-mesenchymal transition	NPA	NPA	NPA	NPA	tumor-suppressive
910	22020746	stomach	gastric cancer	NPA	miR-146a	miR-146a-5p	SMAD4	4089	NPA	increase cell proliferation|inhibit apoptosis	upregulated in 20 gastric cancer tissues compared with matched non-tumor adjacent tissues|inversely correlated with SMAD4 mRNA levels in gastric cancer tissues	NPA	NPA	20 gastric cancer tissues and matched non-tumor adjacent tissues	oncogenic
911	22020560	colorectum	colorectal cancer	NPA	miR-148b	miR-148b-3p	CCKBR	887	NPA	inhibit cell proliferation|suppress tumorigenicity	significantly downregulated in 96 pairs of human colorectal cancer tissues (p<0.0001) and three cell lines (p<0.01) compared with non-tumor adjacent tissues|associated with tumor size (p=0.033) in colorectal cancer patients	HCT-116|HT-29	NPA	96 pairs of human colorectal cancer tissues and non-tumor adjacent tissues	tumor-suppressive
912	22020340	stomach	gastric cancer	NPA	miR-200a	miR-200a-3p	ZEB1|ZEB2	6935|9839	SMAD3	NPA	NPA	SNU484	NPA	NPA	NPA
913	22020340	stomach	gastric cancer	NPA	miR-200b	miR-200b-3p	ZEB1|ZEB2	6935|9839	SMAD3	NPA	NPA	SNU484	NPA	NPA	NPA
914	22020335	NPA	NPA	NPA	miR-372	miR-372-3p	DKK1	22943	CTNNB1|LEF1	promote cell growth|promote cell invasion	NPA	NPA	NPA	NPA	oncogenic
915	22020335	NPA	NPA	NPA	miR-373	miR-373-3p	DKK1	22943	CTNNB1|LEF1	promote cell growth|promote cell invasion	NPA	NPA	NPA	NPA	oncogenic
916	22018986	colorectum	colorectal cancer	NPA	let-7a	let-7a-5p	UHRF2	115426	NPA	reduce cell proliferation|indcue cell cycle G0/G1 arrest|reduce cell migration|reduce tumor growth	NPA	NPA	tumorigenicity assay in nude mice	NPA	tumor-suppressive
917	22018270	stomach	gastric cancer	NPA	miR-27	miR-27a-3p|miR-27b-3p	APC	324	NPA	promote metastasis|promote pithelial-mesenchymal transition	increased in gastric cancer tissues	AGS	NPA	gastric cancer tissues	oncogenic
918	22016468	lung	lung cancer	resveratrol	miR-622	miR-622	KRAS	3845	NPA	inhibit cell proliferation|induce cell cycle G0 arrest|inhibit colony formation	NPA	16HBE-T|H460	nude mice	NPA	tumor-suppressive
919	22015043	uterus	endometrial carcinoma	NPA	miR-200c	miR-200c-3p	NPA	NPA	NPA	promote cell survival|promote cell proliferation|inhibit apoptosis	increased in endometrial carcinoma compared with normal endometrial tissues	HEC-1A|Ishikawa	NPA	endometrial carcinoma and normal endometrial tissues	oncogenic
920	22009755	breast	breast cancer	tamoxifen	miR-181b	miR-181b-5p	TIMP3	7078	NPA	reduce tamoxifen sensitivity	inversely correlated with TIMP3 expression in primary human breast carcinomas	MCF-7	tamoxifen-resistant xenografts in mice	primary human breast carcinomas	NPA
921	22009755	breast	breast cancer	tamoxifen	miR-221	miR-221-3p	TIMP3	7078	NPA	reduce tamoxifen sensitivity	inversely correlated with TIMP3 expression in primary human breast carcinomas	MCF-7	tamoxifen-resistant xenografts in mice	primary human breast carcinomas	NPA
922	22009755	breast	breast cancer	tamoxifen	miR-222	miR-222-3p	TIMP3	7078	NPA	reduce tamoxifen sensitivity	inversely correlated with TIMP3 expression in primary human breast carcinomas	MCF-7	tamoxifen-resistant xenografts in mice	primary human breast carcinomas	NPA
923	22005523	ovary	ovarian cancer	5-aza-CdR|cisplatin|taxol	miR-130b	miR-130b-3p	CSF1	1435	DNA methylation	reduce multidrug resistance	down-regulated in ovarian cancer tissues|associated with FIGO III-IV clinical stages and poorer histological differentiation|downregulated in multidrug resistant ovarian cancer cells	NPA	NPA	ovarian tissues	NPA
924	22001440	cervix	cervical squamous carcinoma	NPA	miR-21	miR-21-5p	CCL20	6364	NPA	increase cell proliferation|inhibit apoptosis|increase cell migration	significantly overexpressed in human cervical squamous cancer tissues and cell lines|correlated with the tumor differentiation and nodal status by ISH	NPA	NPA	human cervical squamous cancer tissues	oncogenic
925	21998710	stomach	gastric cancer	NPA	miR-29a	miR-29a-3p	SAPCD2	89958	NPA	inhibit cell proliferation|induce cell cycle arrest	inversely correlated with SAPCD2 expression in gastric cancer cell lines and GC tissues samples	NPA	NPA	gastric cancer tissue samples	tumor-suppressive
926	21998631	thyroid	familial papillary thyroid cancer	NPA	miR-886-3p	miR-886-3p	NPA	NPA	NPA	inhibit cell proliferation|reduce the number and size of spheroids|inhibit cell migration|induce cell cycle S arrest	differentially expressed between familial and sporadic papillary thyroid cancer tumor samples	NPA	NPA	familial and sporadic papillary thyroid cancer tumor samples	tumor-suppressive
927	21994419	stomach	gastric cancer	NPA	miR-148a	miR-148a-3p	ROCK1	6093	NPA	inhibit cell migration|inhibit cell invasion|reduce lung metastasis	suppressed by more than 4-fold in gastric cancer compared with their corresponding nontumorous tissues|significantly associated with tumor-node-metastasis (TNM) stage and lymph node-metastasis|inversely correlated with ROCK1 expression	NPA	NPA	90 gastric cancer samples	tumor-suppressive
928	21993663	NPA	NPA	vincristine|cisplatin	miR-200b	miR-200b-3p	BCL2|XIAP	596|331	NPA	increase drug sensitivity|increase drug-induced apoptosis	"downregulated in both MDR SGC7901/VCR (vincristine) and A549/CDDP (cisplatin) cells, compared with the parental SGC7901 and A549 cells"	SGC7901|A549	NPA	NPA	NPA
929	21993663	NPA	NPA	vincristine|cisplatin	miR-200c	miR-200c-3p	BCL2|XIAP	596|331	NPA	increase drug sensitivity|increase drug-induced apoptosis	"downregulated in both MDR SGC7901/VCR (vincristine) and A549/CDDP (cisplatin) cells, compared with the parental SGC7901 and A549 cells"	SGC7901|A549	NPA	NPA	NPA
930	21993663	NPA	NPA	vincristine|cisplatin	miR-429	miR-429	BCL2|XIAP	596|331	NPA	increase drug sensitivity|increase drug-induced apoptosis	"downregulated in both MDR SGC7901/VCR (vincristine) and A549/CDDP (cisplatin) cells, compared with the parental SGC7901 and A549 cells"	SGC7901|A549	NPA	NPA	NPA
931	21993544	bladder	bladder urothelial carcinoma	NPA	miR-96	miR-96-5p	NPA	NPA	NPA	increase cell invasion|increase cell differentiation|increase cell growth	upregulated in human bladder urothelial carcinomas compared to normal tissues	T24	NPA	human bladder urothelial carcinomas and normal tissues	oncogenic
932	21989846	liver	hepatocellular carcinoma	NPA	miR-155	miR-155-5p	SOX6	55553	NPA	promote tumorigenesis	gradually increased from normal to cirrhotic liver tissues to HCC tumor tissues	HepG2	NPA	"normal, cirrhotic and HCC tumor tissues"	oncogenic
933	21984339	colorectum	colorectal cancer	NPA	let-7c	let-7c-5p	KRAS|MMP11|PBX3	3845|4320|5090	NPA	inhibit cell migration|inhibit cell invasion	"significantly negatively associated with metastases, advanced TNM stages and poor survival of colorectal cancer patients|inversely correlated with the expressions of MMP11 and PBX3"	LoVo	NPA	primary cancer tissues of colorectal cancer patients	tumor-suppressive
934	21983934	mesothelium	malignant mesothelioma	NPA	miR-205	miR-205-5p	NPA	NPA	NPA	inhibit cell migration|inhibit cell invasion	significantly down-regulated in biphasic and sarcomatoid histotypes	MeT-5A|H2452|MSTO-211H	NPA	"109 malignant mesotheliomas (58 epithelioid, 26 sarcomatoid, and 25 biphasic)"	tumor-suppressive
935	21983130	uterus	ER¦Á+ endometrioid adenocarcinoma	NPA	miR-206	miR-206	NPA	NPA	NPA	inhibit ER¦Á-dependent cell proliferation|reduce cell invasion|induce cell cycle arrest	decreased in ER¦Á-positive EECs	NPA	NPA	30 EEC clinical samples	tumor-suppressive
936	21983127	pancreas	pancreatic cancer	NPA	miR-150	miR-150-5p	MUC4	4585	NPA	inhibit cell growth|inhibit clonogenicity|inhibit cell migration|inhibit cell invasion|increase intercellular adhesion	downregulated in malignant pancreatic tissues|inversely associated with MUC4 protein levels in malignant pancreatic tissues	NPA	NPA	malignant pancreatic tissues	tumor-suppressive
937	21982769	liver	hepatocellular carcinoma	IFN-¦Á	miR-146a	miR-146a-5p	NPA	NPA	NPA	increase IFN-¦Á resistance|inhibit apoptosis	significantly higher in IFN-¦Á-resistant clones	NPA	NPA	NPA	oncogenic
938	21980462	breast	breast cancer	¦Ã-irradiation (IR)	miR-18a	miR-18a-5p	ATM	472	NPA	reduce IR-induced cell cycle arrest|reduce DNA damage repair|increase radiosensitivity	upregulated in both cell lines and patients' tissue samples of breast cancer	NPA	NPA	patients tissue samples of breast cancer	oncogenic
939	21979877	blood	T-cell acute lymphoblastic leukemia	NPA	miR-142-3p	miR-142-3p	NR3C1	2908	NPA	increase cell proliferation	upregulated in human T-leukemic cell lines and primary T-leukemic cells isolated from T-cell acute lymphoblastic leukemia (T-ALL) patients|correlated with patients' prognosis	NPA	NPA	primary T-leukemic cells isolated from T-cell acute lymphoblastic leukemia (T-ALL) patients	oncogenic
940	21978395	brain	astrocytoma	NPA	miR-124	miR-124-3p	NPA	NPA	NPA	inhibit cell migration|inhibit cell proliferation	downregulated significantly in grade I-IV astrocytomas	NPA	NPA	normal brain tissue samples and grade I-III astrocytomas	tumor-suppressive
941	21978395	brain	astrocytoma	NPA	miR-149	miR-149-5p	NPA	NPA	NPA	inhibit cell migration|inhibit cell proliferation	downregulated significantly in grade I-IV astrocytomas	NPA	NPA	normal brain tissue samples and grade I-III astrocytomas	tumor-suppressive
942	21976676	blood	multiple myeloma	5-Aza-2'-deoxycytidine 	miR-34b	miR-34b-5p	NPA	NPA	promoter DNA hypermethylation	reduce cell proliferation|promote apoptosis	NPA	NPA	NPA	"8 normal marrow controls, 8 MM cell lines, 95 diagnostic, and 23 relapsed/progressed MM samples|12 MM patients with paired samples at diagnosis and relapse/progression"	tumor-suppressive
943	21976676	blood	multiple myeloma	5-Aza-2'-deoxycytidine 	miR-34c	miR-34c-5p	NPA	NPA	promoter DNA hypermethylation	reduce cell proliferation|promote apoptosis	NPA	NPA	NPA	"8 normal marrow controls, 8 MM cell lines, 95 diagnostic, and 23 relapsed/progressed MM samples|12 MM patients with paired samples at diagnosis and relapse/progression"	tumor-suppressive
944	21971665	ovary	ovarian cancer	NPA	miR-148a	miR-148a-3p	NPA	NPA	NPA	inhibit cell proliferation	significantly decreased in ovarian cancer tissues compared to normal ovarian epithelium tissues	NPA	NPA	"tissues of 78 patients with epithelial ovarian cancer, 17 normal ovarian epithelium tissues"	tumor-suppressive
945	21971665	ovary	ovarian cancer	NPA	miR-152	miR-152-3p	NPA	NPA	NPA	inhibit cell proliferation	significantly decreased in ovarian cancer tissues compared to normal ovarian epithelium tissues	NPA	NPA	"tissues of 78 patients with epithelial ovarian cancer, 17 normal ovarian epithelium tissues"	tumor-suppressive
946	21970405	uterus	type II endometrial carcinoma	NPA	miR-125b	miR-125b-5p	TP53INP1	94241	NPA	increase cell proliferation|increase cell migration	overexpressed in type II EC cells compared with type I	KLE|AN3CA|ishikawa|RL95-2	NPA	NPA	oncogenic
947	21969817	liver	hepatocellular carcinoma	NPA	miR-191	miR-191-5p	TIMP3	7078	DNA hypomethylation	promote epithelial-mesenchymal transition|increase cell migration|incrase cell invasion	higher in 58.9% HCC tissues than in adjacent noncancerous tissues|associated with poor prognosis	SMMC-771	NPA	73 clinical HCC tissue samples	oncogenic
948	21969367	skin	squamous cell carcinoma	NPA	miR-138	miR-138-5p	FOSL1	8061	NPA	NPA	NPA	NPA	NPA	NPA	NPA
949	21969366	breast	breast cancer	NPA	let-7e	let-7e-5p	CCND1	595	KDM5B	inhibit cell cycle progression	NPA	NPA	NPA	NPA	tumor-suppressive
950	21963845	colorectum	colorectal cancer	NPA	miR-126	miR-126-3p	NPA	NPA	CTNNB1|TCF4	inhibit cell growth	downregulated in two independent series of human primary CRCs relative to normal adjacent mucosa	DLD1	NPA	two independent series of human primary CRCs (n=76) and normal adjacent mucosa (n=34)	tumor-suppressive
951	21963845	colorectum	colorectal cancer	NPA	miR-139-5p	miR-139-5p	NPA	NPA	CTNNB1|TCF4	inhibit cell growth	downregulated in two independent series of human primary CRCs relative to normal adjacent mucosa	DLD1	NPA	two independent series of human primary CRCs (n=76) and normal adjacent mucosa (n=34)	tumor-suppressive
952	21963845	colorectum	colorectal cancer	NPA	miR-145	miR-145-5p	NPA	NPA	CTNNB1|TCF4	inhibit cell growth	downregulated in two independent series of human primary CRCs relative to normal adjacent mucosa	DLD1	NPA	two independent series of human primary CRCs (n=76) and normal adjacent mucosa (n=34)	tumor-suppressive
953	21963845	colorectum	colorectal cancer	NPA	miR-30e-3p	miR-30e-3p	HELZ|PIK3C2A	9931|5286	CTNNB1|TCF4	inhibit cell growth	downregulated in two independent series of human primary CRCs relative to normal adjacent mucosa	DLD1	NPA	two independent series of human primary CRCs (n=76) and normal adjacent mucosa (n=34)	tumor-suppressive
954	21962230	brain	glioma	NPA	miR-185	miR-185-5p	DNMT1	1786	loss of heterozygosity (LOH)	NPA	NPA	NPA	NPA	NPA	NPA
955	21960059	bone and muscle	Ewing's sarcoma	doxorubicin|vincristine	miR-34a	miR-34a-5p	NPA	NPA	NPA	inhibit cell proliferation|reduce malignancy|increase chemo-sensitivity	associated with either event-free or overall survival	NPA	NPA	49 Ewing's sarcoma primary EWSs	tumor-suppressive
956	21959981	bone and muscle	osteosarcoma	NPA	miR-93	miR-93-5p	NPA	NPA	NPA	increase cell proliferation|increase cell invasion	upregulated in primary osteosarcoma cultures compared to normal osteoblasts|significantly higher in metastases from osteosarcoma than in paired primary tumours	143B|MG-63	NPA	metastases from osteosarcoma and paired primary tumours	oncogenic
957	21956418	thyroid	thyroid carcinoma	NPA	miR-191	miR-191-5p	CDK6	1021	NPA	reduce cell growth|reduce cell migration	"down-regulated in follicular adenoma, FTC, and follicular variant of PTC|inversely correlated with CDK6 expression in follicular adenoma and FTC"	WRO	NPA	"tissues from patients with follicular adenoma (n = 24), follicular thyroid carcinoma (FTC, n = 24), papillary thyroid carcinoma (PTC, n = 15), anaplastic thyroid carcinoma (n = 8), and the follicular variant of PTC (n = 6) and normal thyroid"	tumor-suppressive
958	21953646	blood	Hodgkin's lymphoma	NPA	miR-106b	miR-106b-5p	CDKN1A	1026	NPA	promote cell cycle progression	NPA	KM-H2|U-HO1|L428	NPA	NPA	oncogenic
959	21953646	blood	Hodgkin's lymphoma	NPA	miR-17	miR-17-5p	CDKN1A	1026	NPA	promote cell cycle progression	NPA	KM-H2|U-HO1|L428	NPA	NPA	oncogenic
960	21953503	breast	breast tumor-initiating cells	doxorubicin	miR-128	miR-128-3p	BMI1|ABCC5	648|10057	NPA	decrease cell viability|induce apoptosis|increase DNA damage	significantly reduced in chemoresistant BT-ICs enriched from breast cancer cell lines and primary breast tumors|negatively associated with chemotherapeutic resistance and poor survival of breast cancer patients	NPA	NPA	57 breast cancer patients	tumor-suppressive
961	21953056	liver	cholangiocarcinoma	cyclopamine	miR-25	miR-25-3p	TNFRSF10A	8797	NPA	inhibit TRAIL-induced apoptosis	elevated in malignant cholangiocarcinoma cell lines as well as patient samples	NPA	NPA	cholangiocarcinoma patient samples	oncogenic
962	21951844	blood	multiple myeloma	NPA	miR-29b	miR-29b-3p	MCL1	4170	NPA	induce apoptosis	significantly downregulated primary MM cells	NPA	NPA	primary multiple myeloma (MM) cells	tumor-suppressive
963	21949788	skin	melanoma	5-aza-2'-deoxycytidine	miR-34b	miR-34b-5p	NPA	NPA	DNA hypermethylation	reduce cell invasion|reduce cell motility	NPA	WM1552C|A375	NPA	NPA	tumor-suppressive
964	21948564	colorectum	colorectal cancer stem cells	irinotecan	miR-451	miR-451a	MIF	6280	NPA	inhibit cell self-renewal|reduce tumorigenicity|reduce chemoresistance	downregulated in colonspheres versus parental cells	NPA	NPA	NPA	tumor-suppressive
965	21947487	stomach	gastric cancer	NPA	miR-191	miR-191-5p	NDST1	3340	NPA	promote cell growth|inhibit apoptosis	highly expressed in human gastric adenocarcinoma cell line MGC803 and human gastric cancer tissues	MGC803	NPA	human gastric cancer tissues	oncogenic
966	21947305	liver	hepatocellular carcinoma	5-FU	miR-195	miR-195-5p	BCL2L2	599	NPA	reduce 5-FU resistance	downregulated in drug resistant hepatocellular carcinoma cell line BEL-7402/5-FU compared to its parental BEL-7402 cell line	BEL-7402	NPA	NPA	NPA
967	21946813	pancreas	pancreatic cancer	gemcitabine	miR-548d	miR-548d-3p	NPA	NPA	NPA	inhibit cell proliferation|induce apoptosis|induce cell cycle arrest|increase gemcitabine sensitivity	NPA	PANC-1	NPA	NPA	tumor-suppressive
968	21946536	NPA	NPA	NPA	miR-155	miR-155-5p	NPA	NPA	BRCA1|HDAC2	inhibit cell growth	NPA	NPA	NPA	NPA	tumor-suppressive
969	21946411	thyroid	thyroid cancer	trichostatin A|vorinostat	miR-129-5p	miR-129-5p	NPA	NPA	NPA	induce cell death|increase drug sensivitiy	NPA	BCPAP|TPC-1|8505C|CAL62	NPA	NPA	tumor-suppressive
970	21945323	cervix	squamous cervical cancer	NPA	miR-375	miR-375	SP1	6667	NPA	inhibit cell proliferation|block cell cycle G1/S transition|inhibit cell migration|inhibit cell invasion	significantly decreased by 4.45-fold in cervical cancer tissues compared with normal tissues|correlated with lymph node metastasis of cervical cancer|inversely correlated with SP1 expression in cervical cancer tissues	SiHa|CaSki	NPA	170 cervical cancer tissues and 68 normal cervical tissues	tumor-suppressive
971	21941025	prostate	prostate cancer	NPA	miR-26a	miR-26a-5p	NPA	NPA	MYC	inhibit cell proliferation	downregulated in most primary prostate cancers	NPA	NPA	primary prostate cancers	tumor-suppressive
972	21941025	prostate	prostate cancer	NPA	miR-26b	miR-26b-5p	NPA	NPA	MYC	inhibit cell proliferation	downregulated in most primary prostate cancers	NPA	NPA	primary prostate cancers	tumor-suppressive
973	21940630	skin	melanoma	NPA	miR-21	miR-21-5p	PTEN|PDCD4|BTG2	5728|27250|7832	NPA	promote cell proliferation|promote cell migration	NPA	B16	syngeneic C57BL/6 mice with tail vein injection	NPA	oncogenic
974	21936961	blood	myeloma	NPA	miR-15a	miR-15a-5p	NPA	NPA	IL6	induce cell cycle G1/S arrest|reduce cell growth|reduce cell survival	significantly increased after treatment with cytotoxic agents	NPA	NPA	NPA	tumor-suppressive
975	21935572	bladder	bladder cancer	NPA	miR-18a	miR-18a-5p	DICER1	23405	NPA	suppress cell proliferation	NPA	T24	NPA	NPA	tumor-suppressive
976	21934092	colorectum	colorectal cancer	NPA	miR-499-5p	miR-499a-5p	FOXO4|PDCD4	4303|27250	NPA	increase cell migration|increase cell invasion|increase lung and liver metastasis	upregulated in highly invasive CRC cell lines and lymph node-positive CRC specimens	SW480|SW620	NPA	CRC specimens	oncogenic
977	21931765	brain	medulloblastoma	NPA	miR-34a	miR-34a-5p	DLL1	28514	NPA	inhibit cell proliferation|induce apoptosis|induce neural differentiation	NPA	Daoy	cerebellum xenografts of athymic mice	NPA	tumor-suppressive
978	21931274	stomach	gastric cancer	5-Aza-dC	miR-9	miR-9-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion	significantly down-regulated in gastric cancers compared with adjacent normal tissues	NPA	NPA	gastric cancers and adjacent normal tissues	tumor-suppressive
979	21927029	head and neck	oral squamous cell carcinoma	NPA	miR-504	miR-504-5p	FOXP1	27086	CTGF	increase cell migration|increase cell invasion	negatively correlated with FOXP1 expression in OSCC samples	SAS	SAS/CTGF-M3-formed orthotopic tumors	clinical OSCC samples	oncogenic
980	21926171	breast	breast cancer	suberoylanilide hydroxamic acid	miR-200a	miR-200a-3p	KEAP1	9817	NPA	NPA	NPA	NPA	a model of carcinogen-induced mammary hyperplasia	NPA	NPA
981	21925125	stomach	gastric cancer	histone deacetylase inhibitor|DNA methyltransferase	miR-139	miR-139-5p	CXCR4	7852	CD44|ERBB2	NPA	negatively correlated with lymph node metastasis	NPA	NPA	NPA	NPA
982	21924268	head and neck	laryngeal squamous carcinoma	NPA	miR-1	miR-1	FN1	2335	NPA	reduce cell growth|reduce cell migration|reduce cell invasion	NPA	Hep2	NPA	NPA	tumor-suppressive
983	21922148	brain	glioma	NPA	miR-27b	miR-27b-3p	TFAP2A	7020	NPA	promote cell growth|inhibit apoptosis|promote cell invasion	up-regulated in glioma samples and glioma cells	NPA	NPA	glioma samples	oncogenic
984	21922130	head and neck	maxillary sinus squamous cell carcinoma	NPA	miR-375	miR-375	LDHB	3945	NPA	inhibit cell proliferation|inhibit cell invasion	significantly reduced in cancer tissues of maxillary sinus squamous cell carcinoma|inversely correlated with LDHB mRNA levels in clinical MSSCC specimens	IMC-3	NPA	MSSCC specimens	tumor-suppressive
985	21917858	colorectum	colon cancer	NPA	miR-145	miR-145-5p	RPS6KB1	6198	NPA	inhibit tumorigenesis|inhibit tumor angiogenesis	downregulated in colon and ovarian cancer tissues and cell lines|inversely correlated with the amount of RPS6KB1 protein in colon cancer tissues	NPA	NPA	colon cancer tissues	tumor-suppressive
986	21915098	breast	breast cancer	etoposide|rapamycin	miR-101	miR-101-3p	STMN1|RAB5A|ATG4D	3925|5868|84971	NPA	inhibit autophagy	NPA	NPA	NPA	NPA	NPA
987	21912701	kidney	clear cell renal cell carcinoma	NPA	miR-224	miR-224-5p	DIO1	1733	NPA	NPA	statistically significant increased (p?=?0.0002) more than four fold in tumor samples compared to matched control samples|negatively correlated with changes in DIO1 expression	HeLa|Caki-2	NPA	32 samples of ccRCC tumors (T) and in 32 matched control (C) samples	NPA
988	21909380	pancreas	pancreatic cancer stem cells	5-Aza-dC|SAHA	miR-34a	miR-34a-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell cycle progression|inhibit self-renewal|inhibit epithelial-mesenchymal transition|inhibit cell invasion	NPA	NPA	NPA	NPA	tumor-suppressive
989	21901135	colorectum	colon cancer	NPA	miR-143	miR-143-3p	NPA	NPA	NPA	inhibit cell proliferation|induce apoptosis	NPA	HCT116	human colon carcinoma cells xenografted in nude mice	NPA	tumor-suppressive
990	21898400	bone and muscle	fibrosarcoma	NPA	miR-373	miR-373-3p	MTOR|SIRT1	2475|23411	NPA	activate Ras/Raf/MEK/Erk signaling|activate NF-¦ÊB signaling	NPA	HT1080	NPA	NPA	NPA
991	21898400	bone and muscle	fibrosarcoma	NPA	miR-520c	miR-520c-3p	MTOR|SIRT1	2475|23411	NPA	activate Ras/Raf/MEK/Erk signaling|activate NF-¦ÊB signaling	NPA	HT1080	NPA	NPA	NPA
992	21896753	skin	melanoma	NPA	miR-149*	miR-149-3p	GSK3A	2931	TP53	reduce apoptosis|inhibit tumor growth	elevated in fresh human metastatic melanoma isolates|negatively associated with GSK3A expression	NPA	a mouse xenograft model	fresh human metastatic melanoma isolates	oncogenic
993	21893020	skin	melanoma	NPA	miR-193b	miR-193b-3p	MCL1	4170	NPA	NPA	significantly lowly expressed in malignant melanoma than in benign nevi|inversely correlated with MCL1 expression in melanoma samples	NPA	NPA	melanoma and benign nevi	NPA
994	21890460	liver	hepatocellular carcinoma	NPA	miR-423	miR-423-3p	CDKN1A	1026	NPA	promote cell growth|promote cell cycle G1/S transition	NPA	NPA	NPA	NPA	oncogenic
995	21888875	liver	hepatocellular carcinoma portal vein tumor thrombus (PVTT)	NPA	miR-135a	miR-135a-5p	MTSS1	9788	FOXM1	promote invasion|promote metastasis	highly over-expressed in PVTT	CSQT-2	NPA	PVTT tissues	oncogenic
996	21883694	colorectum	colon cancer	NPA	miR-92a	miR-92a-3p	BCL2L11	10018	NPA	inhibit apoptosis	highly expressed in both colon adenomas and carcinoma	NPA	NPA	colon cancer tissues	oncogenic
997	21881409	NPA	NPA	NPA	miR-101	miR-101-3p	MSI1	4440	NPA	inhibit cell proliferation	NPA	NPA	NPA	NPA	tumor-suppressive
998	21881409	NPA	NPA	NPA	miR-128	miR-128-3p	MSI1	4440	NPA	inhibit cell proliferation	NPA	NPA	NPA	NPA	tumor-suppressive
999	21881409	NPA	NPA	NPA	miR-137	miR-137	MSI1	4440	NPA	inhibit cell proliferation	NPA	NPA	NPA	NPA	tumor-suppressive
1000	21881409	NPA	NPA	NPA	miR-138	miR-138-5p	MSI1	4440	NPA	inhibit cell proliferation	NPA	NPA	NPA	NPA	tumor-suppressive
1001	21881409	NPA	NPA	NPA	miR-34a	miR-34a-5p	MSI1	4440	NPA	inhibit cell proliferation	NPA	NPA	NPA	NPA	tumor-suppressive
1002	21880462	lung	lung cancer	cisplatin	miR-98	miR-98-5p	TP53	7157	NPA	NPA	decreased after A549 treated with cisplatin	A549	NPA	NPA	NPA
1003	21880154	blood	pediatric acute promyelocytic leukemia	NPA	miR-125b	miR-125b-5p	BAK1	578	NPA	promote cell proliferation|inhibit apoptosis|increase drug resistance	"highly expressed in pediatric APL compared with other subtypes of AML|correlated with treatment response, as well as relapse of pediatric APL|up-regulated in leukemic drug-resistant cells"	NPA	NPA	169 pediatric acute myelogenous leukemia (AML) samples including 76 APL samples before therapy and 38 APL samples after therapy	oncogenic
1004	21878637	liver	hepatocellular carcinoma	NPA	miR-99a	miR-99a-5p	IGF1R|MTOR	3480|2475	NPA	inhibit cell growth|induce cell cycle G1 arrest	"remarkably decreased in HCC tissues and cell lines|negatively significantly correlated with shorter survival of HCC patients|an independent predictor for the prognosis of HCC patients|inversely correlated with IGF1R, MTOR protein levels in HCC tissues"	NPA	HCC-bearing nude mice	HCC tissues	tumor-suppressive
1005	21878506	head and neck	nasopharyngeal carcinoma	NPA	miR-216b	miR-216b-5p	KRAS	3845	NPA	inhibit cell proliferation|inhibit cell invasion|reduce tumor growth	downregulated in nasopharyngeal carcinoma (NPC) cell lines and specimens|negatively related to advanced clinical stage and lymph node metastasis|inversely correlated with KRAS protein levels during nasopharyngeal tumorigenesis	NPA	nude mice	nasopharyngeal carcinoma  specimens	tumor-suppressive
1006	21875932	NPA	NPA	NPA	miR-31	miR-31-5p	ITGA2|ITGA5|ITGAV|ITGB3	3673|3678|3685|3690	NPA	inhibit cell spreading in a ligand-dependent manner	NPA	NPA	NPA	NPA	NPA
1007	21875770	lung	non-small cell lung cancer	NPA	miR-451	miR-451a	NPA	NPA	NPA	inhibit cell cycle progression|inhibit cell migration|inhibit cell invasion|induce anoikis	"decreased in non-small cell lung cancer (NSCLC) tissues|negatively associated with lymph node metastasis, the stage of TNM classification and poor prognosis of NSCLC patients"	NPA	NPA	non-small cell lung cancer (NSCLC) tissues	tumor-suppressive
1008	21875287	kidney	clear cell renal cell carcinoma	NPA	miR-138	miR-138-5p	HIF1A	3091	NPA	increase apoptosis|reduce cell migration	NPA	786-O	NPA	NPA	tumor-suppressive
1009	21874051	brain	glioma	NPA	miR-128	miR-128-3p	EGFR|PDGFRA	1956|5156	NPA	repress cell growth|promote neuronal differentiation	negatively correlated with aggressive human glioma subtypes	NPA	an autochthonous glioma mouse model	NPA	tumor-suppressive
1010	21874049	NPA	NPA	NPA	miR-200	miR-200a-3p|miR-200b-3p|miR-200c-3p	NPA	NPA	DNA methylation	inhibit cell migration|inhibit tumor growth|reduce metastasis formation	NPA	NPA	nude mice	NPA	tumor-suppressive
1011	21874046	thyroid	papillary thyroid carcinoma	NPA	miR-146b-5p	miR-146b-5p	SMAD4	4089	RET|BRAF	increase cell proliferation|inhibit TGF-¦Â signaling	overexpressed in papillary thyroid carcinomas (PTCs)	TPC-1|BCPAP|PCCL3	NPA	papillary thyroid carcinomas	oncogenic
1012	21873783	head and neck	nasopharyngeal carcinoma	NPA	miR-149	miR-149-5p	NPA	NPA	NPA	promote cell proliferation|promote cell motility|promote cell invasion	higher in NPC cell lines than that in normal immortalized nasopharyngeal epithelial cells	5-8F|6-10B|NP69	NPA	NPA	oncogenic
1013	21872591	colorectum	colorectal cancer	NPA	miR-21	miR-21-5p	RHOB	388	NPA	promote cell proliferation|promote cell invasion|inhibit apoptosis	NPA	NPA	NPA	NPA	oncogenic
1014	21868760	breast	breast cancer	NPA	let-7g	let-7g-5p	GAB2|FN1	9846|2335	EGF|estrogen	inhibit metastasis|inhibit cell invasion	significantly negatively associated with lymph node metastasis and poor survival in breast cancer patients	NPA	NPA	breast cancer patients	tumor-suppressive
1015	21868754	uterus	endometrial cancer	NPA	miR-152	miR-152-3p	E2F3|MET|RICTOR|DNMT1	1871|4233|253260|1786	DNA hypermethylation	inhibit cell growth	NPA	NPA	NPA	NPA	tumor-suppressive
1016	21868360	breast	breast cancer	NPA	miR-221	miR-221-3p	TRPS1	7227	FOSL1|MAP2K1	increase cell migration|increase cell invasion|epithelial-mesenchymal transition	NPA	NPA	NPA	NPA	oncogenic
1017	21868360	breast	breast cancer	NPA	miR-222	miR-222-3p	TRPS1	7227	FOSL1|MAP2K1	increase cell migration|increase cell invasion|epithelial-mesenchymal transition	NPA	NPA	NPA	NPA	oncogenic
1018	21860426	NPA	NPA	NPA	miR-542-3p	miR-542-3p	ILK	3611	SRC	inhibit tumor growth	significantly inversely correlated with ILK expression	NPA	NPA	human colon cancer tissues	tumor-suppressive
1019	21860416	skin	melanoma	NPA	miR-506~514	CLUSTER:miR-506~514	NPA	NPA	NPA	promote cell growth|inhibit apoptosis|increase cell invasion|increase colony formation in soft agar	"consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001)"	NPA	NPA	skin punches from 33 metastatic melanoma patients and 14 normal healthy donors	oncogenic
1020	21857646	brain	CD133+ glioblastoma cancer stem cells	NPA	miR-17	miR-17-5p	CAMTA1	23261	NPA	promote neurosphere formation|inhibit cell differentiation	highly abundant in CD133+ glioblastoma cancer stem cells	NPA	nude mice	NPA	oncogenic
1021	21857646	brain	CD133+ glioblastoma cancer stem cells	NPA	miR-9*	miR-9-3p	CAMTA1	23261	NPA	promote neurosphere formation|inhibit cell differentiation	highly abundant in CD133+ glioblastoma cancer stem cells	NPA	nude mice	NPA	oncogenic
1022	21857646	brain	CD133+ glioblastoma cancer stem cells	NPA	miR-9	miR-9-5p	CAMTA1	23261	NPA	promote neurosphere formation|inhibit cell differentiation	highly abundant in CD133+ glioblastoma cancer stem cells	NPA	nude mice	NPA	oncogenic
1023	21856745	lung	lung cancer with neuroendocrine	NPA	miR-375	miR-375	YAP1	10413	ASH1L	NPA	negatively correlated with YAP1 in a panel of lung cancer cell lines	NPA	NPA	NPA	NPA
1024	21853155	bone and muscle	Ewing's sarcoma	NPA	let-7a	let-7a-5p	NPA	NPA	EWS-FLI-1	inhibit tumor growth	NPA	NPA	NPA	NPA	tumor-suppressive
1025	21852381	kidney	renal cell carcinoma	NPA	miR-708	miR-708-5p	NPA	NPA	NPA	decrease cell growth|decrease clonability|decrease cell invasion|decrease cell migration|increase apoptosis	downregulated widely in human RCC specimens	NPA	murine xenograft models of human RCC	human RCC specimens	tumor-suppressive
1026	21851624	uterus	endometrial cancer	NPA	miR-194	miR-194-5p	BMI1	648	NPA	induce mesenchymal-epithelial transition|inhibit cell invasion	NPA	NPA	NPA	NPA	tumor-suppressive
1027	21847633	liver	hepatocellular carcinoma	hypoxia	miR-199a	miR-199a-5p	HIF1A	3091	NPA	reduce cell proliferation	significantly down-regulated in HCC tissues when compared with pair-matched adjacent non-tumor tissues	SMMC-7721|BEL-7402|BEL-7701|MHCC97H|HepG2|L02	NPA	11 pairs of matched HCC neoplastic and adjacent non-neoplastic tissues	tumor-suppressive
1028	21847129	head and neck	maxillary sinus squamous cell carcinoma	NPA	miR-874	miR-874-3p	PPP1CA	5499	NPA	inhibit cell proliferation|inhibit cell invasion	downregulated in clinical specimens of maxillary sinus squamous cell carcinoma (MSSCC)	NPA	NPA	clinical specimens of maxillary sinus squamous cell carcinoma (MSSCC)	tumor-suppressive
1029	21845495	stomach	gastric cancer	NPA	miR-194	miR-194-5p	NPA	NPA	NPA	inhibit cell invasion	"negatively correlated with larger tumor size (P = 0.002) and more advanced pT stage (P = 0.028) in gastric cancer|significantly lower in Borrmann IV type gastric cancer than in Borrmann I, II, and III types"	SGC-7901	NPA	tissues of 119 patients with gastric cancer	tumor-suppressive
1030	21837748	liver	hepatocellular carcinoma	NPA	miR-200a	miR-200a-3p	HDAC4	9759	HDAC4|SP1	inhibit cell proliferation|inhibit cell migration	reduced in human HCC tissues in comparison with adjacent noncancerous hepatic tissues	NPA	NPA	human HCC tissues and adjacent noncancerous hepatic tissues	tumor-suppressive
1031	21831363	brain	glioblastoma multiforme	NPA	miR-491-5p	miR-491-5p	MMP9	4318	NPA	inhibit cell invasion	high positive correlated with MMP9 expression	U251|U87	NPA	60 glioblastoma multiforme samples	tumor-suppressive
1032	21828058	breast	breast cancer	NPA	miR-214	miR-214-3p	EZH2	2146	NPA	reduce cell proliferation|inhibit cell invasion	inversely correlated with EZH2 mRNA and protein levels in breast cancer cell lines	NPA	NPA	25 primary breast tumors	tumor-suppressive
1033	21823019	ovary	ovarian cancer	cisplatin	miR-125b	miR-125b-5p	BAK1	578	NPA	inhibit cisplatin-induced cytocoxicity|inhibit cisplatin-induced apoptosis	NPA	OV2008|C13*	NPA	NPA	NPA
1034	21822301	stomach	gastric cancer	NPA	miR-335	miR-335-5p	BCL2L2|SP1	599|6667	NPA	inhibit cell invasion|reduce metastasis	"dramatically downregulated in gastric cancer cell lines than in the normal gastric cell line|significantly negatively associated with lymph-node metastasis, poor pT stage, poor pN stage and invasion of lymphatic vessels"	GES-1	NPA	70 gastric cancer tissues	tumor-suppressive
1035	21822286	breast	breast cancer	NPA	miR-200	miR-200a-3p|miR-200b-3p|miR-200c-3p	SEC23A	10484	NPA	promote metastatic colonization|influence cell secretome	associated with increased risk of metastasis in breast cancer	NPA	mouse models	breast cancer tissues	oncogenic
1036	21820606	breast	breast cancer	doxorubicin	miR-21	miR-21-5p	PTEN	5728	NPA	reduce apoptosis|reduce doxorubicin sensitivity	NPA	MCF-7	NPA	NPA	oncogenic
1037	21820586	kidney	renal cell carcinoma	NPA	miR-21	miR-21-5p	TIMP3	7078	NPA	promote cell proliferation|inhibit apoptosis|promote cell survival	NPA	NPA	NPA	NPA	oncogenic
1038	21819631	head and neck	laryngeal carcinoma	NPA	miR-106b	miR-106b-5p	RB1	5925	NPA	reduce cell cycle G0/G1 arrest	inversely correlated with RB1 expression in laryngeal carcinoma tissues	NPA	NPA	laryngeal carcinoma tissues	oncogenic
1039	21818714	ovary	epithelial ovarian cancer	NPA	miR-101	miR-101-3p	NPA	NPA	NPA	increase apoptosis|reduce cell proliferation|reduce cell invasion|reduce tumor growth	decreased in epithelial ovarian carcinoma (EOC) compared with normal tissue	MDAH-2774	tumor xenografts	EOC patient tissues and normal controls	tumor-suppressive
1040	21816922	eye	retinoblastoma	NPA	miR-17~92	CLUSTER:miR-17~92	NPA	NPA	NPA	promote cell proliferation|drive retinoblastoma formation	highly expressed in human retinoblastoma	NPA	NPA	human retinoblastoma	oncogenic
1041	21816906	blood	acute myeloid leukemia	"1,25-Dihydroxyvitamin D(3) (1,25D)|arabinocytosine"	miR-32	miR-32-5p	BCL2L11	10018	NPA	increase cell survival|reduce apoptosis	NPA	NPA	NPA	NPA	oncogenic
1042	21814748	breast	breast cancer	NPA	miR-34a	miR-34a-5p	AXL	558	NPA	NPA	inversely correlated with AXL expression for both cell line and patient tumor samples	MDA-MB-231|MCF7|SK-BR-3	NPA	breast cancer tissues	NPA
1043	21813472	esophagus	oesophageal squamous cell carcinoma	NPA	miR-375	miR-375	IGF1R	3480	NPA	inhibit clonogenicity|inhibit cell motility|inhibit cell proliferation|reduce tumour formation|reduce metastasis	"frequently downregulated in primary oesophageal squamous cell carcinoma (ESCC)|significantly negatively correlated with advanced stage (p=0.003), distant metastasis (p<0.0001), poor overall survival (p=0.048) and disease-free survival (p=0.0006)|inversely correlated with IGF1R expression in clinical specimens"	NPA	mice	primary oesophageal squamous cell carcinoma (ESCC)	tumor-suppressive
1044	21809363	liver	hepatocellular carcinoma	NPA	miR-637	miR-637	LIF	3976	NPA	inhibit cell growth|induce apoptosis	downregulated in most of the hepatocellular carcinoma (HCC) specimens|inversely associated with LIF expression	NPA	nude mice model	hepatocellular carcinoma (HCC) specimens	tumor-suppressive
1045	21809359	liver	cholangiocarcinoma	NPA	miR-494	miR-494-3p	CDK6	1021	NPA	decrease cell growth|induce cell cycle G1/S arrest|inhibit tumor growth	down-regulated in cholangiocarcinoma (CCA)	NPA	xenografts	cholangiocarcinoma (CCA) tissues	tumor-suppressive
1046	21807947	breast	breast cancer	NPA	miR-199a-3p	miR-199a-3p	CAV2	858	NPA	promote cell proliferation|promote cell survival	NPA	MDA-MB-231|MT-1	NPA	NPA	oncogenic
1047	21806946	colorectum	colon cancer	NPA	miR-155	miR-155-5p	PPP2CA|SOCS1	5515|8651	NTSR1|NTS|NF-¦ÊB	promote colony formation|promote tumor growth	increased significantly in human colon tumor samples compared with normal tissues	NCM460|HCT116	HCT-116 mouse xenograft tumors	human colon tumor samples and normal tissues	oncogenic
1048	21806946	colorectum	colon cancer	NPA	miR-21	miR-21-5p	PTEN	5728	NTSR1|NTS|NF-¦ÊB	promote colony formation|promote tumor growth	increased significantly in human colon tumor samples compared with normal tissues	NCM460|HCT116	HCT-116 mouse xenograft tumors	human colon tumor samples and normal tissues	oncogenic
1049	21802841	liver	hepatocellular carcinoma	adriamycin|vincristine	miR-122	miR-122-5p	NPA	NPA	NPA	inhibit cell growth|induce cell cycle G2/M arrest	NPA	NPA	NPA	NPA	tumor-suppressive
1050	21796614	nerve	neuroblastoma	NPA	miR-19b	miR-19b-3p	DKK3	27122	NPA	NPA	NPA	NPA	NPA	NPA	NPA
1051	21796614	nerve	neuroblastoma	NPA	miR-92a	miR-92a-3p	DKK3	27122	NPA	NPA	NPA	NPA	NPA	NPA	NPA
1052	21795477	head and neck	oral squamous cell carcinoma	NPA	miR-218	miR-218-5p	RICTOR	253260	NPA	reduce cell growth|reduce AKT signaling	frequently silenced by DNA hypermethylation in a wide panel of OSCC cell lines and primary tumor tissues	NPA	NPA	OSCC primary tumor tissues	tumor-suppressive
1053	21793034	liver	hepatocellular carcinoma	NPA	miR-29b	miR-29b-3p	MMP2	4313	NPA	inhibit angiogenesis|inhibit invasion|inhibit metastasis	"inversely correlated with tumor angiogenesis, venous invasion, and metastasis in human HCC tissues and mouse xenograft tumors|inversely correlated with MMP-2 expression in human HCC tissues and mouse xenograft tumors"	NPA	in vivo subcutaneous and orthotopic xenograft mouse models	human HCC samples	tumor-suppressive
1054	21790228	bladder	bladder carcinoma	NPA	miR-143	miR-143-3p	COX2	5743	NPA	reduce cell proliferation|reduce cell motility	lowly expressed in a series of human bladder carcinomas as compared to background tissue	T24	NPA	NPA	tumor-suppressive
1055	21784052	blood	acute myeloid leukemia	NPA	miR-10a	miR-10a-5p	MDM4	4194	NPA	NPA	markedly overexpressed in NPM1 mutant AML samples than wild-type samples|inversely associated with MDM4 expression in AML (IR) samples	K562	NPA	bone marrow samples from AML (IR) patients with NPM1 mutations and healthy donors	NPA
1056	21778999	blood	ALK+ anaplastic large-cell lymphoma	NPA	miR-16	miR-16-5p	VEGFA	7422	ALK|HIF1A	reduce angiogenesis|reduce tumor growth	inversely correlated with VEGFA expression in human NPM-ALK+ Anaplastic Large Cell Lymphomas (ALCL)	MEF	NPA	human NPM-ALK+ Anaplastic Large Cell Lymphomas (ALCL)	tumor-suppressive
1057	21777146	lung	lung cancer	NPA	miR-125a-5p	miR-125a-5p	NPA	NPA	NPA	suppress cell proliferation|induce apoptosis	lowly expressed in different lung cancer cell lines than in Human bronchial epithelial (HBE) cells	A549	NPA	NPA	tumor-suppressive
1058	21775132	brain	medulloblastoma	NPA	miR-21	miR-21-5p	NPA	NPA	NPA	promote cell motility|promote cell migration across basement membranes	up-regulated in 29/29 MB primary samples and 6/6 MB-derived cell lines compared to normal cerebellum	NPA	NPA	29 MB primary samples	oncogenic
1059	21770894	head and neck	head and neck squamous cell carcinoma	NPA	miR-138	miR-138-5p	VIM|ZEB2|EZH2	7431|9839|2146	NPA	inhibit epithelial-mesenchymal transition	NPA	NPA	NPA	NPA	tumor-suppressive
1060	21765466	breast	breast cancer	NPA	miR-106a	miR-106a-5p	ZBTB4	57659	NPA	NPA	NPA	MDA-MB-231|MCF-7	NPA	NPA	NPA
1061	21765466	breast	breast cancer	NPA	miR-106b	miR-106b-5p	ZBTB4	57659	NPA	NPA	NPA	MDA-MB-231|MCF-7	NPA	NPA	NPA
1062	21765466	breast	breast cancer	NPA	miR-17-5p	miR-17-5p	ZBTB4	57659	NPA	NPA	NPA	MDA-MB-231|MCF-7	NPA	NPA	NPA
1063	21765466	breast	breast cancer	NPA	miR-20a	miR-20a-5p	ZBTB4	57659	NPA	NPA	NPA	MDA-MB-231|MCF-7	NPA	NPA	NPA
1064	21765466	breast	breast cancer	NPA	miR-93	miR-93-5p	ZBTB4	57659	NPA	NPA	NPA	MDA-MB-231|MCF-7	NPA	NPA	NPA
1065	21763284	liver	HBV+ hepatocellular carcinoma	NPA	miR-29c	miR-29c-3p	TNFAIP3	7128	NPA	inhibit cell proliferation|induce apoptosis	significantly downregulated in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) cell lines as well as in clinical tissues compared with their corresponding controls|inversely correlated with TNFAIP3 expression	HepG2.2.15	NPA	hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) clinical tissues and their corresponding controls	tumor-suppressive
1066	21762626	lung	lung cancer	NPA	miR-155	miR-155-5p	NPA	NPA	NPA	inhibit cell growth|induce cell cycle G0/G1 arrest	NPA	95D	NPA	NPA	tumor-suppressive
1067	21761362	breast	breast cancer	NPA	miR-221	miR-221-3p	DICER1	23405	NPA	NPA	dramatically higher in ESR1- cells than in ESR1+ breast cancer cells	NPA	NPA	NPA	NPA
1068	21761362	breast	breast cancer	NPA	miR-222	miR-222-3p	DICER1	23405	NPA	NPA	dramatically higher in ESR1- cells than in ESR1+ breast cancer cells	NPA	NPA	NPA	NPA
1069	21761362	breast	breast cancer	NPA	miR-29a	miR-29a-3p	DICER1	23405	NPA	NPA	dramatically higher in ESR1- cells than in ESR1+ breast cancer cells	NPA	NPA	NPA	NPA
1070	21761344	blood	multiple myeloma	glucocorticoid	miR-130b	miR-130b-3p	NR3C1	2908	NPA	inhibit apoptosis|increase resistance	differentially expressed between GC-sensitive and GC-resistant MM.1 cell lines	NPA	NPA	NPA	oncogenic
1071	21753766	head and neck	head and neck squamous cell carcinoma	NPA	miR-375	miR-375	MTDH	92140	NPA	inhibit cell proliferation|induce apoptosis	NPA	SAS|FaDu	NPA	NPA	tumor-suppressive
1072	21752897	thyroid	thyroid carcinoma	NPA	miR-1	miR-1	CCND2|CXCR4|CXCL12	894|7852|6387	NPA	inhibit cell proliferation|inhibit cell migration	drastically down-regulated in thyroid adenomas and carcinomas in comparison with normal thyroid tissue|inversely correlated with CXCR4/CXCL12 protein levels in papillary and anaplastic thyroid carcinomas	NPA	NPA	"thyroid adenomas, carcinomas and normal thyroid tissue"	tumor-suppressive
1073	21750653	liver	hepatocellular carcinoma	NPA	miR-122	miR-122-5p	CDK4	1019	NPA	repress unfolded protein response (UPR) pathway|promote drug-induced apoptosis	NPA	NPA	NPA	NPA	NPA
1074	21750649	lung	non-small cell lung cancer	NPA	miR-7	miR-7-5p	BCL2	596	NPA	suppress cell proliferation|induce apoptosis|inhibit cell migration|reduce tumorigenicity in vivo	reduced in cancer cell lines	A549	NPA	NPA	tumor-suppressive
1075	21745735	kidney	renal cell carcinoma	NPA	miR-1	miR-1	TAGLN2	8407	NPA	inhibit cell proliferation|inhibit cell invasion|induce apoptosis|induce cell cycle arrest	significantly suppressed in RCC cell lines and specimens|statistically significant inverse correlated with TAGLN2 expression in RCC specimens	NPA	NPA	40 RCC specimens	tumor-suppressive
1076	21745735	kidney	renal cell carcinoma	NPA	miR-133a	miR-133a-3p	TAGLN2	8407	NPA	inhibit cell proliferation|inhibit cell invasion|induce apoptosis|induce cell cycle arrest	significantly suppressed in RCC cell lines and specimens|statistically significant inverse correlated with TAGLN2 expression in RCC specimens	NPA	NPA	40 RCC specimens	tumor-suppressive
1077	21743493	breast	breast cancer	NPA	miR-155	miR-155-5p	STAB1	23166	FOXP1	NPA	NPA	NPA	NPA	NPA	NPA
1078	21743493	breast	breast cancer	NPA	miR-7	miR-7-5p	STAB1	23166	FOXP1	NPA	NPA	NPA	NPA	NPA	NPA
1079	21743492	brain	glioblastoma	NPA	miR-221	miR-221-3p	PTPRM	5797	NPA	increase cell migration|increase cell growth	inversely correlated with PTPRM expression in human glioma cancer samples	LN-18|LN-229|U87MG|T98G	NPA	human glioma cancer samples	oncogenic
1080	21743492	brain	glioblastoma	NPA	miR-222	miR-222-3p	PTPRM	5797	NPA	increase cell migration|increase cell growth	inversely correlated with PTPRM expression in human glioma cancer samples	LN-18|LN-229|U87MG|T98G	NPA	human glioma cancer samples	oncogenic
1081	21743487	NPA	NPA	NPA	miR-33a	miR-33a-5p	PIM1	5292	NPA	reduce cell proliferation	NPA	K562|LS174T|Skov-3	NPA	NPA	tumor-suppressive
1082	21743299	brain	glioblastoma multiforme	NPA	miR-34a	miR-34a-5p	NOTCH1	4851	NPA	inhibit cell proliferation|induce apoptosis	significantly downregulated in glioblastoma multiforme (GBM) specimens compared with normal brain tissues	U373MG|SHG44	NPA	glioblastoma multiforme (GBM) specimens and normal brain tissues	tumor-suppressive
1083	21741600	skin	melanoma	NPA	miR-30b	miR-30b-5p	GALNT7	117248	NPA	promote cell invasion|promote metastasis|reduce immune cell activation and recruitment	"correlated with stage, metastatic potential, shorter time to recurrence, and reduced overall survival in human melanoma"	NPA	NPA	human melanoma	oncogenic
1084	21741600	skin	melanoma	NPA	miR-30d	miR-30d-5p	GALNT7	117248	NPA	promote cell invasion|promote metastasis|reduce immune cell activation and recruitment	"correlated with stage, metastatic potential, shorter time to recurrence, and reduced overall survival in human melanoma"	NPA	NPA	human melanoma	oncogenic
1085	21738599	breast	breast cancer	NPA	miR-210	miR-210-3p	NPA	NPA	NPA	promote cell proliferation|promote cell invasion|promote cell migration	"associated with tumor proliferation and differentiation|associated with poor clinical outcome in ER-positive, tamoxifen-treated BC patients"	MCF7|MDA-MB-231	NPA	56 systemically untreated BC patients|an independent dataset of 89 ER-positive BC patients homogeneously treated with tamoxifen only	oncogenic
1086	21726338	uterus	choriocarcinoma	NPA	miR-141	miR-141-3p	NPA	NPA	LIF	inhibit cell proliferation	NPA	JEG-3	NPA	NPA	tumor-suppressive
1087	21730286	brain	glioma	NPA	miR-146a	miR-146a-5p	NOTCH1	4851	EGFR	reduce cell proliferation|reduce cell migration|reduce formation and migration of glioma stem-like cells	NPA	NPA	an orthotopic xenograft model	NPA	tumor-suppressive
1088	21726609	lung	lung cancer	NPA	miR-506	miR-506-3p	NPA	NPA	NPA	decrease cell proliferation|induce cell cycle G0/G1 arrest|inhibit cell growth|inhibit tumor growth	reduced in 16HBE-T transformed malignant human bronchial epithelial cells compared with 16HBE normal human bronchial epithelial cells	16HBE-T|16HBE	a nude mouse xenograft model	NPA	tumor-suppressive
1089	21725618	liver	HBV+ hepatocellular carcinoma	NPA	miR-122	miR-122-5p	NDRG3	57446	NPA	inhibit cell proliferation|inhibit HBV replication	down-regulated in the hepatitis B virus (HBV)-related HCC cell line HepG2.2.15 compared to HepG2|inversely correlated with NDRG3 protein in HBV-related HCC specimens	HepG2.2.15|HepG2	NPA	HBV-related HCC specimens	tumor-suppressive
1090	21725603	head and neck	oral squamous cell carcinoma	NPA	let-7d	let-7d-5p	NPA	NPA	NPA	reverse epithelial-mesenchymal transition|inhibit cell migration|inhibit cell invasion	significantly decreased in OSCC cancer cell lines and primary cultures as compared to normal human oral keratinocyte cells	OECM-1	NPA	NPA	tumor-suppressive
1091	21725369	head and neck	tongue squamous cell carcinoma	cisplatin	miR-15b	miR-15b-5p	BMI1	648	NPA	reverse epithelial-mesenchymal transition|increase chemotherapy|inhibit metastasis	negatively associated with chemotherapeutic resistance in TSCCs and poor patient survival	CAL27|SCC25	TSCC xenografts established by CAL27-res cells	clinical TSCC samples	tumor-suppressive
1092	21725369	head and neck	tongue squamous cell carcinoma	cisplatin	miR-200b	miR-200b-3p	BMI1	648	NPA	reverse epithelial-mesenchymal transition|increase chemotherapy|inhibit metastasis	negatively associated with chemotherapeutic resistance in TSCCs and poor patient survival	CAL27|SCC25	TSCC xenografts established by CAL27-res cells	clinical TSCC samples	tumor-suppressive
1093	21725366	ovary	ovarian cancer	NPA	miR-187	miR-187-3p	DAB2	1601	NPA	promote cell proliferation|inhibit migration|reduce epithelial-mesenchymal transition	expressed at higher levels in ovarian cancers than in benign tumors|associated with better OS and recurrence-free survival|an independent prognostic factor for patients with ovarian cancer	NPA	NPA	ovarian cancers and benign tumors|176 patients with ovarian cancer	oncogenic
1094	21724611	NPA	NPA	NPA	miR-296	miR-296-5p	CDKN1A	1026	genomic region 20q13.32 amplification	NPA	highly expressed in many cancer cell lines	NPA	NPA	NPA	NPA
1095	21724256	blood	acute myeloid leukemia	NPA	miR-193b	miR-193b-3p	NPA	NPA	NPA	inhibit cell growth	significantly down-regulated in the examined AML cells	NPA	NPA	NPA	tumor-suppressive
1096	21723890	breast	breast cancer	5-FU	miR-145	miR-145-5p	FSCN1	6624	NPA	reduce cell proliferation|reduce cell motility	inversely correlated with FSCN1 expression in breast cancer cell lines and breast cancer patient tissues	NPA	orthotopic breast cancer mice	breast cancer patient tissues	tumor-suppressive
1097	21723283	skin	melanoma	5AzadC|4-PBA	miR-375	miR-375	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell invasion|inhibit cell motility|induce cell shape changes	NPA	WM1552C	NPA	NPA	tumor-suppressive
1098	21720384	brain	glioma-initiating cells	NPA	miR-302a	miR-302a-3p	CXCR4	7852	NPA	inhibit self-renewal|inhibit cell infiltration	NPA	NPA	NPA	NPA	tumor-suppressive
1099	21712475	lung	lung cancer	NPA	miR-7	miR-7-5p	EGFR	1956	NPA	inhibit cell growth|induce tumor regression	NPA	PC-9|H3255|RPC-9|H1975	mouse xenograft model using RPC-9 and H1975	NPA	tumor-suppressive
1100	21711110	NPA	NPA	NPA	miR-143	miR-143-3p	FHIT	2272	NPA	induce cell cycle G2 arrest|protect cells from DNA damage-induced killing	NPA	NPA	NPA	NPA	NPA
1101	21710544	prostate	prostate cancer	NPA	miR-488*	miR-488-5p	AR	367	NPA	inhibit cell proliferation|induce apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
1102	21709669	pancreas	pancreatic ductal adenocarcinoma	NPA	miR-148a	miR-148a-3p	CDC25B	994	NPA	inhibit cell growth|inhibit colony formation	significantly 4-fold down-regulated in human pancreatic ductal adenocarcinoma (PDAC) as opposed to normal pancreatic ductal cells	IMIM-PC2	NPA	human pancreatic ductal adenocarcinoma (PDAC)	tumor-suppressive
1103	21707582	blood	multiple myeloma	5-Aza-2'-deoxycytidine	miR-203	miR-203a	CREB1	1385	DNA hypermethylation	inhibit cell proliferation	NPA	NPA	NPA	"20 monoclonal gammopathy of undetermined significance (MGUS), 123 diagnostic MM and 19 relapsed MM samples"	tumor-suppressive
1104	21706050	lung	non-small cell lung cancer	NPA	miR-130a	miR-130a-3p	MET	4233	NPA	inhibit cell migration	expressed at low level in lung cancer cell lines	NPA	NPA	NPA	tumor-suppressive
1105	21706045	blood	MLL-AF4 acute lymphoblastic leukemia	NPA	miR-143	miR-143-3p	NPA	NPA	DNA hypermethylation	induce apoptosis|inhibit cell growth	"epigenetically repressed by promoter hypermethylation in MLL-AF4-positive primary blasts and cell lines, but not in normal bone marrow cells and MLL-AF4-negative primary blasts"	NPA	NPA	"MLL-AF4-positive primary blasts, normal bone marrow cells and MLL-AF4-negative primary blasts"	tumor-suppressive
1106	21703189	liver	hepatocellular carcinoma	5-aza-2'-deoxycytidine	miR-125b	miR-125b-5p	PGF	5228	DNA hypermethylation	inhibit cell proliferation|inhibit cell migration|inhibit invasion|inhibit angiogenesis	decreased in in HCC tumor tissues and cell lines	NPA	NPA	HCC tissues	tumor-suppressive
1107	21702042	bladder	bladder cancer	cisplatin	miR-34a	miR-34a-5p	CDK6|SIRT1	1021|23411	NPA	increase cisplatin sensitivity	lowly expressed in many of patients who subsequently did not respond to treatment|significantly differentially expressed between the responder and nonresponder groups|increased postchemotherapy in only two of the eight patients	T24|TCCSUP|5637	NPA	27 preneoadjuvant chemotherapy patient samples|eight sets of pre- and postneoadjuvant chemotherapy patient samples	NPA
1108	21701775	head and neck	maxillary sinus squamous cell carcinoma	NPA	miR-1	miR-1	NPA	NPA	NPA	inhibit cell proliferation|induce apoptosis	significantly downregulated in clinical MSSCC tumor tissues compared with normal tissues	NPA	NPA	clinical MSSCC tumor tissues and normal tissues	tumor-suppressive
1109	21701775	head and neck	maxillary sinus squamous cell carcinoma	NPA	miR-133a	miR-133a-3p	NPA	NPA	NPA	inhibit cell proliferation|induce apoptosis	significantly downregulated in clinical MSSCC tumor tissues compared with normal tissues	NPA	NPA	clinical MSSCC tumor tissues and normal tissues	tumor-suppressive
1110	21693658	bone and muscle	liposarcoma	NPA	miR-143	miR-143-3p	PRC1|TOP2A	9055|7153	NPA	inhibit cell proliferation|induce apoptosis	highly abundant in adipose tissue|downregulated in dedifferentiated liposarcomas	NPA	NPA	"samples of normal adipose tissue, well-differentiated liposarcoma, and dedifferentiated liposarcoma"	tumor-suppressive
1111	21693595	bone and muscle	osteosarcoma	cisplatin|camptothecin|ionizing radiation	miR-138	miR-138-5p	H2AFX	3014	NPA	induce chromosomal instability after DNA damage|inhibit homologous recombination|increase DNA-damaging agents sensivitity	NPA	U2OS	NPA	NPA	NPA
1112	21692045	breast	breast cancer	NPA	miR-340	miR-340-5p	MET	4233	NPA	inhibit cell migration|inhibit cell invasion	"down-regulated in the more aggressive breast cancer cell lines and breast cancer tissue specimens|negatively associated with lymph node metastasis, high tumor histological grade, clinical stage, and shorter overall survival of breast cancer|inversely correlated with MET expression in breast cancer tissue specimens"	NPA	NPA	breast cancer tissue specimens	tumor-suppressive
1113	21690566	colorectum	colon carcinoma	NPA	miR-145	miR-145-5p	NPA	NPA	NPA	reduce cell proliferation|increase apoptosis	NPA	NPA	mouse xenograft tumors	NPA	tumor-suppressive
1114	21690566	colorectum	colon carcinoma	NPA	miR-33a	miR-33a-5p	PIM1	5292	NPA	NPA	NPA	NPA	mouse xenograft tumors	NPA	NPA
1115	21688200	stomach	gastric cancer	NPA	miR-214	miR-214-3p	NPA	NPA	NPA	reduce cell cycle G1 arrest	overexpressed in gastric cancer cell lines compared with normal gastric mucosal cell line	BGC823|MKN45|SGC7901|GES-1	NPA	NPA	oncogenic
1116	21687938	skin	melanoma	NPA	miR-211	miR-211-5p	PRAME	23532	NPA	NPA	commonly downregulated in all of the melanoma cell lines in comparison with the 3 primary cultures of human epidermal melanocytes|inversely correlated with PRAME protein expression in melanoma cell lines and primary cultures of NHEMs	NPA	NPA	NPA	NPA
1117	21685938	head and neck	head and neck squamous cell carcinoma	hyaluronan	miR-21	miR-21-5p	NPA	NPA	CD44|NANOG|STAT3	induce HA chemoresistance	NPA	HSC-3	NPA	NPA	NPA
1118	21685371	blood	acute myeloid leukemia	NPA	miR-29a	miR-29a-3p	SKI	6497	NPA	NPA	down-regulated in AML with -7/del7q|inversely correlated with SKI expression in AML with -7/del7q	NPA	NPA	AML samples	NPA
1119	21684154	stomach	gastric carcinoma	NPA	miR-429	miR-429	MYC	4609	NPA	reduce cell viability|inhibit cell proliferation|inhibit cell attachment	downregulated in human gastric carcinoma tissue and in SGC-7901 cells|significantly lower in tumour tissue of patients with lymph node metastasis than in those without lymph node metastasis	SGC-7901	NPA	52 gastric cancer tissues and their paracancerous tissues	tumor-suppressive
1120	21673316	breast	breast cancer	NPA	miR-221	miR-221-3p	TRPS1	7227	FOSL1|EGFR|MAP2K1	increase cell migration|increase cell invasion|increase epithelial-mesenchymal transition	specificly expressed in basal-like breast subtype of breast cancer	NPA	NPA	NPA	oncogenic
1121	21673316	breast	breast cancer	NPA	miR-222	miR-222-3p	TRPS1	7227	FOSL1|EGFR|MAP2K1	increase cell migration|increase cell invasion|increase epithelial-mesenchymal transition	specificly expressed in basal-like breast subtype of breast cancer	NPA	NPA	NPA	oncogenic
1122	21673066	mesothelium	malignant pleural mesothelioma	5-aza-2'-deoxycytidine	miR-34b	miR-34b-5p	NPA	NPA	DNA hypermethylation in cancer	inhibit cell proliferation|induce cell cycle G1 arrest|inhibit cell migration|inhibit cell invasion|inhibit cell motility	reduced in all methylated malignant pleural mesothelioma (MPM) cell lines	NPA	NPA	NPA	tumor-suppressive
1123	21673066	mesothelium	malignant pleural mesothelioma	5-aza-2'-deoxycytidine	miR-34c	miR-34c-5p	NPA	NPA	DNA hypermethylation in cancer	inhibit cell proliferation|induce cell cycle G1 arrest|inhibit cell migration|inhibit cell invasion|inhibit cell motility	reduced in all methylated malignant pleural mesothelioma (MPM) cell lines	NPA	NPA	NPA	tumor-suppressive
1124	21672940	liver	hepatocellular carcinoma	NPA	miR-124	miR-124-3p	ROCK2|EZH2	9475|2146	NPA	inhibit cell migration|inhibit invasion|inhibit intrahepatic and pulmonary metastasis|inhibit epithelial-mesenchymal	frequently reduced in HCC cells and tissues|negatively significantly associated with a more aggressive and/or poor prognostic phenotype of patients with HCC	NPA	NPA	HCC tissues	tumor-suppressive
1125	21672525	liver	HBV+ hepatocellular carcinoma	NPA	miR-192	miR-192-5p	ERCC3|ERCC4	2071|2072	NPA	inhibit nucleotide excision repair	NPA	HepG2.2.15|HepG2	NPA	NPA	NPA
1126	21671467	liver	hepatocellular carcinoma	NPA	miR-338-3p	miR-338-3p	SMO	54498	NPA	inhibit cell migration|inhibit invasion	down-regulated in liver cancer cell lines	SK-HEP-1|SMMC-7721	NPA	NPA	tumor-suppressive
1127	21670079	NPA	NPA	NPA	miR-193b	miR-193b-3p	PLAU|KRAS	5328|3845	RXRA|MAX	inhibit cell transformation|inhibit cell growth|inhibit cell invasion|inhibit tumor growth	lower in transformed epithelial cells than in nontransformed cells|inversely correlated with PLAU and KRAS expression in human colon adenocarcinomas	NPA	colon- and breast-derived xenografts	human colon adenocarcinomas	tumor-suppressive
1128	21666718	stomach	gastric carcinoma	NPA	miR-370	miR-370-3p	TGFBR2	7048	NPA	promote cell migration|promote cell oncogenic potential|promote abdominal metastatic dissemination	overexpressed in GC tissues|associated with more advanced nodal metastasis and a higher clinical stage compared with controls|highly expressed in the plasma of GC patients compared with controls|inversely correlated with TGFBR2 expression in GC tissues	AGS-GFPM2	nude mice	gastric cancer tissues and normal controls	oncogenic
1129	21666713	NPA	NPA	tamoxifen	miR-451	miR-451a	NPA	NPA	NPA	"suppress cell proliferation|suppress colony formation|markedly reduce activation of HER2, EGFR and MAPK signaling|increase apoptosis"	NPA	NPA	NPA	NPA	tumor-suppressive
1130	21666078	bone and muscle	osteosarcoma	NPA	miR-199a-3p	miR-199a-3p	NPA	NPA	NPA	decrease cell growth|decrease cell migration|block cell cycle G1/S transition	significantly decreased in osteosarcoma cell lines in comparison with osteoblasts	NPA	NPA	osteosarcoma tumor tissues and normal human osteoblasts	tumor-suppressive
1131	21665895	colorectum	colorectal cancer	5-aza-2'-deoxycitidine	miR-345	miR-345-5p	BAG3	9531	DNA hypermethylation in cancer	inhibit cell proliferation|inhibit cell invasion	significantly down-regulated in 51.6% of CRC tissues compared with corresponding non-cancerous tissues|negatively associated with lymph node metastasis and worse histological type	NPA	NPA	CRC tissues compared and corresponding non-cancerous tissues	tumor-suppressive
1132	21665894	pancreas	pancreatic cancer	NPa	miR-132	miR-132-3p	NPA	NPA	DNA hypermethylation in cancer	inhibit cell proliferation|inhibit colony formation	decreased in 16 of 20 pancreatic carcinomas than in adjacent normal tissues	PANC1|SW1990	NPA	20 pancreatic carcinomas and adjacent normal tissues	tumor-suppressive
1133	21658389	liver	hepatocellular carcinoma	NPA	miR-198	miR-198	MET	4233	NPA	inhibit cell migration|inhibit cell invasion	NPA	NPA	NPA	NPA	tumor-suppressive
1134	21658006	esophagus	oesophageal squamous cell carcinoma	NPA	miR-31	miR-31-5p	EMP1|KSR2|RGS4	2012|283455|5999	NPA	promote colony formation|promote cell migration|promote cell invasion	up-regulated in 77.8% of the ESCC tissues|significantly higher in ESCC patients serum than in normal controls|correlated with a poorer prognosis in relapse-free survival and tumour-specific survival	NPA	NPA	45 paired ESCC tissues and 523 serum samples	oncogenic
1135	21656380	brain	glioma	NPA	miR-106a	miR-106a-5p	E2F1	1869	NPA	inhibit cell proliferation|induce apoptosis	lowly expressed in high-grade glioma of human glioma specimens|inversely correlated with E2F1 protein in human glioma specimens	NPA	NPA	human glioma specimens	tumor-suppressive
1136	21656127	lung	non-small cell lung cancer	NPA	miR-222	miR-222-3p	PPP2R2A	5520	HMGA1	increase AKT signaling	NPA	NPA	NPA	NPA	NPA
1137	21654684	nerve	neuroblastoma	NPA	let-7e	let-7e-5p	MYCN	4613	NPA	inhibit cell proliferation|inhibit clonogenic growth	NPA	Kelly	NPA	NPA	tumor-suppressive
1138	21654684	nerve	neuroblastoma	NPA	miR-101	miR-101-3p	MYCN	4613	NPA	inhibit cell proliferation|inhibit clonogenic growth	NPA	Kelly	NPA	NPA	tumor-suppressive
1139	21654684	nerve	neuroblastoma	NPA	miR-19a	miR-19a-3p	MYCN	4613	NPA	NPA	NPA	NPA	NPA	NPA	NPA
1140	21654684	nerve	neuroblastoma	NPA	miR-19b	miR-19b-3p	MYCN	4613	NPA	NPA	NPA	NPA	NPA	NPA	NPA
1141	21654684	nerve	neuroblastoma	NPA	miR-202	miR-202-3p	MYCN	4613	NPA	inhibit cell proliferation|inhibit clonogenic growth	NPA	Kelly	NPA	NPA	tumor-suppressive
1142	21654684	nerve	neuroblastoma	NPA	miR-29a	miR-29a-3p	MYCN	4613	NPA	NPA	NPA	NPA	NPA	NPA	NPA
1143	21654684	nerve	neuroblastoma	NPA	miR-29b	miR-29b-3p	MYCN	4613	NPA	NPA	NPA	NPA	NPA	NPA	NPA
1144	21654684	nerve	neuroblastoma	NPA	miR-29c	miR-29c-3p	MYCN	4613	NPA	NPA	NPA	NPA	NPA	NPA	NPA
1145	21654684	nerve	neuroblastoma	NPA	miR-34a	miR-34a-5p	MYCN	4613	NPA	NPA	NPA	NPA	NPA	NPA	NPA
1146	21654684	nerve	neuroblastoma	NPA	miR-34c	miR-34c-5p	MYCN	4613	NPA	NPA	NPA	NPA	NPA	NPA	NPA
1147	21654684	nerve	neuroblastoma	NPA	miR-449	miR-449a	MYCN	4613	NPA	NPA	NPA	NPA	NPA	NPA	NPA
1148	21654638	liver	hepatocellular carcinoma	NPA	miR-122	miR-122-5p	CUX1	1523	NPA	inhibit tumor agressiveness characteristics	NPA	NPA	transgenic mice with silenced miR-122|orthotopic xenograft tumour model	human clinical samples	tumor-suppressive
1149	21653642	colorectum	colon cancer	NPA	miR-143	miR-143-3p	NPA	NPA	EGFR	inhibit cell growth	reduced in human sporadic and UC colon cancers	HCT116	NPA	human sporadic and ulcerative colitis (UC)-associated colon cancers	tumor-suppressive
1150	21653642	colorectum	colon cancer	NPA	miR-145	miR-145-5p	NPA	NPA	EGFR	inhibit cell growth	reduced in human sporadic and UC colon cancers	HCT116	NPA	human sporadic and ulcerative colitis (UC)-associated colon cancers	tumor-suppressive
1151	21647377	prostate	prostate cancer	NPA	miR-143	miR-143-3p	NPA	NPA	NPA	reduce cell migration|reduce cell invasion|reduce tumor development|reduce bone invasion	"significantly decreased in bone metastasis compared with primary Pca|negatively correlated to bone metastasis, the Gleason score and level of free PSA in primary PCa"	PC-3	NPA	6 primary and 7 bone metastatic PCa samples|other samples of 16 primary PCa and 13 bone metastases	tumor-suppressive
1152	21647377	prostate	prostate cancer	NPA	miR-145	miR-145-5p	NPA	NPA	NPA	reduce cell migration|reduce cell invasion|reduce tumor development|reduce bone invasion	"significantly decreased in bone metastasis compared with primary Pca|negatively correlated to bone metastasis, the Gleason score and level of free PSA in primary PCa"	PC-3	NPA	6 primary and 7 bone metastatic PCa samples|other samples of 16 primary PCa and 13 bone metastases	tumor-suppressive
1153	21646351	cervix	cervical cancer	NPA	miR-372	miR-372-3p	CDK2|CCNA1	1017|8900	NPA	inhibit cell growth|induce cell cycle S/G2 arrest	down-regulated in cervical carcinoma tissues as compared with adjacent normal cervical tissues	NPA	NPA	cervical carcinoma tissues and adjacent normal cervical tissues	tumor-suppressive
1154	21643017	blood	acute myeloid leukemia	NPA	miR-100	miR-100-5p	CTDSPL	10217	NPA	promote cell proliferation|inhibit cell diferentiation|regulate cell cycle G1/S transition|regulate cell cycle S entry	NPA	NPA	NPA	NPA	oncogenic
1155	21643016	NPA	NPA	NPA	miR-296	miR-296-5p	SCRIB	23513	NPA	inhibit cell migration|inhibit cell invasion|inhibit tumor growth	"progressively lost during tumor progression and correlates with metastatic disease in colorectal, breast, lung, gastric, parathyroid, liver and bile ducts cancers"	MDA-MB231	NPA	"colorectal, breast, lung, gastric, parathyroid, liver and bile ducts cancers"	tumor-suppressive
1156	21636858	blood	chronic lymphocytic leukemia	NPA	miR-181b	miR-181b-5p	MCL1	4170	NPA	NPA	"decreased in samples of patients with a progressive (P < .001, training and validation sets) but not in samples of patients with a stable disease (P = .3, training set; P = .2, validation set) over time"	NPA	NPA	leukemic cells isolated from 358 sequential samples of 114 patients with either stable or progressive disease	NPA
1157	21636706	brain	glioblastoma	NPA	miR-21	miR-21-5p	NPA	NPA	NPA	increase cell proliferation|inhibit apoptosis|increase colony formation	expressed at higher levels in primary glioblastoma-tissue and glioblastoma-derived cell lines than in normal brain tissue	NPA	glioblastoma xenograft model in immune-deficient nude mice	primary glioblastoma-tissue and glioblastoma-derived cell lines than in normal brain tissue	oncogenic
1158	21636267	cervix	cervical cancer	NPA	miR-100	miR-100-5p	NPA	NPA	NPA	reduce cell proliferation|inhibit cell cycle progression|induce apoptosis	"significantly and gradually reduced from low-grade CIN, high-grade CIN to cervical cancer tissues|significantly decreased in HPV positive cervical cancer cell lines"	NPA	NPA	"125 cervical tissues including normal cervical epithelium, cervical intraepithelial neoplasia (CIN), and cervical cancer"	tumor-suppressive
1159	21633953	lung	non-small cell lung cancer	NPA	miR-30a	miR-30a-5p	SNAI1	6615	NPA	alter cell morphology|inhibit cell migration|inhibit cell invasion	significantly downregulated in tumors compared to corresponding normal tissues	NPA	a chicken embryonic metastasis assay	64 consecutively resected NSCLC patients	tumor-suppressive
1160	21632853	stomach	gastric cancer	NPA	miR-146a	miR-146a-5p	EGFR|IRAK1	1956|3654	NPA	inhibit cell migration|inhibit cell invasion	significantly lower in in cancer tissues than those in the corresponding noncancerous tissue|negatively associated with lymph node metastasis and venous invasion|an independent prognostic factor for overall survival	NPA	NPA	90 gastric cancer samples	tumor-suppressive
1161	21629773	colorectum	colon cancer	hypoxia	miR-22	miR-22-3p	HIF1A	3091	NPA	inhibit angiogenesis	expressed lower in human colon cancer than in normal colon tissue	HCT116	NPA	human colon cancer and normal colon tissue	tumor-suppressive
1162	21629246	liver	hepatocellular carcinoma	Hepatitis B virus X protein (HBx)	miR-15	miR-15a-5p|miR-15b-5p	CCND1	595	MYC	suppress cell proliferation|inhibit clonogenicity|induce cell cycle G1 arrest|induce apoptosis	NPA	HepG2|SK-HEP-1|Huh7	NPA	NPA	tumor-suppressive
1163	21629246	liver	hepatocellular carcinoma	Hepatitis B virus X protein (HBx)	miR-16	miR-16-5p	CCND1	595	MYC	suppress cell proliferation|inhibit clonogenicity|induce cell cycle G1 arrest|induce apoptosis	NPA	HepG2|SK-HEP-1|Huh7	NPA	NPA	tumor-suppressive
1164	21628394	stomach	gastric cancer	NPA	miR-223	miR-223-3p	EPB41L3	23136	NPA	promote cell migration|promote cell invasion	upregulated in gastric carcinoma|overexpressed only in metastatic gastric cancer cells|associated with poor metastasis-free survival	NPA	NPA	10 paired gastric carcinomas|another 20 paired gastric carcinoma tissues	oncogenic
1165	21622722	thyroid	medullary thyroid cancer	NPA	miR-183	miR-183-5p	NPA	NPA	NPA	promote cell viability	"overexpressed in sporadic medullary thyroid cancer (SMTC) versus hereditary medullary thyroid cancer (HMTC)|associated with lateral lymph node metastases, residual disease, distant metastases, and mortality"	TT	NPA	fresh frozen tissues from patients with SMTC (n = 12) and HMTC (n = 7)|a validation cohort of SMTC and HMTC samples (n = 45)	oncogenic
1166	21618216	breast	breast cancer	NPA	miR-335	miR-335-5p	ESR1|IGF1R|SP1|ID4	2099|3480|6667|3400	NPA	decrease cell viability|induce apoptosis	significantly decreased in primary sporadic breast cancer specimens in comparison to normal controls	NPA	NPA	primary sporadic breast cancer specimens and normal controls	tumor-suppressive
1167	21618027	brain	glioblastoma	radiation	miR-21	miR-21-5p	NPA	NPA	NPA	reduce IR-induced cell growth arrest|reduce apoptosis	upregulated in response to ionizing radiation (IR) in U251 cells	U251	NPA	NPA	oncogenic
1168	21610700	liver	hepatocellular carcinoma	NPA	miR-26a	miR-26a-5p	ESR1	2099	NPA	decrease the tumor cell viability	NPA	NPA	NPA	NPA	tumor-suppressive
1169	21610143	blood	NK/T cell lymphoma	NPA	miR-146a	miR-146a-5p	NPA	NPA	NPA	suppress cell proliferation|induce apoptosis|enhance chemosensitivity|inhibit NF¦ÊB signaling	lowly expressed in the groups of poor prognosis	SNK6|YT	NPA	NK/T cell lymphoma tissues	tumor-suppressive
1170	21598109	esophagus	esophageal squamous cell carcinoma	NPA	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	NPA	NPA	NPA	suppress cell proliferation	significantly lower in ESCC tissues compared with the normal adjacent tissues|inversely correlated with lymph node metastasis in ESCC patients	Eca109	NPA	"45 paired of fresh ESCC and normal adjacent tissues|150 paired of formalin-fixed, paraffin-embeded (FFPE) ESCC and NAT"	tumor-suppressive
1171	21596753	breast	breast cancer	NPA	miR-200a	miR-200a-3p	SIRT1	23411	NPA	prevent epithelial-mesenchymal transition|decrase cell growth|decrease cell migration	inversely correlated with SIRT1 expression in breast cancer patient samples	NPA	NPA	breast cancer patient samples	tumor-suppressive
1172	21594648	colorectum	p53-mutated colon cancer	paclitaxel	miR-22	miR-22-3p	NPA	NPA	NPA	decrease cell proliferation|decrease cell survival|induce cell apoptosis|increase paclitaxel sensitivity	NPA	HT-29|HCT-15|HCT-116	NPA	NPA	tumor-suppressive
1173	21593139	prostate	prostate carcinoma	NPA	miR-200c	miR-200c-3p	SEC23A	10484	NPA	NPA	"upregulated 9.1-fold and 4.5-fold in primary prostate carcinoma (CaP) tissue, respectively"	LNCaP|DU145|293T	NPA	NPA	NPA
1174	21593139	prostate	prostate carcinoma	NPA	miR-375	miR-375	SEC23A	10484	NPA	NPA	"upregulated 9.1-fold and 4.5-fold in primary prostate carcinoma (CaP) tissue, respectively"	LNCaP|DU145|293T	NPA	NPA	NPA
1175	21592959	NPA	NPA	NPA	miR-7	miR-7-5p	EGFR	1956	USP18	inhibit cell proliferation|inhibit soft agar colony formation|increase apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
1176	21592405	brain	malignant astrocytoma	NPA	miR-335	miR-335-5p	DAAM1	23002	NPA	increase cell viability|increase colony-forming ability|increase cell invasion	highly elevated in C6 astrocytoma cells and human malignant astrocytomas	C6|U87-MG	astrocytoma xenografts	human malignant astrocytomas	oncogenic
1177	21575235	lung	non-small cell lung cancer	NPA	miR-15a	miR-15a-5p	NPA	NPA	NPA	synergisticly induce cell cycle arrest	significantly co-regulated in adenocarcinomas of the lung	NPA	NPA	tumour tissue and matched normal lung tissue from 23 patients	tumor-suppressive
1178	21575235	lung	non-small cell lung cancer	NPA	miR-16	miR-16-5p	NPA	NPA	NPA	synergisticly induce cell cycle arrest	significantly co-regulated in adenocarcinomas of the lung	NPA	NPA	tumour tissue and matched normal lung tissue from 23 patients	tumor-suppressive
1179	21575235	lung	non-small cell lung cancer	NPA	miR-34a	miR-34a-5p	NPA	NPA	NPA	synergisticly induce cell cycle arrest	significantly co-regulated in adenocarcinomas of the lung	NPA	NPA	tumour tissue and matched normal lung tissue from 23 patients	tumor-suppressive
1180	21573166	liver	hepatocellular carcinoma	Hepatitis B virus X protein (HBx)	miR-29a	miR-29a-3p	PTEN	5728	NPA	promote cell migration	upregulated in 4 of the 11 clinical HCC samples	HepG2|HepG2-X|HepG2.2.15	p21-HBx transgenic mice	11 clinical HCC samples	oncogenic
1181	21572107	liver	hepatoma	serum deprivation	miR-9	miR-9-5p	ALCAM	214	NF-¦ÊB	promote cell migration	NPA	NPA	NPA	NPA	oncogenic
1182	21572098	nerve	neuroblastoma	NPA	miR-92a|miR-92b	miR-92a-3p|miR-92b-3p	DKK3	27122	MYCN	NPA	NPA	HEK293	NPA	NPA	NPA
1183	21569481	stomach	gastric cancer	NPA	miR-27a	miR-27a-3p	CCND1	595	NPA	inhibit cell proliferation	NPA	NPA	NPA	NPA	tumor-suppressive
1184	21569010	blood	EVI1+ myeloid leukemia	NPA	miR-449a	miR-449a	NOTCH1|BCL2	4851|596	EVI1	induce apoptosis|reduce cell viability	downregulated in MECOM rearranged leukemias	NPA	NPA	"38 MECOM (MDS1 and EVI1 complex)-rearranged patient samples, normal bone marrow controls"	tumor-suppressive
1185	21565979	NPA	NPA	doxorubicin	miR-22	miR-22-3p	CDKN1A	1026	TP53	increase p53-dependent apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
1186	21565830	colorectum	colorectal cancer	NPA	miR-342	miR-342-3p	DNMT1	1786	NPA	inhibit cell proliferation|induce cell cycle G0/G1 arrest|inhibit cell invasion|inhibit tumor growth|inhibit lung metastasis	downregulated in CRC tissues and cell lines	SW480	nude mice	CRC tissues	tumor-suppressive
1187	21562850	colorectum	colorectal cancer	NPA	miR-9	miR-9-5p	NPA	NPA	NPA	increase cell motility|change cell morphology	significantly differentially expressed in M group compared to the NM group	RKO	NPA	15 primary CRC specimens without distant metastasis (NM group) and 10 primary CRC specimens (M group) with distant metastasis (M group)	oncogenic
1188	21562367	stomach	gastric cancer	5-aza-2'-deoxycytidine	miR-10b	miR-10b-5p	MAPRE1	22919	DNA hypermethylation in cancer	decrease colony formation|decrease cell growth	silenced in gastric cancer cells by promoter methylation	NPA	NPA	gastric cancer tissues	tumor-suppressive
1189	21557766	liver	hepatocellular carcinoma	radiation	miR-199b-5p	miR-199b-5p	HIF1A	3091	NPA	inhibit cell growth|enhance radiosensitivity	downregulated in 77% of HCCs|negatively correlated with poorer overall survival and progression-free survival rates|inversely correlated with HIF1A in HCCs	HepG2	NPA	35 matched HCCs and cirrhosis tissues	tumor-suppressive
1190	21552422	stomach	gastric cancer	NPA	miR-148a	miR-148a-3p	CDKN1B	1027	NPA	promote cell proliferation|promote cell cycle progression	frequently and dramatically downregulated in human advanced gastric cancer tissues|inversely correlated with CDKN1B expression in tumor samples	NPA	NPA	human gastric cancer tissues	oncogenic
1191	21552288	lung	non-small cell lung cancer	paclitaxel	miR-135a	miR-135a-5p	APC	324	NPA	promote paclitaxel resistance	upregulated in paclitaxel resistant cells|negatively correlated with APC expression	NPA	mice inoculated subcutaneously with a non-small cell lung carcinoma cell line	NPA	NPA
1192	21551130	esophagus	esophageal squamous cell carcinoma	NPA	miR-29c	miR-29c-3p	CCNE1	898	NPA	induce cell cycle G1/G0 arrest|inhibit cell proliferation	significantly decreased in ESCC tumor tissues and cell lines compared with normal esophageal epithelia	NPA	NPA	26 pairs of esophageal tumor-in-site-tissues and 60 pairs of ESCC tissues	tumor-suppressive
1193	21550168	bladder	bladder cancer	cisplatin	miR-143	miR-143-3p	MAPK7	5598	NPA	inhibit cell growth|induce apoptosis|increase cisplatin sensitivity	down-regulated in human bladder cancer T24 cells	T24	NPA	NPA	tumor-suppressive
1194	21548940	prostate	prostate cancer	NPA	let-7d	let-7d-5p	PBX3	5090	NPA	NPA	down-regulated in malignant compared to benign prostate tissue	NPA	NPA	malignant and benign prostate tissue	NPA
1195	21544242	prostate	prostate cancer	LY294002|U0126	miR-21	miR-21-5p	NPA	NPA	NPA	induce tumor angiogeneis|activate AKT/ERK signaling	NPA	DU145	chicken chorioallantoic membrane	NPA	oncogenic
1196	21541354	skin	melanoma	NPA	miR-17-5p	miR-17-5p	NPA	NPA	NPA	promote cell proliferation	up-regulated in the more-aggressive melanoma cell line	NPA	NPA	15 different metastatic melanoma specimens	oncogenic
1197	21541354	skin	melanoma	NPA	miR-184	miR-184	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell invasion|inhibit tumor formation	down-regulated in the more-aggressive melanoma cell line	NPA	SCID-NOD mice	15 different metastatic melanoma specimens	tumor-suppressive
1198	21541354	skin	melanoma	NPA	miR-185	miR-185-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell invasion|inhibit tumor formation	down-regulated in the more-aggressive melanoma cell line	NPA	SCID-NOD mice	15 different metastatic melanoma specimens	tumor-suppressive
1199	21541354	skin	melanoma	NPA	miR-204	miR-204-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell invasion|inhibit tumor formation	down-regulated in the more-aggressive melanoma cell line	NPA	SCID-NOD mice	15 different metastatic melanoma specimens	tumor-suppressive
1200	21541354	skin	melanoma	NPA	miR-31	miR-31-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell invasion|inhibit tumor formation	down-regulated in the more-aggressive melanoma cell line	NPA	SCID-NOD mice	15 different metastatic melanoma specimens	tumor-suppressive
1201	21541354	skin	melanoma	NPA	miR-34a	miR-34a-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell invasion|inhibit tumor formation	down-regulated in the more-aggressive melanoma cell line	NPA	SCID-NOD mice	15 different metastatic melanoma specimens	tumor-suppressive
1202	21541331	head and neck	nasopharyngeal carcinoma	EBV encoded LMP1 and LMP2A	miR-155	miR-155-5p	KDM3A|BACH1	55818|83990	NPA	NPA	upregulated in two EBV- NPC derived cell lines	CNE1|TW03	NPA	NPA	NPA
1203	21534877	blood	multiple myeloma	bortezomib	miR-15a	miR-15a-5p	NPA	NPA	NPA	induce cell cycle G1/S checkpoint arrest|reduce VEGF secretion	up-regulated in U266 and NCI-H929 cells treated by bortezomib	U266|NCI-H929	NPA	NPA	tumor-suppressive
1204	21533613	esophagus	esophageal squamous cell carcinoma	NPA	miR-375	miR-375	PDK1	5170	promoter DNA hypermethylation in cancer	NPA	downregulated by hypermethylation of the promoter in esophageal cancer tissues|inversely correlated with PDK1 expression in esophageal cancer	NPA	NPA	paired esophageal cancer and adjacent non-cancerous tissues	NPA
1205	21533124	stomach	gastric cancer	NPA	let-7f	let-7f-5p	MYH9	4627	NPA	inhibit cell invasion|inhibit cell migration|inhibit metastasis	decreased in metastatic gastric cancer tissues and cell lines	GC9811|SGC7901	nude mice with xenograft models	gastric cancer tissues	tumor-suppressive
1206	21532615	prostate	prostate cancer	NPA	miR-15a	miR-15a-5p	FGF2|FGFR1	2258|2260	NPA	inhibit tumor growth|reduce considerably the tumor-supportive capability of stromal cells	downregulated in fibroblasts surrounding the prostate tumors of the majority of analyzed patients	NPA	NPA	23 prostate cancer patients	tumor-suppressive
1207	21532615	prostate	prostate cancer	NPA	miR-16	miR-16-5p	FGF2|FGFR1	2258|2260	NPA	inhibit tumor growth|reduce considerably the tumor-supportive capability of stromal cells	downregulated in fibroblasts surrounding the prostate tumors of the majority of analyzed patients	NPA	NPA	23 prostate cancer patients	tumor-suppressive
1208	21531766	brain	glioma stem cells	NPA	miR-9*	miR-9-3p	SOX2	6657	ID4	NPA	NPA	NPA	NPA	NPA	NPA
1209	21530512	liver	hepatocellular carcinoma	sorafenib	miR-1274a	DEAD_ENTRY	ADAM9	8754	NPA	NPA	up-regulated in the cells treated by sorafenib	HepG2	NPA	NPA	NPA
1210	21530489	colorectum	colon carcinoma	NPA	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	FAS	2194	FAS|IFNG	inhibit FAS-induced apoptosis	NPA	HT29	NPA	NPA	NPA
1211	21529905	ovary	CD133/1+ ovarian cancer stem cells	NPA	miR-200a	miR-200a-3p	ZEB2	9839	NPA	reduce cell migration|reduce cell invasion	downregulated in CD133/1+ cells compared with CD133/1- cells	NPA	NPA	NPA	tumor-suppressive
1212	21528065	stomach	gastric cancer	NPA	miR-622	miR-622	ING1	3621	NPA	promote invasion|promote tumorigenesis|promote metastasis	down-regulated in gastric cancer	NPA	nude mice	57 pair matched gastric neoplastic and adjacent non-neoplastic tissues	oncogenic
1213	21524841	liver	hepatocellular carcinoma	NPA	miR-519d	miR-519d-3p	MKI67	4288	NPA	suppress cell growth	downregulated in HCCs	QGY-7703	NPA	NPA	tumor-suppressive
1214	21519788	bladder	bladder cancer	NPA	miR-218	miR-218-5p	NPA	NPA	genomic region 4p15.31 loss	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion|induce apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
1215	21518799	liver	hepatocellular carcinoma	NPA	miR-192	miR-192-5p	NPA	NPA	TP53	inhibit epithelial-mesenchymal transition	NPA	NPA	NPA	92 primary HCCs	tumor-suppressive
1216	21518799	liver	hepatocellular carcinoma	NPA	miR-200	miR-200a-3p|miR-200b-3p|miR-200c-3p	NPA	NPA	TP53	inhibit epithelial-mesenchymal transition	NPA	NPA	NPA	92 primary HCCs	tumor-suppressive
1217	21518471	blood	chronic myeloid leukemia	5-aza	miR-663	miR-663a	NPA	NPA	NPA	inhibit cell proliferation	"lower in cell lines and newly diagnosed CML patients, compared with healthy people"	K562|U937|Kasumi	NPA	newly diagnosed CML patients and healthy people	tumor-suppressive
1218	21515467	colorectum	colorectal carcinoma	NPA	miR-221	miR-221-3p	NPA	NPA	NPA	promote cell proliferation|inhibit apoptosis	NPA	HT-29|Lovo|SW-480|CaCO2	NPA	NPA	oncogenic
1219	21512034	breast	breast cancer	NPA	miR-193b	miR-193b-3p	YWHAZ|SHMT2|AKR1C2	7534|6472|1646	NPA	inhibit cell growth	NPA	MCF7	NPA	NPA	tumor-suppressive
1220	21511813	lung	lung cancer	NPA	miR-192	miR-192-5p	RB1	5925	NPA	inhibit cell proliferation|induce apoptosis	significantly downregulated in lung cancer tissues compared to adjacent non-cancerous lung tissues	A549|H460|95D	nude mouse	lung cancer tissues and adjacent non-cancerous lung tissues	tumor-suppressive
1221	21510944	breast	breast cancer	NPA	miR-26b	miR-26b-5p	SLC7A11	23657	NPA	reduce cell viability|induce apoptosis	down-regulated in human breast cancer specimens and cell lines	MCF7	NPA	human breast cancer specimens	tumor-suppressive
1222	21503569	lung	lung	NPA	miR-182	miR-182-5p	NPA	NPA	NPA	inhibti cell proliferation|regulate cell cycle|inhibit tumor growth|induce apoptosis	NPA	A549	xenograft model	NPA	tumor-suppressive
1223	21502955	blood	malignant lymphoma	NPA	miR-150	miR-150-5p	DKC1|AKT2	1736|208	NPA	induce apoptosis|reduce cell proliferation|induce cell senescence	significantly lower in both NK/T-cell lymphoma lines and samples of primary lymphoma than in normal NK cells	NPA	NPA	samples of primary lymphoma	tumor-suppressive
1224	21502362	NPA	NPA	NPA	miR-22	miR-22-3p	SP1|SIRT1|CDK6	6667|23411|1021	NPA	inhibit cell growth|induce senescence|decrease cell motility|inhibit cell invasion|inhibit tumor growth|inhibit metastasis	up-regulated in human senescent fibroblasts and epithelial cells but down-regulated in various cancer cell lines	NPA	a mouse model of breast carcinoma	NPA	tumor-suppressive
1225	21501518	NPA	NPA	NPA	miR-200c	miR-200c-3p	FN1|MSN|NTRK2|ARHGAP19|LEPR	2335|4478|4915|84986|3953	NPA	inhibit cell migration|increase anoikis sensitivity	NPA	NPA	NPA	NPA	tumor-suppressive
1226	21496429	lung	lung adenocarcinoma	NPA	miR-145	miR-145-5p	OCT4	100860952	NPA	inhibit cell proliferation|reduce the ratio of CD133+ cancer stem cells	significantly down-regulated in lung adenocarcinoma compared with ajacent normal tissue	A549	NPA	lung adenocarcinoma and ajacent normal tissue	tumor-suppressive
1227	21496004	blood	acute myeloid leukemia	NPA	miR-29b	miR-29b-3p	MLLT11	10962	NPA	NPA	inversely correlated with MLLT1 expression in AML patients	NPA	NPA	56 AML patients	NPA
1228	21495032	liver	hepatocellular carcinoma	NPA	miR-503	miR-503-5p	NPA	NPA	NPA	induce cell cycle G1 arrest|inhibit cell proliferation|inhibit cell migration|inhibit invasion	NPA	HCCLM3|MHCC97-L	NPA	NPA	tumor-suppressive
1229	21482222	liver	hepatocellular carcinoma	NPA	miR-142-3p	miR-142-3p	RAC1	5879	NPA	inhibit cell migration|inhibit invasion|inhibit colony formation	NPA	QGY-7703|SMMC-7721	NPA	NPA	tumor-suppressive
1230	21481188	liver	hepatocellular carcinoma	NPA	miR-373	miR-373-3p	PPP6C	5537	NPA	promote cell proliferation|regulate cell cycle progression	upregulated in human hepatocellular carcinoma (HCC) tissues as compared with adjacent normal tissues|inversely correlated with PPP6C mRNA and protein levels	HepG2|QGY-7703	NPA	human hepatocellular carcinoma (HCC) tissues and adjacent normal tissues	oncogenic
1231	21479368	bladder	bladder cancer	5-aza-2'-deoxycytidine	miR-517a	miR-517a-3p	NPA	NPA	NPA	inhibit cell proliferation|induce apoptosis	NPA	BOY|T24	NPA	NPA	tumor-suppressive
1232	21479367	lung	lung adenocarcinoma	NPA	miR-145	miR-145-5p	OCT4	NPA	NPA	reduce cell proliferation|reduce cell invasion|reduce tumorosphere growth capacity|reduce CD133+ initiating cells	NPA	A549	NPA	NPA	tumor-suppressive
1233	21472990	breast	triple negative sporadic breast cancer	NPA	miR-146a	miR-146a-5p	BRCA1	672	NPA	increase cell proliferation|reduce homologous recombination rate	highly expressed in basal-like mammary tumour epithelial cell lines and in triple negative breast tumours	NPA	NPA	NPA	oncogenic
1234	21472990	breast	triple negative sporadic breast cancer	NPA	miR-146b-5p	miR-146b-5p	BRCA1	672	NPA	increase cell proliferation|reduce homologous recombination rate	highly expressed in basal-like mammary tumour epithelial cell lines and in triple negative breast tumours	NPA	NPA	NPA	oncogenic
1235	21472347	lung	non-small cell lung cancer	NPA	let-7g	let-7g-5p	NPA	NPA	NPA	inhibit cell migration	lowly expressed in non-small cell lung cancer (NSCLC) cells compared to normal lung cells	A549	NPA	NPA	tumor-suppressive
1236	21471522	blood	ALK+ anaplastic large cell lymphoma	NPA	miR-29a	miR-29a-3p	NPA	NPA	NPA	induce apoptosis|inhibit tumor growth	lowly expressed in ALK+ anaplastic large cell lymphoma biopsy specimens	NPA	transgenic mice|a xenografted model	ALK+ anaplastic large cell lymphoma biopsy specimens (n = 20)	tumor-suppressive
1237	21471404	brain	glioma	NPA	miR-10b	miR-10b-5p	BCL2L11|TFAP2C|CDKN1A|CDKN2A	10018|7022|1026|1029	NPA	promote cell growth|reduce cell cycle arrest|inhibit apoptosis|reduce tumor growth	not expressed in human brain and strongly upregulated in both low-grade and high-grade gliomas|negatively associated with survival of glioblastoma patients	NPA	a mouse model of human glioma	human brain and low-/high-grade gliomas	oncogenic
1238	21471222	breast	breast cancer	trastuzumab	miR-21	miR-21-5p	PTEN	5728	NPA	promote cell proliferation|induce trastuzumab resistance	associated with poor trastuzumab response in tumor biopsies obtained from patients receiving pre-operative trastuzumab therapy	BT474|SKBR3|MDA-MB-453	resistant breast cancer xenografts	tumor biopsies obtained from patients receiving pre-operative trastuzumab therapy	oncogenic
1239	21468550	bladder	bladder cancer	doxorubicin	miR-21	miR-21-5p	NPA	NPA	NPA	promote cell proliferation|promote doxorubicin chemoreistance|inhibit apoptosis	significantly up-regulated in tumor tissues compared to non-tumor tissues	T24	NPA	bladder cancer tumor tissues and non-tumor tissues	oncogenic
1240	21468029	skin	melanoma	NPA	miR-214	miR-214-3p	TFAP2C|ITGA3	7022|3675	NPA	increase cell movement|increase cell survival to anoikis|promote extravasation|promote lung metastasis formation	NPA	NPA	NPA	NPA	oncogenic
1241	21466664	skin	melanoma	NPA	miR-155	miR-155-5p	SKI	6497	NPA	inhibit cell proliferation	NPA	NPA	NPA	NPA	tumor-suppressive
1242	21465485	kidney	clear cell renal cell carcinoma	NPA	miR-210	miR-210-3p	E2F3	1871	NPA	induce cell cycle G2/M arrest|reduce cell viability|induce centrosome amplification	highly expressed in renal carcinoma cell lines	NPA	NPA	NPA	tumor-suppressive
1243	21464588	lung	lung cancer	¦Ã-irradiation	miR-9	miR-9-5p	NFKB1	4790	NPA	increae ¦Ã-irradiated sensitivity	NPA	H1299	NPA	NPA	NPA
1244	21460854	breast	breast cancer	NPA	miR-155	miR-155-5p	TCF4	6934	NPA	reduce aggressiveness of tumor cell dissemination|inhibit epithelial-to-mesenchymal transition|promote tumor formation	NPA	4T1	NPA	NPA	NPA
1245	21460851	lung	lung cancer	NPA	miR-27a	miR-27a-3p	FBXW7	55294	PPP2R5C	promote cell growth|promote cell transformation	inversely correlated with FBXW7 protein expression in both cell models and human tumor samples	NCI-H226|SK-MES-1	NPA	human lung cancer samples	oncogenic
1246	21460750	skin	melanoma	NPA	miR-125b	miR-125b-5p	NPA	NPA	NPA	induce cell senescence|induce apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
1247	21460242	blood	diffuse large B-cell lymphoma	NPA	miR-34a	miR-34a-5p	FOXP1	27086	MYC	inhibit cell proliferation	NPA	NPA	NPA	NPA	tumor-suppressive
1248	21455217	colorectum	colorectal cancer	NPA	miR-148a	miR-148a-3p	BCL2	596	MYB	induce apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
1249	21454583	skin	melanoma	NPA	miR-205	miR-205-5p	E2F1|E2F5	1869|1875	NPA	inhibit cell proliferation|induce apopotsis|inhibit colony formation|induce senescence	inversely correlated with E2F1 and E2F5 expression in melanoma cell lines	NPA	NPA	NPA	tumor-suppressive
1250	21454413	blood	MALT lymphoma	imatinib	miR-203	miR-203a	NPA	NPA	promoter DNA hypermethylation in cancer	inhibit cell proliferation	strongly downregulated in human MALT lymphoma samples compared with matched adjacent normal material from the same patients	NPA	tumor-bearing mice	human MALT lymphoma samples and matched adjacent normal material from the same patients	tumor-suppressive
1251	21454377	NPA	NPA	NPA	miR-15a	miR-15a-5p	NPA	NPA	E2F1	inhibit cell cycle G1/S transition	NPA	NPA	NPA	NPA	tumor-suppressive
1252	21454377	NPA	NPA	NPA	miR-15b	miR-15b-5p	NPA	NPA	E2F1	inhibit cell cycle G1/S transition	NPA	NPA	NPA	NPA	tumor-suppressive
1253	21454377	NPA	NPA	NPA	miR-16	miR-16-5p	NPA	NPA	E2F1	inhibit cell cycle G1/S transition	NPA	NPA	NPA	NPA	tumor-suppressive
1254	21453483	esophagus	esophageal carcinoma	NPA	miR-223	miR-223-3p	ARTN	9048	NPA	inhibit cell migration|inhibit cell invasion	NPA	KYSE-150|KYSE-510|EC-9706|TE13	NPA	NPA	tumor-suppressive
1255	21448905	lung	non-small cell lung cancer	NPA	miR-328	miR-328-3p	NPA	NPA	NPA	increase cell migration	significantly higher in brain metastasis NSCLCs	A549	NPA	clinically matched NSCLC from seven patients with BM (BM+) and six without BM (BM-)|validation cohort with 15 patients	oncogenic
1256	21446014	prostate	prostate cancer	NPA	miR-204	miR-204-5p	SPDEF	25803	NPA	NPA	over-expressed in human prostate cancer specimens	NPA	NPA	human prostate cancer specimens and normal prostate epithelium	NPA
1257	21444677	breast	invasive breast cancer	NPA	miR-125b	miR-125b-5p	ETS1	2113	promoter DNA hypermethylation in cancer	inhibit cell proliferation|induce cell cyclle G1 arrest|inhibit tumorigenesis	NPA	NPA	NPA	NPA	tumor-suppressive
1258	21444672	lung	lung cancer	AZD6244	miR-17	miR-17-5p	NPA	NPA	STAT3	promote AZD6244 resistance	NPA	NPA	NPA	NPA	NPA
1259	21439283	lung	small cell lung cancer	NPA	miR-126	miR-126-3p	SLC7A5	8140	NPA	inhibit cell proliferation|induce cell cycle G1 arrest	under-expressed in the majority of SCLC tumors	H69	NPA	primary SCLC tumors	tumor-suppressive
1260	21435336	brain	glioma	NPA	miR-381	miR-381-3p	LRRC4	64101	LRRC4	increase cell proliferation	NPA	NPA	NPA	NPA	oncogenic
1261	21435193	skin	melanoma	NPA	miR-211	miR-211-5p	POU3F2	5454	NPA	inhibit cell invasion	greatly decreased in melanoma cells and melanoblasts compared to melanocytes	NPA	NPA	NPA	tumor-suppressive
1262	21430074	prostate	prostate cancer	NPA	miR-101	miR-101-3p	COX2	5743	NPA	inhibit cell growth|inhibit tumor growth	NPA	BPH1	prostate tumor xenografts	NPA	tumor-suppressive
1263	21427707	bone and muscle	osteosarcoma	NPA	miR-143	miR-143-3p	NPA	NPA	NPA	decrease cell invasion|inhibit lung metastasis	NPA	HOS|143B	a mouse model	NPA	tumor-suppressive
1264	21427358	colorectum	colorectal cancer	NPA	miR-95	miR-95-3p	SNX1	6642	NPA	promote cell growth|promote tumorigenicity	up-regulated in nearly half of the tumors examined (42/87) compared with the corresponding noncancerous tissues|inversely correlated with SNX1 protein levels in human CRC tissues	NPA	NPA	87 CRC tumors and the corresponding noncancerous tissues	oncogenic
1265	21426561	esophagus	esophageal squamous cell carcinoma	NPA	miR-205	miR-205-5p	ZEB2	9839	NPA	inhibit cell invasion|inhibit cell migration	exclusively higher in ESCC cell lines than any other types of malignant cell lines and a non-malignant human esophageal squamous cell line Het-1A	OE21|TE10|Het-1A	NPA	NPA	tumor-suppressive
1266	21419107	brain	glioma	NPA	miR-10b	miR-10b-5p	HOXD10	3236	NPA	promote cell invasion	over-expressed in glioma samples|directly associated with the glioma's pathological grade and malignancy	NPA	NPA	glioma samples	oncogenic
1267	21418558	stomach	gastric cancer	NPA	miR-449	miR-449a	GMNN|MET|CCNE2|SIRT1	51053|4233|9134|23411	NPA	inhibit cell proliferation|promote apoptosis|promote senescence	downregulated in human clinical gastric tumours compared to normal tissues	NPA	1-year-old Gastrin KO mice	human clinical gastric tumours and normal tissues	tumor-suppressive
1268	21416062	stomach	gastric cancer	NPA	miR-204	miR-204-5p	EZR	7430	NPA	NPA	downregulated in gastric cancer cells and gastric carcinomas	NPA	NPA	22 gastric carcinomas	NPA
1269	21415212	stomach	gastric cancer	NPA	miR-486	miR-486-5p	OLFM4	10562	genomic loss	inhibit cell proliferation	significantly downregulated in primary GCs and GC cell lines	YCC3|SCH|AGS|YCC6	NPA	primary gastric cancer tissues	tumor-suppressive
1270	21406558	breast	breast cancer metastases	NPA	miR-31	miR-31-5p	ITGA5|RHOA|RDX	3678|387|5962	NPA	induce metastatic regression|prolong survival|induce cell cycle arrest|induce apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
1271	21402698	NPA	NPA	NPA	miR-18a	miR-18a-5p	THBS1	7057	TGFB1	NPA	NPA	HeLa	NPA	NPA	NPA
1272	21402698	NPA	NPA	NPA	miR-24	miR-24-3p	FURIN	5045	TGFB1	NPA	NPA	HeLa	NPA	NPA	NPA
1273	21400511	uterus	endometrioid endometrial cancer	NPA	miR-204	miR-204-5p	FOXC1	2296	NPA	inhibit cell migration|inhibit cell invasion|reduce extracellular matrix-adhesion	downregulated in EECs|inversely correlated with FOXC1 expression in EEC	HEC1A	NPA	EEC tissues	tumor-suppressive
1274	21399664	blood	acute myeloid leukemia	5-azacytidine	miR-193a	miR-193a-3p	KIT	3815	promoter DNA hypermethylation in cancer	inhibit cell growth|induce apoptosis|regulate granulocytic differentiation	"epigenetically repressed by promoter hypermethylation in acute myeloid leukemia (AML) cell lines and primary AML blasts, but not in normal bone marrow cells|inversely correlated with KIT expression in leukemia cell lines and 27 primary AML samples"	NPA	NPA	27 primary AML samples	tumor-suppressive
1275	21396852	bladder	bladder cancer	NPA	miR-133a	miR-133a-3p	GSTP1	2950	NPA	reduce cell viability|promote apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
1276	21393507	breast	breast cancer	NPA	miR-301	miR-301a-3p	FOXF2|BBC3|PTEN|COL2A1	2295|27113|5728|1280	NPA	promote cell proliferation|promote clonogenicity|promote cell migration|promote cell invasion|promote tamoxifen resistance|promote tumor growth|increase microvessel density	NPA	NPA	NPA	NPA	oncogenic
1277	21389093	breast	breast cancer	NPA	miR-200	miR-200a-3p|miR-200b-3p|miR-200c-3p	NPA	NPA	PGI	inhibit epithelial-mesenchymal transition|inhibit pulmonary metastases	NPA	MCF-10A|MDA-MB-231	NPA	NPA	tumor-suppressive
1278	21385904	head and neck	nasopharayngeal carcinoma	NPA	miR-218	miR-218-5p	ROBO1|BIRC5|GJA1	6091|332|2697	NPA	cause significant toxicity|delay tumor growth|regulate cell migration	frequently downregulated in primary NPC tissues and cell lines	NPA	NPA	primary NPC tissues	tumor-suppressive
1279	21383697	NPA	NPA	NPA	miR-99a	miR-99a-5p	MTOR|FGFR3	2475|2261	SRC|EGF|RAS	inhibit tumorigenicity	downregulated in various human lung cancer cells/tissues|inversely correlated with MTOR/FGFR3 expression in various human lung cancer cells/tissues	NPA	NPA	NPA	tumor-suppressive
1280	21383689	testis	testicular cancer	NPA	miR-199a-5p	miR-199a-5p	PODXL	5420	NPA	inhibit cell growth|inhibit cell migration|inhibit cell invasion|inhibit metastasis	significantly downregulated in malignant tumors compared with the non-cancerous|inversely correlated with PODXL expression	NPA	NPA	non-cancerous testicular and malignant groups	tumor-suppressive
1281	21383185	NPA	NPA	NPA	miR-483-3p	miR-483-3p	CTNNB1	1499	CTNNB1|USF1	NPA	NPA	NPA	NPA	NPA	NPA
1282	21378409	head and neck	head and neck squamous cell carcinoma	NPA	miR-1	miR-1	TAGLN2	8407	NPA	decrease cell proliferation|decrease cell invasion|decrease cell migration|induce apoptosis|induce cell cycle arrest	downregulated in HNSCC clinical specimens	NPA	NPA	HNSCC clinical specimens	tumor-suppressive
1283	21372826	brain	glioma	ginsenoside Rh2 (Rh2)	miR-128	miR-128-3p	E2F3	1871	NPA	reduce Rh2-induced apoptosis|reduce Rh2-induced cytotoxicity	upregulated by Rh2 in glioma cell lines	U251|T98MG|A172	NPA	NPA	NPA
1284	21368858	head and neck	nasopharyngeal carcinoma	NPA	miR-101	miR-101-3p	EZH2	2146	NPA	NPA	NPA	NPA	NPA	NPA	NPA
1285	21368858	head and neck	nasopharyngeal carcinoma	NPA	miR-26a	miR-26a-5p	EZH2	2146	NPA	NPA	NPA	NPA	NPA	NPA	NPA
1286	21368858	head and neck	nasopharyngeal carcinoma	NPA	miR-98	miR-98-5p	EZH2	2146	NPA	NPA	underexpressed in relapsed patient samples	NPA	NPA	nasopharyngeal carcinoma (NPC) patient tissues	NPA
1287	21368580	prostate	prostate cancer	NPA	miR-203	miR-203a	CKAP2|LASP1|BIRC5|WASF1|ASAP1|RUNX2	26586|3927|332|8936|50807|860	NPA	induce mesenchymal-epithelial transition|inhibit cell proliferation|inhibit cell migration|inhibit cell invasion	downregulated in clinical primary prostatic tumors compared to normal prostate tissue|downregulated in metastatic prostate cancer cell lines compared to normal epithelial prostatic cells	DU145|PC3	NPA	clinical primary prostatic tumors and normal prostate tissue	tumor-suppressive
1288	21365617	uterus	endometrial cancer	NPA	miR-145	miR-145-5p	OCT4	100860952	NPA	induce cell differentiation|inhibit tumor growth	NPA	Ishikawa	NPA	NPA	tumor-suppressive
1289	21360639	head and neck	laryngeal carcinoma	NPA	miR-16	miR-16-5p	ZYZ	***	NPA	promote cell migration|reduce cell-cell adhesion	upregulated in human laryngeal carcinoma tissues	HEp-2	NPA	human laryngeal carcinoma tissues	oncogenic
1290	21359530	breast	breast cancer	NPA	miR-29b	miR-29b-3p	PTEN	5728	NPA	induce apoptosis|increase cell migration|increase cell invasion	NPA	MCF-7|MDA-MB-231	NPA	NPA	tumor-suppressive
1291	21358675	lung	non-small cell lung cancer	NPA	miR-451	miR-451a	RAB14	51552	NPA	inhibit cell proliferation|inhibit colony formation|induce apoptosis	"downregulated in NSCLC tissues|significantly correlated with tumor differentiation, pathological stage and lymph-node metastasis|correlated with shorter overall survival of NSCLC patients"	NPA	nude mice	NSCLC tissues	tumor-suppressive
1292	21354697	colorectum	p53-mutated colon cancer	paclitaxel	miR-203	miR-203a	NPA	NPA	NPA	decrease cell proliferation|decrease cell survival|induce apoptosis|increase paclitaxel cytotoxicity	NPA	NPA	NPA	NPA	tumor-suppressive
1293	21352815	colorectum	colorectal cancer	NPA	miR-650	miR-650	NDRG2	57447	NPA	NPA	NPA	NPA	NPA	NPA	NPA
1294	21352803	pancreas	pancreatic cancer	NPA	miR-421	miR-421	SMAD4	4089	NPA	promote cell proliferation|promote colony formation	aberrantly upregulated in human clinical specimens of pancreatic cancer|inversely correlated with SMAD4 expression in human clinical specimens of pancreatic cancer	NPA	NPA	human clinical specimens of pancreatic cancer	oncogenic
1295	21352471	liver	hepatocellular cancer stem cells	sorafenib|doxorubicin	let-7c	let-7c-5p	SOCS1|CASP3	8651|836	IL6|TWIST1	inhibit chemosensitivity	upregulated in hepatocellular cancer stem cells	NPA	NPA	NPA	NPA
1296	21352471	liver	hepatocellular cancer stem cells	NPA	miR-181	miR-181a-5p|miR-181b-5p|miR-181c-5p|miR-181d-5p	RASSF1A|TIMP3|NLK	56289|7078|51701	IL6|TWIST1	increase cell motility|increase cell invasion	upregulated in hepatocellular cancer stem cells	NPA	NPA	NPA	oncogenic
1297	21351259	esophagus	esophageal squamous cell carcinoma	NPA	miR-133a	miR-133a-3p	FSCN1	6624	NPA	NPA	significantly downregulated in ESCC clinical specimens	NPA	NPA	ESCC clinical specimens	NPA
1298	21351259	esophagus	esophageal squamous cell carcinoma	NPA	miR-133b	miR-133b	FSCN1	6624	NPA	NPA	significantly downregulated in ESCC clinical specimens	NPA	NPA	ESCC clinical specimens	NPA
1299	21351259	esophagus	esophageal squamous cell carcinoma	NPA	miR-145	miR-145-5p	FSCN1	6624	NPA	NPA	significantly downregulated in ESCC clinical specimens	NPA	NPA	ESCC clinical specimens	NPA
1300	21351256	prostate	prostate cancer	NPA	miR-34c	miR-34c-5p	NPA	NPA	NPA	inhibit cell growth|reduce cell proliferation|induce apoptosis|inhibit cell migration|inhibit cell invasion	"downregulated in PCa on TURPs from PCa patients compared to patients with benign prostatic hyperplasia|inversely correlate to aggressiveness of the tumor, WHO grade, PSA levels and occurrence of metastases"	NPA	NPA	49 TURPs from PCa patients and 25 from patients with benign prostatic hyperplasia	tumor-suppressive
1301	21350001	breast	breast cancer	NPA	miR-195	miR-195-5p	CCND1|RAF1	595|5894	NPA	reduce cell proliferation|reduce cell invasion	significantly downregulated in breast cancer|correlated inversely with malignancy of breast cancer in clinical specimens	NPA	NPA	breast cancer tissues	tumor-suppressive
1302	21350001	breast	breast cancer	NPA	miR-497	miR-497-5p	CCND1|RAF1	595|5894	NPA	reduce cell proliferation|reduce cell invasion	significantly downregulated in breast cancer|correlated inversely with malignancy of breast cancer in clinical specimens	NPA	NPA	breast cancer tissues	tumor-suppressive
1303	21349819	prostate	prostate cancer	5-aza-2'-deoxycytidine	miR-145	miR-145-5p	NPA	NPA	TP53|DNA hypermethylation in cancer	NPA	significantly downregulated in the cancer compared with the normal tissues|downregulated in 28 of 29 cell lines with mutant p53|downregulated in only 6 of 18 cell lines with wild-type p53	NPA	NPA	27 prostate tissues	NPA
1304	21349817	stomach	gastric cancer	NPA	let-7a	let-7a-5p	RAB40C	57799	NPA	decrease cell proliferation|induce cell cycle G1 arrest|suppress anchorage-dependent growth|suppress tumorigenicity	reduced in human gastric cancer tissues and cell lines|significantly correlated with the stage of differentiation	NPA	a nude mouse xenograft model	human gastric cancer tissues	tumor-suppressive
1305	21347720	stomach	gastric cancer	NPA	miR-146a	miR-146a-5p	NPA	NPA	NPA	inhibit cell proliferation|induce apoptosis	decreased in 36 of 43 gastric cancer tissue samples (84%)|negatively correlated with increased tumor size (P = 0.006) and poor differentiation (P = 0.010) in gastric cancer|a positive indicator for longer overall survival time of patients	MKN-45	NPA	43 gastric cancer tissue samples	tumor-suppressive
1306	21343399	breast	breast cancer	bone marrow stromal cells	miR-127	miR-127-3p	CXCL12	6387	NPA	decrease cell proliferation	NPA	MDA-MB-231|T47D	NPA	NPA	tumor-suppressive
1307	21343399	breast	breast cancer	bone marrow stromal cells	miR-197	miR-197-3p	CXCL12	6387	NPA	decrease cell proliferation	NPA	MDA-MB-231|T47D	NPA	NPA	tumor-suppressive
1308	21343399	breast	breast cancer	bone marrow stromal cells	miR-222	miR-222-3p	CXCL12	6387	NPA	decrease cell proliferation	NPA	MDA-MB-231|T47D	NPA	NPA	tumor-suppressive
1309	21343399	breast	breast cancer	bone marrow stromal cells	miR-223	miR-223-3p	CXCL12	6387	NPA	decrease cell proliferation	NPA	MDA-MB-231|T47D	NPA	NPA	tumor-suppressive
1310	21343391	prostate	prostate cancer	NPA	miR-34a	miR-34a-5p	AR	367	NPA	reduce AR-induced cell proliferation	negatively correlated with AR expression in clinical prostate cancers	NPA	NPA	clinical prostate cancers	tumor-suppressive
1311	21343391	prostate	prostate cancer	NPA	miR-34c	miR-34c-5p	AR	367	NPA	reduce AR-induced cell proliferation	negatively correlated with AR expression in clinical prostate cancers	NPA	NPA	clinical prostate cancers	tumor-suppressive
1312	21343296	breast	breast cancer	NPA	miR-520b	miR-520b	HBXIP|IL8	10542|3576	NPA	inhibit cell migration	NPA	MDA-MB-231|LM-MCF-7|MCF-7	NPA	NPA	tumor-suppressive
1313	21336307	breast	breast cancer	NPA	miR-200c	miR-200c-3p	NPA	NPA	TP53	inhibit epithelial-mesenchymal transition|reduce cancer stem cells population	negatively correlated with development of a high tumour grade in a cohort of breast tumours	NPA	NPA	a cohort of breast tumours	tumor-suppressive
1314	21330408	kidney	renal cancer	NPA	miR-205	miR-205-5p	SRC|LYN|YES1	6714|4067|7525	NPA	suppress cell proliferation|induce cell cycle G0/G1 arrest|induce apoptosis|inhibit colony formation|inhibit cell migration|inhibit cell invasion|reduce tumor growth	significantly suppressed in renal cancer cell lines and tumors when compared with normal tissues and a nonmalignant cell line	A498	NPA	renal cancer tissues and normal tissues	tumor-suppressive
1315	21329664	pancreas	pancreatic cancer	terbutaline	miR-132	miR-132-3p	RB1	5925	NPA	promote cell proliferation|reduce cell cycle G2/M arrest	over-expressed in pancreatic adenocarcinoma (PDAC) tissues	Panc-1	NPA	pancreatic adenocarcinoma (PDAC) tissues	oncogenic
1316	21329664	pancreas	pancreatic cancer	terbutaline	miR-212	miR-212-3p	RB1	5925	NPA	promote cell proliferation|reduce cell cycle G2/M arrest	over-expressed in pancreatic adenocarcinoma (PDAC) tissues	Panc-1	NPA	pancreatic adenocarcinoma (PDAC) tissues	oncogenic
1317	21329503	lung	non-small cell lung cancer	cisplatin	miR-451	miR-451a	NPA	NPA	NPA	inhibit cell growth|induce apoptosis|increase sensitivity to cisplate	significantly higher in NSCLC tissues than corresponding noncancerous tissues	A549	NPA	10 pairs of NSCLC and noncancerous tissue samples	tumor-suppressive
1318	21328460	head and neck	head and neck squamous cell carcinoma	NPA	miR-21	miR-21-5p	CDK2AP1	8099	NPA	promote cell proliferation|promote cell invasion	inversely correlated with CDK2AP1 expression in resected primary tumors and tumor-free surgical margins	HaCaT|Tca8113	NPA	resected primary tumors and tumor-free surgical margins of 18 patients with head and neck squamous cell carcinomas	oncogenic
1319	21324318	liver	hepatocellular carcinoma	NPA	miR-517a	miR-517a-3p	NPA	NPA	NPA	increase cell proliferation|increase cell migration|increase cell invasion	overexpressed in proliferation subclass of HCCs	NPA	NPA	89 HCC samples	oncogenic
1320	21324318	liver	hepatocellular carcinoma	NPA	miR-520c	miR-520c-3p	NPA	NPA	NPA	increase cell proliferation|increase cell migration|increase cell invasion	overexpressed in proliferation subclass of HCCs	NPA	NPA	89 HCC samples	oncogenic
1321	21321380	brain	glioblastoma	NPA	miR-101	miR-101-3p	NPA	NPA	NPA	reduce cell growth|reduce cell migration|reduce cell invasion|reduce GBM-induced endothelial tubule formation	down-regulated in GBM	NPA	NPA	GBM tissues	tumor-suppressive
1322	21317930	NPA	NPA	NPA	miR-199a	miR-199a-5p	AXL	558	DNA methylation	inhibit cell migration|inhibit cell invasion|reduce the number of distant lung- or liver-metastases	"completely suppressed in a panel of non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and breast cancer (BRC) cell lines|downregulated and significantly co-expressed with miR-34a in NSCLC tissues"	NPA	NPA	44 NSCLC tissues	tumor-suppressive
1323	21317930	NPA	NPA	NPA	miR-199b	miR-199b-5p	AXL	558	DNA methylation	inhibit cell migration|inhibit cell invasion|reduce the number of distant lung- or liver-metastases	"completely suppressed in a panel of non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and breast cancer (BRC) cell lines|downregulated and significantly co-expressed with miR-34a in NSCLC tissues"	NPA	NPA	44 NSCLC tissues	tumor-suppressive
1324	21317930	NPA	NPA	NPA	miR-34a	miR-34a-5p	AXL	558	DNA methylation	inhibit cell migration|inhibit cell invasion|reduce the number of distant lung- or liver-metastases	"inversely correlated with AXL protein level in a panel of non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and breast cancer (BRC) cell lines|downregulated and significantly co-expressed with miR-199 in NSCLC tissues|positively associated towards a longer survival in NSCLC patients"	NPA	NPA	44 NSCLC tissues	tumor-suppressive
1325	21317927	NPA	NPA	NPA	miR-21	miR-21-5p	ANP32A|SMARCA4	8125|6597	NPA	increase cell viability|inhibit apoptosis	NPA	LNCaP|A172	NPA	NPA	oncogenic
1326	21316602	liver	hepatocellular carcinoma	NPA	miR-199a-3p	miR-199a-3p	PAK4	10298	NPA	suppress tumor growth	consistently decreased in HCC|inversely significantly correlated with poor survival of HCC patients	NPA	NPA	"normal liver, hepatitis liver, and hepatocellular carcinoma (HCC) tissues"	tumor-suppressive
1327	21316602	liver	hepatocellular carcinoma	NPA	miR-199b-3p	miR-199b-3p	PAK4	10298	NPA	suppress tumor growth	consistently decreased in HCC|inversely significantly correlated with poor survival of HCC patients	NPA	NPA	"normal liver, hepatitis liver, and hepatocellular carcinoma (HCC) tissues"	tumor-suppressive
1328	21310526	nerve	neuroblastoma	NPA	miR-542-5p	miR-542-5p	NPA	NPA	NPA	decrease cell invasion|inhibit tumor growth|inhibit metastasis	highly and negatively associated with poor patient survival	NPA	an orthotopic mouse xenograft model	NPA	tumor-suppressive
1329	21308711	prostate	prostate cancer	NPA	miR-125b	miR-125b-5p	MUC1	4582	AR	NPA	NPA	LNCaP|DU145|PC3	NPA	NPA	NPA
1330	21304604	stomach	gastric cancer	NPA	miR-126	miR-126-3p	SOX2	6657	NPA	promote cell growth	highly expressed in some cultured and primary gastric cancer cells	NPA	NPA	primary gastric cancer tissues	oncogenic
1331	21304530	bladder	bladder cancer	NPA	miR-1	miR-1	TAGLN2	8407	NPA	inhibit cell proliferation|induce apoptosis|inhibit cell migration|inhibit cell invasion	downregulated in BC clinical specimens	NPA	NPA	BC clinical specimens	tumor-suppressive
1332	21304530	bladder	bladder cancer	NPA	miR-133a	miR-133a-3p	TAGLN2	8407	NPA	inhibit cell proliferation|induce apoptosis|inhibit cell migration|inhibit cell invasion	downregulated in BC clinical specimens	NPA	NPA	BC clinical specimens	tumor-suppressive
1333	21299870	esophagus	esophageal squamous cell carcinoma	NPA	miR-203	miR-203a	TP63	8626	NPA	inhibit cell proliferation	NPA	Eca109|TE-1	NPA	NPA	tumor-suppressive
1334	21297663	blood	lymphoma	bortezomib	miR-34a	miR-34a-5p	MYC	4609	NPA	induce apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
1335	21294122	head and neck	ALDH1+/CD44+ head and neck squamous cell carcinoma cancer stem cells	NPA	miR-200c	miR-200c-3p	BMI1	648	NPA	inhibit the malignant CSC-like properties|inhibit the lung metastatic ability	significantly decreased in the regional metastatic lymph node of HNSCC tissues compared to parental tumours|significantly down-regulated in HNSCC-ALDH1(+) /CD44(+) compared to the other subsets of HNSCC cells	NPA	ALDH1(+) /CD44(+) -transplanted mice	the regional metastatic lymph node of HNSCC tissues and parental tumours	tumor-suppressive
1336	21293058	skin	squamous cell carcinoma	chemotherapy	miR-193a-5p	miR-193a-5p	TP73	7161	TP63|TP73	promote cell viability|dramaticly reduce chemosensitivity	NPA	NPA	murine SCC	NPA	oncogenic
1337	21292542	head and neck	ALDH1+ head and neck cancer tumor-initiating cells	NPA	let-7a	let-7a-5p	NPA	NPA	NPA	reduce chemoresistance|inhibit metastasis	significantly decreased in HNC tissues as compared to adjacent normal cells|significantly decreased in recurrent HNC tissue and in regional metastatic lymph nodes of HNC patients compared to the parental tumours|down-regulated in HNC-ALDH1(+) cells relative to HNC-ALDH1(-) cells	NPA	ALDH1(+)-transplanted immunocompromised mice	HNC tissues and adjacent normal cells|regional metastatic lymph nodes	tumor-suppressive
1338	21289630	esophagus	esophageal squamous cell carcinoma	cisplatin	miR-141	miR-141-3p	YAP1	10413	NPA	increase cell viability	the most highly expressed in the cisplatin-resistant cell lines	NPA	NPA	NPA	oncogenic
1339	21289483	lung	lung cancer	lung adenocarcinoma	miR-145	miR-145-5p	NPA	NPA	NPA	inhibit cell proliferation	NPA	NPA	NPA	NPA	tumor-suppressive
1340	21283757	colorectum	colon cancer	short chain fatty acid butyrate	miR-106b	miR-106b-5p	CDKN1A	1026	NPA	promote cell proliferation	aberrantly expressed in colon cancer tissues|downregulated in butyrate treated cells	HCT116	NPA	human sporadic colon cancers	oncogenic
1341	21278922	skin	melanoma	NPA	miR-137	miR-137	CTBP1	1487	NPA	NPA	inversely correlated with CTBP1 expressio in melanoma cell lines	NPA	NPA	NPA	NPA
1342	21278789	brain	glioma	hyaluronan	miR-21	miR-21-5p	SPRY2	10253	NPA	promote cell invasion	inversely correlated with SPRY2 protein levels in human glioma tissues	NPA	NPA	human glioma tissues	oncogenic
1343	21278784	colorectum	colorectal carcinoma	NPA	miR-221	miR-221-3p	CDKN1C	1028	NPA	inhibit cell proliferation|induce apoptosis	significantly up-regulated in 90% of CRC samples compared to that in the adjacent non-tumorous tissue|positively correlated to an advanced TNM stage and local invasion|inversely correlated with CDKN1C expression in CRC cells	HT-29|Lovo|SW-480|Caco2	NPA	34 CRC and adjacent non-tumorous tissue samples	tumor-suppressive
1344	21277012	ovary	ovarian cancer	NPA	miR-429	miR-429	NPA	NPA	NPA	induce mesenchymal-epithelial transition	NPA	NPA	NPA	NPA	tumor-suppressive
1345	21271679	breast	breast cancer	NPA	miR-373	miR-373-3p	TXNIP|RABEP1	10628|9135	NPA	NPA	NPA	NPA	NPA	NPA	NPA
1346	21271217	esophagus	esophageal squamous cell carcinoma	NPA	miR-19a	miR-19a-3p	TNFA	7124	NPA	inhibit apoptosis|promote tumor growth	overexpressed in 21 out of 28 (75%) esophageal cancer samples	NPA	NPA	28 esophageal cancer samples	oncogenic
1347	21270667	lung	non-small cell lung cancer	paclitaxel	miR-101	miR-101-3p	EZH2	2146	NPA	reduce cell proliferation|reduce cell invasion|increase paclitaxel-induced apoptosis	NPA	NPA	NPA	20 matched NSCLC and adjacent nontumor lung tissues	tumor-suppressive
1348	21266359	breast	breast cancer	NPA	miR-1258	miR-1258	HPSE	10855	NPA	inhibit cell invasion|reduce brain metastasis	lowest in highly aggressive BMBC cell variants compared with either nontumorigenic or nonmetastatic human mammary epithelial cells|inversely correlated with cancer cell metastatic propensities|inversely correlated with HPSE expression	NPA	NPA	paired clinical specimens of normal mammary gland versus invasive ductal carcinoma|primary breast cancer versus BMBC	tumor-suppressive
1349	21266077	nerve	neuroblastoma	NPA	miR-34a	miR-34a-5p	NPA	NPA	NPA	reduce cell growth|induce cell cycle arrest|induce apoptosis|repress tumor growth	NPA	NB1691|SK-N-AS	CB17-SCID mice	NPA	tumor-suppressive
1350	21264532	stomach	gastric cancer	NPA	miR-107	miR-107	CDK6	1021	NPA	inhibit cell proliferation|induce cell cycle G1 arrest|inhibit cell invasion	inversely correlated with CDK6 expression in gastric cancer cell lines	NPA	NPA	NPA	tumor-suppressive
1351	21264258	brain	glioma	NPA	miR-26b	miR-26b-5p	EPHA2	1969	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion|inhibit vasculogenic mimicry process	inversely correlated with the grade of glioma	NPA	NPA	glioma patients	tumor-suppressive
1352	21258880	NPA	NPA	vincristine|cisplatin	miR-497	miR-497-5p	BCL2	596	NPA	reduce multidrug resistance|increase CDDP-induced apoptosis	downregulated in multidrug-resistant cancer cells	A549|SGC7901	NPA	NPA	NPA
1353	21258769	prostate	prostate cancer	NPA	miR-145	miR-145-5p	FSCN1	6624	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion	NPA	PC3|DU145	NPA	NPA	tumor-suppressive
1354	21258409	breast	PROCR+/ESA+ breast cancer stem cells	NPA	miR-495	miR-495-3p	CDH1|REDD1	51343|54541	TCF3	promote colony formation|promote tumorigenesis	most highly upegulated in PROCR(+)/ESA(+) cells|highly upregulated in CD44+/CD24- BCSCs	NPA	mice	NPA	oncogenic
1355	21249429	breast	breast cancer	NPA	miR-126	miR-126-3p	VEGFA|PIK3R2	7422|5296	NPA	decrease VEGF/PI3K/AKT signaling	down-regulated in breast tumors	293T|MCF-7	NPA	human breast cancer	NPA
1356	21248297	esophagus	esophageal cancer	cisplatin	miR-200c	miR-200c-3p	NPA	NPA	NPA	reduce cisplatin sensitivity|reduce cisplatin-induced apoptosis|promote Akt signaling	positively correlated significantly with shortened overall duration of survival|correlated significantly with response to chemotherapy|significantly increased in cisplatin-resistant cells compared with their parent cells	NPA	NPA	"98 formalin-fixed, paraffin-embedded samples obtained from patients with esophageal cancer who had received preoperative chemotherapy followed by surgery"	NPA
1357	21244495	head and neck	oral squamous cell carcinoma	NPA	miR-181a	miR-181a-5p	NPA	NPA	NPA	promote cell migration|promote cell invasion	"correlated with lymph-node metastasis, vascular invasion, and a poor survival|upregulated both in tumor tissues and plasma"	NPA	NPA	tissue and plasma of OSCC patients	oncogenic
1358	21242962	cervix	cervical cancer	HPV-16 E6	miR-23b	miR-23b-3p	PLAU	5328	TP53	inhibit cell migration	NPA	SiHa|CaSki	NPA	NPA	tumor-suppressive
1359	21242194	colorectum	colorectal adenocarcinoma	fluorouracil|oxaliplatin|teniposide	miR-20a	miR-20a-5p	BNIP2	663	NPA	reduce chemoresistance	NPA	SW620|SW480	NPA	NPA	NPA
1360	21240262	prostate	CD44+ prostate cancer stem cells	NPA	miR-34a	miR-34a-5p	CD44	960	NPA	inhibit clonogenic expansion|inhibit tumor regeneration|inhibit metastasis	underexpressed in CD44(+) prostate cancer cells purified from xenograft and primary tumors	NPA	tumor-bearing mice	primary prostate cancer tissues	tumor-suppressive
1361	21233845	nerve	neuroblastoma	NPA	miR-885-5p	miR-885-5p	CDK2|MCM5	1017|4174	genomic region 3p25.3 deletion	inhibit cell proliferation|induce cell cycle arrest|induce senescence|induce apoptosis	downregulated on loss of 3p25.3 region in neuroblastoma	NPA	NPA	primary neuroblastoma	tumor-suppressive
1362	21226887	head and neck	oral squamous cell carcinoma	NPA	miR-221	miR-221-3p	NPA	NPA	NPA	increase cell growth|increase anchorage-independent colony formation	increased in 40% of OSCC tissues	NPA	nude mice	paired OSCC and matched noncancerous oral mucosa	oncogenic
1363	21226887	head and neck	oral squamous cell carcinoma	NPA	miR-222	miR-222-3p	NPA	NPA	NPA	increase cell growth|increase anchorage-independent colony formation	increased in 40% of OSCC tissues	NPA	nude mice	paired OSCC and matched noncancerous oral mucosa	oncogenic
1364	21225860	breast	breast cancer	NPA	miR-340	miR-340-5p	MET	4233	NPA	inhibit cell migration|inhibit cell invasion	"down-regulated in the more aggressive breast cancer cell lines and breast cancer tissue specimens|negatively associated with lymph node metastasis, high tumor histological grade, clinical stage, and shorter overall survival of breast cancer|inversely correlated with MET expression in breast cancer tissue specimens"	NPA	NPA	breast cancer tissue specimens	tumor-suppressive
1365	21225631	stomach	gastric cancer	NPA	miR-9	miR-9-5p	CDX2	1045	NPA	promote cell growth|reduce cell cycle G1 arrest	significantly higher in CDX2- group than those in the CDX2+ group in primary GC tissues|inversely correlated with CDX2 protein levels in GC cell lines	HEK-293T|MKN45|NUGC-3	NPA	primary GC tissues	oncogenic
1366	21224848	NPA	NPA	NPA	miR-200	miR-200a-3p|miR-200b-3p|miR-200c-3p	JAG1|MAML2|MAML3	182|84441|55534	NPA	NPA	NPA	NPA	NPA	NPA	NPA
1367	21224847	NPA	NPA	NPA	miR-200	miR-200a-3p|miR-200b-3p|miR-200c-3p	JAG1	182	NPA	inhibit cell proliferation	NPA	NPA	NPA	NPA	tumor-suppressive
1368	21224400	ovary	ovarian cancer	cisplatin	miR-376c	miR-376c-3p	ACVR1C	130399	NPA	increase cell proliferation|increase cell survival|enhance spheroid formation|block Nodal-induced apoptosis|blocke cisplatin-induced cell death	high in samples from patients who responded poorly to chemotherapy	NPA	NPA	serous carcinoma samples taken from ovarian cancer patients	oncogenic
1369	21224345	prostate	prostate cancer	castration	miR-616	miR-616-3p	TFPI2	7980	NPA	promote androgen-independent cell proliferation|reduce androgen-induced cell growth|reduce castration resistance	overexpressed in malignant prostate tissues as opposed to benign prostate specimens|inversely correlated with TFPI2 expression in a series of prostate cell lines and clinical specimens	LNCaP	NPA	malignant prostate tissues and benign prostate specimens	NPA
1370	21221794	stomach	gastric cancer	NPA	miR-137	miR-137	NPA	NPA	NPA	induce apoptosis|induce cell cycle G1 arrest	downregulated by hypermethylation of the promoter in gastric cancer tissues	NPA	NPA	paired gastric cancer and adjacent non-cancerous tissues	tumor-suppressive
1371	21220473	stomach	gastric cancer	trastuzumab	miR-125a-5p	miR-125a-5p	ERBB2	2064	NPA	inhibit cell proliferation	"negatively associated with enhanced malignant potential such as tumor size (P = 0.0068), tumor invasion (P = 0.031), liver metastasis (P = 0.029), and poor prognosis (P = 0.0069)|an independent prognostic  factor for survival"	NPA	NPA	87 gastric cancer cases	tumor-suppressive
1372	21219636	breast	breast cancer	NPA	miR-21	miR-21-5p	ANKRD46	157567	NPA	promote cell growth|promote cell migration|promote tumor growth	inversely correlated with ANKRD46 protein levels in breast cancers	MCF-7|MDA-MB-231	nude mice	breast cancers	oncogenic
1373	21218087	esophagus	esophageal squamous cell carcinoma	NPA	miR-143	miR-143-3p	NPA	NPA	NPA	inhibit cell motility	significantly decreased in most of the ESCC tissues examined|correlated with tumor invasion depth	NPA	NPA	86 ESCC patients	tumor-suppressive
1374	21218087	esophagus	esophageal squamous cell carcinoma	NPA	miR-145	miR-145-5p	NPA	NPA	NPA	inhibit cell motility	significantly decreased in most of the ESCC tissues examined|correlated with tumor invasion depth	NPA	NPA	86 ESCC patients	tumor-suppressive
1375	21217773	bone and muscle	Ewing's sarcoma	NPA	miR-145	miR-145-5p	FLI1|EWS-FLI1	2313|***	EWS-FLI1	inhibit cell growth	inversely correlated with EWS-FLI1 expression in four of the Ewing's sarcoma cell lines	NPA	NPA	NPA	tumor-suppressive
1376	21216304	cervix	cervical cancer	NPA	miR-214	miR-214-3p	PLXNB1	5364	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion	associated with metastasis and invasion of cervical tumor|inversely correlated with PLXNB1 expressions in both cervical cancer tissues and HeLa cells	HeLa	NPA	cervical cancer tissues	tumor-suppressive
1377	21212796	nerve	neuroblastoma	all-trans-retinoic acid (ATRA)	miR-10a	miR-10a-5p	NCOR2	9612	NPA	promote cell differentiation	NPA	SK-N-BE|LAN5|SHSY-5Y	NPA	NPA	NPA
1378	21212796	nerve	neuroblastoma	all-trans-retinoic acid (ATRA)	miR-10b	miR-10b-5p	NCOR2	9612	NPA	promote cell differentiation	NPA	SK-N-BE|LAN5|SHSY-5Y	NPA	NPA	NPA
1379	21212412	prostate	prostate cancer	NPA	miR-100	miR-100-5p	SMARCA5|SMARCD1|MTOR	8467|6602|2475	NPA	inhibit cell growth	downregulated in all assays in advanced prostate cancer cell lines relative to the parental cell lines|downregulated in human prostate tumor tissue compared with normal prostate	NPA	NPA	human prostate tumor tissue and normal prostate	tumor-suppressive
1380	21212412	prostate	prostate cancer	NPA	miR-99a	miR-99a-5p	SMARCA5|SMARCD1|MTOR	8467|6602|2475	NPA	inhibit cell growth	downregulated in all assays in advanced prostate cancer cell lines relative to the parental cell lines|downregulated in human prostate tumor tissue compared with normal prostate	NPA	NPA	human prostate tumor tissue and normal prostate	tumor-suppressive
1381	21212412	prostate	prostate cancer	NPA	miR-99b	miR-99b-5p	SMARCA5|SMARCD1|MTOR	8467|6602|2475	NPA	inhibit cell growth	downregulated in all assays in advanced prostate cancer cell lines relative to the parental cell lines|downregulated in human prostate tumor tissue compared with normal prostate	NPA	NPA	human prostate tumor tissue and normal prostate	tumor-suppressive
1382	21207483	head and neck	ALDH1+/CD44+ head and neck squamous cell carcinoma cancer stem cells	NPA	miR-200c	miR-200c-3p	BMI1	648	NPA	inhibit CSC-like properties|inhibit the lung metastatic ability	significantly decreased in the regional metastatic lymph node of HNSCC tissues compared to parental tumours|significantly down-regulated in HNSCC-ALDH1(+)/CD44(+) compared to the other subsets of HNSCC cells	NPA	ALDH1(+)/CD44(+)-transplanted mice	regional metastatic lymph node of HNSCC tissues and their parental tumours	tumor-suppressive
1383	21205967	blood	B-cell chronic lymphocytic leukemia	NPA	miR-15a	miR-15a-5p	TP53	7157	TP53	NPA	NPA	NPA	NPA	blood samples from untreated patients (n = 206) diagnosed with B-cell CLL	NPA
1384	21205967	blood	B-cell chronic lymphocytic leukemia	NPA	miR-16	miR-16-5p	TP53	7157	TP53	NPA	NPA	NPA	NPA	blood samples from untreated patients (n = 206) diagnosed with B-cell CLL	NPA
1385	21205967	blood	B-cell chronic lymphocytic leukemia	NPA	miR-34b	miR-34b-5p	ZAP70	7535	TP53	NPA	NPA	NPA	NPA	blood samples from untreated patients (n = 206) diagnosed with B-cell CLL	NPA
1386	21205967	blood	B-cell chronic lymphocytic leukemia	NPA	miR-34c	miR-34c-5p	ZAP70	7535	TP53	NPA	NPA	NPA	NPA	blood samples from untreated patients (n = 206) diagnosed with B-cell CLL	NPA
1387	21205300	stomach	gastric cancer	NPA	miR-148a	miR-148a-3p	CCKBR	887	NPA	inhibit cell proliferation	"significant down-regulated in 106 gastric cancer tissues and four gastric cancer cell lines, compared with their non-tumor counterparts|inversely correlated with CCKBR protein levels in 49 pairs of tissues"	MGC-803|SGC-7901|BGC-823|AGS	nude mice	106 gastric cancer tissues and their non-tumor counterparts|49 pairs of tissues	tumor-suppressive
1388	21205209	bladder	bladder cancer	NPA	miR-203	miR-203a	BCL2L2	599	NPA	promote apoptosis|inhibit cell proliferation	decreased in bladder cancer tissues|negatively correlated with BCL2L2 level in tumor tissues	NPA	NPA	bladder cancer tissues	tumor-suppressive
1389	21203553	prostate	prostate cancer	disulfiram	miR-17*	miR-17-3p	MNSOD|GPX2|TXNRD2	100233137|2877|10587	NPA	inhibit tumorigencity	NPA	PC-3	NPA	NPA	tumor-suppressive
1390	21203424	breast	breast cancer	NPA	miR-96	miR-96-5p	FOXO3	2309	NPA	induce cell proliferation|increase anchorage-independent cell growth|promote cell cycle G1/S transition	upregulated in breast cancer cells and breast cancer tissues compared with normal breast epithelial cells (NBEC) and normal breast tissues	NPA	NPA	breast cancer tissues and normal breast tissues	oncogenic
1391	21199804	head and neck	nasopharyngeal carcinoma	NPA	miR-26a	miR-26a-5p	EZH2	2146	NPA	inhibit cell proliferation|inhibit colony formation|induce cell cycle G1 arrest	downregulated in NPC specimens and NPC cell lines|inversely correlated with EZH2 mRNA levels in clinical specimens	NPA	NPA	clinical NPC specimens	tumor-suppressive
1392	21197560	prostate	prostate cancer	docetaxel	miR-143	miR-143-3p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell migration|increase docetaxel sensitivity	NPA	NPA	NPA	NPA	tumor-suppressive
1393	21196113	brain	glioblastoma	NPA	miR-124a	miR-124-3p	NPA	NPA	NPA	inhibit cell migration|inhibit cell invasion	markedly lower in over 80% of the GBM clinical specimens compared to normal brain tissue	NPA	NPA	119 cases of histologically confirmed GBM	tumor-suppressive
1394	21195000	breast	breast cancer	ionizing radiation	miR-182	miR-182-5p	BRCA1	672	NPA	impair homologous recombination-mediated repair|increase IR sensitivity	NPA	NPA	NPA	NPA	NPA
1395	22393979	bladder	bladder carcinoma	NPA	miR-100	miR-100-5p	NPA	NPA	NPA	reduce cell proliferation|reduce colony formation	NPA	5637	NPA	NPA	tumor-suppressive
1396	22393947	lung	lung cancer	NPA	miR-663	miR-663a	TGFB1	7040	NPA	increase cell proliferation	highly expressed in patients with lung cancer	NPA	NPA	patients with lung cancer	oncogenic
1397	21189327	NPA	NPA	NPA	miR-199a-3p	miR-199a-3p	SMARCA2	6595	EGR1	NPA	NPA	NPA	NPA	NPA	NPA
1398	21189327	NPA	NPA	NPA	miR-199a-5p	miR-199a-5p	SMARCA2	6595	EGR1	NPA	NPA	NPA	NPA	NPA	NPA
1399	21187425	NPA	NPA	NPA	miR-29	miR-29a-3p|miR-29b-3p|miR-29c-3p	MYB	4602	NPA	inhibit DNA synthesis|induce senescence	NPA	NPA	NPA	NPA	tumor-suppressive
1400	21187425	NPA	NPA	NPA	miR-30	miR-30a-5p|miR-30b-5p|miR-30c-5p|miR-30d-5p|miR-30e-5p	MYB	4602	NPA	inhibit DNA synthesis|induce senescence	NPA	NPA	NPA	NPA	tumor-suppressive
1401	21186079	colorectum	colorectal cancer	NPA	miR-185	miR-185-5p	RHOA|CDC42	387|998	NPA	inhibit cell proliferation|induce cell cycle G1 arrest|induce apoptosis|inhibit cell invasion	NPA	NPA	NPA	NPA	tumor-suppressive
1402	21182263	nerve	neuroblastoma	NPA	miR-34a	miR-34a-5p	YY1	7528	NPA	NPA	NPA	IMR32	NPA	NPA	NPA
1403	21181092	head and neck	head and neck squamous cell carcinoma	NPA	miR-133a	miR-133a-3p	GSTP1	2950	NPA	NPA	NPA	HSC3|SAS	NPA	NPA	NPA
1404	21177782	brain	medulloblastoma	mitomycin C|cisplatin	miR-34a	miR-34a-5p	MAGEA2|MAGEA3|MAGEA6|MAGEA12	266740|4102|4105|4111	NPA	induce apoptosis|induce cell cycle G2 arrest|induce senescence|increase chemosensitivity	NPA	NPA	NPA	NPA	tumor-suppressive
1405	21170987	esophagus	esophageal cancer	NPA	miR-593*	miR-593-5p	PLK1	5347	NPA	reduce cell proliferation|induce cell cycle G2/M arrest	less expressed especially in six EC cell lines than HEEpiC cells|inversely correlated with PLK1 mRNA level in 48 clinical tissue specimens of EC	HEEpiC|HSA/c	NPA	48 clinical tissue specimens of EC	tumor-suppressive
1406	21169410	stomach	scirrhous gastric cancer	NPA	miR-516a-3p	miR-516a-3p	SULF1	23213	NPA	inhibit tumorigenicity	downregulated in 44As3 cells (highly metastatic derivatives) compared with HSC-44PE cells	44As3|HSC-44PE	an established mouse model for peritoneal dissemination of human scirrhous gastric carcinoma cells	NPA	tumor-suppressive
1407	21167132	head and neck	oral squamous cell carcinoma	NPA	miR-181a	miR-181a-5p	KRAS	3845	NPA	suppress cell proliferation|suppress anchorage-independent cell growth	frequently downregulated in OSCC	NPA	NPA	OSCC primary tumor tissues	tumor-suppressive
1408	21159887	prostate	prostate cancer	NPA	miR-203	miR-203a	BIRC5|ZEB2|BMI1|RUNX2	332|9839|648|860	NPA	inhibit epithelial-mesenchymal transition|inhibit cell invasion|inhibit cell motility|inhibit metastasis	specifically downregulated in bone metastatic PCa	NPA	a bone metastatic model of PCa	prostate carcinoma clinical specimens	tumor-suppressive
1409	21159845	thyroid	papillary thyroid carcinoma	NPA	miR-146a	miR-146a-5p	THRB	7068	NPA	NPA	up-regulated in almost all pairs of PTC tumor/normal tissues	NPA	NPA	13 pairs of PTC tumor/normal tissues	NPA
1410	21159845	thyroid	papillary thyroid carcinoma	NPA	miR-21	miR-21-5p	THRB	7068	NPA	NPA	up-regulated in almost all pairs of PTC tumor/normal tissues	NPA	NPA	13 pairs of PTC tumor/normal tissues	NPA
1411	21159816	pancreas	pancreatic cancer	NPA	miR-143	miR-143-3p	KRAS|RREB1	3845|6239	KRAS|RREB1	inhibit tumorigenesis	frequently downregulated in KRAS mutant pancreatic cancers	NPA	NPA	pancreatic cancer tissues	tumor-suppressive
1412	21159816	pancreas	pancreatic cancer	NPA	miR-145	miR-145-5p	KRAS|RREB1	3845|6239	KRAS|RREB1	inhibit tumorigenesis	frequently downregulated in KRAS mutant pancreatic cancers	NPA	NPA	pancreatic cancer tissues	tumor-suppressive
1413	21159652	lung	non-small cell lung cancer	NPA	miR-218	miR-218-5p	PXN	5829	NPA	inhibit cell proliferation|inhibit cell invasion|inhibit colony formation	independently predictor for overall survival and relapse-free survival|negatively associated with PXN expression	NPA	NPA	124 surgically resected lung tumors	tumor-suppressive
1414	21157919	lung	lung cancer	NPA	miR-206	miR-206	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion|induce apoptosis	lower in high metastasis tumors than low metastasis tumors and normal lung tissues	95D	NPA	"high metastasis tumors, low metastasis tumors and normal lung tissues"	tumor-suppressive
1415	21156648	nerve	Schwannoma	NPA	miR-7	miR-7-5p	EGFR|PAK1|TNK2	1956|5585|10188	NPA	inhibit cell growth	significantly downregulated in tumor samples as compared with control nerve tissue|inversely correlated with TNK2 expression levels in human schwannoma samples	NPA	xenograft tumor models	human schwannoma samples	tumor-suppressive
1416	21148309	esophagus	esophageal squamous cell carcinoma	NPA	miR-92a	miR-92a-3p	CDH1	51343	NPA	promote cell migration|promote cell invasion	highly expressed in esophageal squamous cell carcinoma tumor tissues|significantly correlated with the status of lymph node metastasis and TNM stage|associated with poor survival of ESCC patients|an independent prognostic factor	NPA	NPA	107 ESCC patients	oncogenic
1417	21148031	prostate	prostate cancer	NPA	let-7a	let-7a-5p	NPA	NPA	RPS2	reduce cell invasion|reduce tumorigenesis	NPA	IBC-10a|PCa-20a|PC-3ML	SCID mice	NPA	tumor-suppressive
1418	21145831	liver	hepatocellular carcinoma	NPA	miR-145	miR-145-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion	downregulated in in pre-malignant DNs and HCC development	HepG2|Hep3B	NPA	"formalin fixed paraffin embedded (FFPE) dysplastic nodules (DN), small HCCs, and their corresponding non-tumorous livers"	tumor-suppressive
1419	21143953	NPA	NPA	topotecan	miR-21	miR-21-5p	NPA	NPA	AP-1	increase topotecan resistance|increase colony formation	frequently upregulated in side population (SP) cells than in non-SP cells	NPA	NPA	NPA	oncogenic
1420	21138859	prostate	prostate cancer	NPA	miR-296	miR-296-5p	HMGA1	3159	NPA	reduce cell proliferation|reduce cell invasion	negatively strongly linked to more advanced tumor grade and stage|inversely correlated with HMGA1 expression in PC patient samples	NPA	NPA	PC patient samples	tumor-suppressive
1421	21131358	breast	ER+ breast cancer	all-trans-retinoic acid (ATRA)	miR-21	miR-21-5p	PLAT|IL1B|ICAM1	5327|3553|3383	RARA	promote cell growth|inhibit senescence|inhibit ATRA-dependent cell motility	NPA	MCF-7|MDA-MB-231	NPA	NPA	oncogenic
1422	21119662	kidney	clear cell renal cell carcinoma	NPA	miR-584	miR-584-5p	ROCK1	6093	NPA	decrease cell motility	downregulated in RCC (A-498 and 769-P) cells compared with HK-2 cells	HK-2|A-498|HK-2	NPA	NPA	tumor-suppressive
1423	21119604	stomach	gastric cancer	NPA	miR-192	miR-192-5p	ALCAM	214	NPA	increase cell growth|increase cell migration	significantly higher in GC than in NS	HFE145|NCI-N87	NPA	primary human gastric tissues (31 non-neoplastic stomach (NS) and 25 gastric carcinomas (GC))	oncogenic
1424	21119604	stomach	gastric cancer	NPA	miR-215	miR-215-5p	ALCAM	214	NPA	increase cell growth|increase cell migration	significantly higher in GC than in NS	HFE145|NCI-N87	NPA	primary human gastric tissues (31 non-neoplastic stomach (NS) and 25 gastric carcinomas (GC))	oncogenic
1425	21118985	blood	B-cell acute lymphoblastic leukemia	NPA	miR-125b	miR-125b-5p	NPA	NPA	NPA	promote leukemia|promote cell proliferation	overexpressed in patients with myelodysplasia and acute myeloid leukemia up to 90-fold normal	NPA	transplantation experiments in mice	patients with myelodysplasia and acute myeloid leukemia	oncogenic
1426	21118966	NPA	NPA	NPA	miR-183	miR-183-5p	EGR1	1958	NPA	promote cell migration	"significantly overexpressed in these tumor types (synovial sarcoma, rhabdomyosarcoma, and colon cancer) as well as in corresponding tumor cell lines"	NPA	NPA	"synovial sarcoma, rhabdomyosarcoma, and colon cancer"	oncogenic
1427	21118818	nerve	neuroblastoma	retinoic acid (RA)	miR-10a	miR-10a-5p	SRSF1	6426	NPA	promote cell differentiation	induced by RA in neuroblastoma cells	SH-SY5Y|LA-N-1|HeLa	NPA	NPA	NPA
1428	21118818	nerve	neuroblastoma	retinoic acid (RA)	miR-10b	miR-10b-5p	SRSF1	6426	NPA	promote cell differentiation	induced by RA in neuroblastoma cells	SH-SY5Y|LA-N-1|HeLa	NPA	NPA	NPA
1429	21115884	nerve	neuroblastoma	NPA	miR-185	miR-185-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit tumor growth	NPA	NPA	CB17-SCID mice	NPA	tumor-suppressive
1430	21115742	lung	lung cancer	NPA	miR-200	miR-200a-3p|miR-200b-3p|miR-200c-3p	FLT1	2321	NPA	inhibit tumor growth|inhibit metastasis	NPA	NPA	mouse model of K-ras/p53-mutant lung adenocarcinoma	NPA	tumor-suppressive
1431	21114921	stomach	gastric cancer	cisplatin|5-fluorouracil|paclitaxel|adriamycin	miR-200c	miR-200c-3p	NPA	NPA	NPA	increase chemosensitivity|decrease cell proliferation	NPA	SGC7901	NPA	NPA	tumor-suppressive
1432	21113131	pancreas	pancreatic cancer	NPA	miR-301a	miR-301a-3p	NKRF	55922	NF-¦ÊB	activate NF-¦ÊB signaling|promote tumor growth	up-regulated in human pancreatic adenocarcinoma tissues	NPA	xenograft tumour	human pancreatic adenocarcinoma tissues	oncogenic
1433	21112564	liver	CD133+ hepatocellular carcinoma cancer stem cells	NPA	miR-130b	miR-130b-3p	TP53INP1	94241	NPA	increase chemoresistance|promote CSC growth|promote CSC self-renewal	overexpressed in CD133+ CSCs	NPA	NPA	41 separate HCC tissue specimens	oncogenic
1434	21112327	head and neck	oral squamous cell carcinoma	NPA	miR-124	miR-124-3p	ITGB1	3688	NPA	reduce cell adherence|reduce cell motility	NPA	NPA	NPA	NPA	tumor-suppressive
1435	21112326	pancreas	pancreatic cancer	NPA	miR-483-3p	miR-483-3p	SMAD4	4089	NPA	promote cell proliferation|promote colony formation	strongly enhanced in pancreatic cancer tissues compared to side normal tissues|inversely correlated with SMAD4 expression in human clinical specimens	NPA	NPA	pancreatic cancer tissues and side normal tissues	oncogenic
1436	21109987	ovary	ovarian cancer	progesterone	let-7i	let-7i-5p	PGRMC1	10857	NPA	NPA	NPA	SKOV-3	NPA	NPA	NPA
1437	21109987	ovary	ovarian cancer	progesterone	miR-98	miR-98-5p	PGRMC1	10857	NPA	NPA	NPA	SKOV-3	NPA	NPA	NPA
1438	21109942	head and neck	head and neck squamous cell carcinoma	NPA	miR-133a	miR-133a-3p	CAV1	857	NPA	reduce cell proliferation|reduce cell migration|reduce cell invasion	NPA	NPA	NPA	NPA	tumor-suppressive
1439	21109473	skin	melanoma	NPA	miR-211	miR-211-5p	TGFBR2|NFAT5	7048|10725	NPA	reduce cell migration|reduce cell invasion	lowly expressed in malignant and highly invasive human melanomas	NPA	NPA	human melanomas	tumor-suppressive
1440	21106054	pancreas	pancreatic cancer	gemcitabine	miR-15a	miR-15a-5p	WNT3A|FGF7	89780|2252	NPA	inhibit cell viability	downregulated in pancreatic cancer specimens	NPA	NPA	10 pancreatic cancer tissues and their adjacent benign tissues	tumor-suppressive
1441	21106054	pancreas	pancreatic cancer	gemcitabine	miR-214	miR-214-3p	ING4	51147	NPA	decrease gemcitabine sensitivity	upregulated in pancreatic cancer specimens	NPA	NPA	10 pancreatic cancer tissues and their adjacent benign tissues	NPA
1442	21105030	breast	breast cancer	NPA	miR-31	miR-31-5p	WASF3	10810	NPA	reduce cell invasion	correlated inversely with breast cancer progression in humans|inversely correlated with WASF3 expression levels in invasive versus noninvasive breast cancer cell lines	NPA	NPA	NPA	tumor-suppressive
1443	21104017	esophagus	esophageal squamous cell carcinoma	NPA	miR-21	miR-21-5p	NPA	NPA	NPA	promote cell proliferation	significantly higher in tumor compared with adjacent normal tissues|significantly higher expressed in patients with cancer cell invasion deep into esophageal serosa	Eca109	NPA	18 pairs of Kazakh's ESCC and adjacent normal tissues	oncogenic
1444	21102523	breast	breast cancer	NPA	miR-181a	miR-181a-5p	ATM	472	TGFB1	induce sphere formation	"elevated in mammospheres grown in undifferentiating conditions, compared with cells grown in two-dimensional conditions"	NPA	NPA	NPA	oncogenic
1445	21102523	breast	breast cancer	NPA	miR-181b	miR-181b-5p	ATM	472	TGFB1	induce sphere formation	"elevated in mammospheres grown in undifferentiating conditions, compared with cells grown in two-dimensional conditions"	NPA	NPA	NPA	oncogenic
1446	21092188	lung	non-small cell lung cancer	NPA	miR-145	miR-145-5p	MYC	4609	NPA	inhibit cell growth|block cell cycle G1/S transition	downregulated in tumor tissues relative to adjacent non-tumor tissues	A549|H23	NPA	tumor tissues and adjacent non-tumor tissues	tumor-suppressive
1447	21088996	pancreas	pancreatic ductal adenocarcinoma	NPA	miR-21	miR-21-5p	NPA	NPA	NPA	promote cell proliferation|inhibit cell death	upregulated in PDAC primary tissues relative to adjacent normal tissue|correlated with disease stage in the primary tumours	MIA-Pa-Ca-2	NPA	24 PDAC tumour/matched adjacent normal tissue samples	oncogenic
1448	21086164	liver	hilar cholangiocarcinoma	NPA	miR-373	miR-373-3p	MBD2	8932	NPA	NPA	"decreased in hilar cholangiocarcinoma|negativelyclosely associated with poor cell differentiation, advanced clinical stage, and shorter survival in hilar cholangiocarcinoma"	QBC(939)|HIBEpic	NPA	hilar cholangiocarcinoma tissues	NPA
1449	21081469	stomach	gastric cancer	nicotine	miR-16	miR-16-5p	NPA	NPA	NF-¦ÊB	promote nicotine-induced cell proliferation	upregulated upon nicotine stimulation	NPA	NPA	NPA	NPA
1450	21081469	stomach	gastric cancer	nicotine	miR-21	miR-21-5p	NPA	NPA	NF-¦ÊB	promote nicotine-induced cell proliferation	upregulated upon nicotine stimulation	NPA	NPA	NPA	NPA
1451	21079996	head and neck	tongue squamous cell carcinoma	NPA	miR-138	miR-138-5p	GNAI2	2771	NPA	reduce cell proliferation|induce cell cycle arrest|induce apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
1452	21078976	colorectum	colorectal cancer	5-fluorouracil	miR-21	miR-21-5p	MSH2|MSH6	4436|2956	NPA	reduce 5-FU-induced cell cycle G2/M damage arrest|reduce apoptosis|reduce 5-FU sensitivity	highly expressed in colorectal tumors	NPA	xenograft	colorectal tumor tissues	oncogenic
1453	21077158	skin	melanoma	NPA	miR-196a	miR-196a-5p	HOXC8	3224	NPA	reduce cell invasion	significantly down-regulated in malignant melanoma cell lines and tissue samples	NPA	NPA	melanocytes and melanoma tissue samples	tumor-suppressive
1454	21075312	kidney	renal cell carcinoma	NPA	miR-145	miR-145-5p	MYC	4609	FOXO1|FOXO3	NPA	NPA	NPA	NPA	NPA	NPA
1455	21072171	skin	melanoma	NPA	miR-211	miR-211-5p	KCNMA1	3778	MITF	inhibit cell growth|inhibit cell invasion	consistently reduced in all eight non-pigmented melanoma cell lines compared with melanocytes|reduced in 21 out of 30 distinct melanoma samples from patients|inversely correlated with KCNMA1 mRNA and protein levels	NPA	NPA	"30 distinct melanoma samples from patients, classified as primary in situ, regional metastatic, distant metastatic, and nodal metastatic"	tumor-suppressive
1456	21071579	prostate	prostate cancer	genistein	miR-221	miR-221-3p	DIRAS3	9077	NPA	NPA	upregulated in prostate cancer cell lines|inversely correlated with DIRAS3 in prostate cancer cell lines	PC-3	NPA	NPA	NPA
1457	21071579	prostate	prostate cancer	genistein	miR-222	miR-222-3p	DIRAS3	9077	NPA	NPA	upregulated in prostate cancer cell lines|inversely correlated with DIRAS3 in prostate cancer cell lines	PC-3	NPA	NPA	NPA
1458	21070600	blood	leukemia	doxorubicin	miR-27a	miR-27a-3p	NPA	NPA	NPA	increase doxorubicin sensitivity	expressed at lower levels in a panel of relapse patients compared with primary patients at diagnosis	K562	NPA	a panel of relapse patients and primary patients at diagnosis	NPA
1459	21070600	blood	leukemia	doxorubicin	miR-331-5p	miR-331-5p	NPA	NPA	NPA	increase doxorubicin sensitivity	expressed at lower levels in a panel of relapse patients compared with primary patients at diagnosis	K562	NPA	a panel of relapse patients and primary patients at diagnosis	NPA
1460	21067862	colorectum	colon cancer	5-fluorouracil	miR-34a	miR-34a-5p	NPA	NPA	NPA	inhibit cell growth|reduce 5-FU resistance	lowly expressed in the 5-FU-resistant cells|up-regulated in the parental cells after the 5-FU treatment	DLD-1	NPA	NPA	tumor-suppressive
1461	21062447	colorectum	colon cancer	5-fluorouracil	miR-31	miR-31-5p	NPA	NPA	NPA	promote cell migration|promote cell invasion|promote cell proliferation	NPA	HCT116	NPA	NPA	oncogenic
1462	21059650	breast	breast cancer	NPA	miR-19	miR-19a-3p	F3	2152	NPA	NPA	NPA	MCF-7|T47D|ZR-75-1|MDA-MB-231|BT-20	NPA	NPA	NPA
1463	21057533	NPA	NPA	NPA	miR-548a-5p	miR-548a-5p	LRP1B	53353	NPA	NPA	overexpressed in cancer cell lines	NPA	NPA	NPA	NPA
1464	21055388	liver	hepatocellular carcinoma	NPA	miR-199a-3p	miR-199a-3p	CD44	960	NPA	reduce cell proliferation|reduce cell invasion	significantly reduced in 7 HCC cell lines|inversely correlated with CD44 protein in primary HCC specimens	SNU449|SNU423	NPA	primary HCC specimens	tumor-suppressive
1465	21053104	stomach	gastric cancer	5-Aza-2'-deoxycitidine	miR-212	miR-212-3p	MYC	4609	promoter DNA hypermethylation in cancer	NPA	significantly reduced in GC tissues compared to normal tissues|higher in normal gastric mucosa cell line in gastric cancer cell lines	BGC-823|SGC-7901|MKN-45|GES	NPA	GC tissues and normal tissues	NPA
1466	21051724	skin	uveal melanoma	5-aza-2'-deoxycytidine|trichostatin A	miR-137	miR-137	MITF|CDK6	4286|1021	NPA	induce cell cycle G1 arrest|decrease cell growth	lower in uveal melanoma cell lines than in uveal melanocytes	NPA	NPA	NPA	tumor-suppressive
1467	21048943	lung	lung cancer	cigarette smoke condensate	miR-31	miR-31-5p	DKK1|DACT3	22943|147906	CEBPB	enhance cell proliferation|promote tumorigenicity	significantly elevated in lung cancer specimens relative to adjacent normal lung tissues	NPA	NPA	lung cancer specimens and adjacent normal lung tissues	oncogenic
1468	21048306	stomach	gastric cancer	NPA	miR-199a	miR-199a-5p	MAP3K11	4296	NPA	increase cell proliferation|increase cell migration|increase cell invasion	"highly expressed in gastric cancer compared to normal gastric tissues and in metastatic, compared to non-metastatic gastric cancer tissues|significantly correlated with clinical progression in gastric cancer"	NPA	NPA	gastric cancer and normal gastric tissues	oncogenic
1469	21045151	NPA	ALDH1+ cancer stem cells	NPA	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	LIN28A	79727	LIN28A	reduce the population of ALDH1+ tumor cells	NPA	NPA	NPA	NPA	NPA
1470	21044961	esophagus	esophageal squamous cell carcinoma	NPA	miR-210	miR-210-3p	FGFRL1	53834	NPA	inhibit cell survival|inhibit cell proliferation|induce cell death|induce cell cycle G1/G0 and G2/M arrest	down-regulated in human esophageal squamous cell carcinoma and derived cell lines|marked decreased especially in poorly differentiated carcinomas	NPA	NPA	human esophageal squamous cell carcinoma	tumor-suppressive
1471	21042775	ovary	ovarian epithelial carcinoma	NPA	miR-21	miR-21-5p	NPA	NPA	NPA	promote cell proliferation|promote cell migration|promote cell invasion	"significantly overexpressed in human EOC tissues and cell lines|correlated with histological differentiation, clinicopathological stage, and lymph node metastasis"	NPA	NPA	human EOC tissues	oncogenic
1472	21042732	NPA	NPA	NPA	miR-221	miR-221-3p	BBC3	27113	NPA	promote cell proliferation|inhibit mitochondrial-mediated apoptosis	NPA	A549|MCF-7	NPA	NPA	oncogenic
1473	21042732	NPA	NPA	NPA	miR-222	miR-222-3p	BBC3	27113	NPA	promote cell proliferation|inhibit mitochondrial-mediated apoptosis	NPA	A549|MCF-7	NPA	NPA	oncogenic
1474	21040528	blood	mantle cell lymphoma	radiation	miR-17~92	CLUSTER:miR-17~92	NPA	NPA	NPA	increase cell survival|increase cell proliferation|decrease cell death	NPA	NPA	NPA	NPA	oncogenic
1475	21038412	liver	hepatocelluar carcinoma	NPA	miR-122	miR-122-5p	IGF1R	3480	CEBPA|GSK3B	suppress cell proliferation	frequently downregulated in HCC tissues|negatively associated with worse survival of HCC patients	NPA	NPA	livers of different development stages and human hepatocellular carcinoma (HCC) tissues	tumor-suppressive
1476	21035172	uterus	endometrial endometrioid carcinoma	NPA	miR-141	miR-141-3p	NPA	NPA	NPA	promote cell growth	up-regulated in EECs as compared with that in normal endometrial tissues	HEC-1A|Ishikawa	NPA	EECs and normal endometrial tissues	oncogenic
1477	21035172	uterus	endometrial endometrioid carcinoma	NPA	miR-200a	miR-200a-3p	NPA	NPA	NPA	promote cell growth	up-regulated in EECs as compared with that in normal endometrial tissues	HEC-1A|Ishikawa	NPA	EECs and normal endometrial tissues	oncogenic
1478	21035172	uterus	endometrial endometrioid carcinoma	NPA	miR-200b	miR-200b-3p	NPA	NPA	NPA	promote cell growth	up-regulated in EECs as compared with that in normal endometrial tissues	HEC-1A|Ishikawa	NPA	EECs and normal endometrial tissues	oncogenic
1479	21035172	uterus	endometrial endometrioid carcinoma	NPA	miR-200c	miR-200c-3p	NPA	NPA	NPA	promote cell growth	up-regulated in EECs as compared with that in normal endometrial tissues	HEC-1A|Ishikawa	NPA	EECs and normal endometrial tissues	oncogenic
1480	21035172	uterus	endometrial endometrioid carcinoma	NPA	miR-429	miR-429	NPA	NPA	NPA	promote cell growth	up-regulated in EECs as compared with that in normal endometrial tissues	HEC-1A|Ishikawa	NPA	EECs and normal endometrial tissues	oncogenic
1481	21029372	stomach	gastric cancer	NPA	miR-107	miR-107	DICER1	23405	NPA	promote cell migration|promote cell invasion	frequently up-regulated in gastric cancers|significantly associated with gastric cancer metastasis	NPA	nude mice	gastric cancers	oncogenic
1482	20979124	liver	liver cancer	NPA	miR-194	miR-194-5p	NPA	NPA	NPA	reduce cell migration|reduce cell invasion	"low in liver mesenchymal-like cancer cell lines|highly expressed in hepatic epithelial cells, but not in Kupffer cells or hepatic stellate cells"	NPA	NPA	NPA	tumor-suppressive
1483	20978511	liver	hepatocellular carcinoma	interferon-¦Á|5-fluorouracil	miR-21	miR-21-5p	NPA	NPA	NPA	increase IFN-¦Á/5-FU resistance|inhibit apoptosis	significantly associated with the clinical response to the IFN-¦Á/5-FU combination therapy and survival rate	HepG2	NPA	clinical HCC specimens	oncogenic
1484	20978205	lung	lung cancer	NPA	miR-7	miR-7-5p	ERF	2107	EGFR|MYC|RAS	promote cell growth|promote tumor formation	NPA	NPA	NPA	NPA	oncogenic
1485	20978187	breast	Er¦Á+ breast cancer	NPA	miR-375	miR-375	RASD1	51655	NPA	promote cell proliferation	highly expressed in ER¦Á-positive breast cell lines	MCF-7	NPA	NPA	oncogenic
1486	20965124	stomach	gastric cancer	NPA	miR-101	miR-101-3p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion|reduce tumor growth	down-regulated in gastric cancer tissues and cells	NPA	NPA	gastric cancer tissues	tumor-suppressive
1487	20962848	NPA	NPA	NPA	miR-130b	miR-130b-3p	NPA	NPA	TP63	suppress metastasis	NPA	NPA	NPA	NPA	tumor-suppressive
1488	20957176	skin	melanoma	NPA	miR-200a	miR-200a-3p	NPA	NPA	NPA	prefer protrusion-associated elongated mode of invasion	increased in melanoma cell lines compared to normal melanocytes	NPA	NPA	NPA	NPA
1489	20957176	skin	melanoma	NPA	miR-200c	miR-200c-3p	NPA	NPA	NPA	"prefer the rounded, amoeboid-like mode of invasion"	increased in melanoma cell lines compared to normal melanocytes	NPA	NPA	NPA	NPA
1490	20956945	NPA	NPA	NPA	miR-21	miR-21-5p	NPA	NPA	HRAS	promote tumor growth	overexpressed mainly in anaplastic thyroid carcinomas|inversely correlated with tumor progression in non-small-cell lung cancers	NPA	mice	human thyroid cancers and non-small-cell lung cancers	oncogenic
1491	20956944	NPA	NPA	NPA	miR-93	miR-93-5p	ITGB8	3696	NPA	enhance cell survival|promote sphere formation|promote tumor growth|promote angiogenesis	NPA	U87	NPA	NPA	oncogenic
1492	20956939	NPA	NPA	tamoxifen	miR-101	miR-101-3p	MAGI2	9863	NPA	promote estrogen-independent cell growth|activate Akt signaling	NPA	MCF-7	NPA	NPA	oncogenic
1493	20952513	breast	breast cancer	NPA	miR-26a	miR-26a-5p	MTDH|EZH2	92140|2146	NPA	induce apoptosis|reduce colony forming|reduce tumor load	downregulated in breast cancer specimens and cell lines	MCF7	MCF7 xenografts	NPA	tumor-suppressive
1494	20951946	blood	multiple myeloma	NPA	miR-192	miR-192-5p	MDM2	4193	TP53	NPA	NPA	NPA	NPA	NPA	NPA
1495	20951946	blood	multiple myeloma	NPA	miR-194	miR-194-5p	MDM2|IGF1|IGF1R	4193|3479|3480	TP53	reduce migration of plasma cells into bone marrow	NPA	NPA	NPA	NPA	tumor-suppressive
1496	20951946	blood	multiple myeloma	NPA	miR-215	miR-215-5p	MDM2|IGF1|IGF1R	4193|3479|3480	TP53	reduce migration of plasma cells into bone marrow	NPA	NPA	NPA	NPA	tumor-suppressive
1497	20951699	liver	hepatocellular carcinoma	NPA	miR-139	miR-139-5p	ROCK2	9475	NPA	reduce cell migration|reduce cell invasion	"negatively associated significantly with poor prognosis of patients and features of metastatic tumors, including venous invasion, microsatellite formation, absence of tumor encapsulation, and reduced differentiation|reduced in metastatic HCC tumors compared with primary tumors|correlated inversely with ROCK2 protein in human HCC samples"	SMMC-7721|BEL7402|MHCC97L	orthotopic liver tumors in mice	metastatic HCC tumors and primary tumors	tumor-suppressive
1498	20948989	prostate	prostate cancer	NPA	miR-449a	miR-449a	CCND1	595	NPA	induce Rb-dependent cell cycle arrest|induce Rb-dependent senescence	NPA	DU-145	NPA	NPA	tumor-suppressive
1499	20947150	cervix	cervical squamous cell carcinoma	NPA	miR-886-5p	miR-886-5p	NPA	NPA	NPA	reduce apoptosis|promote cell proliferation	significantly over-expressed between CSCC tissues and adjacent non-tumor tissues	H8	NPA	cervical squamous cell carcinomas (CSCC) and adjacent non-tumor tissues	oncogenic
1500	20945501	prostate	prostate cancer	NPA	miR-141	miR-141-3p	NPA	NPA	AR	enhance cell growth	over-expressed in PC and castration-resistant prostate cancer (CRPC) compared to benign prostate hyperplasia	LNCaP	13 intact-castrated prostate cancer (PC) xenograft pairs	clinical specimens of untreated (PC) and castration-resistant prostate cancer (CRPC)	oncogenic
1501	20933503	brain	glioma	NPA	miR-218	miR-218-5p	IKBKB	3551	NPA	reduce cell migration|reduce cell invasion	markedly downregulated in glioma cell lines and in human primary glioma tissues	NPA	NPA	human primary glioma tissues	tumor-suppressive
1502	20932331	breast	breast cancer	NPA	miR-339-5p	miR-339-5p	NPA	NPA	NPA	decrease cell migration|decrease cell invasion	downregulated in the aggressive cell lines and in breast cancer tissues compared with benign tissues|negatively associated with an increase in metastasis to lymph nodes and with high clinical stages|independent prognostic factor for breast cancer patients	MCF-7|MDA-MB-468|MDA-MB-231	NPA	breast cancer tissues and benign tissues	tumor-suppressive
1503	20931398	blood	acute myeloid leukemia	NPA	miR-126	miR-126-3p	NPA	NPA	NPA	inhibit apoptosis|increase cell viability	specifically aberrantly overexpressed in core binding factor (CBF) AMLs including both t(8;21)/AML1-ETO and inv(16)/CBFB-MYH11 samples	NPA	NPA	52 acute myeloid leukemia (AML) samples	oncogenic
1504	20931396	NPA	NPA	NPA	miR-331-3p	miR-331-3p	ERBB2	2064	NPA	reduce Akt signaling	NPA	NPA	NPA	NPA	NPA
1505	20931396	NPA	NPA	NPA	miR-7	miR-7-5p	EGFR	1956	NPA	reduce Akt signaling	NPA	NPA	NPA	NPA	NPA
1506	20924108	liver	hepatocellular carcinoma	dioxin	miR-191	miR-191-5p	NPA	NPA	NPA	promote cell proliferation|inhibit apoptosis|promote tumor growth	NPA	NPA	an orthotopic xenograft mouse model of HCC	NPA	oncogenic
1507	20889924	blood	acute myeloid leukemia	NPA	miR-34a	miR-34a-5p	E2F3	1871	CEBPA	inhibit cell proliferation|reprogram granulocytic differentiation	NPA	NPA	NPA	NPA	tumor-suppressive
1508	20889127	breast	breast cancer	NPA	miR-378*	miR-378-5p	ESRRG|GABPA	2104|2551	ERBB2	induce a metabolic shift|reduce oxygen consumption|increase lactate production|increase cell proliferation	correlated with progression of human breast cancer	NPA	NPA	human breast cancer tissues	oncogenic
1509	20886540	prostate	prostate cancer	NPA	miR-125b	miR-125b-5p	TP53|BBC3|BAK1	7157|27113|578	NPA	promote tumor growth|reduce drug sensitivity	NPA	NPA	male athymic mice xenograft tumor	NPA	oncogenic
1510	20885442	lung	non-small cell lung cancer	NPA	miR-210	miR-210-3p	SDHD	6392	NPA	alter cell viability|induce a loss of mitochondrial membrane potential and the apparition of an aberrant mitochondrial phenotype	overexpressed at late stages of non-small cell lung cancer	A549	NPA	non-small cell lung cancer samples	NPA
1511	20883704	colorectum	colon cancer	NPA	miR-34a	miR-34a-5p	NPA	NPA	NPA	inhibit cell proliferation|induce senescence-like phenotypes	down-regulated in human colon cancer	NPA	NPA	human colon cancer tissues	tumor-suppressive
1512	20878953	prostate	prostate cancer	radiation	miR-106b	miR-106b-5p	NPA	NPA	NPA	override radiation-induced cell cycle G2/M arrest|override radiation-induced cell growth inhibition	NPA	NPA	NPA	NPA	oncogenic
1513	20878132	bone and muscle	osteosarcoma	NPA	miR-143	miR-143-3p	BCL2	596	NPA	reduce cell viability|promote apoptosis|suppress tumorigenicity	down-regulated in osteosarcoma cell lines and primary tumor samples	NPA	NPA	primary osteosarcoma tumor samples	tumor-suppressive
1514	20878113	lung	lung adenocarcinoma	curcumin	miR-186*	miR-186-3p	CASP10	843	NPA	NPA	significantly downregulated by curcumin treatment	A549	NPA	NPA	NPA
1515	20876285	breast	ER¦Á+ breast cancer	tamoxifen	miR-15a	miR-15a-5p	NPA	NPA	NPA	increase tamoxifen sensitivity	NPA	MCF-7	MCF-7 xenografts	NPA	NPA
1516	20876285	breast	ER¦Á+ breast cancer	tamoxifen	miR-16	miR-16-5p	NPA	NPA	NPA	increase tamoxifen sensitivity	NPA	MCF-7	MCF-7 xenografts	NPA	NPA
1517	20874002	brain	glioma	NPA	miR-146b-5p	miR-146b-5p	EGFR	1956	genomic region 10q24.3 loss	decrease cell invasion|decrease cell migration	NPA	U87-MG	tumor-bearing mice	NPA	tumor-suppressive
1518	20871609	nerve	neuroblastoma	NPA	miR-380-5p	miR-380-5p	TP53	7157	NPA	block oncogene-induced senescence|promote tumor formation|reduce apoptosis	highly expressed in mouse embryonic stem cells and neuroblastomas|positively correlated with poor outcome in neuroblastomas with neuroblastoma derived v-myc myelocytomatosis viral-related oncogene (MYCN) amplification	NPA	an orthotopic mouse model of neuroblastoma	neuroblastomas	oncogenic
1519	20869762	ovary	ovarian cancer	NPA	miR-22	miR-22-3p	NPA	NPA	NPA	inhibit cell migration|inhibit cell invasion	differentially expressed between paired high and low metastatic serous ovarian cancer cells	SKOV-3ip|SKOV-3	NPA	NPA	tumor-suppressive
1520	20869334	brain	glioma	ionizing radiation	miR-100	miR-100-5p	ATM	472	NPA	increase radiation sensitivity	highly-expressed in M059J cells	M059J	NPA	NPA	NPA
1521	20859956	liver	hepatocellular carcinoma	NPA	miR-122a	miR-122-5p	PRDX2	7001	NPA	inhibit cell growth|induce apoptosis	downregulated in hepatocellular carcinoma	NPA	NPA	NPA	tumor-suppressive
1522	20858276	breast	breast cancer	NPA	miR-183	miR-183-5p	NPA	NPA	NPA	inhibit cell migration	downregulated in breast cancer	NPA	NPA	primary breast tumours and tumour associated normal tissue	tumor-suppressive
1523	20857258	bladder	bladder cancer	arsenic trioxide	miR-19a	miR-19a-3p	PTEN	5728	NPA	promote cell growth|inhibit apoptosis	NPA	T24	NPA	NPA	oncogenic
1524	20856158	nerve	vestibular schwannoma	NPA	miR-21	miR-21-5p	NPA	NPA	NPA	increase cell proliferation|inhibit apoptosis	consistently overexpressed  in vestibular schwannomas compared with normal vestibular nerve tissue	NPA	NPA	vestibular schwannomas and normal vestibular nerve tissue	oncogenic
1525	20851997	NPA	NPA	NPA	miR-17	miR-17-5p	CDKN1A	1026	NPA	inhibit ras-induced senescence|enhance oncogenic transformation by ras	NPA	NPA	NPA	NPA	oncogenic
1526	20851997	NPA	NPA	NPA	miR-20a	miR-20a-5p	CDKN1A	1026	NPA	inhibit ras-induced senescence|enhance oncogenic transformation by ras	NPA	NPA	NPA	NPA	oncogenic
1527	20843787	breast	breast cancer	hyaluronan	miR-10b	miR-10b-5p	NPA	NPA	TWIST1|CD44|SRC	promote cell invasion	NPA	MDA-MB-231	NPA	NPA	oncogenic
1528	20843712	bladder	bladder cancer	NPA	miR-1	miR-1	LASP1	3927	NPA	inhibit cell viability	NPA	NPA	NPA	NPA	tumor-suppressive
1529	20843712	bladder	bladder cancer	NPA	miR-133a	miR-133a-3p	LASP1	3927	NPA	inhibit cell viability	NPA	NPA	NPA	NPA	tumor-suppressive
1530	20843712	bladder	bladder cancer	NPA	miR-218	miR-218-5p	LASP1	3927	NPA	inhibit cell viability	NPA	NPA	NPA	NPA	tumor-suppressive
1531	20842113	liver	hepatocellular carcinoma	NPA	miR-22	miR-22-3p	HDAC4	9759	NPA	inhibit cell proliferation|inhibit tumourigenicity	downregulated in HCC|predictor of poor survival in HCC patients	NPA	NPA	160 paired HCC tissue samples	tumor-suppressive
1532	20841506	blood	non-Hodgkin lymphoma	follicular dendritic cells (FDC)	miR-181a	miR-181a-5p	BIM1	856739	NPA	promote FDC-induced apoptosis resistance	NPA	NPA	NPA	NPA	NPA
1533	20841484	nerve	neuroblastoma	all-trans-retinoic acid	miR-152	miR-152-3p	DNMT1	1786	NPA	inhibit cell invasion|inhibit anchorage-independent cell growth	NPA	NPA	NPA	NPA	tumor-suppressive
1534	20832755	lung	non-small cell lung cancer	NPA	miR-21	miR-21-5p	NPA	NPA	NPA	enhance tumorigenesis|inhibit apoptosis|activate Ras/MEK/ERK signaling	increased and associated with poor survival in NSCLC	NPA	transgenic mice with loss-of-function and gain-of-function miR-21 alleles	NPA	oncogenic
1535	20832727	NPA	cancer stem cells	NPA	miR-200b	miR-200b-3p	SUZ12	23512	NPA	block the formation and maintenance of mammospheres|inhibit tumor growth	down-regulated during CSC formation	NPA	mouse xenografts	NPA	tumor-suppressive
1536	20831814	head and neck	oral squamous cell carcinoma	NPA	miR-21	miR-21-5p	PDCD4	27250	NPA	NPA	NPA	NPA	NPA	NPA	oncogenic
1537	20831567	colorectum	colorectal cancer	NPA	miR-26b	miR-26b-5p	NPA	NPA	NPA	reduce cell growth|induce apoptosis	significant decreased in HUES-17s and LoVo cells	HUES-17|LoVo|SW480|HT29|Caco-2	NPA	NPA	tumor-suppressive
1538	20827722	liver	HCC	NPA	miR-125b	miR-125b-5p	LIN28B	389421	NPA	suppress cell growth|induce cell cycle G1/S arrest|inhibit cell migration|inhibit cell invasion	NPA	NPA	NPA	NPA	tumor-suppressive
1539	20826811	head and neck	nasopharyngeal carcinoma	NPA	miR-200a	miR-200a-3p	ZEB2	9839	NPA	inhibit epithelial-mesenchymal transition|reduce CD133(+) side population|reduce sphere formation capacity|reduce tumorigenicity	NPA	CNE-1|C666-1	nude mice	NPA	tumor-suppressive
1540	20826792	colorectum	colon carcinoma	NPA	miR-21	miR-21-5p	TIAM1	7074	TGFB1|TNFA	enhance cell morphological changes|promote cell motility|promote cell invasion	NPA	LIM 1863	NPA	NPA	oncogenic
1541	20826792	colorectum	colon carcinoma	NPA	miR-31	miR-31-5p	TIAM1	7074	TGFB1|TNFA	enhance cell morphological changes|promote cell motility|promote cell invasion	NPA	LIM 1863	NPA	NPA	oncogenic
1542	20820187	prostate	prostate cancer	androgen	miR-148a	miR-148a-3p	CAND1	55832	NPA	promote cell proliferation	NPA	LNCaP	NPA	NPA	oncogenic
1543	20819078	head and neck	tongue squamous cell carcinoma	NPA	miR-7	miR-7-5p	IGF1R	3480	NPA	reduce IGF1-induced Akt signaling|reduce cell proliferation|induce cell cycle arrest|induce apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
1544	20818426	breast	breast cancer	NPA	miR-145	miR-145-5p	F11R	50848	NPA	decrease cell motility	downregulated compared with healthy control tissue	MDA-MB-231|MCF-7|MDA-MB-468|SK-BR-3|Ishikawa	NPA	NPA	tumor-suppressive
1545	20816961	head and neck	tongue squamous cell carcinoma	NPA	miR-24	miR-24-3p	DND1	373863	NPA	promote cell proliferation|reduce apoptosis	upregulated in tongue squamous cell carcinoma (TSCC)	NPA	NPA	tongue squamous cell carcinoma (TSCC) tissues	oncogenic
1546	20816946	brain	glioma	NPA	miR-451	miR-451a	NPA	NPA	NPA	inhibit cell growth|induce cell cycle G0/G1 arrest|increase apoptosis|reduce cell invasion	downregulated in human glioblastoma cells	A172|LN229|U251	NPA	NPA	tumor-suppressive
1547	20813833	prostate	prostate cancer	NPA	miR-21	miR-21-5p	NPA	NPA	IFNA|IFNB|STAT3|NF-¦ÊB	suppress IFN-induced apoptosis	NPA	NPA	NPA	NPA	oncogenic
1548	20813046	brain	glioblastoma	NPA	miR-221	miR-221-3p	BBC3	27113	NPA	inhibit apoptosis|induce cell survival	inversely correlated with BBC3 expression in glioma tissues	NPA	xenograft model	glioma tissues	oncogenic
1549	20813046	brain	glioblastoma	NPA	miR-222	miR-222-3p	BBC3	27113	NPA	inhibit apoptosis|induce cell survival	inversely correlated with BBC3 expression in glioma tissues	NPA	xenograft model	glioma tissues	oncogenic
1550	20809749	stomach	gastric cancer	NPA	let-7a	let-7a-5p	NPA	NPA	NPA	reduce cell proliferation|induce cell cycle G0/G1 arrest|inhibit cell growth	NPA	SGC-7901	gastric cancer cell xenografts	NPA	tumor-suppressive
1551	20807887	blood	TEL-AML1+ leukemia	NPA	miR-320a	miR-320a	BIRC5	332	TEL-AML1	induce apoptosis	expressed at lower levels in TEL-AML1+ leukemias compared with immunophenotype-matched nonTEL-AML1 acute lymphoblastic leukemia subtypes|inversely correlated with BIRC5 expression levels within TEL-AML1+ leukemias	NPA	NPA	TEL-AML1+ leukemias and immunophenotype-matched nonTEL-AML1 acute lymphoblastic leukemia subtypes	tumor-suppressive
1552	20807887	blood	TEL-AML1+ leukemia	NPA	miR-494	miR-494-3p	BIRC5	332	TEL-AML1	induce apoptosis	expressed at lower levels in TEL-AML1+ leukemias compared with immunophenotype-matched nonTEL-AML1 acute lymphoblastic leukemia subtypes|inversely correlated with BIRC5 expression levels within TEL-AML1+ leukemias	NPA	NPA	TEL-AML1+ leukemias and immunophenotype-matched nonTEL-AML1 acute lymphoblastic leukemia subtypes	tumor-suppressive
1553	20805998	prostate	prostate cancer	NPA	miR-200	miR-200a-3p|miR-200b-3p|miR-200c-3p	NOTCH1	4851	NPA	inhibit prostasphere-forming ability|inhibit epithelial-mesenchymal transition	NPA	NPA	mice	NPA	tumor-suppressive
1554	20801640	head and neck	laryngeal squamous cell carcinoma	NPA	miR-21	miR-21-5p	NPA	NPA	NPA	promote cell proliferation|promote cell invasion|reduce cell cycle G1 arrest|reduce apoptosis|promote tumor growth	overexpressed in laryngeal squamous cell carcinoma (LSCC)|correlated with advanced stage	Hep-2	LSCC xenograft tumours	laryngeal squamous cell carcinoma tissues	oncogenic
1555	20799954	liver	hepatocellular carcinoma	NPA	miR-199a-5p	miR-199a-5p	DDR1	780	NPA	inhibit cell invasion	significantly down-regulated in 65.2% of HCC tissues and in four of five cell lines	HepG2|SNU-182	NPA	tumor and adjacent non-tumor liver tissues from 23 patients with HCC undergoing liver resection	tumor-suppressive
1556	20798686	breast	breast cancer	cyclophosphamide|epirubicin|taxotere|5-fluorouracil	miR-448	miR-448	SATB1	6304	NF-¦ÊB	inhibit epithelial-mesenchymal transition	"downregulated in all patients who received cyclophosphamide (CP), epirubicin plus taxotere/CP, epirubicin plus 5-fluorouracil chemotherapy"	NPA	NPA	breast cancer patients	tumor-suppressive
1557	20797623	NPA	NPA	NPA	miR-181b	miR-181b-5p	CYLD	1540	STAT3	promote cell transformation|promote tumor growth	NPA	NPA	xenografts	NPA	oncogenic
1558	20739924	liver	hepatocellular carcinoma	NPA	miR-122	miR-122-5p	NPA	NPA	NPA	regulate mitochondrial metabolism	under-expressed in HCCs	NPA	mouse liver	96 pairs of tumor/non-tumor HCC tissues|additional 180 HCC and 40 liver cirrhotic patients	tumor-suppressive
1559	20737575	colorectum	colon cancer	5-fluorouracil	miR-145	miR-145-5p	FLI1	2313	NPA	inhibit cell proliferation|increase 5-FU sensitivity	down-regulated in colon carcinoma tissues |inversely correlated with FLI1 expression in colon cancer tissues and cell lines	LS174T	NPA	colon cancer tissues	tumor-suppressive
1560	20737563	prostate	prostate cancer	NPA	miR-205	miR-205-5p	NPA	NPA	NPA	induce apoptosis|induce cell cycle arrest|reduce cell growth|reduce cell migration|reduce clonability|reduce cell invasion	downregulated in prostate cancer	NPA	NPA	prostate cancer tissues	tumor-suppressive
1561	20736365	breast	breast cancer	NPA	miR-196a	miR-196a-5p	HOXC8	3224	NPA	inhibit cell migration|inhibit metastasis	correlation between the ratio of miR-196 to HOXC8 messages and the migratory behavior of breast cancer cell lines as well as the metastatic status of clinical samples	MDA-MB-231	NPA	NPA	tumor-suppressive
1562	20736365	breast	breast cancer	NPA	miR-196b	miR-196b-5p	HOXC8	3224	NPA	inhibit cell migration|inhibit metastasis	correlation between the ratio of miR-196 to HOXC8 messages and the migratory behavior of breast cancer cell lines as well as the metastatic status of clinical samples	MDA-MB-231	NPA	NPA	tumor-suppressive
1563	20732742	head and neck	nasopharyngeal carcinoma	NPA	miR-10b	miR-10b-5p	NPA	NPA	TWIST1	promote cell invasion|promote metastasis	highly expressed in EBV+ LMP1-expressing NPC cells	C666-1	tumor-bearing nude mice	NPA	oncogenic
1564	20729973	breast	breast cancer	cisplatin	miR-125b	miR-125b-5p	MUC1	4582	NPA	inhibit cell growth|increase cisplatin-induced apoptosis	downregulated in breast cancer cells	BT-549|ZR-75-1	NPA	NPA	oncogenic
1565	20728447	lung	lung cancer	NPA	miR-542-3p	miR-542-3p	BIRC5	332	NPA	inhibit cell proliferation|induce cell cycle G1 & G2/M arrest	NPA	A549	NPA	NPA	tumor-suppressive
1566	20728239	lung	non-small cell lung cancer	radiation	miR-126	miR-126-3p	NPA	NPA	NPA	inhibit cell growth|promote irradiation induced apoptosis	upregulated in radiotherapy sensitive group	SK-MES-1	NPA	30 non-small cell lung cancer patients who have been treated by postoperative radiotherapy	tumor-suppressive
1567	20727858	colorectum	colorectal cancer	NPA	miR-195	miR-195-5p	BCL2	596	NPA	reduce cell viability|promote cell apoptosis|suppress tumorigenicity	downregulated in cancer tissues compared with matched non-neoplastic mucosa tissues	HT29|LoVo	NPA	81 human colorectal cancer tissues and matched non-neoplastic mucosa tissues	tumor-suppressive
1568	20713524	NPA	NPA	NPA	miR-335	miR-335-5p	RB1	5925	TP53	inhibit cell proliferation|inhibit neoplastic cell transformation|induce cell cycle arrest	differentially expressed in human cancer cells	NPA	NPA	NPA	tumor-suppressive
1569	20712078	stomach	gastric cancer	NPA	miR-101	miR-101-3p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion|inhibit tumor growth	down-regulated in gastric cancer tissues and cells	NPA	NPA	gastric cancer tissues	tumor-suppressive
1570	20703102	pancreas	pancreatic cancer	NPA	miR-17-5p	miR-17-5p	NPA	NPA	NPA	promote cell growth|promote cell invasion	expressed higher in pancreatic cancer cells than primary cultured normal ductal cells|overexpressed in pancreatic cancer in FFPE and microdissected samples|associated with a poor prognosis	SUIT-2|KP-2	NPA	"primary cultures of normal human pancreatic ductal cells, formalin-fixed paraffin-embedded (FFPE) tissue samples derived from 80 patients who underwent pancreatectomy for pancreatic cancer and microdissected cells (including normal ductal epithelial, pancreatic intraepithelial neoplasia-1B and invasive ductal carcinoma cells)"	oncogenic
1571	20700123	head and neck	hypopharyngeal squamous cell carcinoma	NPA	miR-489	miR-489-3p	PTPN11	5781	NPA	inhibit cell growth	downregulated in hypopharyngeal squamous cell carcinoma (HSCC) samples	NPA	NPA	10 HSCC clinical samples	tumor-suppressive
1572	20698883	stomach	gastric cancer	NPA	miR-23a	miR-23a-3p	IL6R	3570	NPA	promote cell proliferation	inversely correlated with IL6R mRNA and protein levels	MGC803	NPA	NPA	oncogenic
1573	20696752	lung	non-small cell lung cancer	5-aza-2'-deoxycytidine|cisplatin|cetuximab	miR-200c	miR-200c-3p	NPA	NPA	NPA	inhibit cell invasion|reduce mesenchymal phenotype|reduce metastasis formation	inversely associated with a poor grade of differentiation and a higher propensity to lymph node metastases	NCI-H1299 cells	NPA	primary tumor specimens obtained from 69 patients with consecutively resected NSCLC	tumor-suppressive
1574	20693279	blood	chronic myelogenous leukemia	imatinib	miR-181b	miR-181b-5p	MCL1	4170	LYN	NPA	significantly reduced (?11- to 25-fold) in MYL-R cells	K562|HL-60	NPA	NPA	NPA
1575	20687223	prostate	prostate cancer	paclitaxel	miR-34a	miR-34a-5p	SIRT1	23411	NPA	reduce paclitaxel resistance	reduced in PC3PR cells compared with PC3 cells	PC3	NPA	NPA	NPA
1576	20682795	colorectum	colorectal cancer	NPA	miR-137	miR-137	KDM1A	23028	promoter DNA hypermethylation in cancer	inhibit cell proliferation	only expressed in colonocytes in normal mucosa|inversely correlated with the level of methylation	NPA	NPA	"409 colorectal tissues [21 normal colonic mucosa from healthy individuals (N-N), 160 primary CRC tissues and their corresponding normal mucosa (N-C), and 68 adenomas]"	tumor-suppressive
1577	20680522	colorectum	colorectal cancer	NPA	miR-126	miR-126-3p	NPA	NPA	NPA	inhibit cell growth	significantly lower in colorectal cancer tissues than those in non-tumor tissues	NPA	NPA	colorectal cancer tissues and non-tumor tissues	tumor-suppressive
1578	20675343	pancreas	pancreatic ductal adenocarcinoma	NPA	miR-217	miR-217	KRAS	3845	NPA	inhibit cell growth|inhibit anchorage-independent colony formation|decrease tumor growth	downregulated in 76.2% (16/21) of PDAC tissues and in all tested PDAC cell lines when compared with the corresponding normal pancreatic tissue|negatively correlated with KRAS protein expression in PDAC cell lines	NPA	nude mouse xenografts	21 PDAC tissues and the corresponding normal pancreatic tissue	tumor-suppressive
1579	20670480	blood	leukemia	arabinosylcytosine	miR-21	miR-21-5p	PDCD4	27250	NPA	reduce arabinosylcytosine sensitivity|increase cell viability|reduce apoptosis	NPA	HL60	NPA	NPA	NPA
1580	20668064	breast	breast cancer	NPA	miR-16	miR-16-5p	PPM1D	8493	NPA	suppress cell self-renewal|suppress cell growth|increase doxorubicin sensitivity	markedly downregulated in mammary tumor stem cells	MCF-7	NPA	NPA	tumor-suppressive
1581	20668041	pituitary	sporadic pituitary adenoma	NPA	miR-128a	miR-128-3p	WEE1	7465	NPA	inhibit cell proliferation	significantly overexpressed in NFA samples	HeLa	NPA	"A total of 57 pituitary tissue samples including 27 nonfunctional pituitary adenomas (NFAs), 15 GH-producing adenomas with or without prolactin overproduction, and 15 normal pituitary glands"	tumor-suppressive
1582	20668041	pituitary	sporadic pituitary adenoma	NPA	miR-155	miR-155-5p	WEE1	7465	NPA	inhibit cell proliferation	significantly overexpressed in NFA samples	HeLa	NPA	"A total of 57 pituitary tissue samples including 27 nonfunctional pituitary adenomas (NFAs), 15 GH-producing adenomas with or without prolactin overproduction, and 15 normal pituitary glands"	tumor-suppressive
1583	20668041	pituitary	sporadic pituitary adenoma	NPA	miR-516a-3p	miR-516a-3p	WEE1	7465	NPA	inhibit cell proliferation	significantly overexpressed in NFA samples	HeLa	NPA	"A total of 57 pituitary tissue samples including 27 nonfunctional pituitary adenomas (NFAs), 15 GH-producing adenomas with or without prolactin overproduction, and 15 normal pituitary glands"	tumor-suppressive
1584	20667897	brain	glioma	NPA	miR-326	miR-326	PKM	5315	NPA	induce apoptosis|reduce metabolic activity	NPA	NPA	NPA	NPA	tumor-suppressive
1585	20665731	brain	glioblastoma	NPA	miR-125a	miR-125a-5p	PDPN	10630	NPA	inhibit cell invasion|induce apoptosis|inhibit cell proliferation	downregulated in glioblastomas and also in CD133-positive cells	NPA	NPA	glioblastomas	tumor-suppressive
1586	20665731	brain	glioblastoma	NPA	miR-29b	miR-29b-3p	PDPN	10630	NPA	inhibit cell invasion|induce apoptosis|inhibit cell proliferation	downregulated in glioblastomas and also in CD133-positive cells	NPA	NPA	glioblastomas	tumor-suppressive
1587	20658525	ovary	ovarian cancer	NPA	miR-125b	miR-125b-5p	BCL3	602	NPA	induce cell cycle arrest|reduce cell proliferation|reduce clonal formation|reduce tumor formation	underexpressed in human OC specimens	NPA	nude mice	human OC specimens	tumor-suppressive
1588	20657750	prostate	prostate cancer	NPA	miR-29b	miR-29b-3p	MCL1|COL1A1|COL4A1	4170|1277|1282	DENND4A	inhibit tumor growth	NPA	NPA	NPA	NPA	tumor-suppressive
1589	20655737	liver	hepatocellular carcinoma	NPA	miR-193b	miR-193b-3p	CCND1|ETS1	595|2113	NPA	inhibit colony formation|inhibit tumor development|induce cell cycle arrest|inhibit cell migration|inhibit cell invasion	significantly down-regulated in most of the HCC tissues compared to the matching non-tumoural liver tissues	NPA	nude mice	HCC tissues and adjacent normal liver tissues	tumor-suppressive
1590	20651244	blood	diffuse large B-cell lymphoma	NPA	let-7b	let-7b-5p	PRDM1	639	NPA	NPA	overexpressed in DLBCL relative to normal GCB cells	NPA	NPA	a cohort of 25 primary DLBCL	NPA
1591	20647341	colorectum	colorectal cancer	5-fluorouracil	miR-192	miR-192-5p	NPA	NPA	NPA	reduce cell proliferation|inhibit cell cycle progression	NPA	NPA	NPA	NPA	tumor-suppressive
1592	20647341	colorectum	colorectal cancer	5-fluorouracil	miR-215	miR-215-5p	NPA	NPA	NPA	reduce cell proliferation|inhibit cell cycle progression	NPA	NPA	NPA	NPA	tumor-suppressive
1593	20644734	skin	melanoma	NPA	miR-148	miR-148a-3p|miR-148b-3p	MITF	4286	NPA	NPA	NPA	NPA	NPA	NPA	NPA
1594	20638779	pancreas	pancreatic adenocarcinoma	NPA	miR-27a	miR-27a-3p	SPRY2	10253	NPA	promote cell growth|promote colony formation|promote cell migration	NPA	NPA	NPA	NPA	oncogenic
1595	20628378	pancreas	pancreatic cancer	NPA	miR-520h	miR-520h	NPA	NPA	NPA	inhibit cell migration|inhibit cell invasion|reduce side population cells	NPA	PANC-1	NPA	NPA	tumor-suppressive
1596	20626035	breast	breast cancer	NPA	miR-16	miR-16-5p	ELAVL1	1994	NPA	NPA	inversely correlated with HuR protein level in human breast carcinoma	MDA-MB-231	NPA	human breast carcinoma tissues	NPA
1597	20624637	ovary	ovarian cancer	paclitaxel	miR-27a	miR-27a-3p	NPA	NPA	NPA	induce paclitaxel resistance|reduce paclitaxel-induced apoptosis	up-regulated in paclitaxel-resistant ovarian cancer cell line A2780/Taxol as compared with its parental line A2780	A2780	NPA	NPA	NPA
1598	20623644	nerve	neuroblastoma	NPA	miR-149*	miR-149-3p	AKT1|E2F1	207|1869	NPA	induce apoptosis	inversely correlated with E2F1 expressions in neuroblastoma samples	Be2C|HeLa	NPA	neuroblastoma samples	tumor-suppressive
1599	20620960	NPA	NPA	NPA	miR-200c	miR-200c-3p	PTPN13	5783	NPA	increase CD95-induced apoptosis	reduced expression during tumor progression	NPA	NPA	NPA	tumor-suppressive
1600	20619534	stomach	gastric cancer	NPA	miR-126	miR-126-3p	CRK	1398	NPA	inhibit cell growth|induce cell cycle G0/G1 arrest|inhibit cell migration|inhibit cell invasion|inhibit tumorigenicity|inhibit metastasis	"significantly down-regulated in gastric cancer tissues compared with matched normal tissues|associated with clinicopathological features, including tumour size, lymph node metastasis, local invasion and tumour-node-metastasis (TNM) stage"	SGC-7901	NPA	gastric cancer tissues and matched normal tissues	tumor-suppressive
1601	20618998	stomach	gastric carcinoma	NPA	miR-221	miR-221-3p	PTEN	5728	NPA	promote cell growth|promote cell invasion |reduce radiosensitivity	NPA	SGC7901	NPA	NPA	oncogenic
1602	20618998	stomach	gastric carcinoma	NPA	miR-222	miR-222-3p	PTEN	5728	NPA	promote cell growth|promote cell invasion |reduce radiosensitivity	NPA	SGC7901	NPA	NPA	oncogenic
1603	20610624	pancreas	pancreatic cancer	NPA	miR-96	miR-96-5p	KRAS	3845	NPA	induce apoptosis|decrease cell migration|decrease cell invasion|reduce tumor growth	downregulated or deleted in human clinical specimens	NPA	NPA	human clinical pancreatic cancer specimens	tumor-suppressive
1604	20607356	brain	glioblastoma	NPA	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	NPA	NPA	NPA	reduce cell proliferation|reduce cell migration|reduce tumor growth	NPA	U251|U87	nude mice	NPA	tumor-suppressive
1605	20603620	NPA	NPA	NPA	miR-185	miR-185-5p	SIX1	6495	NPA	reduce anchorage-independent cell growth|reduce cell migration|reduce tumor growth|increase TRAIL-mediated apoptosis	"decreased in ovarian cancers, pediatric renal tumors and multiple breast cancer cell lines"	NPA	NPA	NPA	tumor-suppressive
1606	20603000	NPA	NPA	NPA	miR-103	miR-103a-3p	DICER1	23405	NPA	promote cell migration|promote metastatis|induce epithelial-mesenchymal transition	positively associated with metastasis and poor outcome	NPA	NPA	human breast cancer tissues	oncogenic
1607	20603000	NPA	NPA	NPA	miR-107	miR-107	DICER1	23405	NPA	promote cell migration|promote metastatis|induce epithelial-mesenchymal transition	positively associated with metastasis and poor outcome	NPA	NPA	human breast cancer tissues	oncogenic
1608	20602797	liver	hepatocellular carcinoma	NPA	miR-183	miR-183-5p	PDCD4	27250	NPA	inhibit TGF-beta induced apoptosis	significantly up-regulated (twofold to 367-fold) in 17 samples compared with the matching nontumoral liver tissues	NPA	NPA	25 HCC samples	oncogenic
1609	20596961	blood	acute myeloid leukemia	NPA	miR-181b	miR-181b-5p	MAP3K10	4294	NPA	promote cell proliferation	highly expressed in acute myeloid leukemia (AML)	HL-60	NPA	acute myeloid leukemia (AML) patients	oncogenic
1610	20588276	prostate	prostate cancer	NPA	miR-145	miR-145-5p	NPA	NPA	DNA methylation	induce apoptosis|induce cell cycle G2/M arrest	lowly expressed in prostate cell lines compared with the normal cell line and in cancerous regions of human prostate tissue when compared with the matched adjacent normal	PC3|LNCaP|DU145|PWR-1E	NPA	cancerous regions of human prostate tissue and the matched adjacent normal	tumor-suppressive
1611	22966364	esophagus	esophageal squamous cell carcinoma	NPA	miR-34b	miR-34b-5p	NPA	NPA	NPA	increase cell growth	significantly higher in ESCC than that in the corresponding normal esophageal mucosa|more highly expressed in tumors with more advanced stages	NPA	NPA	88 ESCC patients	oncogenic
1612	20583868	pancreas	pancreatic carcinoma	NPA	miR-20a	miR-20a-5p	STAT3	6774	NPA	reduce cell proliferation|reduce cell invasion	NPA	BxPC-3|Panc-1|H6C7	NPA	NPA	tumor-suppressive
1613	20581857	prostate	prostate cancer	docetaxel	miR-21	miR-21-5p	PDCD4	27250	NPA	increase docetaxel resistance	NPA	PC3	NPA	NPA	NPA
1614	20579395	pancreas	pancreatic cancer	NPA	miR-200c	miR-200c-3p	NPA	NPA	NPA	promote cell proliferation|inhibit cell invasion	positively correlated with better survival rates	NPA	NPA	macro-dissected formalin-fixed paraffin-embedded (FFPE) tissue samples obtained from 99 patients who underwent pancreatectomy for pancreatic cancer	NPA
1615	20579385	cervix	cervical cancer	NPA	miR-124	miR-124-3p	NPA	NPA	DNA hypermethylation in cancer	inhibit cell migration|inhibit cell proliferation	reduced expressions significantly correlated with increased methylation levels in cervical tissue specimens	SiHa|CaSki|HeLa	NPA	139 cervical tissue specimens	tumor-suppressive
1616	20578129	liver	HBV+ hepatocellular carcinoma	NPA	miR-152	miR-152-3p	DNMT1	1786	NPA	decrease global DNA methylation	frequently down-regulated in HBV-related HCC tissues in comparison with adjacent noncancerous hepatic tissues|inversely correlated with DNMT1 mRNA expression in HBV-related HCCs	NPA	NPA	HBV-related HCC tissues and adjacent noncancerous hepatic tissues	tumor-suppressive
1617	20577838	blood	acute promyelocytic leukemia	all-trans-retinoid acid	miR-146a	miR-146a-5p	SMAD4	4089	NPA	NPA	NPA	NB4	NPA	NPA	NPA
1618	20576283	liver	hepatocellular carcinoma	NPA	miR-181a	miR-181a-5p	SPP1	6696	NPA	NPA	NPA	HepG2|Hep3B	NPA	NPA	NPA
1619	20574517	brain	medulloblastoma	NPA	miR-128a	miR-128-3p	BMI1	648	NPA	inhibit cell growth|change intracellular redox state|promote senescence	significantly down regulated in medulloblastoma|associated with normal neuronal differentiation	NPA	NPA	medulloblastoma tissues	tumor-suppressive
1620	20574151	breast	breast cancer	NPA	miR-520b	miR-520b	CD46	4179	NPA	increase complement-dependent cytotoxicity sensitivity	lower in the breast cell lines	HBL-100|MCF-7|LM-MCF-7|MDA-MB-231	NPA	NPA	NPA
1621	20574151	breast	breast cancer	NPA	miR-520e	miR-520e	CD46	4179	NPA	increase complement-dependent cytotoxicity sensitivity	lower in the breast cell lines	HBL-100|MCF-7|LM-MCF-7|MDA-MB-231	NPA	NPA	NPA
1622	20570349	blood	acute leukemia	NPA	miR-196a	miR-196a-5p	ERG	2078	NPA	NPA	NPA	NPA	NPA	NPA	NPA
1623	20570349	blood	acute leukemia	NPA	miR-196b	miR-196b-5p	ERG	2078	NPA	NPA	NPA	NPA	NPA	NPA	NPA
1624	20569443	lung	non-small cell lung cancer	NPA	miR-125a-3p	miR-125a-3p	NPA	NPA	NPA	inhibit cell invasion|inhibit cell migration	lower in NSCLC tissues	A549|SPC-A-1	NPA	NSCLC tissues	tumor-suppressive
1625	20569443	lung	non-small cell lung cancer	NPA	miR-125a-5p	miR-125a-5p	NPA	NPA	NPA	promote cell invasion|promote cell migration	lower in NSCLC tissues	A549|SPC-A-1	NPA	NSCLC tissues	tumor-suppressive
1626	20562918	NPA	NPA	NPA	miR-22	miR-22-3p	MYCBP	26292	NPA	inhibit cell proliferation|inhibit anchorage-independent cell growth	NPA	NPA	NPA	NPA	tumor-suppressive
1627	20562915	kidney	renal cancer	NPA	miR-23b	miR-23b-3p	PRODH	5625	NPA	reduce ROS|activate HIF signaling|reduce apoptosis	upregulated in renal cancer|negatively correlated with POX protein expressions in pairs of human renal carcinoma and normal tissues	NPA	NPA	pairs of human renal carcinoma and normal tissues	oncogenic
1628	20550523	nerve	malignant peripheral nerve sheath tumor	NPA	miR-10b	miR-10b-5p	NF1	4763	NPA	reduce cell proliferation|reduce cell migration|reduce cell invasion	up-regulated in primary Schwann cells isolated from NF1 neurofibromas and in cell lines and tumor tissues from malignant peripheral nerve sheath tumors (MPNSTs)	SK-ES-1|293T	NPA	tumor tissues from malignant peripheral nerve sheath tumors (MPNSTs)	tumor-suppressive
1629	20549700	bladder	bladder cancer	NPA	miR-125b	miR-125b-5p	E2F3	1871	NPA	suppress colony formation|suppress tumor development	significantly decreased in bladder cancer tissues and four bladder cancer cell lines|inversely correlated with E2F3 protein levels in bladder cancer tissues	NPA	nude mice	bladder cancer tissues	tumor-suppressive
1630	20548334	stomach	gastric cancer	NPA	miR-375	miR-375	JAK2	3717	NPA	inhibit cell proliferation	greatly downregulated in gastric cancer tissues|significantly decreased in more than 90% of primary gastric cancers compared with their nontumor counterparts from patients undergoing gastric resection|inversely correlated with JAK2 protein level in gastric cancer	NPA	NPA	paired gastric cancer and their adjacent nontumor tissues	tumor-suppressive
1631	20543867	breast	breast cancer	NPA	miR-661	miR-661	PVRL1|STARD10	5818|10809	NPA	promote cell invasion|promote epithelial-mesenchymal transition	NPA	MCF7	NPA	NPA	oncogenic
1632	20542001	NPA	NPA	NPA	miR-504	miR-504-5p	TP53	7157	NPA	promote tumorigenecity	NPA	NPA	NPA	NPA	oncogenic
1633	20535543	breast	ER¦Á+ breast cancer	NPA	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	ESR1	2099	NPA	inhibit cell proliferation|induce apoptosis	down-regulated in human breast cancer tissues at stages of DCIS and IDC compared to benign stage|inversely correlated with ESR1 expression in FFPE tissues	MCF7	NPA	"formalin-fixed paraffin-embedded (FFPE) breast tissues, which included benign (n = 13), ductal carcinoma in situ (DCIS) (n = 16), and invasive ductal carcinoma (IDC) (n = 15)"	tumor-suppressive
1634	20525879	liver	hepatocellular carcinoma	NPA	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	MYC|HMGA2	4609|8091	LIN28B	NPA	NPA	HA22T	NOD/SCID mice	NPA	tumor-suppressive
1635	20518884	liver	hepatocellular carcinoma	NPA	miR-92a	miR-92a-3p	NPA	NPA	NPA	promote cell proliferation	highly expressed in HCCs|decreased in the plasmas from HCC patients compared with that from the healthy donors	NPA	NPA	HCC tissues and plasmas	tumor-suppressive
1636	20514462	brain	glioma	NPA	miR-21	miR-21-5p	NPA	NPA	NPA	promote cell proliferation|inhibit apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
1637	20514450	stomach	gastric cancer	NPA	miR-663	miR-663a	NPA	NPA	NPA	induce morphology changes|inhibit cell proliferation|induce mitotic catastrophe	downregulated in human gastric cancer cell lines unlike in normal cells	BGC823|SNU5	NPA	NPA	tumor-suppressive
1638	20514397	breast	breast cancer	NPA	miR-1226	miR-1226-3p	MUC1	4582	NPA	increase reactive oxygen species|reduce the mitochondrial transmembrane potential|decrease cell survival	expressed in human breast cancer cell lines and non-malignant mammary epithelial cells	NPA	NPA	NPA	tumor-suppressive
1639	20514023	breast	breast cancer	NPA	miR-200c~141	CLUSTER:miR-200c~141	NPA	NPA	NPA	weakly reduce EGF-driven invasion|induce cell cycle G1 arrest	NPA	NPA	NPA	NPA	tumor-suppressive
1640	20514023	breast	breast cancer	NPA	miR-200ba~429	CLUSTER:miR-200ba~429	PLCG1	5335	NPA	strongly reduce EGF-driven invasion|induce cell cycle G2/M arrest and reduce G1 population	NPA	NPA	NPA	NPA	tumor-suppressive
1641	20510161	stomach	gastric cancer	NPA	miR-331-3p	miR-331-3p	E2F1	1869	NPA	block cell cycle G1/S transition|reduce colony formation|reduce cell growth	down-regulated in gastric cancer cell lines	SGC-7901|AGS	NPA	NPA	tumor-suppressive
1642	20507733	stomach	gastric cancer	NPA	miR-29	miR-29a-3p|miR-29b-3p|miR-29c-3p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell migration	low expression in SGC7901 and BGC823 gastric cancer cells	SGC7901|BGC823	NPA	NPA	tumor-suppressive
1643	20505989	breast	breast cancer	NPA	miR-17-5p	miR-17-5p	HBP1	26959	NPA	promote cell invasion|promote cell migration	highly expressed in high-invasive MDA-MB-231 breast cancer cells but not in low-invasive MCF-7 breast cancer cells	MCF7|MDA-MB-231	NPA	NPA	oncogenic
1644	20505319	colorectum	colorectal cancer	NPA	miR-133b	miR-133b	MET	4233	NPA	inhibit cell proliferation|induce apoptosis	greatly downregulated in human CRC cells compared to normal colon cells|significant in six of eight human CRC tissues compared with adjacent normal tissues	SW-620|HT-29	NPA	eight human CRC tissues and adjacent normal tissues	tumor-suppressive
1645	20502458	bone and muscle	rhabdomyosarcoma	NPA	miR-206	miR-206	NPA	NPA	NPA	inhibit cell growth|inhibit cell migration|induce apoptosis	expressed lower in RMSs compared with skeletal muscle but generally higher than in other normal tissues|negatively correlated with poor overall survival|an independent predictor of shorter survival in metastatic embryonal and alveolar cases without PAX3/7-FOXO1 fusion genes|negatively significantly correlated with high SIOP stage and the presence of metastases at diagnosis	NPA	NPA	"163 and 84 primary paediatric RMSs, plus control tissues"	tumor-suppressive
1646	20501828	liver	hepatocellular carcinoma	NPA	miR-199a-3p	miR-199a-3p	MTOR	2475	NPA	induce cell cycle G1 arrest|inhibit cell invasion|enhance susceptibility to hypoxia|increase doxorubicin-induced apoptosis	negatively associated with shorter time to recurrence after HCC resection in patients|inversely correlated with MTOR expression in human HCC tissues	NPA	NPA	human HCC tissues	tumor-suppressive
1647	20498642	breast	breast tumor-initiating cells	NPA	miR-30	miR-30a-5p|miR-30b-5p|miR-30c-5p|miR-30d-5p|miR-30e-5p	UBE2I|ITGB3	7329|3690	NPA	inhibit cell self-renewal capacity|induce apoptosis|reduce tumorigenesis and lung metastasis	breast tumor-initiating cells (reduced in BT-ICs)	NPA	nonobese diabetic/severe combined immunodeficient mice	NPA	tumor-suppressive
1648	20498629	NPA	NPA	hypoxia	miR-210	miR-210-3p	ISCU|COX10	23479|1352	NPA	decrease mitochondrial function|upregulate the glycolysis|activate the generation of reactive oxygen species	NPA	NPA	NPA	NPA	NPA
1649	20485139	esophagus	esophageal squamous cell carcinoma	NPA	miR-296	miR-296-5p	NPA	NPA	NPA	promote cell growth|reduce ADR-induced apoptosis	"increasingly up-regulated in esophagitis tissues, esophageal carcinoma in situ, and esophageal squamous cell cancer tissues|negatively correlated with long-term survivors with node-positive disease from those dying within 20 months by predicting survival (median, 23.7 vs. 12.9 months)"	NPA	NPA	"esophagitis tissues, esophageal carcinoma in situ, and esophageal squamous cell cancer tissues"	oncogenic
1650	20484043	breast	breast cancer	NPA	miR-92	miR-92a-3p|miR-92b-3p	ESR2	2100	NPA	NPA	significantly negatively correlated with both ESR2 mRNA and protein	MCF-7	NPA	a cohort of primary breast tumors	NPA
1651	20484036	adrenal gland	childhood adrenocortical tumor	NPA	miR-100	miR-100-5p	IGF1R|MTOR	3480|2475	NPA	NPA	differentially downregulated in childhood adrenocortical tumors (ACT)	NPA	NPA	NPA	NPA
1652	20484036	adrenal gland	childhood adrenocortical tumor	NPA	miR-99	miR-99a-5p|miR-99b-5p	IGF1R|MTOR	3480|2475	NPA	NPA	differentially downregulated in childhood adrenocortical tumors (ACT)	NPA	NPA	NPA	NPA
1653	20480266	bone and muscle	osteosarcoma	NPA	miR-21	miR-21-5p	RECK	8434	NPA	promote cell invasion|promote cell migration	significantly overexpressed in osteosarcoma tissues|negatively correlated with RECK protein in human osteosarcoma tissues	MG-63	NPA	human osteosarcoma tissues	oncogenic
1654	20480203	skin	malignant melanoma	NPA	miR-196a	miR-196a-5p	HOXB7	3217	NPA	NPA	strongly reduced expression in melanoma cells compared to healthy melanocytes	NPA	NPA	NPA	NPA
1655	20478051	prostate	prostate cancer	NPA	miR-101	miR-101-3p	EZH2	2146	AR|HIF1A|ARNT	reduce cell invasion|inhibit cell migration|regulate cell proliferation	NPA	PC-3|DU145|LNCaP	NPA	NPA	tumor-suppressive
1656	20473940	colorectum	colorectal cancer	NPA	miR-137	miR-137	CDC42	998	NPA	inhibit cell proliferation|induce G1 cell cycle arrest|inhibit cell invasion	inversely correlated with Cdc42 expression in colorectal cancer cell lines	NPA	NPA	NPA	tumor-suppressive
1657	20470934	brain	glioma	NPA	miR-34a	miR-34a-5p	SIRT1	23411	NPA	inhibit cell growth|induce cell cycle G0/G1 arrest|induce apoptosis|reduce cell migration|reduce cell invasion	markedly reduced in p53-mutant cells U251 compared with A172 and SHG-44 cells expressing wild-type p53 and normal brains	U251|A172|SHG-44	NPA	NPA	tumor-suppressive
1658	20470754	lung	lung cancer	NPA	miR-301	miR-301a-3p	MEOX2	4223	NPA	increase mitotic index|inhibit colony formation	NPA	A549	NPA	NPA	oncogenic
1659	20466878	bone and muscle	rhabdomyosarcoma	NPA	miR-1	miR-1	NPA	NPA	NPA	inhibit cell growth|induce promyogenic differentiation	drastically reduced in representative cell lines from each major rhabdomyosarcoma subtype (embryonal and alveolar)	NPA	NPA	NPA	tumor-suppressive
1660	20466878	bone and muscle	rhabdomyosarcoma	NPA	miR-133a	miR-133a-3p	NPA	NPA	NPA	inhibit cell growth	drastically reduced in representative cell lines from each major rhabdomyosarcoma subtype (embryonal and alveolar)	NPA	NPA	NPA	tumor-suppressive
1661	20463022	mesothelium	mesothelioma	NPA	miR-31	miR-31-5p	NPA	NPA	genomic region 9p21.3 loss	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion|inhibit clonogenicity|inhibit cell cycle	hardly expressed in malignant mesothelioma (MM) cell lines derived from patients with more aggressive disease	NPA	NPA	NPA	tumor-suppressive
1662	20460403	NPA	NPA	NPA	miR-21	miR-21-5p	RHOB	388	NPA	promote cell migration|promote cell invasion|promote cell elongation	NPA	Huh-7|HepG2|MDA-MB-231	NPA	NPA	oncogenic
1663	20460378	breast	breast cancer	paclitaxel	miR-125b	miR-125b-5p	BAK1	578	NPA	reduce Taxol-induced cytotoxicity|reduce Taxol-induced apoptosis|increase taxol resistance	up-regulated in Taxol-resistant cancer cells	NPA	NPA	NPA	NPA
1664	20458444	ovary	ovarian cancer	NPA	miR-20a	miR-20a-5p	APP	351	NPA	enhance cell long-term proliferation|increase cell invasion	NPA	OVCAR3	NPA	NPA	oncogenic
1665	20447717	liver	hepatocellular carcinoma	NPA	miR-21	miR-21-5p	PTEN|PDCD4|RECK	5728|27250|8434	NPA	promote cell proliferation|inhibit apoptosis|promote cell invasion	elevated in hepatocellular carcinoma	NPA	NPA	paired HCC tissues	oncogenic
1666	20447714	liver	HBV+ hepatocellular carcinoma	Hepatitis B virus X protein (HBx)	let-7a	let-7a-5p	STAT3	6774	NPA	inhibit cell proliferation	significantly inversely correlated with HBx expression in HCC patients	HepG2	NPA	normal liver as well as paired HCC-tumor and adjacent non-tumorous liver	tumor-suppressive
1667	20445018	blood	myeloproliferative neoplasm	NPA	miR-28	miR-28-5p	MPL|E2F6	4352|1876	NPA	inhibit terminal differentiation	overexpressed in platelets of a fraction of MPN patients and expressed at constant low levels in platelets from healthy subjects	NPA	NPA	MPN patients and healthy subjects	oncogenic
1668	20444703	breast	breast cancer	NPA	miR-10b	miR-10b-5p	TIAM1	7074	NPA	inhibit cell migration|inhibit cell invasion	NPA	NPA	NPA	NPA	tumor-suppressive
1669	20444294	liver	hepatocellular carcinoma	12-O-tetradecanoylphorbol 13-acetate (TPA)	miR-101	miR-101-3p	EZH2|EED	2146|8726	PRKCA|MAPK1	NPA	down-regulated in human hepatoma tissues|induced by TPA	HepG2	NPA	20 pairs of human hepatoma tissues	tumor-suppressive
1670	20440510	head and neck	nasopharyngeal carcinoma	5-azacytidine|zebularine	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	NPA	NPA	NPA	inhibit cell proliferation	reduced in nasopharyngeal carcinoma cells in comparison with the normal nasopharyngeal cells	NP69|NP460|HK1|HONE1	NPA	NPA	tumor-suppressive
1671	20436681	NPA	NPA	hypoxia	miR-210	miR-210-3p	ISCU	23479	NPA	induce reactive oxygen species	NPA	NPA	NPA	NPA	NPA
1672	22966344	pancreas	pancreatic cancer	NPA	miR-16	miR-16-5p	BCL2	596	NPA	reduce cell survival	NPA	NPA	NPA	NPA	tumor-suppressive
1673	20423907	liver	hepatocellular carcinoma	NPA	miR-372	miR-372-3p	PRKACB	5567	HULC	NPA	NPA	NPA	NPA	NPA	NPA
1674	20420807	lung	lung adenocarcinoma	NPA	miR-182	miR-182-5p	RGS17	26575	NPA	inhibit cell proliferation|inhibit anchorage-independent cell growth	NPA	NPA	NPA	NPA	tumor-suppressive
1675	20418948	prostate	prostate cancer	NPA	let-7a	let-7a-5p	E2F2|CCND2	1870|894	NPA	inhibit cell proliferation|induce cell cycle G1/S arrest|inhibit tumor growth	decreased in resected prostate cancer samples and prostate cancer cell lines	PC3|LNCaP	xenograft models	resected prostate cancer samples	tumor-suppressive
1676	20409325	nerve	neuroblastoma	NPA	miR-184	miR-184	AKT2	208	MYCN	induce apoptosis|inhibit cell proliferation	NPA	NPA	NPA	NPA	tumor-suppressive
1677	20406904	breast	breast cancer	NPA	miR-17	miR-17-5p	IL8	3576	NPA	inhibit cell migration|inhibit cell invasion	reduced in highly invasive breast cancer cell lines and node-positive breast cancer specimens	MCF7|MDA-MB-231	NPA	NPA	tumor-suppressive
1678	20406904	breast	breast cancer	NPA	miR-20	miR-20a-5p	IL8	3576	NPA	inhibit cell migration|inhibit cell invasion	reduced in highly invasive breast cancer cell lines and node-positive breast cancer specimens	MCF7|MDA-MB-231	NPA	NPA	tumor-suppressive
1679	20406806	prostate	prostate cancer	paclitaxel	miR-148a	miR-148a-3p	RPS6KA5	9252	NPA	inhibit cell growth|inhibit cell migration|inhibit cell invasion|increase paclitaxel sensitivity	lower in PC3 and DU145 hormone-refractory prostate cancer cells in comparison to PrEC normal human prostate epithelial cells and LNCaP hormone-sensitive prostate cancer cells	PC3|DU145|PrEC|LNCaP	NPA	NPA	tumor-suppressive
1680	20404570	lung	lung adenocarcinoma	NPA	miR-129	miR-129-5p	CDK6	1021	NPA	induce cell cycle G1 arrest	NPA	NPA	mouse	NPA	tumor-suppressive
1681	20390345	breast	breast cancer	doxorubicin	miR-200b	miR-200b-3p	FTH1	2495	NPA	increase doxorubicin sensitivity	NPA	MDA-MB-231	NPA	NPA	NPA
1682	20388878	breast	breast cancer	NPA	miR-206	miR-206	MET	4233	NPA	inhibit cell proliferation of ER¦Á+ cells	NPA	NPA	NPA	NPA	tumor-suppressive
1683	20388878	breast	breast cancer	NPA	miR-221	miR-221-3p	FOXO3	2309	ESR1	increase cell proliferation of ER¦Á+ cells	NPA	NPA	NPA	NPA	oncogenic
1684	20388878	breast	breast cancer	NPA	miR-222	miR-222-3p	FOXO3	2309	ESR1	increase cell proliferation of ER¦Á+ cells	NPA	NPA	NPA	NPA	oncogenic
1685	20388802	lung	non-small cell lung cancer	NPA	miR-212	miR-212-3p	PEA15	8682	NPA	increase TRAIL-induced cell death	rarely expressed in NSCLCs|inversely correlated PEA15 expression in NSCLSs	NPA	NPA	NSCLC tissues	tumor-suppressive
1686	20388800	NPA	NPA	NPA	miR-483-3p	miR-483-3p	BBC3	27113	NPA	reduce apoptosis|promote tumorigenicity	"overexpressed in 100% of Wilms' tumors|highly or even extremely highly expressed in colon, breast, and liver cancers in approximately 30% of the cases"	HepG2	NPA	"Wilms' tumors and colon, breast, and liver cancers"	oncogenic
1687	20385359	blood	KIT-driven acute myeloid leukemia	NPA	miR-29b	miR-29b-3p	SP1	6667	MYC|SP1|NF-¦ÊB|KIT|HDAC1	NPA	NPA	NPA	NPA	NPA	NPA
1688	20382698	breast	breast cancer	NPA	miR-27a	miR-27a-3p	NPA	NPA	NPA	reduce cell cycle G0/G1 arrest|promote E2-induced G/S transition	NPA	MCF-7	NPA	NPA	NPA
1689	20381459	stomach	gastric cancer	NPA	miR-650	miR-650	ING4	51147	NPA	promote tumorigenesis|promote cell proliferation	NPA	NPA	NPA	NPA	oncogenic
1690	20372864	liver	hepatocellular carcinoma	taxol	miR-512-3p	miR-512-3p	CFLAR	8837	NPA	promote taxol-induced apoptosis	NPA	HepG2	NPA	NPA	tumor-suppressive
1691	20371610	breast	breast cancer	NPA	miR-155	miR-155-5p	FOXO3	2309	NPA	promote cell surivival|induce chemoresistance|inhibit apoptosis	frequently up-regulated in breast cancer|inversely correlated with FOXO3 expression in a panel of breast cancer cell lines and tumors	NPA	NPA	breast cancer tissues	oncogenic
1692	20369013	head and neck	head and neck squamous cell carcinoma	NPA	miR-204	miR-204-5p	NPA	NPA	NPA	reduce cell adhesion|reduce cell migration|reduce cell invasion|reduce lung metastasis	NPA	NPA	NPA	NPA	tumor-suppressive
1693	20364114	liver	HBV+ hepatocellular carcinoma	NPA	miR-602	miR-602	NPA	NPA	NPA	inhibit apoptosis|promote cell proliferation	"highly expressed in chronic HBV hepatitis, liver cirrhosis and HCC"	HepG2|HepG2.2.15|HepG2-HBX	NPA	"chronic HBV hepatitis, liver cirrhosis and HCC samples"	oncogenic
1694	20354523	ovary	ovarian cancer	NPA	let-7f	let-7f-5p	KLK10	5655	decrease cell proliferation	NPA	NPA	NPA	NPA	NPA	tumor-suppressive
1695	20354523	ovary	ovarian cancer	NPA	miR-224	miR-224-5p	KLK10	5655	NPA	decrease cell proliferation	NPA	NPA	NPA	NPA	tumor-suppressive
1696	20354523	ovary	ovarian cancer	NPA	miR-516a	miR-516a-5p	KLK10	5655	decrease cell proliferation	NPA	NPA	NPA	NPA	NPA	tumor-suppressive
1697	20354188	breast	breast cancer	NPA	miR-155	miR-155-5p	SOCS1	8651	NPA	promote cell proliferation|promote formation of soft agar foci|promote tumor development	inversely correlated with SOCS1 expression in breast cancer cell lines as well as in a subset of primary breast tumors	NPA	nude mice	breast cancer tissues	oncogenic
1698	20353999	prostate	prostate cancer	NPA	miR-143	miR-143-3p	MYO6	4646	NPA	NPA	reduced in primary prostate cancers compared with noncancer prostate tissues	NPA	NPA	primary prostate cancers and noncancer prostate tissues	NPA
1699	20353999	prostate	prostate cancer	NPA	miR-145	miR-145-5p	MYO6	4646	NPA	NPA	reduced in primary prostate cancers compared with noncancer prostate tissues	NPA	NPA	primary prostate cancers and noncancer prostate tissues	NPA
1700	20351277	colorectum	colorectal cancer	NPA	miR-155	miR-155-5p	MLH1|MSH2|MSH6	4292|4436|2956	NPA	induce a mutator phenotype|induce microsatellite instability	overexpression in a number of MSI tumors with unknown cause of MMR inactivation|inversely correlated with MLH1 or MSH2 proteins in human colorectal cancer	NPA	NPA	colorectal cancer tissues	NPA
1701	20351093	ovary	ovarian cancer	NPA	miR-34a	miR-34a-5p	NOTCH1|JAG1	4851|182	NPA	suppress cell invasion	NPA	HeLa|SiHa|C4I|C33a|CaSki|BeWo|JAR	NPA	NPA	tumor-suppressive
1702	20347499	liver	hepatocellular carcinoma	sorafenib	let-7c	let-7c-5p	BCL2L1	598	NPA	promote sorafenib-induced apoptosis	downregulated in Huh7 hepatoma cells in comparison with primary human hepatocytes	Huh7|HepG2	NPA	NPA	tumor-suppressive
1703	20347499	liver	hepatocellular carcinoma	sorafenib	let-7g	let-7g-5p	BCL2L1	598	NPA	promote sorafenib-induced apoptosis	downregulated in Huh7 hepatoma cells in comparison with primary human hepatocytes	Huh7|HepG2	NPA	NPA	tumor-suppressive
1704	20346171	breast	breast cancer	NPA	miR-21	miR-21-5p	TIMP3	7078	NPA	promote cell invasion	overexpressed in 25 breast cancer tissues in comparison with matched normal breast epithelium|closely correlated incidence of lymph node metastasis|inversely correlated TIMP3 protein levels in breast cancer cell lines	NPA	NPA	32 matched breast cancer and normal breast tissues	oncogenic
1705	20338660	liver	hepatocellular carcinoma	NPA	let-7g	let-7g-5p	COL1A2	1278	NPA	inhibit cell migration|inhibit cell growth	significantly lower in metastatic HCCs compared to metastasis-free HCCs|negatively predictor of poor survival in HCC patients|inversely correlated with COL1A2 expression in HCC clinical specimens	NPA	NPA	metastatic HCCs and metastasis-free HCCs	tumor-suppressive
1706	20332243	prostate	prostate cancer	NPA	miR-145	miR-145-5p	BNIP3	664	TP53	reduce cell growth|increase cell death	significantly decreased in prostate cancer|negatively associated with unfavorable outcome	PC-3|DU145	NPA	prostate cancer (n = 134) and benign prostate (n = 83) tissue sample	tumor-suppressive
1707	20331975	stomach	gastric cancer	NPA	miR-129	miR-129-5p	SOX4	6659	NPA	induce apoptosis	epigenetic silenced in gastric cancer|inversely associated with SOX4 expression in gastric cancer	NPA	NPA	gastric cancer tissues	tumor-suppressive
1708	20309945	liver	hepatocellular carcinoma	NPA	let-7g	let-7g-5p	MYC	4609	NPA	inhibit cell proliferation	"markedly lowered in the HepG2, Hep3B and Huh7 cells, yet higher in the Bel-7404 HCC cell line"	HepG2|Hep3B|Huh7|Bel-7404	NPA	NPA	tumor-suppressive
1709	20308559	colorectum	colon cancer	NPA	miR-107	miR-107	ARNT	405	TP53	inhibit hypoxic signaling|suppress tumor angiogenesis|suppress tumor growth	inversely correlated with ARNT expression in human clinical colon cancer specimens	NPA	mice	human clinical colon cancer specimens	tumor-suppressive
1710	20305691	brain	glioblastoma	NPA	miR-17~92	CLUSTER:miR-17~92	CTGF	1490	NPA	inhibit apoptosis|promote cell proliferation	significantly higher in primary astrocytic gliomas relative to those of normal brain|significantly increased with tumor grade progression	NPA	NPA	primary astrocytic gliomas (n=82) and those of normal brain (n=8)	oncogenic
1711	20305651	liver	hepatocellular carcinoma	NPA	miR-151	miR-151a-5p	ARHGDIA	396	genomic region 8q24.3 amplification	increase cell migration|increase cell invasion	frequently amplified and correlated with intrahepatic metastasis of HCC	NPA	NPA	HCC tissues	oncogenic
1712	20305372	NPA	NPA	NPA	miR-519	miR-519a-3p|miR-519b-3p|miR-519c-3p|miR-519d-3p|miR-519e-3p	NPA	NPA	NPA	reduce tumorigenesis	markedly reduced in cancer tissues when compared with healthy tissues	NPA	athymic mice	"pairs of cancer and adjacent healthy tissues from ovary, lung, and kidney"	tumor-suppressive
1713	20304954	skin	melanoma	NPA	miR-193b	miR-193b-3p	CCND1	595	NPA	repress cell proliferation	significantly down-regulated in the melanoma tissues	Malme-3M	NPA	tissue samples from benign nevi and metastatic melanomas	tumor-suppressive
1714	20300657	stomach	gastric cancer	NPA	miR-218	miR-218-5p	ROBO1	6091	NPA	inhibit cell invasion|inhibit metastasis	decreased in metastatic GC	NPA	NPA	gastric cancer tissues	tumor-suppressive
1715	20237410	lung	lung cancer	NPA	miR-31	miR-31-5p	LATS2|PPP2R2A	26524|5520	NPA	increase cell growth	prominently overexpressed in lung cancers in paired normal-malignant lung tissues from mice and humans|inversely correlated with LATS2/PPP2R2A in mouse and human lung cancers	NPA	mice	paired normal-malignant lung tissues	oncogenic
1716	20233879	NPA	NPA	NPA	miR-519c	miR-519c-3p	HIF1A	3091	HGF	suppress tumor angiogenesis|suppress tumor growth|suppress metastasis	correlated with better prognosis in cancer patients	NPA	mice	cancer patients	tumor-suppressive
1717	20232393	head and neck	tongue squamous cell carcinoma	NPA	miR-138	miR-138-5p	RHOC|ROCK2	389|9475	NPA	inhibit cell migration|inhibit cell invasion	NPA	NPA	NPA	NPA	tumor-suppressive
1718	20227367	brain	glioma	glucose	miR-451	miR-451a	CAB39	51719	NPA	promote cell growth in high glucose|increase glucose deprivation sensitivity|inhibit cell migration in low glucose	highly expressed in abundant glucose and decreased in low glucose|associated with shorter survival in glioblastoma patients	NPA	NPA	glioblastoma patients	oncogenic
1719	20226166	liver	hepatocellular carcinoma	NPA	miR-375	miR-375	YAP1	10413	NPA	inhibit cell proliferation|inhibit cell invasion	significantly down-regulated in the tumor versus adjacent non-tumor tissues of HCC patients	NPA	NPA	tumor versus adjacent non-tumor tissues of 48 HCC patients	tumor-suppressive
1720	20223231	lung	non-small cell lung cancer	NPA	miR-21	miR-21-5p	PTEN	5728	NPA	increase cell growth|increase cell invasion	overexpressed in tumor tissues relative to adjacent non-tumor tissues	NPA	NPA	20 paired NSCLC and adjacent non-tumor lung tissues	oncogenic
1721	20215506	stomach	gastric carcinoma	NPA	miR-375	miR-375	YWHAZ	7534	NPA	reduce cell viability|induce caspase-mediated apoptosis	most downregulated in gastric carcinoma	NPA	NPA	gastric carcinoma samples	tumor-suppressive
1722	20214878	NPA	NPA	12-O-tetradecanoylphorbol-13-acetate (TPA)	miR-22	miR-22-3p	MAX	4149	NPA	inhibit cell growth|induce cell cycle G1 arrest	NPA	HL-60	NPA	NPA	tumor-suppressive
1723	20209605	liver	hepatocellular carcinoma	NPA	miR-17-5p	miR-17-5p	NPA	NPA	NPA	promote cell proliferation|promote cell migration	overexpressed in hepatocellular carcinoma (HCC)	NPA	NPA	NPA	oncogenic
1724	20203269	blood	chronic lymphocytic leukemia	NPA	miR-221	miR-221-3p	NPA	NPA	NPA	promote cell proliferation|promote fast cell cycle progression into S phase	increased in leukemic cells obtained from peripheral blood (PB) of 38 patients with CLL|increased in different anatomic compartments (lymph nodes or bone marrow) of the same patients compared with PB	MEC1	NPA	38 patients with CLL	oncogenic
1725	20203269	blood	chronic lymphocytic leukemia	NPA	miR-222	miR-222-3p	NPA	NPA	NPA	promote cell proliferation|promote fast cell cycle progression into S phase	increased in leukemic cells obtained from peripheral blood (PB) of 38 patients with CLL|increased in different anatomic compartments (lymph nodes or bone marrow) of the same patients compared with PB	MEC1	NPA	38 patients with CLL	oncogenic
1726	20198336	brain	glioma	NPA	miR-221	miR-221-3p	NPA	NPA	NPA	promote cell proliferation|promote cell invasion|promote tumor growth|activate Akt signaling	NPA	NPA	a subcutaneous mouse model	NPA	oncogenic
1727	20198336	brain	glioma	NPA	miR-222	miR-222-3p	NPA	NPA	NPA	promote cell proliferation|promote cell invasion|promote tumor growth|activate Akt signaling	NPA	NPA	a subcutaneous mouse model	NPA	oncogenic
1728	20198305	head and neck	laryngeal carcinoma	NPA	miR-34c	miR-34c-5p	MET	4233	NPA	inhibit cell growth|inhibit cell invasion	down-regulated in laryngeal carcinoma|inversely correlated with MET expression in 10 paired fresh samples from tumor tissues and adjacent normal tissues	NPA	NPA	10 paired fresh samples from tumor tissues and adjacent normal tissues	tumor-suppressive
1729	20195546	NPA	NPA	NPA	miR-24	miR-24-3p	FAF1	11124	NPA	induce apoptosis	NPA	DU-145|HGC-27|MGC-803|HeLa	NPA	NPA	tumor-suppressive
1730	20190740	blood	Notch-induced T-cell acute lymphoblastic leukemia	NPA	miR-19	miR-19a-3p	BCL2L11|PRKAA1|PPP2R5E|PTEN	10018|5562|5529|5728	NPA	promote leukaemogenesis	NPA	NPA	NPA	NPA	oncogenic
1731	21779448	breast	breast cancer	NPA	miR-181b	miR-181b-5p	CBX7	23492	HMGA1|CBX7	promote cell cycle progression	overexpressed in several malignant neoplasias including breast carcinomas	MCF7	NPA	breast carcinomas samples	oncogenic
1732	20186752	liver	hepatocellular carcinoma	NPA	miR-34a	miR-34a-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell migration|inhibit cell invasion	NPA	HepG2	NPA	NPA	tumor-suppressive
1733	20180843	breast	ER¦Á+ breast cancer	NPA	miR-22	miR-22-3p	ESR1	2099	NPA	inhibit cell growth	significantly inversely associated with ESR1 protein expression in five breast cancer cell lines and 23 clinical biopsies|frequently downregulated in ERalpha-positive human breast cancer cell lines and clinical samples	HEK-293T|MCF-7|MDA-MB-231	NPA	23 clinical breast cancer biopsies	tumor-suppressive
1734	20180642	kidney	renal cell carcinoma	NPA	let-7f	let-7f-5p	KLK10	5655	NPA	NPA	NPA	ACHN	NPA	NPA	NPA
1735	20179198	ovary	ovarian cancer	NPA	miR-31	miR-31-5p	NPA	NPA	NPA	inhibit cell proliferation|induce apoptosis	the most underexpressed miRNA in serous ovarian cancer	OVCAR8|OVCA433|SKOV3|HEY|OVSAYO	NPA	NPA	tumor-suppressive
1736	20176475	stomach	gastric cancer	NPA	miR-130b	miR-130b-3p	NPA	NPA	NPA	increase cell viability|reduce cell death	significantly higher in 15 gastric tumours compared to matched normal tissue	NPA	NPA	15 gastric tumours and matched normal tissue	oncogenic
1737	20173740	breast	breast cancer	NPA	miR-9	miR-9-5p	CDH1	51343	MYC|MYCN	increase cell motility|increase cell invasion|increase tumor angiogenesis	upregulated in breast cancer cells|correlated with tumour grade and metastatic status in human cancers	NPA	mice	breast cancer tissues	oncogenic
1738	20162574	NPA	NPA	vincristine|cisplatin	miR-181b	miR-181b-5p	BCL2	596	NPA	increase drug sensitivity|induce drug-induced apoptosis	downregulated in multidrug-resistant cancer cells	A549|SGC7901	NPA	NPA	tumor-suppressive
1739	20160723	bladder	bladder cancer	NPA	miR-133a	miR-133a-3p	FSCN1	6624	NPA	inhibit cell viability	NPA	NPA	NPA	NPA	tumor-suppressive
1740	20160723	bladder	bladder cancer	NPA	miR-145	miR-145-5p	FSCN1	6624	NPA	inhibit cell viability	markedly repressed in the tumour lesion	NPA	NPA	NPA	tumor-suppressive
1741	20150764	NPA	NPA	NPA	miR-122	miR-122-5p	NPA	NPA	NPA	inhibit cell growth|induce apoptosis|induce cell cycle arrest	NPA	HepG2|Hep3B|Huh7|PLC/PRF/5|NCI-H460|HeLa	NPA	NPA	tumor-suppressive
1742	20148895	blood	leukemia	arsenic trioxide	miR-21	miR-21-5p	PDCD4	27250	NPA	promote cell growth|reduce apoptosis|reduce cell cycle G1 arrest	NPA	K562	NPA	NPA	oncogenic
1743	20146264	liver	cholangiocarcinoma	NPA	miR-148a	miR-148a-3p	DNMT1	1786	IL6	reduce cell proliferation	decreased in cholangiocarcinoma cells	NPA	NPA	NPA	tumor-suppressive
1744	20146264	liver	cholangiocarcinoma	NPA	miR-152	miR-152-3p	DNMT1	1786	IL6	reduce cell proliferation	decreased in cholangiocarcinoma cells	NPA	NPA	NPA	tumor-suppressive
1745	20145132	head and neck	head and neck squamous cell carcinoma	NPA	miR-31	miR-31-5p	HIF1AN	55662	NPA	increase tumor growth	most markedly upregulated in HNSCC tissues|inversely correlated with HIF1AN expression in tumor tissues	NPA	tumor xenografts	HNSCC tissues	tumor-suppressive
1746	20143188	blood	acute promyelocytic leukemia	arsenic trioxide	miR-21	miR-21-5p	PDCD4	27250	NPA	promote cell growth|reduce apoptosis|reduce cell cycle G1 arrest|induce ATO resistance	NPA	HL60|K562	NPA	NPA	oncogenic
1747	20141427	blood	chronic myelogenous leukemia	NPA	miR-21	miR-21-5p	PDCD4	27250	NPA	promote cell migration|reduce apoptosis|promote cell growth	"overexpressed in a variety of cancers, including leukemia"	K562	NPA	NPA	oncogenic
1748	20138800	head and neck	oral squamous cell carcinoma	NPA	miR-24	miR-24-3p	NPA	NPA	NPA	promote cell growth	up-regulated in OSCC tissues relative to control samples|significantly higher in the plasma of OSCC patients than control individuals|higher in OSCC cell lines relative to normal oral keratinocytes	NPA	NPA	tissues and plasma of OSCC and control samples	oncogenic
1749	20133617	blood	diffuse large B cell lymphoma	NPA	miR-155	miR-155-5p	SMAD5	4090	NPA	reduce cell cycle arrest	NPA	NPA	NPA	NPA	oncogenic
1750	20133587	blood	MLL-rearranged acute leukemia	NPA	miR-17~92	CLUSTER:miR-17~92	NPA	NPA	NPA	increase cell proliferation|inhibit apoptosis|increase colony formation	frequently amplified and aberrantly overexpressed in mixed lineage leukemia (MLL)-rearranged acute leukemias	NPA	NPA	mixed lineage leukemia (MLL)-rearranged acute leukemias	oncogenic
1751	20124483	pancreas	pancreatic cancer	"3,3'-diinodolylmethane|isoflavone"	miR-146a	miR-146a-5p	NPA	NPA	NPA	inhibit cell invasion	downregulated in pancreatic cancer cells compared with normal human pancreatic duct epithelial cells	NPA	NPA	NPA	tumor-suppressive
1752	20113523	brain	glioblastoma	taxol	miR-21	miR-21-5p	NPA	NPA	NPA	reduce apoptosis|promote cell invasion|reduce taxol sensitivity	NPA	U251|LN229	NPA	NPA	oncogenic
1753	20103675	liver	hepatocellular carcinoma	NPA	miR-222	miR-222-3p	PPP2R2A	5520	NPA	increase cell motility	overexpressed in tumors relative to its premalignant counterpart|correlated significantly with advanced stage HCC and with the shorter disease-free survival of patients	Hep3B|HKCI-9	NPA	HCC tumors and matching adjacent cirrhotic livers	oncogenic
1754	20102618	stomach	gastric adenocarcinoma	NPA	miR-9	miR-9-5p	NFKB1	4790	NPA	inhibit cell growth|inhibit tumor growth	downregulated in human gastric adenocarcinoma	MGC803	xenograft tumors derived from them in SCID mice	human gastric adenocarcinoma tissues	tumor-suppressive
1755	20099276	breast	breast cancer	cisplatin	miR-345	miR-345-5p	ABCC1	4363	NPA	NPA	NPA	MCF-7	NPA	NPA	NPA
1756	20099276	breast	breast cancer	cisplatin	miR-7	miR-7-5p	ABCC1	4363	NPA	NPA	NPA	MCF-7	NPA	NPA	NPA
1757	20098684	colorectum	colon cancer	NPA	miR-145	miR-145-5p	YES1|STAT1	7525|6772	NPA	NPA	NPA	NPA	NPA	NPA	NPA
1758	20097187	lung	non-small cell lung cancer	gefitinib	let-7a	let-7a-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit tumor growth|enhance gefitinib sensitivity	NPA	H460|A549	SCID/beige mice tumor xenografts	NPA	tumor-suppressive
1759	20097187	lung	non-small cell lung cancer	gefitinib	miR-126	miR-126-3p	NPA	NPA	NPA	inhibit cell proliferation|inhibit tumor growth|enhance gefitinib sensitivity	NPA	H460|A549	SCID/beige mice tumor xenografts	NPA	tumor-suppressive
1760	20097187	lung	non-small cell lung cancer	gefitinib	miR-145	miR-145-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit tumor growth|enhance gefitinib sensitivity	NPA	H460|A549	SCID/beige mice tumor xenografts	NPA	tumor-suppressive
1761	20094072	colorectum	colorectal cancer	NPA	miR-143	miR-143-3p	NPA	NPA	NPA	inhibit cell growth|inhibit tumor growth	frequently decreased in the adenomas and cancers	DLD-1	xenografted tumors of DLD-1	63 cancer specimens and 65 adenoma specimens	tumor-suppressive
1762	20086245	blood	mantle cell lymphoma	NPA	miR-29	miR-29a-3p|miR-29b-3p|miR-29c-3p	CDK6	1021	NPA	NPA	most frequently decreased in MCL compared with normal B lymphocytes|associated with prognosis|inversely correlated with CDK6 in MCL	NPA	NPA	30 patients with MCL	NPA
1763	20080834	stomach	gastric cancer	5-aza-2'-deoxycytidine	miR-181c	miR-181c-5p	NOTCH4|KRAS	4855|3845	NPA	decrease cell growth	decreased in 9 of 16 primary gastric carcinoma (GC) cases compared with the corresponding non-cancerous stomach tissues	KATO-III|MKN45	NPA	16 primary gastric carcinoma (GC) cases and the corresponding non-cancerous stomach tissues	tumor-suppressive
1764	20080666	brain	glioblastoma	NPA	miR-26a	miR-26a-5p	PTEN|RB1|MAP3K2	5728|5925|10746	NPA	increase AKT signaling|promote cell proliferation|decrease apoptosis|promote tumor growth	NPA	NPA	mouse brain	NPA	oncogenic
1765	20080637	nerve	neuroblastoma	NPA	miR-18a	miR-18a-5p	ESR1	2099	MYCN	promote cell growth	up-regulated in MYCN-amplified samples of NB tumors	NPA	NPA	human neuroblastoma tumors	oncogenic
1766	20080637	nerve	neuroblastoma	NPA	miR-19a	miR-19a-3p	ESR1	2099	MYCN	promote cell growth	up-regulated in MYCN-amplified samples of NB tumors	NPA	NPA	human neuroblastoma tumors	oncogenic
1767	20080624	nerve	neuroblastoma	ionizing radiation	miR-421	miR-421	ATM	472	MYCN	change cell cycle S-phase checkpoint|increase radiation sensitivty	NPA	NPA	NPA	NPA	oncogenic
1768	20075075	esophagus	esophageal squamous cell carcinoma	NPA	miR-10b	miR-10b-5p	KLF4	9314	NPA	increase cell motility|increase cell invasion	elevated in 95% (38 of 40) of cancer tissues	KYSE140|EC9706	NPA	40 human esophageal cancer samples and their paired normal adjacent tissues	oncogenic
1769	20073067	prostate	prostate cancer	5-aza-2'-deoxycytidine|trichostatin A	miR-193b	miR-193b-3p	NPA	NPA	NPA	reduce cell growth|decrease cells in cell cycle S phase	decreased in clinical prostate cancer samples compared to benign prostatic hyperplasia	22Rv1	NPA	prostate cancer samples and benign prostatic hyperplasia	tumor-suppressive
1770	20067763	stomach	gastric cancer	NPA	miR-150	miR-150-5p	EGR2	1959	NPA	promote tumorigenesis|promote cell proliferation	overexpressed in gastric cancer cell lines and tissues	NPA	NPA	gastric cancer tissues	oncogenic
1771	20061417	thyroid	anaplastic thyroid carcinoma	NPA	miR-146a	miR-146a-5p	NPA	NPA	NF-¦ÊB	promote oncogenic potential|reduce drug-induced apoptosis	overexpressed in human ATC specimens compared with the normal thyroid tissue	FRO	NPA	human ATC specimens and the normal thyroid tissue	oncogenic
1772	20054866	liver	hepatocellular carcinoma	NPA	miR-30d	miR-30d-5p	GNAI2	2771	NPA	promote cell migration|promote cell invasion|promote metastasis	frequently up-regulated in HCC|highly associated with the intrahepatic metastasis	NPA	NPA	HCC tissues	oncogenic
1773	20054641	breast	breast cancer	letrozole	miR-128a	miR-128-3p	TGFBR1	7046	NPA	induce letrozole-resistance	hormone-responsive and selectively up-regulated in the letrozole-resistant cell lines	NPA	NPA	NPA	NPA
1774	20053927	head and neck	nasopharyngeal carcinoma	NPA	miR-141	miR-141-3p	BRD3|UBAP1|PTEN	8019|51271|5728	MYC|BPIFA1	regulate cell cycle|regulate apoptosis|regulate cell growth|regulate cell migration|regulate cell invasion	up-regulated in NPC specimens in comparison with normal nasopharyngeal epithelium	NPA	NPA	NPC specimens and normal nasopharyngeal epithelium	oncogenic
1775	20048743	brain	glioblastoma	NPA	miR-21	miR-21-5p	NPA	NPA	NPA	reduce apoptosis|promote cell cycle progression|reduce tumor growth	frequently overexpressed in human glioblastoma (GBM) cell lines	U251|LN229	xenograft tumors	NPA	oncogenic
1776	21368878	prostate	prostate cancer	5-aza-2'-deoxycytidine	miR-205	miR-205-5p	BCL2L2	599	NPA	promote chemotherapy-induced apoptosis	"significantly downregulated in WPE1-NB26 cells, as well as in other cell lines representing advanced-stage prostate cancers"	WPE1-NA22|WPE1-NB26	NPA	NPA	tumor-suppressive
1777	21368878	prostate	prostate cancer	NPA	miR-31	miR-31-5p	E2F6	1876	NPA	promote chemotherapy-induced apoptosis	"significantly downregulated in WPE1-NB26 cells, as well as in other cell lines representing advanced-stage prostate cancers"	WPE1-NA22|WPE1-NB26	NPA	NPA	tumor-suppressive
1778	21368870	testis	testicular embryonal carcinoma	NPA	miR-383	miR-383-5p	IRF1	3659	NPA	inhibit cell proliferation|induce cell cycle G1 arrest|induce apoptosis	negatively associated with hyperactive proliferation of germ cells in patients with mixed patterns of maturation arrest (MA)|negatively correlated with IRF1 protein expression in vivo	NT2	NPA	germ cells in patients with mixed patterns of maturation arrest (MA)	tumor-suppressive
1779	20041405	liver	hepatocellular carcinoma	NPA	miR-29	miR-29a-3p|miR-29b-3p|miR-29c-3p	BCL2|MCL1	596|4170	NPA	promote apoptosis|inhibit tumor formation	frequently reduced in HCC tissues|negatively significantly associated with worse disease-free survival of HCC patients	NPA	tumor in nude mice	HCC tissues	tumor-suppressive
1780	20041160	colorectum	colorectal cancer	NPA	miR-24	miR-24-3p	NPA	NPA	NPA	inhibit cell proliferation|induce cell cycle G2/S arrest	deregulated in human colorectal cancer tumors and downregulated in a subset of tumors	NPA	NPA	human colorectal cancer tumors	tumor-suppressive
1781	20039318	colorectum	colorectal cancer	NPA	miR-491	miR-491-5p	BCL2L1	598	NPA	decrease cell viability|induce apoptosis|reduce tumor growth	NPA	DLD-1	DLD-1 in nude mice	NPA	tumor-suppressive
1782	20034472	lung	non-small cell lung cancer	NPA	miR-126	miR-126-3p	NPA	NPA	NPA	inhibit cell proliferation	NPA	A549	NPA	NPA	tumor-suppressive
1783	20033209	lung	lung cancer	NPA	let-7a	let-7a-5p	NPA	NPA	NPA	inhibit tumor growth	NPA	A549	nude mice	NPA	tumor-suppressive
1784	20029046	blood	acute myeloid leukemia	NPA	miR-223	miR-223-3p	E2F1	1869	CEBPA|E2F1	block cell-cycle progression	down-regulated in different subtypes of acute myeloid leukemia	NPA	mice	NPA	tumor-suppressive
1785	20023705	breast	breast cancer	NPA	miR-224	miR-224-5p	CXCR4|CDC42	7852|998	UBC9	inhibit cell invasion	NPA	MCF-7	NPA	NPA	tumor-suppressive
1786	20023698	liver	hepatocellular carcinoma	doxorubicin	miR-181b	miR-181b-5p	TIMP3	7078	TGFB1 	promote cell growth|promote clonogenic survival|promote cell migration|promote cell invasion|increase doxorubicin resistance	NPA	NPA	C57BL/6 mice fed choline-deficient and amino acid defined (CDAA) diet develop preneoplastic lesions at 65 weeks and hepatocellular carcinomas after 84 weeks	NPA	oncogenic
1787	20023696	bone and muscle	Kaposi's sarcoma	NPA	miR-146a	miR-146a-5p	CXCR4	7852	NF-¦ÊB	NPA	increased in clinical samples of KS	NPA	NPA	clinical samples of KS	NPA
1788	20022054	kidney	clear cell renal cell carcinoma	NPA	miR-17-5p	miR-17-5p	NPA	NPA	NPA	increase cell proliferation	over-expressed in clear cell renal cell carcinoma	ACHN	NPA	clear cell renal cell carcinoma tissues	tumor-suppressive
1789	20022054	kidney	clear cell renal cell carcinoma	NPA	miR-20a	miR-20a-5p	NPA	NPA	NPA	increase cell proliferation	over-expressed in clear cell renal cell carcinoma	ACHN	NPA	clear cell renal cell carcinoma tissues	tumor-suppressive
1790	20021821	brain	glioma	NPA	miR-221	miR-221-3p	NPA	NPA	NPA	increase cell invasion|reduce cell cycle G0/G1 arrest|reduce apoptosis|promote tumor growth	NPA	U251	xenograft tumors in nude mice	NPA	oncogenic
1791	20021821	brain	glioma	NPA	miR-222	miR-222-3p	NPA	NPA	NPA	increase cell invasion|reduce cell cycle G0/G1 arrest|reduce apoptosis|promote tumor growth	NPA	U251	xenograft tumors in nude mice	NPA	oncogenic
1792	20020497	stomach	gastric cancer	NPA	miR-212	miR-212-3p	MECP2	4204	NPA	decrease cell growth	decreased in all 8 GC cell lines|significantly decreased in 6 of 11 cases human primary GC tissues	NPA	NPA	11 cases human primary GC tissues	tumor-suppressive
1793	20018759	liver	hepatocellular carcinoma	NPA	miR-221	miR-221-3p	DDIT4	54541	NPA	enhance cell growth	most up-regulated miRNAs in tumor samples	NPA	mouse model of liver cancer	"104 HCC, 90 adjacent cirrhotic livers, 21 normal livers"	oncogenic
1794	20008935	blood	B-cell lymphoma	NPA	miR-19	miR-19a-3p	PTEN	5728	NPA	inhibit apoptosis|promote cell survival	NPA	NPA	Emu-myc model of mouse B-cell lymphoma	NPA	oncogenic
1795	20008931	blood	B-cell lymphoma	NPA	miR-17~92	CLUSTER:miR-17~92	NPA	NPA	NPA	suppress apoptosis	NPA	NPA	NPA	NPA	oncogenic
1796	19996289	prostate	agressive prostate cancer	NPA	miR-145	miR-145-5p	NPA	NPA	NPA	inhibit cell growth|induce apoptosis	NPA	NPA	NPA	62 prostate cancer patients with aggressive phenotype (Gleason grade >or= 8) and 63 prostate cancer patients with nonaggressive phenotype (Gleason grade <or= 5)	tumor-suppressive
1797	19996289	prostate	agressive prostate cancer	NPA	miR-331-3p	miR-331-3p	NPA	NPA	NPA	inhibit cell growth|induce apoptosis	NPA	NPA	NPA	62 prostate cancer patients with aggressive phenotype (Gleason grade >or= 8) and 63 prostate cancer patients with nonaggressive phenotype (Gleason grade <or= 5)	tumor-suppressive
1798	19996288	NPA	NPA	NPA	miR-145	miR-145-5p	MUC1	4582	NPA	suppress cell invasion|suppress lung metastasis	NPA	NPA	an experimental metastasis animal model	NPA	tumor-suppressive
1799	19962668	liver	hepatocellular carcinoma	NPA	miR-221	miR-221-3p	PTEN|TIMP3	5728|7078	MET|JUN	induce TRAIL resistance|increase cell migration	"overexpressed in aggressive non-small cell lung cancer and hepatocarcinoma cells, as compared with less invasive and/or normal lung and liver cells"	NPA	NPA	non-small cell lung cancer and hepatocarcinoma and less invasive and/or normal lung and liver tissues	oncogenic
1800	19962668	lung	non-small cell lung cancer	NPA	miR-221	miR-221-3p	PTEN|TIMP3	5728|7078	MET|JUN	induce TRAIL resistance|increase cell migration	"overexpressed in aggressive non-small cell lung cancer and hepatocarcinoma cells, as compared with less invasive and/or normal lung and liver cells"	NPA	NPA	non-small cell lung cancer and hepatocarcinoma and less invasive and/or normal lung and liver tissues	oncogenic
1801	19962668	liver	hepatocellular carcinoma	NPA	miR-222	miR-222-3p	PTEN|TIMP3	5728|7078	MET|JUN	induce TRAIL resistance|increase cell migration	"overexpressed in aggressive non-small cell lung cancer and hepatocarcinoma cells, as compared with less invasive and/or normal lung and liver cells"	NPA	NPA	non-small cell lung cancer and hepatocarcinoma and less invasive and/or normal lung and liver tissues	oncogenic
1802	19962668	lung	non-small cell lung cancer	NPA	miR-222	miR-222-3p	PTEN|TIMP3	5728|7078	MET|JUN	induce TRAIL resistance|increase cell migration	"overexpressed in aggressive non-small cell lung cancer and hepatocarcinoma cells, as compared with less invasive and/or normal lung and liver cells"	NPA	NPA	non-small cell lung cancer and hepatocarcinoma and less invasive and/or normal lung and liver tissues	oncogenic
1803	19956871	liver	hepatocellular carcinoma	NPA	miR-15b	miR-15b-5p	NPA	NPA	NPA	decrease cell proliferation|enhance apoptosis	negatively correlated with recurrence	NPA	NPA	25 pairs of HCC and adjacent non-tumor liver tissues	tumor-suppressive
1804	19956384	thyroid	papillary thyroid carcinoma	NPA	let-7f	let-7f-5p	NPA	NPA	NPA	inhibit MAPK signaling|reduce cell growth	reduced expression in RET/PTC malignant transformation	PCCL3|TPC-1	NPA	NPA	tumor-suppressive
1805	19955368	brain	glioma	NPA	miR-326	miR-326	NOTCH1|NOTCH2	4851|4853	NOTCH1	induce cytotoxicity|reduce tumorigenicity	downregulated in gliomas via decreased expression of its host gene	NPA	NPA	glioma tissues	tumor-suppressive
1806	19955085	prostate	prostate cancer	NPA	miR-128	miR-128-3p	NPA	NPA	NPA	inhibit cell invasion	downregulated in invasive prostate cancer cells compared with benign prostate epithelial cell lines	NPA	NPA	15 clinical prostate cancer specimens	tumor-suppressive
1807	19948152	brain	glioma stem cells	NPA	miR-125b	miR-125b-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell cycle G1/S transition	downregulated in human U251 glioma stem cells	U251	NPA	NPA	tumor-suppressive
1808	19944013	NPA	NPA	NPA	miR-16	miR-16-5p	CCNE1	898	NPA	induce cell cycle G0/G1 arrest	NPA	NPA	NPA	NPA	tumor-suppressive
1809	19941032	brain	glioblastoma	NPA	miR-128	miR-128-3p	NPA	NPA	NPA	decrease cell proliferation	significantly down-regulated in glioblastoma multiforme (GBM) and in GBM cell lines when compared to age-matched controls|inversely correlated with WHO tumor grade	CRL-1690|CRL-2610	NPA	glioblastoma multiforme (GBM) and age-matched controls	tumor-suppressive
1810	19940135	NPA	NPA	NPA	miR-183	miR-183-5p	ITGB1|KIF2A	3688|3796	NPA	reduce cell invasion|reduce cell migration	NPA	NPA	NPA	NPA	tumor-suppressive
1811	19937137	stomach	gastric cancer	NPA	miR-372	miR-372-3p	LATS2	26524	NPA	promote cell proliferation|reduce cell cycle G2/M arrest|reduce apoptosis	expressed only in AGS human gastric adenocarcinoma cell line	AGS	NPA	NPA	oncogenic
1812	19935649	NPA	NPA	NPA	miR-183	miR-183-5p	BMI1	648	ZEB1	reduce tumour-initiating capacity	NPA	NPA	NPA	NPA	tumor-suppressive
1813	19935649	NPA	NPA	NPA	miR-200c	miR-200c-3p	BMI1	648	ZEB1	reduce tumour-initiating capacity	NPA	NPA	NPA	NPA	tumor-suppressive
1814	19935649	NPA	NPA	NPA	miR-203	miR-203a	BMI1	648	ZEB1	reduce tumour-initiating capacity	NPA	NPA	NPA	NPA	tumor-suppressive
1815	19931509	head and neck	nasopharyngeal carcinoma	NPA	miR-200a	miR-200a-3p	ZEB2|CTNNB1	9839|1499	NPA	inhibit cell growth|inhibit cell migration|inhibit cell invasion	downregulation in NPC|increased with the degree of differentiation in a panel of NPC cell lines	C666-1|CNE-1|CNE-2|HNE1	NPA	nasopharyngeal carcinoma tissues	tumor-suppressive
1816	19926638	colorectum	colorectal cancer	NPA	miR-675	miR-675-5p	RB1	5925	NPA	increase cell growth|increase colony formation	upregulated in human colon cancer cell lines and primary human colorectal cancer (CRC) tissues compared with adjacent non-cancerous tissues|inversely correlated with RB1 expression in human CRC tissues	NPA	NPA	primary human colorectal cancer (CRC) tissues and adjacent non-cancerous tissues	oncogenic
1817	19915607	bladder	bladder cancer	NPA	miR-145	miR-145-5p	CBFB|PPP3CA|CLINT1	865|5530|9685	NPA	induce apoptosis	"reduced in bladder cancer and urothelial carcinoma in situ, compared with normal urothelium"	T24|SW780	NPA	"bladder cancer, urothelial carcinoma and normal urothelium"	tumor-suppressive
1818	19903841	ovary	ovarian cancer	NPA	miR-15a	miR-15a-5p	BMI1	648	NPA	reduce cell proliferation|reduce clonal growth	underexpressed in ovarian cell lines and in primary ovarian tissues|significantly inversely correlated with BMI1 protein levels in ovarian cancer patients and cell lines	NPA	NPA	primary ovarian tissues	tumor-suppressive
1819	19903841	ovary	ovarian cancer	NPA	miR-16	miR-16-5p	BMI1	648	NPA	reduce cell proliferation|reduce clonal growth	underexpressed in ovarian cell lines and in primary ovarian tissues|significantly inversely correlated with BMI1 protein levels in ovarian cancer patients and cell lines	NPA	NPA	primary ovarian tissues	tumor-suppressive
1820	19900756	uterus	choriocarcinoma	NPA	miR-199b	miR-199b-5p	SET	6418	NPA	NPA	underexpressed in choriocarcinoma compared with non-cancerous trophoblasts	NPA	NPA	"choriocarcinoma and non-cancerous trophoblasts|formalin-fixed paraffin-embedded human choriocarcinoma, mole, and non-cancer trophoblast tissues"	NPA
1821	19893619	NPA	NPA	hypoxia	miR-20b	miR-20b-5p	HIF1A|VEGFA	3091|7422	HIF1A	increase cell growth|increase cell survival	NPA	NPA	NPA	NPA	oncogenic
1822	19891584	liver	hepatocellular carcinoma	NPA	miR-122	miR-122-5p	NPA	NPA	NPA	increase cell viability|induce apoptosis	NPA	HepG2|Huh7	NPA	NPA	oncogenic
1823	19890957	stomach	gastric cancer	NPA	miR-218	miR-218-5p	VOPP1	81552	NPA	inhibit cell proliferation|increase apoptosis	"reduced significantly in gastric cancer tissues,  in H. pylori-infected gastric mucosa, and in H. pylori-infected AGS cells"	AGS	NPA	"20 noncardia gastric cancer tissues, 10 H. pylori-infected and 8 uninfected normal gastric biopsies"	tumor-suppressive
1824	19890883	nerve	malignant peripheral nerve sheath tumor	NPA	miR-34a	miR-34a-5p	NPA	NPA	TP53	promote apoptosis	down-regulated in most MPNSTs compared to neurofibromas	MPNST-14|MPNST-724	NPA	benign and malignant peripheral nerve sheath tumours	tumor-suppressive
1825	19890474	blood	diffuse large B cell lymphoma	NPA	miR-155	miR-155-5p	INPP5D	3635	TNFA	promote TNFalpha-dependent growth	elevated in diffuse large B cell lymphoma (DLBCL)	NPA	xenografts	diffuse large B cell lymphoma (DLBCL) samples	oncogenic
1826	19887623	uterus	endometrial cancer	NPA	miR-129	miR-129-5p	SOX4	6659	DNA hypermethylation in cancer	reduce cell proliferation	lost in 27 of 31 primary endometrial tumors compared with the matched endometria	NPA	NPA	31 primary endometrial tumors and the matched endometria	tumor-suppressive
1827	19887617	breast	breast cancer	Y27632	miR-17	miR-17-5p	NPA	NPA	NPA	increase cell migration|increase cell invasion|increase metastasis	elevated in metastatic breast cancer cells compared with nonmetastatic cells	NPA	"a novel ""human breast cancer metastasis to human bone"" mouse model"	NPA	oncogenic
1828	19883630	breast	breast cancer	VP-16|doxorubicin	miR-326	miR-326	ABCC1	4363	NPA	reduce chemotherapy resistance	downregulated in MCF-7/VP (resistant) compared to MCF-7|downregulated in a panel of advanced breast cancer tissues	MCF-7	NPA	NPA	tumor-suppressive
1829	19881956	ovary	ovarian cancer	NPA	miR-125a	miR-125a-5p	NPA	NPA	EGFR|ETV4	inhibit epithelial-mesenchymal transition	NPA	NPA	NPA	NPA	tumor-suppressive
1830	19878981	NPA	NPA	NPA	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	IL6	3569	NF-¦ÊB|LIN28|IL6	inhibit cell transformation	NPA	NPA	NPA	NPA	tumor-suppressive
1831	19859982	cervix	cervical cancer	NPA	miR-214	miR-214-3p	MAP2K3|MAPK8	5606|5599	NPA	inhibit cell proliferation	downregulated in cervical cancer compared with normal tissue	HeLa	NPA	cervical cancer and normal tissue	tumor-suppressive
1832	19855844	prostate	prostate cancer	NPA	miR-143	miR-143-3p	MAPK4	5596	NPA	inhibit cell proliferation|reduce tumor growth	inversely correlated with advanced stages of prostate cancer	NPA	mice	human prostate cancers	tumor-suppressive
1833	19854497	ovary	ovarian cancer	NPA	miR-200	miR-200a-3p|miR-200b-3p|miR-200c-3p	ZEB1|ZEB2	6935|9839	ZEB1|ZEB2	NPA	substantially higher in all three primary tumor types compared to normal HOSE samples	NPA	NPA	a panel of 70 ovarian cancer tissues	NPA
1834	19850741	blood	acute myeloid leukemia	NPA	miR-29b	miR-29b-3p	MCL1	4170	NPA	induce apoptosis|reduce tumorigenicity	inversely correlated with MCL1 expression in primary AML samples	NPA	a xenograft leukemia model	45 primary AML samples	tumor-suppressive
1835	19843643	liver	hepatocellular carcinoma	5-aza-2'-deoxycytidine	miR-124	miR-124-3p	CDK6|VIM|SMYD3|IQGAP1	1021|7431|64754|8826	DNA hypermethylation in cancer	inhibit cell growth	inversely correlated with methylation status	NPA	NPA	primary tumors of HCC with paired non-tumorous liver tissues	tumor-suppressive
1836	19843643	liver	hepatocellular carcinoma	5-aza-2'-deoxycytidine	miR-203	miR-203a	ABCE1	6059	DNA hypermethylation in cancer	inhibit cell growth	inversely correlated with methylation status	NPA	NPA	primary tumors of HCC with paired non-tumorous liver tissues	tumor-suppressive
1837	19843160	colorectum	colorectal cancer	5-fluorouracil	miR-143	miR-143-3p	NPA	NPA	NPA	reduce cell viability|increase cell death induced by 5-FU	NPA	HCT116	NPA	NPA	tumor-suppressive
1838	19839716	breast	breast cancer	NPA	miR-205	miR-205-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit anchorage-independent cell growth|inhibit cell invasion	significantly underexpressed in breast tumors compared with matched normal breast tissue	MCF-7|MDA-MB-231|MCF-10A	NPA	NPA	tumor-suppressive
1839	19839049	breast	breast cancer	NPA	miR-200	miR-200a-3p|miR-200b-3p|miR-200c-3p	ZEB1	6935	NPA	inhibit epithelial-mesenchymal transition	NPA	MDA-MB-231|BT-549	NPA	NPA	tumor-suppressive
1840	19833767	NPA	NPA	NPA	miR-449a	miR-449a	CDK6|CDC25A	1021|993	E2F1	induce cell cycle G1 arrest	NPA	NPA	NPA	NPA	tumor-suppressive
1841	19833767	NPA	NPA	NPA	miR-449b	miR-449b-5p	CDK6|CDC25A	1021|993	E2F1	induce cell cycle G1 arrest	NPA	NPA	NPA	NPA	tumor-suppressive
1842	19830692	skin	malignant melanoma	NPA	miR-15b	miR-15b-5p	NPA	NPA	NPA	promote cell proliferation|reduce apoptosis	significantly upregulated in melanomas compared with melanocytic nevi|significantly associated with poor recurrence free survival and overall survival	NPA	NPA	in formalin fixed paraffin embedded tissue of 11 melanocytic nevi versus 16 melanomas|128 primary melanomas from patients with detailed clinical follow-up information	oncogenic
1843	19830559	colorectum	colorectal cancer	NPA	miR-141	miR-141-3p	ZEB2	9839	NPA	inhibit cell migration|inhibit cell invasion	inversely correlated with ZEB2 protein levels in CRC cells	NPA	NPA	NPA	tumor-suppressive
1844	19826043	blood	acute myeloid leukemia	NPA	miR-24	miR-24-3p	DUSP16	80824	RUNX1|AML1-ETO	promote cell growth|promote cell proliferation|block granulocytic differentiation	NPA	NPA	NPA	NPA	oncogenic
1845	19826040	colorectum	colon cancer	NPA	miR-21	miR-21-5p	CDC25A	993	NPA	inhibit cell cycle G1/S transtion|participate DNA damage-induced cell cycle G2/M checkpoint	underexpressed in a subset of Cdc25A-overexpressing colon cancers	NPA	NPA	NPA	oncogenic
1846	19818775	lung	lung cancer	NPA	let-7a	let-7a-5p	UHRF2	115426	NPA	inhibit cell growth	NPA	A549	NPA	NPA	tumor-suppressive
1847	19818597	lung	non-small cell lung cancer	NPA	miR-29a	miR-29a-3p	NPA	NPA	NPA	reduce cell invasion|reduce cell proliferation 	reduced in more invasive cell lines of human NSCLC cell lines	NPA	NPA	NPA	tumor-suppressive
1848	19802518	stomach	gastric carcinoma	NPA	miR-421	miR-421	NPA	NPA	NPA	increase cell growth	over-expressed in 73.33% (44/60) of the gastric cancer samples examined	MGC-803|SGC-7901	NPA	60 gastric carcinoma and 18 non-tumor tissues	oncogenic
1849	19801681	NPA	NPA	NPA	miR-200	miR-200a-3p|miR-200b-3p|miR-200c-3p	WASF3	10810	NPA	reduce cell invasion	inversely correlated with WASF3 expression in invasive versus non-invasive cancer cells	NPA	NPA	NPA	tumor-suppressive
1850	19793168	liver	hepatocellular carcinoma	NPA	miR-224	miR-224-5p	NPA	NPA	NPA	promote cell proliferation|promote cell migration|promote cell invasion	significantly upregulated in HepG2 than L02 cells	HepG2|L02	NPA	NPA	oncogenic
1851	19787239	head and neck	laryngeal cancer	NPA	let-7a	let-7a-5p	NPA	NPA	NPA	inhibit cell proliferation|induce apoptosis	"significantly downregulated both in human laryngeal squamous cancer tissues and in Hep-2 cells, a laryngeal cancer cell line, as compared with adjacent normal tissues and BEAS-2B cells, respectively|significantly further decreased in non-differentiated (G3) cancer tissues as compared with moderately and well differentiated cancer tissues (G2 and G1)|no significant difference between the cancer specimens with different T stages or specimens from patients with different lymph node metastasis status"	Hep-2|BEAS-2B	NPA	human laryngeal squamous cancer tissues and adjacent normal tissues	tumor-suppressive
1852	19782034	NPA	NPA	hypoxia	miR-210	miR-210-3p	NPA	NPA	HIF1A	repress tumor initiation	an in vivo marker for tumor hypoxia in primary head and neck tumor samples	NPA	human head and neck or pancreatic tumor cells implanted into immunodeficient mice	primary head and neck tumor samples	tumor-suppressive
1853	19775293	brain	glioma	NPA	miR-17	miR-17-5p	NPA	NPA	NPA	increase cell viability|increase cell proliferation|inhibit apoptosis|increase cell invasion	increased during cancer progression of human gliomas	A172|T98G	NPA	four patients with primary WHO grade II gliomas that spontaneously progressed to WHO grade IV secondary glioblastomas	tumor-suppressive
1854	19775293	brain	glioma	NPA	miR-184	miR-184	NPA	NPA	NPA	inhibit cell viability|inhibit cell proliferation|induce apoptosis|inhibit cell invasion	reduced during cancer progression of human gliomas	A172|T98G	NPA	four patients with primary WHO grade II gliomas that spontaneously progressed to WHO grade IV secondary glioblastomas	tumor-suppressive
1855	19773441	brain	glioblastoma	NPA	miR-34a	miR-34a-5p	MET|NOTCH1|NOTCH2	4233|4851|4853	NPA	inhibit cell proliferation|inhibit cell cycle progression|inhibit cell survival|inhibit cell invasion	down-regulated in glioblastoma tissues as compared with normal brain|down-regulaed in mutant p53 gliomas as compared with wild-type p53 gliomas|inversely correlated with MET levels in the same tumors	NPA	in vivo glioma xenograft	glioblastoma tissues and normal brain of human specimens	tumor-suppressive
1856	19771525	prostate	prostate cancer	NPA	miR-17-3p	miR-17-3p	NPA	NPA	NPA	reduce cell motility|reduce cell invasion|inhibit tumor growth	reduced in LCM-purified clinical human prostatectomy specimens	P69|M12|F6	"male athymic, nude mice"	LCM-purified clinical human prostatectomy specimens	tumor-suppressive
1857	19767219	bladder	bladder cancer	NPA	miR-221	miR-221-3p	NPA	NPA	NPA	inhibit apoptosis	significantly up-regulated in bladder cancer T24 cells and RT4 cells compared to human normal urothelial cells	T24|RT4	NPA	NPA	oncogenic
1858	19749093	blood	MLL-AF4 acute lymphocytic leukemia	glucocorticoids	miR-128b	miR-128-3p	MLL|AFF1	4297|4299	NPA	increase glucocorticoids sensitivity	down-regulated in MLL-rearranged ALL relative to other types of ALL	NPA	NPA	ALL samples	tumor-suppressive
1859	19749093	blood	MLL-AF4 acute lymphocytic leukemia	glucocorticoids	miR-221	miR-221-3p	CDKN1B	1027	NPA	increase glucocorticoids sensitivity	down-regulated in MLL-rearranged ALL relative to other types of ALL	NPA	NPA	ALL samples	tumor-suppressive
1860	19747919	pancreas	pancreatic cancer	NPA	miR-10a	miR-10a-5p	NPA	NPA	RARA	promote metastasis|promote cell invasion	increased in metastatic pancreatic adenocarcinoma	NPA	xenotransplantation experiments in zebrafish embryos	NPA	oncogenic
1861	19739117	head and neck	nasopharyngeal cancer	NPA	miR-100	miR-100-5p	PLK1	5347	NPA	NPA	inversely correlated with PLK1 expression	C666-1	NPA	40 primary nasopharyngeal cancer (NPC) biopsies	NPA
1862	19738602	prostate	prostate cancer	NPA	miR-16	miR-16-5p	NPA	NPA	NPA	reduce cell proliferation|inhibit tumor growth	lowly expressed in human prostate tumors versus normal prostate tissues	22Rv1|Du145|PPC-1|PC-3M-luc	prostate cancer xenograft model	human prostate tumors and normal prostate tissues	tumor-suppressive
1863	19738047	prostate	prostate cancer	castration	miR-21	miR-21-5p	NPA	NPA	AR	promote cell proliferation|promote tumor growth|overcome castration-induced growth arrest	elevated in prostate cancer when compared with adjacent normal tissue	NPA	NPA	prostate cancer and adjacent normal tissue	oncogenic
1864	19734943	NPA	NPA	5-fluorouracil	miR-140	miR-140-3p	HDAC4	9759	NPA	inhibit cell proliferation|induce cell cycle G1/G2 arrest|increase CSC resistance to 5-FU	significantly elevated in CD133(+hi)CD44(+hi) colon cancer stem-like cells	U2OS|HCT116	NPA	NPA	tumor-suppressive
1865	19730444	breast	breast cancer	NPA	miR-145	miR-145-5p	ESR1	2099	TP53	induce apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
1866	19730150	pancreas	pancreatic adenocarcinoma	gemcitabine	miR-21	miR-21-5p	NPA	NPA	NPA	promote cell proliferation|inhibit apoptosis|reduce cell cycle G1 arrest|reduce gemcitabine sensitivity	NPA	HS766T	NPA	NPA	oncogenic
1867	19730150	pancreas	pancreatic adenocarcinoma	gemcitabine	miR-221	miR-221-3p	NPA	NPA	NPA	promote cell proliferation|inhibit apoptosis|reduce cell cycle G1 arrest|reduce gemcitabine sensitivity	NPA	HS766T	NPA	NPA	oncogenic
1868	19726678	liver	hepatocellular carcinoma	sorafenib	miR-122	miR-122-5p	ADAM10|SRF|IGF1R	102|6722|3480	NPA	inhibit cell growth|decrease clonogenic survival|inhibit cell migration|inhibit cell invasion	abundantly expressed in hepatocytes but barely detectable in primary human HCCs	Huh7|Hep3B|SK-Hep-1	NPA	hepatocytes and primary human HCCs	tumor-suppressive
1869	19723635	cervix	cervical cancer	NPA	miR-206	miR-206	NOTCH3	4854	NPA	induce apoptosis|inhibit cell migration|inhibit focus formation	NPA	HeLa	NPA	NPA	tumor-suppressive
1870	19714243	pancreas	pancreatic cancer	NPA	miR-34a	miR-34a-5p	NPA	NPA	NPA	inhibit cell growth|inhibit cell invasion|induce apoptosis|induce cell cycle arrest|reduce the population of CD44+/CD133+ pancreatic cancer tumor-initiating cells	NPA	MiaPaCa2|BxPC3	NPA	NPA	tumor-suppressive
1871	19713529	nerve	neuroblastoma	NPA	miR-128	miR-128-3p	RELN|DCX	5649|1641	NPA	reduce cell motility|inhibit cell invasion|inhibit cell growth	NPA	NPA	NPA	NPA	tumor-suppressive
1872	19711427	liver	hepatocellular carcinoma	NPA	miR-155	miR-155-5p	CEBPB	1051	NF¦ÊB	promote cell growth	significantly (P = 0.0004) up-regulated in primary human HCCs compared with matching liver tissues	NPA	C57BL/6 mice choline-deficient and amino acid-defined (CDAA) diet	primary human HCCs and matching liver tissues	oncogenic
1873	19710019	bone and muscle	rhabdomyosarcoma	NPA	miR-1	miR-1	MET	4233	NPA	inhibit cell growth|inhibit cell migration	suppressed in rhabdomyosarcomas and found at very low levels in a rhabdomyosarcoma RD cell line|inversely correlated with MET expression in tissue samples of human rhabdomyosarcoma	RD	NPA	tissue samples of human rhabdomyosarcoma	tumor-suppressive
1874	19710019	bone and muscle	rhabdomyosarcoma	NPA	miR-206	miR-206	MET	4233	NPA	inhibit cell growth|inhibit cell migration	suppressed in rhabdomyosarcomas and found at very low levels in a rhabdomyosarcoma RD cell line|inversely correlated with MET expression in tissue samples of human rhabdomyosarcoma	RD	NPA	tissue samples of human rhabdomyosarcoma	tumor-suppressive
1875	19703993	brain	meningioma	NPA	miR-200a	miR-200a-3p	CTNNB1	1499	NPA	inhibit cell growth	downregulated in human meningioma|inversely correlated with CTNNB1 in human meningioma samples	NPA	NPA	human meningioma samples	tumor-suppressive
1876	19702828	ovary	ovarian cancer	NPA	miR-9	miR-9-5p	NFKB1	4790	NPA	inhibit cell growth	downregulated in human ovarian cancer relative to normal ovary|inversely correlated with NFKB1 mRNA and protein levels in ovarian cancer cells	NPA	NPA	human ovarian cancer and normal ovary	tumor-suppressive
1877	19702827	lung	lung cancer	NPA	miR-125a-5p	miR-125a-5p	NPA	NPA	EGFR	inhibit cell migration|inhibit cell invasion	negatively correlated with lung carcinogenesis in lung cancer samples	NPA	NPA	lung cancer samples	tumor-suppressive
1878	19701247	breast	breast cancer	NPA	miR-193b	miR-193b-3p	PLAU	5328	NPA	inhibit cell invasion|inhibit tumor growth	NPA	MDA-MB-231|MDA-MB-435	an immunodeficient mouse model with xenograft tumors	NPA	tumor-suppressive
1879	19696787	NPA	NPA	NPA	miR-34a	miR-34a-5p	MYC	4609	ELK1	NPA	strongly induced during oncogene-induced cellular senescence	NPA	NPA	NPA	tumor-suppressive
1880	19692702	blood	chronic lymphocytic leukemia	NPA	miR-107	miR-107	PLAG1	5324	NPA	NPA	downregulated in primary cells of CLL patients compared with peripheral B cells of healthy donors	NPA	NPA	primary cells of 50 treatment-naive CLL patients and peripheral B cells of 14 healthy donors	tumor-suppressive
1881	19692702	blood	chronic lymphocytic leukemia	NPA	miR-181a	miR-181a-5p	PLAG1	5324	NPA	NPA	downregulated in primary cells of CLL patients compared with peripheral B cells of healthy donors	NPA	NPA	primary cells of 50 treatment-naive CLL patients and peripheral B cells of 14 healthy donors	tumor-suppressive
1882	19692702	blood	chronic lymphocytic leukemia	NPA	miR-181b	miR-181b-5p	PLAG1	5324	NPA	NPA	downregulated in primary cells of CLL patients compared with peripheral B cells of healthy donors	NPA	NPA	primary cells of 50 treatment-naive CLL patients and peripheral B cells of 14 healthy donors	tumor-suppressive
1883	19692702	blood	chronic lymphocytic leukemia	NPA	miR-424	miR-424-5p	PLAG1	5324	NPA	NPA	downregulated in primary cells of CLL patients compared with peripheral B cells of healthy donors	NPA	NPA	primary cells of 50 treatment-naive CLL patients and peripheral B cells of 14 healthy donors	tumor-suppressive
1884	19688090	lung	non-small cell lung cancer	NPA	miR-107	miR-107	NPA	NPA	NPA	inhibit cell growth|induce cell cycle G1 arrest	NPA	H1299	NPA	NPA	tumor-suppressive
1885	19688090	lung	non-small cell lung cancer	NPA	miR-185	miR-185-5p	NPA	NPA	NPA	inhibit cell growth|induce cell cycle G1 arrest	NPA	H1299	NPA	NPA	tumor-suppressive
1886	19684618	breast	breast cancer	NPA	miR-18a	miR-18a-5p	ESR1	2099	NPA	NPA	higher expression in ERalpha-negative as compared with ERalpha-positive clinical tumors	NPA	NPA	NPA	NPA
1887	19684618	breast	breast cancer	NPA	miR-18b	miR-18b-5p	ESR1	2099	NPA	NPA	higher expression in ERalpha-negative as compared with ERalpha-positive clinical tumors	NPA	NPA	NPA	NPA
1888	19684618	breast	breast cancer	NPA	miR-193b	miR-193b-3p	ESR1	2099	NPA	NPA	NPA	NPA	NPA	NPA	NPA
1889	19684618	breast	breast cancer	NPA	miR-206	miR-206	ESR1	2099	NPA	NPA	NPA	NPA	NPA	NPA	NPA
1890	19684618	breast	breast cancer	NPA	miR-302c	miR-302c-3p	ESR1	2099	NPA	NPA	NPA	NPA	NPA	NPA	NPA
1891	19682430	cervix	cervical carcinoma	NPA	miR-21	miR-21-5p	PDCD4	27250	NPA	promote cell proliferation	NPA	HeLa	NPA	NPA	oncogenic
1892	19676043	brain	glioblastoma	NPA	miR-153	miR-153-3p	BCL2|MCL1	596|4170	NPA	inhibit cell proliferation|increase apoptosis	significantly lower level in glioblastoma (GBM) relative to non-neoplastic brain tissue	DBTRG-05MG	NPA	NPA	tumor-suppressive
1893	19671867	liver	hepatocellular carcinoma	NPA	miR-221	miR-221-3p	BMF	90427	NPA	inhibit apoptosis	associated with tumor multifocality and reduced time to recurrence after surgery|inversely correlated with BMF expression in HCC tissues	NPA	NPA	HCC tissues	oncogenic
1894	19671845	bladder	bladder cancer	NPA	miR-200b	miR-200b-3p	ERRFI1	54206	NPA	decrease cell migration|increase sensitivity to EGFR-blocking agents	NPA	UMUC3|T24	NPA	NPA	tumor-suppressive
1895	19671845	bladder	bladder cancer	NPA	miR-200c	miR-200c-3p	ERRFI1	54206	NPA	decrease cell migration|increase sensitivity to EGFR-blocking agents	NPA	UMUC3|T24	NPA	NPA	tumor-suppressive
1896	19671678	lung	lung cancer	NPA	miR-197	miR-197-3p	TUSC2	11334	NPA	NPA	expressed at higher levels in both SCLCs and NSCLCs than in HBECs|negatively correlated with TUSC2 expression in NSCLC tumor specimens	NPA	NPA	NSCLC tumor specimens	oncogenic
1897	19671678	lung	lung cancer	NPA	miR-93	miR-93-5p	TUSC2	11334	NPA	NPA	expressed at higher levels in small-cell lung cancer cell lines (SCLC) than in non-small-cell lung cancer cell lines (NSCLC) and immortalized human bronchial epithelial cells (HBEC)|negatively correlated with TUSC2 expression in NSCLC tumor specimens	NPA	NPA	NSCLC tumor specimens	oncogenic
1898	19671678	lung	lung cancer	NPA	miR-98	miR-98-5p	TUSC2	11334	NPA	NPA	expressed at higher levels in small-cell lung cancer cell lines (SCLC) than in non-small-cell lung cancer cell lines (NSCLC) and immortalized human bronchial epithelial cells (HBEC)	NPA	NPA	NPA	oncogenic
1899	19666866	blood	classic Hodgkin lymphoma	NPA	miR-135a	miR-135a-5p	JAK2	3717	NPA	induce apoptosis|decrease cell growth	negatively correlated a higher probability of relapse (P = .04) and a shorter disease-free survival (P = .02)	NPA	NPA	89 homogeneously treated cHL patients with a median follow-up of 80 months	tumor-suppressive
1900	19665999	NPA	NPA	NPA	miR-205	miR-205-5p	LRP1	4035	NPA	inhibit cell migration	NPA	U87|SK-LU-1	NPA	NPA	tumor-suppressive
1901	19665978	breast	breast cancer	NPA	miR-200c	miR-200c-3p	BMI1	648	NPA	inhibit clonal expansion|inhibit cancer stem cells growth	"downregulated in human breast cancer stem cells, normal human and murine mammary stem/progenitor cells, and embryonal carcinoma cells"	NPA	NPA	NPA	tumor-suppressive
1902	19654003	lung	lung cancer	gemcitabine	miR-133b	miR-133b	MCL1|BCL2L2	4170|599	NPA	induce apoptosis following gemcitabine exposure	the lowest expression of miRNA in lung tumor tissue (28-fold reduction) compared to adjacent uninvolved tissue	H2009	NPA	lung tumor tissues and adjacent uninvolved tissues	tumor-suppressive
1903	19652553	NPA	NPA	hypoxia	miR-210	miR-210-3p	MNT	4335	HIF1A	reduce hypoxia-induced cell cycle arrest	elevated in multiple cancer types|correlated with metastasis of breast and melanoma tumors	NPA	NPA	NPA	oncogenic
1904	19638978	colorectum	colorectal cancer	NPA	miR-143	miR-143-3p	DNMT3A	1788	NPA	reduce cell growth|reduce colony formation	frequently downregulated in 87.5% (35 of 40) of colorectal carcinoma tissues compared with their adjacent non-cancerous colonic tissues|inversely correlated with DNMT3A mRNA and protein expression in CRC tissues	NPA	NPA	40 colorectal carcinoma tissues and their adjacent non-cancerous colonic tissues	tumor-suppressive
1905	19632201	bone and muscle	osteosarcoma	NPA	miR-34	miR-34a-5p|miR-34b-5p|miR-34c-5p	NPA	NPA	NPA	induce cell cycle arrest|induce apoptosis	decreased in tumor samples	U2OS|SAOS-2	NPA	117 primary osteosarcoma samples	tumor-suppressive
1906	19620785	bone and muscle	rhabdomyosarcoma	NPA	miR-206	miR-206	NPA	NPA	NPA	promote myogenic differentiation|block tumor growth	barely detectable in primary rhabdomyosarcoma (RMS) of both the embryonal and alveolar subtypes	NPA	xenografted mice	primary rhabdomyosarcoma (RMS)	tumor-suppressive
1907	19617899	liver	hepatocellular carcinoma	NPA	miR-122	miR-122-5p	NPA	NPA	HNF1A|HNF3A|HNF3B	inhibit cell migration|inhibit cell invasion	repressed in HCCs with poor prognosis	NPA	NPA	primary HCCs	tumor-suppressive
1908	19607815	stomach	gastrointestinal cancer	NPA	miR-122a	miR-122-5p	NPA	NPA	APC	inhibit cell growth	down-regulated in gastrointestinal cancer cell lines as well as primary carcinoma tissues	NPA	NPA	gastrointestinal primary carcinoma tissues	tumor-suppressive
1909	19597473	lung	small cell lung cancer	NPA	miR-17~92	CLUSTER:miR-17~92	NPA	NPA	NPA	promote cell growth|reduce reactive oxygen species (ROS) generation	NPA	NPA	NPA	NPA	oncogenic
1910	19597470	prostate	prostate cancer	NPA	miR-330	miR-330-5p	E2F1	1869	NPA	inhibit cell growth|induce apoptosis	significantly lower expressed in human prostate cancer cell lines than in nontumorigenic prostate epithelial cells|inversely correlated with E2F1 expression in cell lines and prostate cancer specimens	PC-3	NPA	prostate cancer tissues	tumor-suppressive
1911	19585654	liver	hepatocellular carcinoma cancer stem-like cells	NPA	miR-181	miR-181a-5p|miR-181b-5p|miR-181c-5p|miR-181d-5p	CDX2|GATA6|NLK	1045|2627|51701	NPA	promote tumor initiating ability	upregulated in EpCAM(+) HCC cells	NPA	NPA	NPA	oncogenic
1912	19584290	NPA	NPA	NPA	miR-29a	miR-29a-3p	CD276	80381	NPA	NPA	"down-regulated in a broad spectrum of solid tumors, including neuroblastoma, sarcomas, brain tumors, and tumor cell lines|highly expressed in normal tissues|inversely correlated with CD276 protein expression in both cell lines and tumor tissues tested"	NPA	NPA	"a broad spectrum of solid tumors, including neuroblastoma, sarcomas, brain tumors"	NPA
1913	19584290	NPA	NPA	NPA	miR-29b	miR-29b-3p	CD276	80381	NPA	NPA	"down-regulated in a broad spectrum of solid tumors, including neuroblastoma, sarcomas, brain tumors, and tumor cell lines|highly expressed in normal tissues|inversely correlated with CD276 protein expression in both cell lines and tumor tissues tested"	NPA	NPA	"a broad spectrum of solid tumors, including neuroblastoma, sarcomas, brain tumors"	NPA
1914	19584290	NPA	NPA	NPA	miR-29c	miR-29c-3p	CD276	80381	NPA	NPA	"down-regulated in a broad spectrum of solid tumors, including neuroblastoma, sarcomas, brain tumors, and tumor cell lines|highly expressed in normal tissues|inversely correlated with CD276 protein expression in both cell lines and tumor tissues tested"	NPA	NPA	"a broad spectrum of solid tumors, including neuroblastoma, sarcomas, brain tumors"	NPA
1915	19584283	liver	hepatocellular carcinoma	NPA	miR-122	miR-122-5p	CCNG1	900	NPA	reduce cell invasion|induce doxorubicin-induced apoptosis	downregulated with shorter survival and time to recurrence	NPA	NPA	HCC patients	tumor-suppressive
1916	19584269	breast	breast cancer	NPA	miR-661	miR-661	MTA1	9112	CEBPA	inhibit cell motility|inhibit cell invasion|inhibit cell growth|inhibit tumorigenicity	down-regulated in a breast cancer progression model consisting of MCF-10A cell lines	MCF10A	NPA	NPA	tumor-suppressive
1917	19584056	prostate	prostate cancer	NPA	miR-331-3p	miR-331-3p	ERBB2	2064	NPA	inhibit AR signaling|inhibit PI3K/AKT signaling	decreased in prostate cancer tissue relative to normal adjacent prostate tissue	NPA	NPA	prostate cancer tissue and normal adjacent prostate tissue	tumor-suppressive
1918	19578755	skin	melanoma	NPA	miR-155	miR-155-5p	NPA	NPA	NPA	inhibit cell proliferation|induce apoptosis	down-regulated in the majority of melanoma cell lines with respect to melanocytes	NPA	NPA	NPA	tumor-suppressive
1919	19578724	prostate	prostate cancer	NPA	miR-21	miR-21-5p	BMPR2	659	NPA	NPA	NPA	PC3|LNCAP	NPA	NPA	NPA
1920	19574223	breast	breast cancer	NPA	miR-182	miR-182-5p	FOXO1	2308	NPA	increase cell growth	highly expressed in MCF-7 breast cancer cells	MCF-7	NPA	NPA	oncogenic
1921	19574223	breast	breast cancer	NPA	miR-27a	miR-27a-3p	FOXO1	2308	NPA	increase cell growth	highly expressed in MCF-7 breast cancer cells	MCF-7	NPA	NPA	oncogenic
1922	19574223	breast	breast cancer	NPA	miR-96	miR-96-5p	FOXO1	2308	NPA	increase cell growth	highly expressed in MCF-7 breast cancer cells	MCF-7	NPA	NPA	oncogenic
1923	19572217	liver	hepatocellular carcinoma intrahepatic metastases	NPA	miR-9	miR-9-5p	NPA	NPA	NPA	promote cell migration	up-regulated in primary HCC with metastases	SK-Hep-1	NPA	primary metastasis-free HCC and primary HCC with intrahepatic metastases	oncogenic
1924	19570947	breast	breast cancer	NPA	miR-125b	miR-125b-5p	CYP24A1	1591	NPA	NPA	significantly (P < 0.0005) lower in cancer tissues than those in normal tissues|inversely correlated with CYP24 protein levels in cancer tissues	KGN|MCF-7	NPA	human breast cancer and adjacent normal tissues	NPA
1925	21475881	brain	glioma	NPA	miR-221	miR-221-3p	CDKN1B	1027	NPA	NPA	upregulated with glioma malignancy	NPA	NPA	human glioma tissues of varying grades of malignancy	NPA
1926	19559015	brain	glioblastoma multiforme	VM-26	miR-21	miR-21-5p	LRRFIP1	9208	NPA	induce VM-26 resistance	NPA	U373	NPA	NPA	NPA
1927	19549910	lung	non-small cell lung cancer	NPA	miR-15a	miR-15a-5p	CCND1|CCND2|CCNE1	595|894|898	NPA	induce cell cycle arrest in G(1)-G(0)	frequently deleted or down-regulated in squamous cell carcinomas and adenocarcinomas of the lung	A549|H2009	NPA	laser capture microdissected tissues	tumor-suppressive
1928	19549910	lung	non-small cell lung cancer	NPA	miR-16	miR-16-5p	CCND1|CCND2|CCNE1	595|894|898	NPA	induce cell cycle arrest in G(1)-G(0)	frequently deleted or down-regulated in squamous cell carcinomas and adenocarcinomas of the lung	A549|H2009	NPA	laser capture microdissected tissues	tumor-suppressive
1929	19546886	head and neck	laryngeal carcinoma	NPA	miR-21	miR-21-5p	BTG2	7832	NPA	promote cell proliferation|promote cell cycle G1/S transition	upregulated in laryngeal carcinoma tissues	HEp-2	NPA	laryngeal carcinoma tissues and normal tissues	oncogenic
1930	19546220	breast	breast cancer	NPA	miR-27b	miR-27b-3p	ST14	6768	NPA	increase cell invasion	increased during cancer progression of human breast tumors	MDA-MB-231|MCF10A|ZR75	NPA	NPA	oncogenic
1931	19544444	prostate	prostate cancer	NPA	miR-200b	miR-200b-3p	NPA	NPA	NPA	inhibit cell migration|inhibit cell invasion|reduce cell adhesion|reduce cell detachment	NPA	PC-3	NPA	NPA	tumor-suppressive
1932	19540661	head and neck	head and neck squamous cell carcinoma	NPA	miR-138	miR-138-5p	NPA	NPA	NPA	inhibit cell invasion|induce cell cycle arrest|induce apoptosis	reduced in highly metastatic cancer cells	NPA	NPA	NPA	tumor-suppressive
1933	19535919	NPA	NPA	rapamycin	miR-30a	miR-30a-5p	BECN1	8678	NPA	inhibit autophagy	NPA	NPA	NPA	NPA	NPA
1934	19530237	blood	EBV-positive Burkitt lymphoma	NPA	miR-127	miR-127-3p	PRDM1	639	NPA	block the B-cell differentiation process	strongly upregulated only in EBV-positive BL samples compared to normal conrols|differentially expressed between EBV-positive and EBV-negative Burkitt lymphomas (BLs)	NPA	NPA	"EBV-positive, EBV-negative Burkitt lymphomas (BLs) and normal controls"	NPA
1935	19524507	breast	breast cancer	NPA	miR-31	miR-31-5p	RHOA	387	NPA	inhibit metastasis|inhibit local invasion|inhibit extravasation|reduce initial survival at a distant site|reduce metastatic colonization	inversely correlated with metastasis in human breast cancer patients	NPA	NPA	human breast cancer patients	tumor-suppressive
1936	19524505	liver	hepatocellular carcinoma	NPA	miR-26a	miR-26a-5p	CCND2|CCNE2	894|9134	NPA	induce cell cycle arrest|inhibit cell proliferation|induce tumor-specific apoptosis	reduced in hepatocellular carcinoma cells	NPA	a mouse model of HCC using adeno-associated virus (AAV)	NPA	tumor-suppressive
1937	19520829	brain	glioma	NPA	miR-222	miR-222-3p	ICAM1	3383	DICER1	inhibit CTL-mediated cytolysis	inversely correlated with ICAM1 expression	U87	NPA	30 primary glioblastoma tissues	NPA
1938	19520829	brain	glioma	NPA	miR-339	miR-339-5p	ICAM1	3383	DICER1	inhibit CTL-mediated cytolysis	inversely correlated with ICAM1 expression	U87	NPA	30 primary glioblastoma tissues	NPA
1939	19509158	head and neck	tongue squamous cell carcinoma	NPA	miR-21	miR-21-5p	NPA	NPA	NPA	increase cell survival|increase cell growth|inhibit apoptosis	overexpressed in TSCC relative to adjacent normal tissues|an independent prognostic factor indicating poor survival	NPA	NPA	103 patients of tongue squamous cell carcinomas	oncogenic
1940	19503096	stomach	gastric cancer	5-aza-2'-deoxycytidine (5-Aza-CdR)|4-phenylbutyric acid (PBA)	miR-512-5p	miR-512-5p	MCL1	4170	DNA hypermethylation|histone modifications|Alu repeats	induce apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
1941	19501585	esophagus	esophageal squamous cell carcinoma	NPA	miR-373	miR-373-3p	LATS2	26524	NPA	promote cell growth	over-expressed in ESCC samples	NPA	NPA	esophageal cancer tissues from esophageal squamous cell carcinoma (ESCC) patients	oncogenic
1942	19501389	ovary	ovarian cancer	NPA	miR-200ba~429	CLUSTER:miR-200ba~429	NPA	NPA	NPA	inhibit cell migration	significantly associated with cancer recurrence and overall survival	NPA	NPA	55 advanced ovarian tumors	tumor-suppressive
1943	19493678	lung	EGFR mutant non-small cell lung cancer	NPA	miR-145	miR-145-5p	NPA	NPA	NPA	inhibit cell growth	downregulated in lung cancer tissues	NPA	NPA	lung cancer tissue and adjacent normal lung parenchyma of 10 non-smoking patients	tumor-suppressive
1944	19490101	liver	hepatocellular carcinoma	NPA	miR-23b	miR-23b-3p	PLAUR|MET	5329|4233	NPA	inhibit cell migration|inhibit cell proliferation	NPA	SKHep1C3	NPA	NPA	tumor-suppressive
1945	19487573	brain	glioma	NPA	miR-26a	miR-26a-5p	PTEN	5728	NPA	promote tumor formation	frequently amplified at the DNA level in human glioma	NPA	NPA	NPA	oncogenic
1946	19487542	head and neck	oral tongue squamous cell carcinoma	NPA	miR-222	miR-222-3p	MMP1|SOD2	4312|6648	NPA	inhibit cell invasion	NPA	NPA	NPA	NPA	tumor-suppressive
1947	19487295	bladder	bladder cancer	NPA	miR-129	miR-129-5p	GALNT1|SOX4	2589|6659	NPA	inhibit cell growth|induce cell death	associated with disease progression	T24|SW780	NPA	11 normal and 106 bladder tumor samples	tumor-suppressive
1948	19486885	NPA	NPA	NPA	miR-548d-3p	miR-548d-3p	ERBB2	2064	NPA	NPA	NPA	NPA	NPA	NPA	NPA
1949	19486885	NPA	NPA	NPA	miR-559	miR-559	ERBB2	2064	NPA	NPA	NPA	NPA	NPA	NPA	NPA
1950	19486339	liver	hepatocellular carcinoma	NPA	miR-106b	miR-106b-5p	E2F1	1869	NPA	promote cell proliferation	overexpressed in HCCs	NPA	NPA	HCC samples	oncogenic
1951	19486339	liver	hepatocellular carcinoma	NPA	miR-93	miR-93-5p	E2F1	1869	NPA	promote cell proliferation	overexpressed in HCCs	NPA	NPA	HCC samples	oncogenic
1952	19472311	liver	HBV+ hepatocellular carcinoma	Hepatitis B virus X protein (HBx)	miR-143	miR-143-3p	FNDC3B	64778	NF¦ÊB	promote cell invasion|promote cell migration|promote metastasis	upregulated in HCCs	NPA	p21-HBx transgenic mice	HCC patients	oncogenic
1953	19471102	brain	glioma	all-trans-retinoic acid (ATRA)	miR-125b	miR-125b-5p	BMF	90427	NPA	increase cell viability|increase cell proliferation|inhibit apoptosis|reduce ATRA sensitivity	NPA	U343	NPA	NPA	oncogenic
1954	19464056	blood	T-cell leukemia Jurkat cells	CH-11	miR-143	miR-143-3p	NPA	NPA	NPA	inhibit cell growth|increase CH-11 induced apptosis	NPA	NPA	NPA	NPA	tumor-suppressive
1955	19441017	liver	hepatocellular carcinoma	NPA	miR-195	miR-195-5p	CCND1|CDK6|E2F3	595|1021|1871	NPA	inhibit cell cycle G1/S transition|inhibit colony formation	significantly reduced in HCCs	NPA	nude mice	HCC tissues	tumor-suppressive
1956	19437538	breast	breast cancer	NPA	miR-125b	miR-125b-5p	VDR	7421	NPA	increase cell proliferation	downregulated in cancer	MCF-7|KGN	NPA	NPA	oncogenic
1957	19435910	blood	acute lymphoblastic leukemia	NPA	miR-124a	miR-124-3p	CDK6	1021	DNA hypermethylation|histone modifications	reduce tumorigenicity	down-regulated in ALL	NPA	a xenogeneic in vivo Rag2(-/-)gammac(-/-) mouse model	353 patients diagnosed with ALL	tumor-suppressive
1958	19435871	NPA	NPA	NPA	miR-200c	miR-200c-3p	TUBB3	10381	NPA	reduce cell migration|reduce cell invasion|reduce resistance of microtubule-binding chemotherapeutic agents	"high in well-differentiated endometrial, breast, and ovarian cancer cell lines, but extremely low in poorly differentiated cancer cells"	NPA	NPA	NPA	tumor-suppressive
1959	19435867	pancreas	pancreatic cancer	chemoresistance	miR-21	miR-21-5p	NPA	NPA	NPA	increase cell proliferation|increase cell invasion|increase gemcitabine chemoresistance	markedly overexpressed in cancer tissues in nonmalignant tissues	NPA	NPA	25 cancer tissues and 25 normal tissues	oncogenic
1960	19427019	brain	medulloblastoma	NPA	miR-124	miR-124-3p	SLC16A1	6566	NPA	inhibit cell proliferation	"significant down-regulation in 21 (72%) tumors by at least 2-fold, with 11 of them exhibiting greater than 10-fold reduced level compared to normal cerebella"	ONS-76|DAOY	NPA	29 medulloblastomas	tumor-suppressive
1961	19424584	brain	glioma	NPA	miR-221	miR-221-3p	NPA	NPA	NPA	promote cell cycle G1/S transition|promote cell proliferation|increase tumor growth	NPA	U251	U251 glioma subcutaneous mice	NPA	oncogenic
1962	19424584	brain	glioma	NPA	miR-222	miR-222-3p	NPA	NPA	NPA	promote cell cycle G1/S transition|promote cell proliferation|increase tumor growth	NPA	U251	U251 glioma subcutaneous mice	NPA	oncogenic
1963	19423651	breast	breast cancer	NPA	miR-206	miR-206	NPA	NPA	EGF|EGFR	reduce cell proliferation|induce apoptosis	NPA	MDA-MB-231|MCF-7	NPA	NPA	tumor-suppressive
1964	19422085	esophagus	esophageal adenocarcinoma	NPA	miR-106b	miR-106b-5p	CDKN1A	1026	NPA	promote cell proliferation|promote cell cycle progression|inhibit apoptosis	upregulated progressively at successive stages of neoplasia	HEEpiC|QhTRT|ChTRT|GihTRT|OE-33	NPA	"22 normal epithelia, 24 Barrett's esophagus (BE), and 22 esophageal adenocarcinoma (EAC)"	oncogenic
1965	19422085	esophagus	esophageal adenocarcinoma	NPA	miR-25	miR-25-3p	BCL2L11	10018	NPA	promote cell proliferation|promote cell cycle progression|inhibit apoptosis	upregulated progressively at successive stages of neoplasia	HEEpiC|QhTRT|ChTRT|GihTRT|OE-33	NPA	"22 normal epithelia, 24 Barrett's esophagus (BE), and 22 esophageal adenocarcinoma (EAC)"	oncogenic
1966	19422085	esophagus	esophageal adenocarcinoma	NPA	miR-93	miR-93-5p	CDKN1A	1026	NPA	promote cell proliferation|promote cell cycle progression|inhibit apoptosis	upregulated progressively at successive stages of neoplasia	HEEpiC|QhTRT|ChTRT|GihTRT|OE-33	NPA	"22 normal epithelia, 24 Barrett's esophagus (BE), and 22 esophageal adenocarcinoma (EAC)"	oncogenic
1967	19418581	colorectum	colorectal cancer	NPA	miR-196a	miR-196a-5p	NPA	NPA	NPA	increase AKT signaling|increase cell detachment|increase cell migration|increase cell invasion	NPA	SW480	a xenograft lung metastasis model	NPA	oncogenic
1968	19414598	breast	breast cancer	NPA	miR-22	miR-22-3p	ESR1	2099	NPA	inhibit ESR1 dependent cell proliferation	NPA	NPA	NPA	NPA	NPA
1969	19407485	pancreas	pancreatic cancer	5-aza-2'-deoxycytidine	miR-107	miR-107	NPA	NPA	NPA	inhibit cell growth	overexpressed in 5-Aza-dC treated cells	MiaPACA-2|PANC-1	NPA	NPA	tumor-suppressive
1970	19401561	blood	multiple myeloma	NPA	miR-15a	miR-15a-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell growth	downregulated in multiple myeloma	NPA	NPA	bone marrow derived CD138(+) MM cells versus their normal cellular counterparts	tumor-suppressive
1971	19401561	blood	multiple myeloma	NPA	miR-16	miR-16-5p	NPA	NPA	NPA	inhibit cell proliferation|inhibit cell growth	downregulated in multiple myeloma	NPA	NPA	bone marrow derived CD138(+) MM cells versus their normal cellular counterparts	tumor-suppressive
1972	19396866	head and neck	oral squamous cell carcinoma	NPA	miR-100	miR-100-5p	NPA	NPA	NPA	inhibit cell proliferation	down-regulated in OSCC tumor and cell lines	NPA	NPA	oral squamous cell carcinoma tissues	tumor-suppressive
1973	19396866	head and neck	oral squamous cell carcinoma	NPA	miR-125b	miR-125b-5p	NPA	NPA	NPA	inhibit cell proliferation	down-regulated in OSCC tumor and cell lines	NPA	NPA	oral squamous cell carcinoma tissues	tumor-suppressive
1974	19378336	bladder	bladder cancer	NPA	miR-133a	miR-133a-3p	NPA	NPA	NPA	inhibit cell growth	significantly downregulated in bladder cancer tissues	KK47	NPA	"14 bladder cancers (BC), 5 normal bladder epithelium (NBE) samples|104 BCs and 31 NBEs"	tumor-suppressive
1975	19378336	bladder	bladder cancer	NPA	miR-199a*	miR-199a-3p	NPA	NPA	NPA	inhibit cell growth	significantly downregulated in bladder cancer tissues	KK47	NPA	"14 bladder cancers (BC), 5 normal bladder epithelium (NBE) samples|104 BCs and 31 NBEs"	tumor-suppressive
1976	19378336	bladder	bladder cancer	NPA	miR-30-3p	miR-30a-3p	NPA	NPA	NPA	inhibit cell growth	significantly downregulated in bladder cancer tissues	KK47	NPA	"14 bladder cancers (BC), 5 normal bladder epithelium (NBE) samples|104 BCs and 31 NBEs"	tumor-suppressive
1977	19372139	NPA	NPA	NPA	miR-18a*	miR-18a-3p	KRAS	3845	NPA	inhibit cell proliferation	NPA	HT29|A432|WRL-68	NPA	NPA	tumor-suppressive
1978	19363643	stomach	gastric cancer	NPA	miR-141	miR-141-3p	NPA	NPA	NPA	inhibit cell proliferation	significantly down-regulated in 80% (28/35) of primary gastric cancer tissues compared with pair-matched adjacent non-tumor tissues (P < 0.01)	MGC-803|HGC-27|SGC-7901|BGC-823	NPA	35 pair-matched gastric neoplastic and adjacent non-neoplastic tissues	tumor-suppressive
1979	19360360	breast	breast cancer	NPA	miR-145	miR-145-5p	RTKN	6242	NPA	inhibit cell growth|induce apoptosis	down-regulated in human cancer cell line MCF-7 when compared to normal human mammary epithelial cell line MCF10A	MCF-7|MFC10A	NPA	NPA	tumor-suppressive
1980	19342367	esophagus	esophageal adenocarcinoma	NPA	miR-196a	miR-196a-5p	KRT5|SPRR2C|S100A9	3852|6702|6280	NPA	NPA	"highly expressed in esophageal adenocarcinoma (EA), Barrett's esophagus (BE), and dysplastic lesions compared with normal squamous mucosa, and in high-grade dysplasia compared with BE and low-grade dysplasia"	NPA	NPA	microdissected paraffin-embedded tissues from 11 patients|frozen tumor tissues from 10 additional patients who had advanced EA	NPA
1981	19323605	pancreas	pancreatic ductal adenocarcinoma	NPA	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	NPA	NPA	NPA	inhibit cell proliferation	"strongly reduced in PDAC samples, as compared with adjacent tissue"	Capan-1	NPA	PDAC samples and adjacent tissue	tumor-suppressive
1982	19318487	stomach	gastric cancer	radiation	miR-451	miR-451a	MIF	6280	NPA	reduce cell proliferation|increase radiotherapy	positively associated with better prognosis|decreased in gastric and colorectal cancer versus nontumoral tissues	NPA	NPA	paraffin-embedded tumor samples of 21 patients with gastric cancer stage III uniformly treated with surgical resection followed by chemoradiation|24 other patients	tumor-suppressive
1983	19308264	brain	medulloblastoma	5-aza-deoxycytidine	miR-199b-5p	miR-199b-5p	HES1	3280	NPA	inhibit cell proliferation	significantly higher in the non-metastatic cases than in the metastatic cases|positively correlated with the survival	Med8a|UW228	xenograft model in the mouse cerebellum	61 patients with medulloblastoma tumors	tumor-suppressive
1984	19308091	breast	breast cancer	NPA	miR-21	miR-21-5p	PDCD4	27250	BMP6|ZEB1|PLAT	NPA	NPA	MDA-MB-231	NPA	NPA	NPA
1985	19302977	prostate	prostate cancer	NPA	miR-21	miR-21-5p	MARCKS	4082	NPA	inhibit apoptosis|promote cell motility|promote cell invasion	NPA	DU145|PC-3	NPA	NPA	oncogenic
1986	19296470	liver	hepatocellular carcinoma	NPA	miR-122	miR-122-5p	ADAM17	6868	NPA	inhibit cell migration|inhibit cell invasion|inhibit cell growth|inhibit in vivo tumorigenesis|inhibit angiogenesis|inhibit intrahepatic metastasis	down-regulated in liver cancers with intrahepatic metastasis	Mahlavu|SK-HEP-1	orthotopic liver cancer model|nude mice	NPA	tumor-suppressive
1987	19296468	liver	cholangiocarcinoma	NPA	miR-21	miR-21-5p	PDCD4|TIMP3	27250|7078	NPA	NPA	overexpressed in cholangiocarcinomas	NPA	NPA	five primary CCAs and five normal bile duct specimens|18 additional primary CCAs and 12 normal liver specimens	oncogenic
1988	19296468	liver	cholangiocarcinoma	NPA	miR-21	miR-21-5p	PDCD4|TIMP3	27250|7078	NPA	NPA	up-regulated in CCAs	NPA	NPA	"five primary cholangiocarcinomas (CCAs) and five normal bile duct specimens (NBDs), 18 additional primary CCAs and 12 normal liver specimens"	oncogenic
1989	19276373	breast	breast cancer	gefitinib|lapatinib	miR-205	miR-205-5p	ERBB3	2065	NPA	reduce clonogenic potential|induce apoptosis	down-modulated in breast tumors compared with normal breast tissue	SKBr3	NPA	breast tumors and normal breast tissue	tumor-suppressive
1990	19276261	esophagus	esophageal squamous cell carcinoma	NPA	miR-21	miR-21-5p	PDCD4	27250	NPA	increase cell proliferation|increase cell invasion	overexpressed in 18 out of 20 cancer tissues compared with matched normal epitheliums|positively correlated with lymph node metastasis or venous invasion|strong positive staining in paraffin-embedded esophageal squamous cell carcinoma tissues	TE6|TE8|TE10|TE11|TE12|TE14|KYSE30	NPA	20 matched normal esophageal epitheliums and esophageal squamous cell carcinomas	oncogenic
1991	19270061	breast	breast cancer	mitoxantrone	miR-328	miR-328-3p	ABCG2	9429	NPA	increase mitoxantrone sensitivity	NPA	MCF-7|MCF-7/MX100	NPA	NPA	NPA
1992	19265686	brain	glioma	NPA	miR-146b	miR-146b-5p	MMP16	4325	NPA	inhibit cell migration|inhibit cell invasion	significantly downregulated in human glioblastoma tissue	U373	NPA	human glioblastoma tissue	tumor-suppressive
1993	19264808	breast	breast cancer	estradiol	miR-21	miR-21-5p	PDCD4|PTEN|BCL2	27250|5728|596	NPA	NPA	NPA	MCF-7	NPA	NPA	oncogenic
1994	19258506	bladder	bladder transitional cell carcinoma	NPA	miR-101	miR-101-3p	EZH2	2146	NPA	inhibit cell proliferation|inhibit colony formation	down-regulated in bladder transitional cell carcinoma patient samples	NPA	NPA	bladder transitional cell carcinoma (TCC) patient samples	tumor-suppressive
1995	19258499	blood	acute myeloid leukemia	NPA	miR-34b	miR-34b-5p	CREB1	1385	NPA	inhibit cell cycle progression|reduce anchorage-independent cell growth	expressed significantly less in myeloid cell lines	NPA	NPA	a cohort of 78 pediatric patients at diagnosis of acute myeloid leukemia	tumor-suppressive
1996	19252524	prostate	prostate cancer	NPA	miR-449a	miR-449a	HDAC1	3065	NPA	inhibit cell growth|reduce cell viability	downregulated in prostate cancer tissues relative to patient-matched control tissue	PC-3	NPA	prostate cancer tissues and patient-matched control tissue	tumor-suppressive
1997	21475818	esophagus	esophageal squamous cell carcinoma	NPA	miR-21	miR-21-5p	NPA	NPA	NPA	promote cell proliferation	significantly higher in ESCC tissues than the corresponding non-cancerous mucosa|significantly higher in patients with more advanced (T3 or T4) tumors than in those with less advanced (T1 or T2) tumors|significantly higher in patients with patients with more invasive infiltrative growth pattern tumors	TE1|ET9	NPA	38 ESCC specimens and their paired non-cancerous mucosa	oncogenic
1998	19244118	prostate	prostate cancer	NPA	miR-205	miR-205-5p	PRKCE	5581	NPA	inhibit epithelial-to-mesenchymal transition|reduce cell migration|reduce cell invasion	significantly lower in cancer than in normal prostate cell lines as well as in tumor compared with matched normal prostate tissues	NPA	NPA	prostate cancer and matched normal prostate tissues	tumor-suppressive
1999	19238171	breast	breast cancer	NPA	miR-205	miR-205-5p	ERBB3|VEGFA	2065|7422	NPA	inhibit cell proliferation|inhibit anchorage-independent cell growth|inhibit cell invasion|inhibit lung metastasis	significantly underexpressed in breast tumor compared to the matched normal breast tissue	MCF-7|MDA-MB-231|MCF-10A	NPA	breast tumor and the matched normal breast tissue	tumor-suppressive
2000	19232136	breast	breast cancer	NPA	miR-10a	miR-10a-5p	HOXD4_promoter	***	NPA	NPA	NPA	NPA	NPA	NPA	NPA
2001	19228723	lung	lung cancer	NPA	miR-142-5p	miR-142-5p	NPA	NPA	NPA	inhibit cell growth	repressed in lung cancer tissues than normal tissues|repressed in transgenic lung cancers	NPA	transgenic mice	lung cancer tissues and normal tissues	tumor-suppressive
2002	19228723	lung	lung cancer	NPA	miR-145	miR-145-5p	NPA	NPA	NPA	inhibit cell growth	repressed in lung cancer tissues than normal tissues|repressed in transgenic lung cancers	NPA	transgenic mice	lung cancer tissues and normal tissues	tumor-suppressive
2003	19228723	lung	lung cancer	NPA	miR-34c	miR-34c-5p	NPA	NPA	NPA	inhibit cell growth	repressed in lung cancer tissues than normal tissues|repressed in transgenic lung cancers	NPA	transgenic mice	lung cancer tissues and normal tissues	tumor-suppressive
2004	19223510	NPA	NPA	NPA	miR-30e	miR-30e-5p	UBC9	7329	NPA	inhibit cell growth	underexpressed in tumors	NPA	NPA	eight pairs of matched breast tumor specimens	tumor-suppressive
2005	19223090	lung	lung cancer	NPA	miR-126	miR-126-3p	VEGFA	7422	NPA	inhibit cell growth|induce cell cycle G1 arrest	down-regulated in cancer cells	A549|Y-90|SPC-A1	nude mice tumor xenograft model	NPA	tumor-suppressive
2006	19221487	blood	myeloid leukemia	"1,25-dihydroxyvitamin D3"	miR-181a	miR-181a-5p	CDKN1B	1027	NPA	reduce cell cycle G1 arrest|reduce drug-induced cell differentiation	NPA	HL60|U937	NPA	NPA	NPA
2007	19219026	NPA	NPA	NPA	miR-23a	miR-23a-3p	GLS	27165	MYC	inhibit glutamine catabolism	NPA	P-493|PC3	NPA	NPA	NPA
2008	19219026	NPA	NPA	NPA	miR-23b	miR-23b-3p	GLS	27165	MYC	inhibit glutamine catabolism	NPA	P-493|PC3	NPA	NPA	NPA
2009	19211935	blood	acute myeloid leukemia	NPA	miR-29b	miR-29b-3p	DNMT3A|DNMT3B|SP1	1788|1789|6667	NPA	induce global DNA hypomethylation	NPA	NPA	NPA	NPA	NPA
2010	19211792	NPA	NPA	NPA	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	NPA	NPA	MYC|LIN29B	NPA	NPA	NPA	NPA	NPA	NPA
2011	19202062	NPA	NPA	NPA	miR-145	miR-145-5p	MYC	4609	TP53	NPA	NPA	NPA	NPA	NPA	tumor-suppressive
2012	19190326	breast	breast cancer	NPA	miR-146a	miR-146a-5p	NPA	NPA	BRMS1	inhibit cell invasion|inhibit cell migration|reduce lung metastasis	NPA	MDA-MB-231|MDA-MB-435	NPA	NPA	tumor-suppressive
2013	19190326	breast	breast cancer	NPA	miR-146b	miR-146b-5p	NPA	NPA	BRMS1	inhibit cell invasion|inhibit cell migration|reduce lung metastasis	NPA	MDA-MB-231|MDA-MB-435	NPA	NPA	tumor-suppressive
2014	19188590	skin	melanoma	NPA	miR-182	miR-182-5p	FOXO3|MITF	2309|4286	genomic_amplification	promote cell migration|increase metastasis|promote cell survival	commonly up-regulated in human melanoma cell lines and tissue samples|correlated with progression from primary to metastatic melanoma	NPA	NPA	human melanoma tissue samples	oncogenic
2015	19177201	blood	Hodgkin lymphoma	NPA	miR-155	miR-155-5p	AGTR1|FGF7|ZNF537|ZIC3|IKBKE	185|2252|57616|7547|9641	NPA	NPA	highly expressed in Hodgkin lymphomas	NPA	NPA	NPA	NPA
2016	19158933	prostate	prostate cancer	NPA	miR-373	miR-373-3p	CD44	960	NPA	increase cell migration|increase cell invasion	decreased in prostate cancer cell lines and tissues	PC-3M	NPA	prostate cancer tissues	oncogenic
2017	19158933	prostate	prostate cancer	NPA	miR-520c	miR-520c-3p	CD44	960	NPA	increase cell migration|increase cell invasion	decreased in prostate cancer cell lines and tissues	PC-3M	NPA	prostate cancer tissues	oncogenic
2018	19157460	bladder	bladder cancer	NPA	miR-143	miR-143-3p	NPA	NPA	NPA	inhibit cell proliferation|inhibit RAS signaling	significantly down-regulated in bladder tumor tissues compared with normal adjacent tissues	EJ|T24	NPA	bladder tumor tissues and normal adjacent tissues	tumor-suppressive
2019	19155302	liver	hepatocellular carcinoma	NPA	miR-101	miR-101-3p	MCL1	4170	NPA	inhibit colony formation|induce apoptosis	down-regulated in HCCs	NPA	nude mice	human HCCs and normal hepatic tissues	tumor-suppressive
2020	19155294	blood	MLL rearrangement leukemia	NPA	miR-17~92	CLUSTER:miR-17~92	APP|RASSF2	351|9770	NPA	NPA	overexpressed in human MLL rearrangement leukemias	NPA	mouse	human MLL rearrangement leukemias	NPA
2021	19153603	breast	breast cancer	NPA	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	HMGA2	8091	PEBP1|LIN28	reduce bone metastasis	NPA	NPA	mice bearing RKIP-expressing breast tumour cells	NPA	tumor-suppressive
2022	19153141	stomach	gastric cancer	NPA	miR-106b	miR-106b-5p	CDKN1A	1026	NPA	increase cell cycle G1/S transition	upregulated in gastric cancer tissues compared to the corresponding normal tissues	NPA	NPA	gastric cancer tissues and the corresponding normal tissues	oncogenic
2023	19153141	stomach	gastric cancer	NPA	miR-221	miR-221-3p	CDKN1A|CDKN1C	1026|1028	NPA	increase cell cycle G1/S transition|increase tumor growth	upregulated in gastric cancer tissues compared to the corresponding normal tissues	NPA	mouse xenograft model	gastric cancer tissues and the corresponding normal tissues	oncogenic
2024	19153141	stomach	gastric cancer	NPA	miR-222	miR-222-3p	CDKN1A|CDKN1C	1026|1028	NPA	increase cell cycle G1/S transition|increase tumor growth	upregulated in gastric cancer tissues compared to the corresponding normal tissues	NPA	mouse xenograft model	gastric cancer tissues and the corresponding normal tissues	oncogenic
2025	19153141	stomach	gastric cancer	NPA	miR-25	miR-25-3p	CDKN1C	1028	NPA	increase cell cycle G1/S transition	upregulated in gastric cancer tissues compared to the corresponding normal tissues	NPA	NPA	gastric cancer tissues and the corresponding normal tissues	oncogenic
2026	19153141	stomach	gastric cancer	NPA	miR-93	miR-93-5p	CDKN1A	1026	NPA	increase cell cycle G1/S transition	upregulated in gastric cancer tissues compared to the corresponding normal tissues	NPA	NPA	gastric cancer tissues and the corresponding normal tissues	oncogenic
2027	19151778	blood	acute promyelocytic leukemia	all-trans-retinoic acid (ATRA)	miR-342	miR-342-3p	NPA	NPA	SPI1|IRF1|IRF9	promote ATRA-induced cell differentiation	NPA	NPA	NPA	NPA	NPA
2028	19148830	blood	T-cell acute lymphoblastic leukemia	etoposide	miR-17~92	CLUSTER:miR-17~92	NPA	NPA	NKX2-5	increase cell viability	NPA	MOLT-4	NPA	NPA	oncogenic
2029	19141645	NPA	NPA	hypoxia	miR-210	miR-210-3p	RAD52	5893	HIF1A	affect DNA repair and genetic instability in cancer	up-regulated in a hypoxia-inducible factor-1alpha-dependent manner in hypoxic cells	NPA	NPA	NPA	NPA
2030	19141645	NPA	NPA	hypoxia	miR-373	miR-373-3p	RAD23B	5887	HIF1A	affect DNA repair and genetic instability in cancer	up-regulated in a hypoxia-inducible factor-1alpha-dependent manner in hypoxic cells	NPA	NPA	NPA	NPA
2031	19137007	colorectum	colorectal cancer	NPA	miR-143	miR-143-3p	KRAS	3845	NPA	inhibit cell proliferation	differentially expressed in colorectal cancers compared with adjacent tissues	LoVo	NPA	13 pairs of matched colorectal cancer and normal adjacent tissue samples	tumor-suppressive
2032	19135980	brain	glioma	NPA	miR-15b	miR-15b-5p	CCNE1	898	NPA	induce cell cycle G0/G1 arrest	NPA	NPA	NPA	NPA	tumor-suppressive
2033	19135902	blood	leukemia	12-O-tetradecanoylphorbol-13-acetate (TPA)	miR-320	miR-320a|miR-320b|miR-320c|miR-320d|miR-320e	TFRC	7037	NPA	inhibit cell proliferation	NPA	HL-60	NPA	NPA	tumor-suppressive
2034	19133651	liver	hepatocellular carcinoma	NPA	miR-101	miR-101-3p	FOS	2353	NPA	inhibit cell invasion|inhibit cell migration	significantly down-regulated in HCCs	NPA	NPA	20 human HCC specimens and the matched non-tumor liver tissues	tumor-suppressive
2035	19133256	colorectum	colon cancer	NPA	miR-101	miR-101-3p	COX2	5743	NPA	NPA	NPA	NPA	NPA	colon cancer tissues and liver metastases derived from CRC patients	NPA
2036	19126397	skin	cutaneous melanoma	NPA	miR-221	miR-221-3p	KIT|CDKN1B	3815|1027	NPA	NPA	commonly up-regulated in melanomas	NPA	NPA	NPA	NPA
2037	19117988	head and neck	head and neck squamous cell carcinoma	NPA	miR-15a	miR-15a-5p	CCNE1	898	PRKCA	NPA	NPA	NPA	NPA	NPA	NPA
2038	19107213	prostate	prostate carcinoma	NPA	miR-221	miR-221-3p	NPA	NPA	NPA	increase tumor growth	general upregulation in patient-derived primary cell lines	LNCaP|PC3	LNCaP-derived tumors in SCID mice	NPA	oncogenic
2039	19107213	prostate	prostate carcinoma	NPA	miR-222	miR-222-3p	NPA	NPA	NPA	increase tumor growth	general upregulation in patient-derived primary cell lines	LNCaP|PC3	LNCaP-derived tumors in SCID mice	NPA	oncogenic
2040	19096009	blood	chronic lymphocytic leukemia	NPA	miR-106b	miR-106b-5p	ITCH	83737	E2F1|MYC	NPA	NPA	NPA	NPA	NPA	NPA
2041	19088023	colorectum	colon cancer	NPA	miR-192	miR-192-5p	DHFR	1719	TP53	inhibit cell proliferation|induce cell cycle G1 and G2 arrest	NPA	HCT116|RKO	NPA	NPA	tumor-suppressive
2042	19074899	ovary	epithelial ovarian cancer	cisplatin	let-7i	let-7i-5p	NPA	NPA	NPA	increase cisplatin sensitivity	significantly reduced in chemotherapy-resistant patients|significantly associated with the shorter progression-free survival of patients with late-stage ovarian cancer	NPA	NPA	69 epithelial ovarian cancer patients|another cohort with 62 patients|72 patients with late-stage ovarian cancer|an independent sample set with 53 patients	tumor-suppressive
2043	19074879	NPA	NPA	NPA	miR-199*	miR-199a-3p|miR-199b-3p	MET	4233	NPA	inhibit cell invasion|inhibit cell migration	NPA	NPA	NPA	NPA	tumor-suppressive
2044	19074879	NPA	NPA	NPA	miR-34b	miR-34b-5p	MET	4233	NPA	inhibit cell invasion|inhibit cell migration	NPA	NPA	NPA	NPA	tumor-suppressive
2045	19074879	NPA	NPA	NPA	miR-34c	miR-34c-5p	MET	4233	NPA	inhibit cell invasion|inhibit cell migration	NPA	NPA	NPA	NPA	tumor-suppressive
2046	19074876	NPA	NPA	genotoxic stress	miR-192	miR-192-5p	NPA	NPA	TP53	induce cell cycle arrest	NPA	NPA	NPA	NPA	tumor-suppressive
2047	19074876	NPA	NPA	genotoxic stress	miR-215	miR-215-5p	NPA	NPA	TP53	induce cell cycle arrest	NPA	NPA	NPA	NPA	tumor-suppressive
2048	19074875	NPA	NPA	5-fluorouracil	miR-192	miR-192-5p	NPA	NPA	TP53	inhibit colony formation|induce cell cycle arrest|increase cell detachment	detected at high levels in normal colon tissue but were severely reduced in many colon cancer samples	NPA	NPA	normal colon tissue and colon cancer samples	tumor-suppressive
2049	19074875	NPA	NPA	5-fluorouracil	miR-215	miR-215-5p	NPA	NPA	TP53	inhibit colony formation|induce cell cycle arrest|increase cell detachment	detected at high levels in normal colon tissue but were severely reduced in many colon cancer samples	NPA	NPA	normal colon tissue and colon cancer samples	tumor-suppressive
2050	19074828	blood	chronic myeloid leukemia	NPA	miR-10a	miR-10a-5p	USF2	7392	NPA	inhibit cell growth	downregulated in mononuclear and CD34(+) cells from patients with CML compared with healthy controls|down-regulated in 71% of the CML patients	NPA	NPA	85 newly diagnosed patients	tumor-suppressive
2051	19073608	NPA	NPA	NPA	miR-7	miR-7-5p	EGFR	1956	NPA	induce cell cycle arrest|induce cell death	NPA	NPA	NPA	NPA	tumor-suppressive
2052	19070389	liver	intrahepatic cholangiocarcinoma	NPA	miR-204	miR-204-5p	NPA	NPA	NPA	increase chemotherapeutic drug-triggered apoptosis	down-regulated in ICCs	NPA	NPA	"27 human ICCs, 10 normal cholangiocyte cells and 8 normal liver tissues"	tumor-suppressive
2053	19070389	liver	intrahepatic cholangiocarcinoma	NPA	miR-320	miR-320a|miR-320b|miR-320c|miR-320d|miR-320e	NPA	NPA	NPA	increase chemotherapeutic drug-triggered apoptosis	down-regulated in ICCs	NPA	NPA	"27 human ICCs, 10 normal cholangiocyte cells and 8 normal liver tissues"	tumor-suppressive
2054	19062714	colorectum	colorectal carcinoma	NPA	miR-143	miR-143-3p	NPA	NPA	NPA	inhibit cell proliferation	downregulated in tumors compared with adjacent normal tissues in 81% of colorectal carcinoma specimens	SW480	NPA	colorectal carcinoma specimens	tumor-suppressive
2055	19048628	breast	breast cancer	NPA	miR-17	miR-17-5p	BRCA1	672	NPA	NPA	NPA	NPA	NPA	42 patients with familial breast cancer	NPA
2056	19033458	skin	aggressive squamous cell carcinoma	NPA	miR-205	miR-205-5p	INPPL1	3636	NPA	increase Akt signaling|inhibit apoptosis	elevated in aggressive squamous cell carcinomas	NPA	NPA	NPA	oncogenic
2057	19029026	skin	uveal melanoma	NPA	miR-34a	miR-34a-5p	MET	4233	NPA	inhibit cell growth|inhibit cell migration	underexpressed in uveal melanoma cells than melanocytes	HEK293	NPA	NPA	tumor-suppressive
2058	19027010	liver	hepatocellular carcinoma	NPA	miR-18a	miR-18a-5p	ESR1	2099	NPA	promote cell proliferation	highly expressed in female HCCs	NPA	NPA	male and female HCC tissues	oncogenic
2059	19013014	brain	glioblastoma	NPA	miR-21	miR-21-5p	PDCD4|MTAP|SOX5	27250|4507|6660	NPA	inhibit apoptosis	NPA	T98G|A172|U87|U251	NPA	NPA	oncogenic
2060	19010882	brain	glioma	NPA	miR-128	miR-128-3p	BMI1	648	NPA	reduce cell proliferation|reduce tumor growth|block cell self-renewal	significantly downregulated in human glioblastoma specimens versus adjacent brain devoid of tumor	NPA	glioma xenograft	human glioblastoma specimens and adjacent brain devoid of tumor	tumor-suppressive
2061	19008416	prostate	prostate cancer	NPA	miR-101	miR-101-3p	EZH2	2146	NPA	genomic loss	decreased during cancer progression	NPA	NPA	16 clinically localized prostate cancer cells and 33 metastatic disease cells 	NPA
2062	19006648	liver	hepatocellular carcinoma	NPA	miR-34a	miR-34a-5p	MET	4233	NPA	inhibit cell migration|inhibit cell invasion	significantly down-regulated in HCCs	HepG2	NPA	25 HCC tissues and adjacent normal tissues	tumor-suppressive
2063	18977327	brain	glioma	NPA	miR-296	miR-296-5p	HGS	9146	NPA	promote angiogenesis	elevated in primary tumor endothelial cells isolated from human brain tumors compared to normal brain endothelial cells	NPA	tumor xenografts	NPA	oncogenic
2064	18977326	bone and muscle	skeletal myogenesis and rhabdomyosarcoma	NPA	miR-29	miR-29a-3p|miR-29b-3p|miR-29c-3p	YY1	7528	NF-kB|YY1|Polycomb	inhibit tumor growth|promote differentiation	epigenetically silenced in primary tumors	NPA	RMS in mice	primary tumors	tumor-suppressive
2065	18973228	brain	medulloblastoma	NPA	miR-125a	miR-125a-5p	NTRK3	4916	NPA	inhibit cell growth|induce apoptosis	downregulated in tumor samples	NPA	NPA	NPA	tumor-suppressive
2066	18973228	brain	medulloblastoma	NPA	miR-9	miR-9-5p	NTRK3	4916	NPA	inhibit cell growth|induce apoptosis	downregulated in tumor samples	NPA	NPA	NPA	tumor-suppressive
2067	18946016	head and neck	oral carcinoma	NPA	miR-211	miR-211-5p	NPA	NPA	NPA	increase cell proliferation|increase cell migration|increase colony formation	"correlated with the most advanced nodal metastasis, vascular invasion, and poor prognosis of oral carcinoma"	SAS|OECM-1	NPA	NPA	oncogenic
2068	18941111	blood	B-cell lymphoma	NPA	miR-17~92	CLUSTER:miR-17~92	CDKN1A	1026	NPA	increase cell growth|increase cell cycle G1/S transition	NPA	Raji|SUDHL4|Jeko-1	NPA	NPA	oncogenic
2069	18936236	blood	acute myeloid leukemia	NPA	miR-125b	miR-125b-5p	NPA	NPA	t(2;11)(p21;q23) translocation	inhibit terminal differentiation	NPA	HL60|NB4	NPA	NPA	NPA
2070	18931683	prostate	prostate cancer	NPA	miR-15a~16-1	CLUSTER:miR-15a~16-1	CCND1|WNT3A	595|89780	NPA	inhibit cell survival|ihibit cell proliferation|inhibit cell invasion|induce cell cycle arrest|inudce apoptosis	significantly decreased in cancer cells of advanced prostate tumors	NPA	immunodeficient NOD-SCID mice	NPA	tumor-suppressive
2071	18922890	breast	breast cancer	NPA	miR-7	miR-7-5p	PAK1	5585	HOXD10	inhibit cell motility|inhibit cell invasion|inhibit anchorage-independent cell growth	NPA	NPA	NPA	NPA	tumor-suppressive
2072	18850008	NPA	NPA	NPA	miR-21	miR-21-5p	PDCD4|PTEN	27250|5728	RAS|AP-1	NPA	the most frequently upregulated oncomir in solid tumors	NPA	NPA	NPA	oncogenic
2073	18841558	brain	glioma	NPA	miR-21	miR-21-5p	NPA	NPA	NPA	promote cell growth|inhibit apoptosis|increase cell invasion	NPA	U87	NPA	NPA	oncogenic
2074	18840437	lung	lung cancer	NPA	miR-183 	miR-183-5p	EZR	7430	NPA	inhibit cell migration|inhibit cell invasion	reversely correlated with the metastatic potential of lung cancer cells	NPA	NPA	NPA	tumor-suppressive
2075	18834857	breast	breast cancer	NPA	miR-126	miR-126-3p	IRS1	3667	NPA	block cell cycle G1-G0/S transition	underexpressed in breast cancer cells	HEK293|MFC-7	NPA	NPA	tumor-suppressive
2076	18834855	prostate	p53-defective prostate cancer	camptothecin	miR-34a	miR-34a-5p	SIRT1	23411	NPA	induce cell cycle arrest|inhibit cell growth|induce apoptosis	markedly reduced in p53-null PC3 cells and p53-mutated DU145 cells compared with LNCaP cells expressing wild-type p53	PC3|DU145|LNCaP	NPA	NPA	tumor-suppressive
2077	18832181	blood	acute myeloid leukemia	NPA	miR-126	miR-126-3p	NPA	NPA	NPA	inhibit apoptosis|increase cell viability|increase colony formation	upregulated in core-binding factor (CBF) AMLs	NPA	NPA	"t(15;17), MLL rearrangements, and core-binding factor (CBF) AMLs including both t(8;21) and inv(16) samples"	oncogenic
2078	18832181	blood	acute myeloid leukemia	NPA	miR-126*	miR-126-5p	NPA	NPA	NPA	inhibit apoptosis|increase cell viability|increase colony formation	upregulated in core-binding factor (CBF) AMLs	NPA	NPA	"t(15;17), MLL rearrangements, and core-binding factor (CBF) AMLs including both t(8;21) and inv(16) samples"	oncogenic
2079	18829576	brain	glioblastoma	NPA	miR-21	miR-21-5p	HNRNPK|TP63	3190|8626	NPA	increase cell growth|inhibit apoptosis|promote cell cycle	NPA	NPA	NPA	NPA	oncogenic
2080	18818396	blood	myeloid leukemia	NPA	miR-15a	miR-15a-5p	MYB	4602	MYB	induce cell cycle G1 arrest	NPA	K562	NPA	NPA	tumor-suppressive
2081	18818206	lung	lung cancer	NPA	miR-1	miR-1	MET|PIM1|FOXP1|HDAC4	4233|5292|27086|9759	CEBPA	inhibit cell growth|reduce replication potential|inhibit cell migration|inhibit clonogenic survival|inhibit tumor formation	down-regulated in human primary lung cancer tissues	A549|H1299|N417	nude mice	human primary lung cancer tissues	tumor-suppressive
2082	18810376	brain	glioma	NPA	miR-128	miR-128-3p	E2F3	1871	NPA	inhibit cell proliferation	down-regulated in glioma tissues and cell lines when compared to normal brain tissues	T98G	NPA	glioma tissues and normal brain tissues	tumor-suppressive
2083	18805502	breast	breast cancer	NPA	miR-192	miR-192-5p	ZEB1	6935	NPA	NPA	NPA	MDA-MB-231|MCF-7	NPA	NPA	NPA
2084	18803879	stomach	p53-mutant gastric cancer	NPA	miR-34	miR-34a-5p|miR-34b-5p|miR-34c-5p	BCL2	596	NPA	inhibit cell growth|induce cell cycle G1 arrest|inhibit tumorshphere formation and growth	NPA	Kato III|MKN-45	NPA	NPA	tumor-suppressive
2085	18798260	head and neck	head and neck squamous cell carcinoma	NPA	miR-21	miR-21-5p	NPA	NPA	NPA	increase cell growth|inhibit apoptosis	upregulated in cancer tissues	JHU-011|JHU-012	NPA	"4 primary HNSCC, 4 normal mucosal controls"	oncogenic
2086	18794849	stomach	gastric cancer	NPA	miR-21	miR-21-5p	RECK	8434	NPA	promote cell proliferation|promote cell invasion|inhibit apoptosis|promote cell migration	significantly overexpressed in human gastric cancer tissues|significantly overexpressed in H. pylori-infected gastric mucosa	AGS	NPA	human gastric cancer tissues|H. pylori-infected gastric mucosa	oncogenic
2087	18790736	breast	breast cancer	tamoxifen	miR-221	miR-221-3p	ESR1	2099	NPA	reduce tamoxifen resistance|induce cell cycle arrest|induce apoptosis	NPA	MCF-7|T47D	NPA	NPA	NPA
2088	18790736	breast	breast cancer	tamoxifen	miR-222	miR-222-3p	ESR1	2099	NPA	reduce tamoxifen resistance|induce cell cycle arrest|induce apoptosis	NPA	MCF-7|T47D	NPA	NPA	NPA
2089	18789835	stomach	gastric adenocarcinoma	NPA	miR-27a	miR-27a-3p	PHB	5245	NPA	promote cell growth	up-regulated in human gastric adenocarcinoma	NPA	NPA	gastric adenocarcinoma samples	oncogenic
2090	18765229	brain	glioblastoma	Imatinib mesylate	miR-451	miR-451a	NPA	NPA	SMAD3|SMAD4	inhibit neurosphere formation|inhibited GBM cell growth	upregulated in CD133- cancer cells than CD133+ cells	NPA	NPA	NPA	tumor-suppressive
2091	18758960	NPA	NPA	doxorubicin|paclitaxel|interferon-gamma	let-7a	let-7a-5p	CASP3	836	NPA	increase resistance|inhibit drug-induced apoptosis	NPA	A431|HepG2|A10A|MCF7	NPA	NPA	NPA
2092	18755897	colorectum	p53+ colon cancer	NPA	miR-34a	miR-34a-5p	SIRT1	23411	TP53	induce apoptosis	NPA	NPA	NPA	NPA	tumor-suppressive
2093	18755840	NPA	NPA	NPA	miR-302	miR-302a-3p	NPA	NPA	NPA	reprogram cancer cells to pluripotent states	NPA	NPA	NPA	NPA	NPA
2094	18728182	blood	multiple myeloma	NPA	miR-106b~25	CLUSTER:miR-106b~25	KAT2B	8850	NPA	NPA	upregulated in MMs and MGUS compared to healthy plasma cells	NPA	nude mice	"CD138+ bone marrow PCs from subjects with MM (n = 16), monoclonal gammopathy of undetermined significance (MGUS) (n = 6), and normal donors (n = 6)"	NPA
2095	18728182	blood	multiple myeloma	NPA	miR-181a	miR-181a-5p	KAT2B	8850	NPA	reduce tumor growth	upregulated in MMs and MGUS compared to healthy plasma cells	NPA	nude mice	"CD138+ bone marrow PCs from subjects with MM (n = 16), monoclonal gammopathy of undetermined significance (MGUS) (n = 6), and normal donors (n = 6)"	tumor-suppressive
2096	18728182	blood	multiple myeloma	NPA	miR-181b	miR-181b-5p	KAT2B	8850	NPA	reduce tumor growth	upregulated in MMs and MGUS compared to healthy plasma cells	NPA	nude mice	"CD138+ bone marrow PCs from subjects with MM (n = 16), monoclonal gammopathy of undetermined significance (MGUS) (n = 6), and normal donors (n = 6)"	tumor-suppressive
2097	18728182	blood	multiple myeloma	NPA	miR-19a	miR-19a-3p	SOCS1	8651	NPA	reduce tumor growth	upregulated in MMs but not in MGUS compared to healthy plasma cells	NPA	nude mice	"CD138+ bone marrow PCs from subjects with MM (n = 16), monoclonal gammopathy of undetermined significance (MGUS) (n = 6), and normal donors (n = 6)"	tumor-suppressive
2098	18728182	blood	multiple myeloma	NPA	miR-19b	miR-19b-3p	SOCS1	8651	NPA	reduce tumor growth	upregulated in MMs but not in MGUS compared to healthy plasma cells	NPA	nude mice	"CD138+ bone marrow PCs from subjects with MM (n = 16), monoclonal gammopathy of undetermined significance (MGUS) (n = 6), and normal donors (n = 6)"	tumor-suppressive
2099	18719384	NPA	NPA	NPA	miR-34a	miR-34a-5p	CDK6	1021	promoter CpG hypermethylation	induce senescence|induce cell cycle arrest	downregulated in cancers	NPA	NPA	24 primary prostate carcinomas|32 primary melanomas	tumor-suppressive
2100	18713946	blood	lymphoma	NPA	miR-26a	miR-26a-5p	EZH2	2146	MYC	inhibit cell proliferation|inhibit cell cycle progression	downregulated in primary human Burkitt lymphoma samples	NPA	a murine lymphoma model	primary human Burkitt lymphoma samples	tumor-suppressive
2101	18710654	brain	glioma	NPA	miR-181a	miR-181a-5p	NPA	NPA	NPA	inhibit cell growth|induce apoptosis|inhibit cell invasion	NPA	NPA	NPA	NPA	tumor-suppressive
2102	18710654	brain	glioma	NPA	miR-181b	miR-181b-5p	NPA	NPA	NPA	inhibit cell growth|induce apoptosis|inhibit cell invasion	NPA	NPA	NPA	NPA	tumor-suppressive
2103	18708755	NPA	NPA	NPA	miR-15a	miR-15a-5p	MYB	4602	PAX5	NPA	NPA	NPA	NPA	NPA	NPA
2104	18708755	NPA	NPA	NPA	miR-16	miR-16-5p	MYB	4602	PAX5	NPA	NPA	NPA	NPA	NPA	NPA
2105	18708351	breast	breast cancer	tamoxifen	miR-221	miR-221-3p	CDKN1B	1027	NPA	increase tamoxifen resistance	significantly (2-fold) elevated in HER2/neu-positive primary human breast cancer tissues compared with HER2/neu-negative tissue samples	MCF-7	NPA	primary breast tumors	oncogenic
2106	18708351	breast	breast cancer	tamoxifen	miR-222	miR-222-3p	CDKN1B	1027	NPA	increase tamoxifen resistance	significantly (2-fold) elevated in HER2/neu-positive primary human breast cancer tissues compared with HER2/neu-negative tissue samples	MCF-7	NPA	primary breast tumors	oncogenic
2107	18700235	NPA	NPA	NPA	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	DICER1	23405	DICER1	NPA	NPA	NPA	NPA	NPA	NPA
2108	18695042	breast	breast cancer	NPA	miR-17	miR-17-5p	CCND1	595	CCND1	inhibit cell proliferation|inhibit colony formation	NPA	NPA	NPA	NPA	tumor-suppressive
2109	18695042	breast	breast cancer	NPA	miR-20	miR-20a-5p	CCND1	595	CCND1	inhibit cell proliferation|inhibit colony formation	NPA	NPA	NPA	NPA	tumor-suppressive
2110	18692484	liver	hepatocellular carcinoma	NPA	miR-122	miR-122-5p	BCL2L2	599	NPA	induce apoptosis|reduce cell viability	frequently down-regulated in human hepatocellular carcinoma (HCC)	HepG2|Hep3B	NPA	NPA	tumor-suppressive
2111	18688024	liver	hepatocellular carcinoma	NPA	miR-17~92	CLUSTER:miR-17~92	NPA	NPA	NPA	promote cell proliferation	NPA	NPA	NPA	NPA	oncogenic
2112	18688024	liver	hepatocellular carcinoma	NPA	miR-21	miR-21-5p	NPA	NPA	NPA	promote cell proliferation	NPA	NPA	NPA	NPA	oncogenic
2113	18686603	brain	glioma	NPA	miR-9	miR-9-5p	CBX7	23492	NPA	decrease cell survival|increase cell cycle G1 cells	up-regulated in glioma tissues and cell lines	T98G|293ET	NPA	"2 human normal brain tissues, 9 glioma tissues"	tumor-suppressive
2114	18682393	NPA	NPA	NPA	miR-150	miR-150-5p	P2RX7	5027	NPA	NPA	higher in cancer than in normal cells	NPA	NPA	NPA	NPA
2115	18682393	NPA	NPA	NPA	miR-186	miR-186-5p	P2RX7	5027	NPA	NPA	higher in cancer than in normal cells	NPA	NPA	NPA	NPA
2116	18679415	skin	malignant melanoma	NPA	let-7a	let-7a-5p	ITGB3	3690	NPA	inhibit cell invasion	down-regulated in melanomas by primary melanocytes and malignant melanoma cell lines	NPA	NPA	NPA	tumor-suppressive
2117	18676867	colorectum	colon cancer	NPA	miR-145	miR-145-5p	NPA	NPA	NPA	inhibit cell growth	the lowest expression in cancer relative to normal tissue	NPA	NPA	10 normal mucosa samples and 49 stage II colon cancers	tumor-suppressive
2118	18676839	prostate	prostate cancer	NPA	miR-1	miR-1	XPO6|JAK2	23214|3717	NPA	NPA	NPA	NPA	NPA	60 primary prostate tumors and 16 nontumor prostate tissues	NPA
2119	18676839	prostate	prostate cancer	NPA	miR-106b	miR-106b-5p	E2F1|CDKN1A	1869|1026	NPA	NPA	significantly higher in primary prostate tumors	NPA	NPA	60 primary prostate tumors and 16 nontumor prostate tissues	NPA
2120	18676839	prostate	prostate cancer	NPA	miR-32	miR-32-5p	BCL2L11	10018	NPA	NPA	significantly higher in primary prostate tumors	NPA	NPA	60 primary prostate tumors and 16 nontumor prostate tissues	NPA
2121	18668526	prostate	prostate cancer	radiation	miR-521	miR-521	NPA	NPA	NPA	increase radiation sensitivity	NPA	NPA	NPA	NPA	NPA
2122	18663744	colorectum	colon cancer	NPA	miR-126	miR-126-3p	PIK3R2	5296	NPA	NPA	ubiquitously downregulated in colon cancer lines compared to normal human colon epithelia	NPA	NPA	matched normal colon and primary colon tumors	tumor-suppressive
2123	18663355	esophagus	esophageal adenocarcinoma	NPA	miR-196a	miR-196a-5p	ANXA1	301	NPA	promote cell proliferation|increase anchorage-independent growth|inhibit apoptosis	increased in esophageal adenocarcinomas	NPA	NPA	10 esophageal adenocarcinomas|paired normal/tumor tissues from additional 10 patients	oncogenic
2124	18645025	breast	breast cancer	doxorubicin	miR-451	miR-451a	NPA	NPA	NPA	increase drug sensitivity	NPA	MCF-7	NPA	NPA	tumor-suppressive
2125	18632633	colorectum	colorectal cancer	NPA	miR-135	miR-135a-5p|miR-135b-5p	APC	324	NPA	induce Wnt signaling	upregulated in colorectal adenomas and carcinomas	NPA	NPA	colorectal adenomas and carcinomas	NPA
2126	18632605	lung	lung cancer	NPA	miR-17~92	CLUSTER:miR-17~92	HIF1A	3091	NPA	NPA	NPA	NPA	NPA	NPA	NPA
2127	18607543	brain	medulloblastoma	NPA	miR-124a	miR-124-3p	CDK6	1021	NPA	decrease cell growth	significantly decreased in medulloblastoma cells compared to normal adult cerebellum	NPA	NPA	NPA	tumor-suppressive
2128	18602365	lung	non-small cell lung cancer	NPA	miR-126	miR-126-3p	CRK	1398	NPA	inhibit cell migration|inhibit cell invasion|decrease cell adhesion	NPA	NPA	NPA	NPA	tumor-suppressive
2129	18596939	cervix	cervical cancer	NPA	miR-143	miR-143-3p	NPA	NPA	NPA	inhibit cell growth	downregulated in cervical cancer tissues	CaSki	NPA	age-matched normal cervix and cervical cancer tissues	tumor-suppressive
2130	18596939	cervix	cervical cancer	NPA	miR-145	miR-145-5p	NPA	NPA	NPA	inhibit cell growth	downregulated in cervical cancer tissues	CaSki	NPA	age-matched normal cervix and cervical cancer tissues	tumor-suppressive
2131	18596939	cervix	cervical cancer	NPA	miR-146a	miR-146a-5p	NPA	NPA	NPA	promote cell proliferation	upregulated in cervical cancer tissues	CaSki	NPA	age-matched normal cervix and cervical cancer tissues	oncogenic
2132	18593903	liver	hepatocellular carcinoma	5-azacytidine	miR-1	miR-1	FOXP1|MET	27086|4233	DNMT1|DNA hypermethylation	inhibitcell cycle progression|inhibit cell growth|induce apoptosis	significantly down-regulated in HCCs	NPA	NPA	primary human HCCs and matching liver tissues	tumor-suppressive
2133	18593897	breast	ERalpha-positive breast cancer	NPA	miR-206	miR-206	NPA	NPA	NPA	inhibit cell growth	markedly decreased in ERalpha-positive human breast cancer tissues	MCF-7	NPA	breast cancer tissues	tumor-suppressive
2134	18591254	brain	glioma	NPA	miR-21	miR-21-5p	RECK|TIMP3	8434|7078	NPA	promote cell invasion|promote cell migration	significantly elevated in glioblastoma (GBM)	NPA	NPA	NPA	oncogenic
2135	18577219	brain	glioblastoma multiforme	NPA	miR-124	miR-124-3p	NPA	NPA	NPA	induce cell cycle arrest	significantly decreased in anaplastic astrocytomas and glioblastoma multiforme relative to non-neoplastic brain tissues	U87|U251|SF6969	mouse oligodendroglioma	"anaplastic astrocytomas, glioblastoma multiforme and non-neoplastic brain tissues"	tumor-suppressive
2136	18577219	brain	glioblastoma multiforme	NPA	miR-137	miR-137	NPA	NPA	NPA	induce cell cycle arrest	significantly decreased in anaplastic astrocytomas and glioblastoma multiforme relative to non-neoplastic brain tissues	U87|U251|SF6969	mouse oligodendroglioma	"anaplastic astrocytomas, glioblastoma multiforme and non-neoplastic brain tissues"	tumor-suppressive
2137	18555017	liver	hepatocellular carcinoma	NPA	miR-223	miR-223-3p	STMN1	3925	NPA	inhibit cell viability	down-regulated in HCCs	NPA	NPA	"HCC tissues derived from chronic carriers of HBV, HCV, and nonviral-associated patients"	tumor-suppressive
2138	18538733	blood	chronic myelogenous leukemia|acute lymphoblastic leukemia	NPA	miR-203	miR-203a	ABL1|BCR-ABL1	25|***	chromosomal region deletion|DNA hypermethylation	inhibit cell proliferation	NPA	NPA	NPA	NPA	tumor-suppressive
2139	18521080	liver	hepatocellular carcinoma	NPA	miR-221	miR-221-3p	CDKN1C|CDKN1B	1028|1027	NPA	promote cell growth|increase cells in cell cycle S-phase	up-regulated in HCCs	NPA	NPA	"primary tumors, matched HCC and cirrhosis samples"	oncogenic
2140	18519671	colorectum	colorectal cancer	5-aza-2'-deoxycytidine	miR-34b	miR-34b-5p	NPA	NPA	DNA hypermethylation	NPA	NPA	NPA	NPA	111 primary CRC tumors and normal colonic mucosa	NPA
2141	18519671	colorectum	colorectal cancer	5-aza-2'-deoxycytidine	miR-34c	miR-34c-5p	NPA	NPA	DNA hypermethylation	NPA	NPA	NPA	NPA	111 primary CRC tumors and normal colonic mucosa	NPA
2142	18508316	liver	hepatocellular carcinoma	NPA	miR-23a~27a~24	CLUSTER:miR-23a~27a~24	NPA	NPA	TGFB1	inhibit apoptosis|promote cell proliferation	remarkably upregulated in HCC tissues versus normal liver tissues	Huh7	NPA	HCC tissues and normal liver tissues	oncogenic
2143	18505919	nerve	neuroblastoma with 1p36 deletion	NPA	miR-34a	miR-34a-5p	BCL2|MYCN	596|4613	NPA	inhibit cell growth|induce cell cycle arrest|induce apoptosis	decreased in primary tumors (n = 54) with 1p36 deletion	NPA	NPA	primary neuroblastomas (n = 54)	tumor-suppressive
2144	18504438	nerve	neuroblastoma with MYCN amplification	NPA	miR-34a	miR-34a-5p	MYCN	4613	NPA	inhibit cell growth|induce apoptosis|decrease DNA synthesis	neuroblastoma tumors with 1p36 loss expressed lower level of miR-34a than those with normal copies of 1p36	NPA	NPA	NPA	tumor-suppressive
2145	18504431	breast	breast cancer	NPA	miR-146	miR-146a-5p|miR-146b-5p	NPA	NPA	NPA	inhibit cell invasion|inhibit cell migration|inhibit NF-kB signaling	NPA	MDA-MB-231	NPA	NPA	tumor-suppressive
2146	18497571	prostate	prostate cancer	doxorubicin	miR-34	miR-34a-5p|miR-34b-5p|miR-34c-5p	NPA	NPA	NPA	induce apoptosis	NPA	LNCaP|DU145|PC3	NPA	NPA	tumor-suppressive
2147	18493594	nerve	neuroblastoma	NPA	miR-17-5p	miR-17-5p	BCL2L11|CDKN1A	10018|1026	MYCN	promote cell growth|promote therapy resistance	upregulated in primary neuroblastomas	NPA	NPA	primary neuroblastomas	oncogenic
2148	18483491	head and neck	head and neck squamous cell carcinoma	NPA	miR-203	miR-203a	TP63	8626	NPA	control cell survival	NPA	NPA	NPA	NPA	tumor-suppressive
2149	18483486	NPA	NPA	NPA	miR-141	miR-141-3p	TGFB2|ZEB1	7042|6935	ZEB1	inhibit epithelial-mesenchymal transition	NPA	NPA	NPA	NPA	NPA
2150	18483486	NPA	NPA	NPA	miR-200c	miR-200c-3p	TGFB2|ZEB1	7042|6935	ZEB1	inhibit epithelial-mesenchymal transition	NPA	NPA	NPA	NPA	NPA
2151	18483394	blood	mantle cell lymphoma	NPA	miR-16	miR-16-5p	CCND1	595	NPA	NPA	NPA	NPA	NPA	NPA	NPA
2152	18483236	brain	glioblastoma	NPA	miR-7	miR-7-5p	EGFR	1956	NPA	decrease cell viability|decrease cell invasion	down-regulated in glioblastoma versus surrounding brain	NPA	NPA	glioblastoma and surrounding brain	tumor-suppressive
2153	18456660	NPA	NPA	NPA	miR-199*	miR-199a-3p|miR-199b-3p	MET	4233	NPA	induce apoptosis	NPA	A549	NPA	NPA	tumor-suppressive
2154	18451220	head and neck	tongue squamous cell carcinoma	NPA	miR-184	miR-184	NPA	NPA	NPA	promote cell proliferation|inhibit apoptosis	overexpressed in cancer tissues	Cal27|HN21B|HN96	NPA	laser microdissected cells of 4 tongue carcinomas and paired normal tissues|20 paired tongue SCC and the normal tissues	oncogenic
2155	18451214	cervix	invasive squamous cell carcinomas	NPA	miR-199a	miR-199a-5p	NPA	NPA	NPA	inhibit cell growth	NPA	SiHa|ME-180	NPA	10 early stage invasive squamous cell carcinomas (ISCC) and 10 normal cervical squamous epithelial specimens	tumor-suppressive
2156	18449891	stomach	gastric cancer	multidrug resistance	miR-15b	miR-15b-5p	BCL2	596	NPA	increase drug sensitivity|reduce multidrug resistance|promote VCR-induced apoptosis	downregulated in multidrug- resistant gastric cancer cell line SGC7901/VCR compared to its parental SGC7901 cell line	SGC7901/VCR|SGC7901	NPA	NPA	tumor-suppressive
2157	18449891	stomach	gastric cancer	multidrug resistance	miR-16	miR-16-5p	BCL2	596	NPA	increase drug sensitivity|reduce multidrug resistance|promote VCR-induced apoptosis	downregulated in multidrug- resistant gastric cancer cell line SGC7901/VCR compared to its parental SGC7901 cell line	SGC7901/VCR|SGC7901	NPA	NPA	tumor-suppressive
2158	18429962	thyroid	anaplastic thyroid cancer	NPA	miR-17~92	CLUSTER:miR-17~92	NPA	NPA	NPA	promote cell growth|inhibit cell senescence	robustly overexpressed in cancer lesions compared to adjacent normal tissue	ARO|FRO	NPA	6 clinical ATC samples	oncogenic
2159	18417445	skin	melanoma	NPA	miR-221	miR-221-3p	CDKN1B|KIT	1027|3815	ZBTB16	promote cell proliferation|block differentiation	NPA	NPA	NPA	NPA	oncogenic
2160	18417445	skin	melanoma	NPA	miR-222	miR-222-3p	CDKN1B|KIT	1027|3815	ZBTB16	promote cell proliferation|block differentiation	NPA	NPA	NPA	NPA	oncogenic
2161	18406353	NPA	NPA	NPA	miR-34a	miR-34a-5p	CCND1|CDK6	595|1021	NPA	induce cell cycle G1 arrest	NPA	A549	NPA	NPA	tumor-suppressive
2162	18403645	uterus	uterine leiomyoma	NPA	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	HMGA2	8091	NPA	inhibit cell proliferation	significantly dysregulated in uterine leiomyomas|high in small leiomyomas and lower in large leiomyomas	NPA	NPA	a large cohort of leiomyomas (n = 120)	tumor-suppressive
2163	18390668	head and neck	nasopharyngeal carcinoma	NPA	miR-29c	miR-29c-3p	NPA	NPA	NPA	NPA	significantly downregulated in tumors as in normal epithelium	NPA	NPA	31 laser-capture-microdissected nasopharyngeal carcinomas (NPCs) and 10 normal healthy nasopharyngeal epithelial samples	NPA
2164	18381893	NPA	NPA	NPA	miR-200	miR-200a-3p|miR-200b-3p|miR-200c-3p	ZEB1|ZEB2	6935|9839	NPA	reduce cell motility|inhibit epithelial-to-mesenchymal transition	NPA	NPA	NPA	NPA	tumor-suppressive
2165	18379589	skin	melanoma	NPA	let-7b	let-7b-5p	CCND1	595	NPA	inhibit cell cycle progression|inhibit anchorage-independent cell growth	significantly downregulated in primary melanomas as compared with benign nevi	NPA	NPA	benign melanocytic nevi (n = 10) and primary malignant melanomas (n = 10)	tumor-suppressive
2166	18376396	breast	invasive breast cancer	NPA	miR-200	miR-200a-3p|miR-200b-3p|miR-200c-3p	ZEB1|ZEB2	6935|9839	NPA	inhibit epithelial to mesenchymal transition	downregulated in invasive breast cancer cell lines with mesenchymal phenotype|downregulated in metaplastic breast cancer specimens lacking E-cadherin	NPA	NPA	metaplastic breast cancer specimens	tumor-suppressive
2167	18376396	breast	invasive breast cancer	NPA	miR-205	miR-205-5p	ZEB1|ZEB2	6935|9839	NPA	inhibit epithelial to mesenchymal transition	downregulated in invasive breast cancer cell lines with mesenchymal phenotype|downregulated in metaplastic breast cancer specimens lacking E-cadherin	NPA	NPA	metaplastic breast cancer specimens	tumor-suppressive
2168	18372920	NPA	NPA	NPA	miR-21	miR-21-5p	PDCD4	27250	NPA	promote cell transformation	NPA	MCF-7	mouse	NPA	oncogenic
2169	18328430	stomach	gastric cancer	NPA	miR-106b~25	CLUSTER:miR-106b~25	E2F1	1869	E2F1	impair the TGFbeta tumor suppressor pathway	NPA	NPA	NPA	NPA	NPA
2170	18319255	liver	hepatocellular carcinoma	NPA	miR-224	miR-224-5p	API5	8539	NPA	promote cell proliferation|induce apoptosis	significantly up-regulated in HCCs	NPA	NPA	19 HCC patients	oncogenic
2171	18316599	skin	melanoma	NPA	miR-137	miR-137	MITF	4286	NPA	NPA	NPA	NPA	NPA	NPA	NPA
2172	18308936	lung	non-small cell lung cancer	NPA	let-7g	let-7g-5p	HMGA2	8091	NPA	induce cell cycle arrest|induce cell death|inhibit cell proliferation	NPA	NPA	murine tumor xenografts	NPA	tumor-suppressive
2173	18270520	breast	breast cancer	NPA	miR-21	miR-21-5p	TPM1|PDCD4|SERPINB5	7168|27250|5268	NPA	promote cell invasion|promote metastasis	NPA	MDA-MB-231	NPA	NPA	oncogenic
2174	18264139	colorectum	colorectal cancer	NPA	miR-342	miR-342-3p	NPA	NPA	EVL_intron|DNA hypermethylation	induce apoptosis	commonly suppressed in human colorectal cancer	HT29	NPA	colorectal adenocarcinomas and adenomas|histologically normal colorectal mucosa from individuals with concurrent cancer and mucosa from individuals without colorectal cancer	tumor-suppressive
2175	18246122	lung	non-small cell lung cancer	TRAIL	miR-221	miR-221-3p	KIT|CDKN1B	3815|1027	NPA	inhibit TRAIL-dependent apoptosis	increased in TRAIL-resistant NSCLC cells	NPA	NPA	NPA	oncogenic
2176	18246122	lung	non-small cell lung cancer	TRAIL	miR-222	miR-222-3p	KIT|CDKN1B	3815|1027	NPA	inhibit TRAIL-dependent apoptosis	increased in TRAIL-resistant NSCLC cells	NPA	NPA	NPA	oncogenic
2177	18201269	thyroid	anaplastic thyroid carcinoma	NPA	miR-138	miR-138-5p	TERT	7015	NPA	NPA	significantly downregulated in anaplastic thyroid carcinoma cell lines in comparison with papillary thyroid carcinomas	NPA	NPA	11 thyroid carcinoma patients (three ATC and eight PTC)	NPA
2178	18199536	ovary	ovarian cancer	cisplatin	miR-214	miR-214-3p	PTEN	5728	NPA	induce cell survival|induce cisplatin resistance	upregulated in ovarian cancers	NPA	NPA	NPA	oncogenic
2179	18193184	prostate	prostate cancer	NPA	miR-126*	miR-126-5p	NPA	NPA	NPA	reduce cell migration|reduce cell invasion	NPA	LNCaP	NPA	NPA	tumor-suppressive
2180	18193036	NPA	NPA	NPA	miR-373	miR-373-3p	CD44	960	NPA	promote cell migration|promote cell invasion	significant upregulation in clinical breast cancer metastasis samples	NPA	NPA	clinical breast cancer metastasis samples	oncogenic
2181	18193036	NPA	NPA	NPA	miR-520c	miR-520c-3p	CD44	960	NPA	promote cell migration|promote cell invasion	NPA	NPA	NPA	NPA	oncogenic
2182	18185580	breast	breast cancer metastasis	NPA	miR-126	miR-126-3p	NPA	NPA	NPA	reduce tumor growth|reduce cell proliferation	down-regulated in the majority of primary breast tumours from patients who relapse and negatively associated with poor distal metastasis-free survival	NPA	NPA	primary breast tumours	tumor-suppressive
2183	18185580	breast	breast cancer metastasis	NPA	miR-335	miR-335-5p	TNC|SOX4	3371|6659	NPA	inhibit metastasis|inhibit cell migration	down-regulated in the majority of primary breast tumours from patients who relapse and negatively associated with poor distal metastasis-free survival	NPA	NPA	primary breast tumours	tumor-suppressive
2184	18174313	prostate	hormone-refractory prostate carcinoma	NPA	miR-146b	miR-146b-5p	ROCK1	6093	NPA	reduce cell proliferation|reduce cell invasion|reduce metastasis	downregulated in hormone-refractory prostate carcinomas (HRPC) compared to androgen-sensitive noncancerous prostate epithelium	PC3	NPA	hormone-refractory prostate carcinomas (HRPC) and androgen-sensitive noncancerous prostate epithelium	tumor-suppressive
2185	18083101	breast	breast cancer self-renewing tumor-initiating cells	NPA	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	NPA	NPA	NPA	reduce cell proliferation|reduce mammosphere formation|reduce the proportion of undifferentiated cells|inhibit tumor formation|inhibit metastasis	markedly reduced in breast tumor-initiating cells and increased with differentiation	NPA	NPA	NPA	tumor-suppressive
2186	18077375	NPA	NPA	NPA	miR-378	miR-378-3p	SUFU|TUSC2	51684|11334	NPA	increase cell survival|promote tumor growth|promote angiogenesis	NPA	NPA	NPA	NPA	oncogenic
2187	18056640	prostate	prostate cancer	NPA	miR-125b	miR-125b-5p	NPA	NPA	AR	promote androgen-independent cell growth	differentially expressed in benign and malignant prostate tissues	NPA	NPA	benign and malignant prostate tissues	oncogenic
2188	18006846	breast	breast cancer	NPA	miR-27a	miR-27a-3p	NPA	NPA	NPA	increase cells in cell cycle G2-M phase|decrease celles in cell cycle S phase	NPA	MDA-MB-231	NPA	NPA	oncogenic
2189	17991735	breast	breast cancer	NPA	miR-21	miR-21-5p	PDCD4	27250	NPA	increase cell growth	NPA	MCF-7	NPA	NPA	oncogenic
2190	17968323	colorectum	colorectal cancer	NPA	miR-21	miR-21-5p	PDCD4	27250	NPA	increase cell invasion	NPA	RKO|Colo206f	chicken-embryo-metastasis assay	22 colorectal cancer patients	oncogenic
2191	17942906	blood	Burkitt lymphoma	compound 10058-F4	let-7a	let-7a-5p	NPA	NPA	MYC	inhibit cell proliferation	NPA	Namalwa	NPA	NPA	tumor-suppressive
2192	17914108	thyroid	thyroid papillary carcinoma	NPA	miR-221	miR-221-3p	CDKN1B	1027	NPA	promote cell transition to cell cycle S phase	up-regulated  in human thyroid papillary carcinomas in comparison with the normal thyroid tissue	TPC-1	NPA	human thyroid papillary carcinomas	oncogenic
2193	17914108	thyroid	thyroid papillary carcinoma	NPA	miR-222	miR-222-3p	CDKN1B	1027	NPA	promote cell transition to cell cycle S phase	up-regulated  in human thyroid papillary carcinomas in comparison with the normal thyroid tissue	TPC-1	NPA	human thyroid papillary carcinomas	oncogenic
2194	17911264	pancreas	pancreatic ductal adenocarcinoma	NPA	miR-155	miR-155-5p	TP53INP1	94241	NPA	NPA	overexpressed in PDAC cells	MiaPaCa2	nude mice	NPA	oncogenic
2195	17898713	breast	breast cancer	NPA	miR-10b	miR-10b-5p	HOXD10	3236	TWIST1	promote cell migration|promote cell invasion|promote metastasis	highly expressed in metastatic breast cancer cells and correlated with clinical progression	NPA	mouse	primary breast carcinomas	oncogenic
2196	17892514	blood	B-cell malignancy	NPA	miR-143	miR-143-3p	MAPK7	5598	NPA	inhibit cell growth	extremely low in 13 chronic lymphocytic leukemia patients and eight of nine B-cell lymphoma ones	Raji	NPA	13 chronic lymphocytic leukemia patients and eight of nine B-cell lymphoma ones	tumor-suppressive
2197	17892514	blood	B-cell malignancy	NPA	miR-145	miR-145-5p	NPA	NPA	NPA	inhibit cell growth	extremely low in 13 chronic lymphocytic leukemia patients and eight of nine B-cell lymphoma ones	Raji	NPA	13 chronic lymphocytic leukemia patients and eight of nine B-cell lymphoma ones	tumor-suppressive
2198	17890317	lung	non-small cell lung cancer	NPA	miR-29	miR-29a-3p|miR-29b-3p|miR-29c-3p	DNMT3A|DNMT3B	1788|1789	NPA	aberrant DNA methylation	down-regulated in lung cancer	NPA	NPA	NSCLC tissues	tumor-suppressive
2199	17875987	colorectum	colon cancer	adriamycin	miR-34a	miR-34a-5p	NPA	NPA	NPA	inhibit cell proliferation|induce senescence-like phenotype	9 of 25 human colon cancers (36%) showed decreased expression compared with counterpart normal tissues	HCT116|RKO	mouse model	25 human colon cancers and the counterpart normal tissues	tumor-suppressive
2200	17827156	colorectum	colon cancer	NPA	miR-145	miR-145-5p	IRS1	3667	NPA	inhibit cell growth	NPA	NPA	NPA	NPA	tumor-suppressive
2201	17823410	ovary	ovarian carcinoma	doxorubicin	miR-34b	miR-34b-5p	NPA	NPA	TP53	inhibit cell proliferation|inhibit colony formation	down-regulated in p53-null human ovarian carcinoma cells	NPA	mouse	NPA	tumor-suppressive
2202	17823410	ovary	ovarian carcinoma	doxorubicin	miR-34c	miR-34c-5p	NPA	NPA	TP53	inhibit cell proliferation|inhibit colony formation	down-regulated in p53-null human ovarian carcinoma cells	NPA	mouse	NPA	tumor-suppressive
2203	17804704	NPA	NPA	NPA	miR-200c	miR-200c-3p	NPA	NPA	NPA	alter cell morphology	NPA	A549|MDA-MB-231|MCF7	NPA	NPA	tumor-suppressive
2204	17721077	brain	glioblastoma	NPA	miR-221	miR-221-3p	CDKN1B	1027	NPA	NPA	upregulated in glioblastoma relative to adjacent normal brain tissue	NPA	NPA	glioblastoma and adjacent normal brain tissue	oncogenic
2205	17721077	brain	glioblastoma	NPA	miR-222	miR-222-3p	CDKN1B	1027	NPA	NPA	upregulated in glioblastoma relative to adjacent normal brain tissue	NPA	NPA	glioblastoma and adjacent normal brain tissue	oncogenic
2206	17699775	lung	lung cancer	NPA	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	NPA	NPA	NPA	inhibit cell divsion|inhibit cell cycle progression	poorly expressed or deleted in human lung tumors	A549	NPA	human lung tumors and normal tissues	tumor-suppressive
2207	17681183	liver	hepatocellular carcinoma	NPA	miR-21	miR-21-5p	PTEN	5728	NPA	increase cell proliferation|increase cell migration|increase cell invasion	highly overexpressed in HCCs	NPA	NPA	HCC tissues	oncogenic
2208	17656095	lung	non-small cell lung cancer	NPA	miR-34	miR-34a-5p|miR-34b-5p|miR-34c-5p	BCL2	596	TP53	inhibit cell growth	dramatically reduced in cancer tissues	NPA	NPA	14 non-small cell lung cancers	tumor-suppressive
2209	17627278	brain	glioblastoma	NPA	miR-221	miR-221-3p	CDKN1B	1027	NPA	promote the aggressive growth of human glioblastoma	highly expressed in glioblastomas	NPA	NPA	NPA	oncogenic
2210	17627278	brain	glioblastoma	NPA	miR-222	miR-222-3p	CDKN1B	1027	NPA	promote the aggressive growth of human glioblastoma	highly expressed in glioblastomas	NPA	NPA	NPA	oncogenic
2211	17621267	liver	cholangiocarcinoma	5-aza-2'-deoxycytidine	miR-370	miR-370-3p	MAP3K8	1326	IL6|5-Aza	NPA	NPA	NPA	xenografts	NPA	tumor-suppressive
2212	17616664	liver	hepatocellular carcinoma	NPA	miR-122a	miR-122-5p	CCNG1	900	NPA	NPA	down-regulated in HCCs	NPA	NPA	HCCs and cirrhotic livers	NPA
2213	17600087	ovary	ovarian cancer	NPA	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	HMGA2	8091	NPA	NPA	highly expressed in less advanced cancers	NCI-60	NPA	NPA	NPA
2214	17569667	prostate	prostate carcinoma	NPA	miR-221	miR-221-3p	CDKN1B	1027	NPA	promote cell cycle G1/S transition|increase colony formation	overexpressed in the PC3 cellular model of aggressive prostate carcinoma as compared with LNCaP and 22Rv1 cell line models of slowly growing carcinomas	LNCaP|PC3|22Rv1	NPA	NPA	oncogenic
2215	17569667	prostate	prostate carcinoma	NPA	miR-222	miR-222-3p	CDKN1B	1027	NPA	promote cell cycle G1/S transition|increase colony formation	overexpressed in the PC3 cellular model of aggressive prostate carcinoma as compared with LNCaP and 22Rv1 cell line models of slowly growing carcinomas	LNCaP|PC3|22Rv1	NPA	NPA	oncogenic
2216	17563749	thyroid	thyroid anaplastic carcinoma	NPA	miR-125b	miR-125b-5p	NPA	NPA	NPA	inhibit cell growth	significantly decreased in anaplastic carcinomas compared to normal thyroid tissue	NPA	NPA	anaplastic carcinomas and normal thyroid tissues	tumor-suppressive
2217	17563749	thyroid	thyroid anaplastic carcinoma	NPA	miR-26	miR-26a-5p|miR-26b-5p	NPA	NPA	NPA	inhibit cell growth	significantly decreased in anaplastic carcinomas compared to normal thyroid tissue	NPA	NPA	anaplastic carcinomas and normal thyroid tissues	tumor-suppressive
2218	17554199	NPA	NPA	NPA	miR-34a	miR-34a-5p	NPA	NPA	TP53	induce apoptosis|induce cell cycle G1 arrest|inhibit cell proliferation	NPA	NPA	NPA	NPA	tumor-suppressive
2219	17496199	blood	multiple myeloma	NPA	miR-21	miR-21-5p	NPA	NPA	STAT3|IL6	inhibit apoptosis	NPA	NPA	NPA	NPA	oncogenic
2220	17483472	nerve	neuroblastoma	NPA	miR-125a	miR-125a-5p	NTRK3	4916	NPA	inhibit cell growth	down-regulated in primary neuroblastoma tumors	NPA	NPA	primary neuroblastoma tumors	tumor-suppressive
2221	17483472	nerve	neuroblastoma	NPA	miR-125b	miR-125b-5p	NTRK3	4916	NPA	inhibit cell growth	down-regulated in primary neuroblastoma tumors	NPA	NPA	primary neuroblastoma tumors	tumor-suppressive
2222	17483472	nerve	neuroblastoma	NPA	miR-9	miR-9-5p	NTRK3	4916	NPA	inhibit cell growth	down-regulated in primary neuroblastoma tumors	NPA	NPA	primary neuroblastoma tumors	tumor-suppressive
2223	17437991	lung	lung cancer	NPA	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	HMGA2	8091	NPA	reduce cell proliferation	NPA	NPA	NPA	NPA	tumor-suppressive
2224	17404574	liver	cholangiocarcinoma	NPA	miR-29b	miR-29b-3p	MCL1	4170	NPA	increase TRAIL-mediated apoptosis	downregulated in malignant cells	H69|KMCH	NPA	NPA	tumor-suppressive
2225	17384677	lung	lung cancer	NPA	miR-17-5p	miR-17-5p	NPA	NPA	NPA	inhibit apoptosis	NPA	NPA	NPA	NPA	oncogenic
2226	17384677	lung	lung cancer	NPA	miR-20a	miR-20a-5p	NPA	NPA	NPA	inhibit apoptosis	NPA	NPA	NPA	NPA	oncogenic
2227	17363372	NPA	NPA	NPA	miR-21	miR-21-5p	TPM1	7168	NPA	promote cell growth	overexpressed in tumor tissues compared with the matched normal tissues	MCF-7	NPA	NPA	oncogenic
2228	17322030	NPA	NPA	NPA	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	HMGA2	8091	NPA	inhibit cell growth	NPA	NPA	NPA	NPA	NPA
2229	17312270	breast	breast cancer	NPA	miR-206	miR-206	ESR1	2099	ESR1	NPA	NPA	MCF-7|HeLa|MB-MDA-231	NPA	NPA	NPA
2230	17297439	nerve	neuroblastoma	NPA	miR-34a	miR-34a-5p	E2F3	1871	NPA	inhibit cell proliferation	generally expressed at lower levels in unfavorable primary NB tumors	NPA	NPA	unfavorable primary NB tumors and normal adrenal tissue	tumor-suppressive
2231	17284533	blood	chronic myeloid leukemia CD34+ cells	imatinib	miR-17~92	CLUSTER:miR-17~92	NPA	NPA	MYC	increase cell proliferation|increase imatinib-induced cell death	up-regulation of polycistronic pri-miRNA transcripts in CML and mature miRNAs in CP but not in BC CML	K562	NPA	"purified normal (n = 4), early chronic-phase (CP) (n = 24), and blast-crisis (BC) (n = 7) CML CD34(+) cells"	oncogenic
2232	17260024	blood	acute promyelocytic leukemia	NPA	miR-107	miR-107	NFIA	4774	all-trans-retinoic acid	NPA	upregulated in acute promyelocytic leukemia patients	NPA	NPA	acute promyelocytic leukemia patients	NPA
2233	17220301	liver	malignant cholangiocyte	NPA	let-7a	let-7a-5p	STAT3	6774	NF2	NPA	NPA	NPA	NPA	NPA	NPA
2234	17178851	blood	B-cell chronic lymphocytic leukemia	NPA	miR-181	miR-181a-5p|miR-181b-5p|miR-181c-5p|miR-181d-5p	TCL1A	8115	NPA	NPA	NPA	NPA	NPA	"indolent CLL, aggressive CLL, and aggressive CLL showing 11q deletion"	NPA
2235	17178851	blood	B-cell chronic lymphocytic leukemia	NPA	miR-29	miR-29a-3p|miR-29b-3p|miR-29c-3p	TCL1A	8115	NPA	NPA	NPA	NPA	NPA	"indolent CLL, aggressive CLL, and aggressive CLL showing 11q deletion"	NPA
2236	17135249	prostate	prostate cancer	doxorubicin	miR-20a	miR-20a-5p	E2F2|E2F3	1870|1871	E2F1|E2F2|E2F3	inhibit apoptosis	NPA	NPA	NPA	NPA	oncogenic
2237	17110380	breast	breast cancer	NPA	miR-125a	miR-125a-5p	ERBB2|ERBB3	2064|2065	NPA	inhibit cell growth|inhibit cell migration|inhibit cell invasion	NPA	SKBR3|MCF10A	NPA	NPA	tumor-suppressive
2238	17110380	breast	breast cancer	NPA	miR-125b	miR-125b-5p	ERBB2|ERBB3	2064|2065	NPA	inhibit cell growth|inhibit cell migration|inhibit cell invasion	NPA	SKBR3|MCF10A	NPA	NPA	tumor-suppressive
2239	17072344	breast	breast cancer	NPA	miR-21	miR-21-5p	BCL2	596	NPA	increase cell proliferation|inhibit apoptosis|increase tumor growth	highly overexpressed in breast tumors compared to the matched normal breast tissues	MCF-7	xenograft mouse model	matched normal breast tissue and breast tumor tissues	oncogenic
2240	16982751	breast	breast cancer	NPA	miR-27b	miR-27b-3p	CYP1B1	1545	NPA	NPA	decreased in cancerous tissues	MCF-7|Jurkat	NPA	breast cancerous and adjacent noncancerous tissues from 24 patients	tumor-suppressive
2241	16969504	colorectum	colon cancer	NPA	miR-143	miR-143-3p	MAPK7	5598	NPA	inhibit cell growth	extremely reduced in colon cancer cells	DLD-1|SW480	NPA	NPA	tumor-suppressive
2242	16969504	colorectum	colon cancer	NPA	miR-145	miR-145-5p	NPA	NPA	NPA	inhibit cell growth	extremely reduced in colon cancer cells	DLD-1|SW480	NPA	NPA	tumor-suppressive
2243	16940181	breast	breast cancer	NPA	miR-17-5p	miR-17-5p	NCOA3	8202	NPA	inhibit cell proliferation	low in breast cancer cell lines	NPA	NPA	NPA	tumor-suppressive
2244	16822819	thyroid	follicular thyroid carcinoma	NPA	miR-197	miR-197-3p	NPA	NPA	NPA	promote cell proliferation	significantly overexpressed in cancer tissues	HEK293|FTC133|K5	NPA	"45 primary thyroid samples (23 FTC, 20 FA, four normal control thyroid)"	oncogenic
2245	16822819	thyroid	follicular thyroid carcinoma	NPA	miR-346	miR-346	NPA	NPA	NPA	promote cell proliferation	significantly overexpressed in cancer tissues	HEK293|FTC133|K5	NPA	"45 primary thyroid samples (23 FTC, 20 FA, four normal control thyroid)"	oncogenic
2246	16762633	liver	cholangiocarcinoma	NPA	miR-141	miR-141-3p	NPA	NPA	NPA	promote cell growth	highly over-expressed in malignant cholangiocytes	NPA	NPA	NPA	oncogenic
2247	16762633	liver	cholangiocarcinoma	gemcitabine	miR-200	miR-200a-3p|miR-200b-3p|miR-200c-3p	NPA	NPA	NPA	decrease apoptosis	highly over-expressed in malignant cholangiocytes	NPA	xenografts	NPA	oncogenic
2248	16762633	liver	cholangiocarcinoma	gemcitabine	miR-21	miR-21-5p	PTEN	5728	NPA	decrease apoptosis	highly over-expressed in malignant cholangiocytes	NPA	xenografts	NPA	oncogenic
2249	16564011	testis	testicular germ cell tumors	NPA	miR-372	miR-372-3p	LATS2	26524	NPA	promote cell proliferation	NPA	NPA	NPA	NPA	oncogenic
2250	16564011	testis	testicular germ cell tumors	NPA	miR-373	miR-373-3p	LATS2	26524	NPA	promote cell proliferation	NPA	NPA	NPA	NPA	oncogenic
2251	16330772	blood	erythroleukemia	NPA	miR-221	miR-221-3p	KIT	3815	NPA	inhibit cell proliferation	gradually and sharply down-modulated in erythropoietic (E) culture of cord blood CD34+ progenitor cells	NPA	NOD-SCID mice	NPA	tumor-suppressive
2252	16330772	blood	erythroleukemia	NPA	miR-222	miR-222-3p	KIT	3815	NPA	inhibit cell proliferation	gradually and sharply down-modulated in erythropoietic (E) culture of cord blood CD34+ progenitor cells	NPA	NOD-SCID mice	NPA	tumor-suppressive
2253	16266980	lung	lung cancer	NPA	miR-17~92	CLUSTER:miR-17~92	NPA	NPA	NPA	promote cell growth	markedly overexpressed in lung cancers	NPA	NPA	NPA	oncogenic
2254	16166262	blood	chronic lymphocytic leukemia	NPA	miR-15	miR-15a-5p|miR-15b-5p	BCL2	596	NPA	induce apoptosis	down-regulated in the majority of CLLs	NPA	NPA	NPA	tumor-suppressive
2255	16166262	blood	chronic lymphocytic leukemia	NPA	miR-16	miR-16-5p	BCL2	596	NPA	induce apoptosis	down-regulated in the majority of CLLs	NPA	NPA	NPA	tumor-suppressive
2256	16024602	brain	glioblastoma	NPA	miR-21	miR-21-5p	NPA	NPA	NPA	inhibit apoptosis	strongly over-expressed in tumor tissues	A172|U87|U373|LN229|LN428|LN308	NPA	human glioblastoma tumor tissues and nonneoplastic fetal and adult brain tissues	oncogenic
2257	15944707	blood	B-cell lymphoma	NPA	miR-17~92	CLUSTER:miR-17~92	NPA	NPA	NPA	increase tumor development	substantially increased in cancers	NPA	mouse B-cell lymphoma model	B-cell lymphoma samples and normal tissues	oncogenic
2258	15766527	lung	lung cancer	NPA	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	RAS	51655	NPA	NPA	lower in lung tumors than in normal lung tissue	NPA	NPA	lung tumors and normal lung tissue	NPA
2259	15172979	lung	lung cancer	NPA	let-7	let-7a-5p|let-7b-5p|let-7c-5p|let-7d-5p|let-7e-5p|let-7f-5p|let-7g-5p|let-7i-5p	NPA	NPA	NPA	inhibit cell growth	reduced in human lung cancers	A549	NPA	143 lung cancer cases	tumor-suppressive